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The physiological actions of the neuropeptides VIP, PACAP-27 and
PACAP-38 are mediated by VPACi, VPAC2 and PACi receptors which
preferentially couple to G-proteins that stimulate adenylate cyclase and hence
increase the concentration of intracellular cAMP ([cAMPJi), although stimulation of
calcium ([Ca2+]j) and phospholipase D levels have also been reported. The activation
of these receptors has been implicated in a plethora of physiological processes (e.g.
control of circadian rhythms) and clinical conditions (e.g. Alzheimer's disease),
although the availability and paucity of selective, non-peptide ligands has hindered
advances in this field. Moreover, as new peptide ligands have been developed, their
intracellular signalling properties have not been systematically evaluated, with the
use of different expression systems and assay methodologies resulting in
inconsistencies in the literature. To address these issues, chapter one of this thesis
describes the thorough and systematic characterisation of human (h) VPAC/PAC
receptor pharmacology using non-radioactive, high-throughput (HT) amenable,
2~bwhole cell, [cAMPJi and [Ca ]i assays. Chapter two describes HT-screening studies
that were performed through an industrial collaboration, in an attempt to identify
receptor selective, non-peptide ligands and finally, in chapter three the potential roles
for VPAC/PAC receptors in the brain were explored using both in vitro and in vivo
techniques.
Standardised [cAMP]; and [Ca2+]i assays (96-well plate) were used to
directly compare hVPAC/PAC receptor pharmacology in CHO-K1 cells stably
expressing the receptors, with additional studies evaluating cell lines with
endogenous receptor expression. A range of peptide agonists were utilised in these
studies, including non-selective (e.g. PACAP-27) and classical ligands (e.g. VIP), as
well as recently described (e.g. R3P65) and highly selective compounds (e.g.
maxadilan). The agonist rank order of potencies were identical between assays for
each receptor in all of the cell lines examined, with EC50 values consistently ~ 100
2_j_fold lower in the [Ca ]j assay. The pharmacology of the reportedly selective peptide
antagonists PG7-269 (VPACi), PG99-465 (VPAC2) and M65 (PAC,) was also
examined, with these studies identifying complexities in the pharmacology of PG99-
465.
The standardised assay conditions and the excellent correlation between the
[cAMPJi and [Ca2+]j data, underpinned the establishment of an HT [Ca2+]j assay
(384-well plate) which was used to identify hVPAC receptor selective ligands from
the compound libraries of the Fujisawa Pharmaceutical Company. Approximately
I
100,000 compounds were tested, with several non-peptides identified as potential
ligands. The potency and selectivity of these compounds were subsequently fully
2"fcharacterised using the 96- and 3 84-well [Ca ]; assay formats, although none were
as potent as the peptides examined in chapter one.
In the final section of this thesis, putative roles for VPAC/PAC receptors in
the brain were investigated. Firstly, as VIP and PACAP are thought to stimulate the
release of cytokines from astrocytes in the brain, VPAC/PAC receptor pharmacology
was examined in primary cultures of rat cortical astrocytes (RCA). Receptor
9+
characterisation studies ([cAMP]j and [Ca ]j assays) established that the PACi was
the predominant VPAC/PAC receptor subtype in RCA, with preliminary studies also
showing that VIP and PACAP-27 stimulated the release of the cytokines IL-1 [3 and
TNF-a from these cells. In addition, behavioural studies using mice further
examined the role of the VPAC2 receptor in the maintenance of circadian activity
rhythms, as previous collaborative studies have highlighted an important role for this
receptor. Temporarily moving the mice from their home cages was found to be as
disruptive to their activity cycles as anaesthesia/surgery, a finding which has
implications for all work of this nature. Finally, PG99-465 was administered to mice
and wheel running activity in response to an advance in the light/dark cycle
monitored, however no significant alterations in response to the phase advance were
found.
The findings described in this thesis clearly demonstrate the importance of
systematically characterising VPAC/PAC receptor pharmacology, with these studies
highlighting that there remains a paucity of receptor selective, non-peptide ligands.
Moreover, identifying or designing such non-peptide ligands thus remains an
important task, with the success of such studies critical to delineating the
physiological roles for VPAC/PAC receptors in normal and disease states.
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The VIP and PACAP peptides have been intensively studied over the past
thirty years and alongside their associated G-protein coupled receptors (GPCRs)
have been implicated in a plethora of physiological processes, with new and exciting
roles continuing to be described in the literature. The physiological properties of the
peptides/receptors have been investigated using a range of in vitro and in vivo
technologies, including cell-based functional approaches, transgenic animals and
rodent models of various diseases. As a consequence of the many interesting
functions reported for these peptides and their cognate receptors in recent years, they
remain attractive drug targets, with the ultimate goal being to develop selective,
potent, non-peptide ligands as potential therapeutic tools for a variety of diseases and
disorders. In this introduction I shall describe the discovery of the VIP and PACAP
peptides, the cloning of their cognate receptors, the pharmacology and distribution of
these receptors and finally, I shall discuss some of the many physiological roles
associated with the peptides and receptors.
A.l. VIP and PACAP peptides
A.l.l. Discovery of VIP
The isolation and purification of 'vasoactive intestinal peptide' (VIP) was
reported some 36 years ago by Said and Mutt (1970), who at the time were
investigating the high incidence of systemic hypotension in patients with severe lung
injuries (Said & Mutt, 1970). Whilst looking for the vasoactive substance
responsible for the reduction in blood pressure, a 28 amino acid vasoactive peptide
(VIP) was isolated from pig small intestine, an organ which originates from the same
embryonic bud as the lung. Initial experiments showed the peptide to have a diverse
range of effects including: increasing vasodilatation and lowering arterial blood
pressure (Said & Mutt, 1970), causing smooth muscle relaxation in respiratory and
intestinal tissues (Piper et al., 1970), as well as stimulating electrolyte secretion in
the gut (Barbezat & Grossman, 1971). Details regarding the mechanisms by which
VIP mediated these effects began to emerge a few years later and appeared to
primarily depend upon the stimulation of adenylate cyclase (AC) and the resulting
production of cyclic adenosine monophosphate (cAMP) production. The first
association between VIP and AC was reported in 1973, when VIP was shown to
increase the activity of this enzyme in liver tissue (Desbuguois et al., 1973). Around
2
the same time, it was also reported that patients who had tumours expressing high
concentrations of VIP or elevated plasma VIP levels were often found to have
diarrhoea (Bloom et al., 1973; Said & Faloona, 1975). These secretory effects of
VIP on the gut were likened to that of cholera endotoxin (which was thought to
stimulate AC) and were subsequently shown to occur through stimulation of AC and
cAMP (Schwartz et al., 1974; Swift et al., 1975). Since these early studies, many
other investigations have verified that VIP activity is generally synonymous with an
increase in AC activity and cAMP levels. As a consequence of the isolation of VIP
from the gut and its effect on electrolyte secretion, it was initially defined as a gut
hormone. However, further investigation of VIP distribution and function
demonstrated that this peptide had a much more widespread distribution, and through
immunohistochemical and radioimmuno assays, this peptide was shown to be mainly
localised in neurons throughout the CNS and PNS in several species (Larsson et al.,
\916z-, Larsson et al., 1976b). This lead to the suggestion that VIP may also have a
role as a neurotransmitter, in addition to being a gut hormone, with findings from
many subsequent studies continuing to support a putative neurotransmitter role for
this peptide (Bryant et al., 1976; Duckies & Said, 1982; Fahrenkrug & Hannibal,
2004; Van Geldre & Lefebvre, 2004).
A.1.2. VIP gene products
The human VIP gene was cloned in 1985 and was subsequently mapped to
chromosome 6, region q25 [Entrez GenelD: 7432; http://www.ncbi.nlm.nih.gov]
(Tsukada et al., 1985; Gozes et al., 1987). The rat and mouse VIP genes were both
cloned in 1991 and have chromosomal locations lpll [rat: Entrez GenelD: 117064]
and 10A1 [Entrez GenelD: 22353] (Lamperti et al., 1991).
Translation of the mRNA sequence produced from transcription of the
human VIP gene yields a 170 amino acid precursor named prepro-VIP. Post-
translational processing of this precursor yields the 28 amino acid VIP, in addition to
the 27 amino acid peptide histidine methionine (PHM) in humans or peptide histidine
isoleucine (PHI) in rodents (Figure A.l; Itoh et al., 1983). Two alternatively
processed forms of the latter peptide have been isolated, namely PHV-42 and PHI-
GLY (Yiangou et al., 1986; Cauvin et al., 1990b). VIP and PHM/PHI are located on
two adjacent exons and share 44 % amino acid sequence identity (Tatemoto & Mutt,
1981; Bodner et al., 1985).
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Figure A.l Schematic illustration of the peptide products produced from
processing of the VIP precursor (Fahrenkrug & Hannibal,
2004).
The rate of transcription of the VIP gene can be regulated by many factors.
One of the first reported regulators of this gene was cAMP, which was shown to act
via a 17 base pair cAMP response element (CRE) in the VIP gene sequence
(Hayakawa et al., 1984; Ohsawa et al., 1985; Tsukada et al., 1987). Transcription of
the VIP gene has also been shown to be enhanced by the activation of protein kinase
C (PKC), an effect which has been suggested to be mediated in part by the CRE,
although there is some debate over this issue (Ohsawa et al., 1985; Hahm & Eiden,
1996). In addition, the VIP gene is reported to contain a cytokine-responsive area
that is sensitive to factors such as ciliary neurotrophic factor and leukaemia
inhibitory factor (Symes et al., 1994). GPCRs can also mediate VIP gene
expression, with the cholinergic agonist carbachol shown to increase VIP mRNA
expression in neuroblastoma cell lines via specific muscarinic receptors (Kristensen
et al., 1997). Furthermore, even at nanomolar concentrations pituitary adenylate
cyclase activating polypeptide (PACAP) has been shown to increase the rate of VIP
gene transcription in NB-OK-1 cells, leading to a rapid increase in intracellular VIP
levels, which is suggested to be cAMP independent (Georg & Fahrenkrug, 2000).
Indeed, Adler and Fink (1993) have shown that VIP mRNA levels in SHSY-5Y cells
are increased by calcium and cAMP independently, with only the calcium mediated
pathway involving new protein synthesis.
A.1.3. Discovery of PACAP
While attempting to isolate hypothalamic hypophysiotropic hormones,
characterised by their ability to stimulate AC in ovine pituitary extracts, Arimura and
colleagues discovered a novel, 38 amino acid peptide (Miyata et al., 1989). When
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tested in similar tissue extracts prepared from rats, this peptide was again observed to
potently activate AC and as a consequence was named PACAP-38 (pituitary
adenylate cyclase activating polypeptide; Miyata et al., 1989). Less than a year later
a second peptide, produced as a side product during PACAP-38 purification from
hypothalamic extracts, was shown to produce an identical level of AC stimulation in
terms of potency (EC50 for both: 0.3 nM) and maximal stimulation (Miyata et al.,
1990). Following sequence analysis, this second peptide was demonstrated to be a
C-terminally truncated form of PACAP-38 that was 27 amino acids in length and
was therefore named PACAP-27. The PACAP peptides were suggested to be closely
related to VIP as a result of the high level of amino acid homology that was evident
between their sequences (68 %; Table A.l; Miyata et al., 1990). Early studies in
which the physiological actions of the three peptides were directly compared in
cultured rat pituitary cells, revealed that both PACAP peptides were 1000 times more
potent than VIP in their ability to active AC (Miyata et al., 1990).
A.l.4. The PACAP gene
The human PACAP gene was cloned in 1992 and mapped to the PI 1 region
of chromosome 18 [Entrez GenelD: 116] (Hosoya et al., 1992). The rat PACAP
gene has been mapped to 9q37 [Entrez GenelD: 24166], with the mouse gene also
cloned and mapped to chromosome 17 [Entrez GenelD: 11516] (Cai et al., 1995;
Okazaki et al., 1995; Yamamoto et al., 1998).
Transcription of the human PACAP gene and subsequent translation of the
mRNA product yields a 176 amino acid precursor called prepro-PACAP (Hosoya et
al., 1992). This precursor can be cleaved and modified (Figure A.2) to produce
1 1
signal peptide prp pacap
1
signal fe=tice "big PRP* PACAP 3-3
II
prp pacapct
Figure A.2 The basic structure of the PACAP precursor and the resulting
mature peptide products (Fahrenkrug & Hannibal, 2004).
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PACAP-27 and PACAP-38, in addition to a third peptide named PACAP-related
peptide (PRP; 29 amino acids), with which the PACAP peptides share just over 20 %
amino acid homology (Okazaki et al., 1992). The PACAP and VIP precursor
peptides are relatively similar in terms of general structure and processing, as can be
seen in Figure A.3 (Vaudry et al., 2000). As for VIP, multiple factors are known to
stimulate PACAP gene expression, including PACAP-38, phorbol esters and cAMP
analogues (Suzuki et al., 1994; Yamamoto et al., 1998).
24
Human prepro-PACAP
82 110 132 169 176








1 21 81 107 125 152 170
Human prepro-VIP
Figure A.3 The general organisation of the human VIP and PACAP
precursors. The sequence homologies between mature peptide
products are shown, with conserved amino acids highlighted in black
(Vaudry et al., 2000).
A.1.5. Distribution ofVIP and PACAP
Many studies have investigated the distribution of VIP and PACAP in a
variety of species. In general, these peptides are found throughout the body,
including in the brain and in nerves innervating peripheral organs, as well as in non-
neuronal cells and tissues in the periphery. There is a generally distinct pattern of
distribution for VIP and PACAP in the CNS, however the locations of the peptides
appear more similar in the periphery (Fahrenkrug & Hannibal, 2004). The
distribution of the peptides shall be discussed here in brief, however more detailed
reviews can be found elsewhere (Besson et al., 1979; Arimura et al., 1991; Masuo et
al., 1993; Vaudry et al., 2000).
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A.l.5.1. VIP/PACAP distribution in the nervous system
In the CNS, VIP and PACAP are generally found in different layers or cells
of particular structures, with few reports describing their co-localisation (Fahrenkrug
& Hannibal, 2004). VIP has a widespread distribution throughout the brain, with
high expression found in the cerebral cortex, hippocampus, amygdala
suprachiasmatic nucleus (SCN) and hypothalamus (Roberts et al., 1980; Card et al.,
1981; Said, 1984; Fahrenkrug & Hannibal, 2004). The majority of investigations
into PACAP expression in the CNS have focussed on PACAP-38, as this is the
predominant form found in the brain, with some reports suggesting that PACAP-27
expression accounts for only 10 % of the total PACAP content in the brain (Arimura
et al., 1991). In the CNS, the highest levels of PACAP-38 expression have been
reported to be in the hypothalamus, particularly in the SCN and the paraventricular
and periventricular nuclei (Arimura et al., 1991; Masuo et al., 1993). Other brain
areas in which a high expression of this peptide has been detected include multiple
brainstem nuclei, the arcuate nucleus, the amygdala, thalamic nuclei, the cerebral
cortex, the medulla oblongata and the posterior pituitary (Arimura et al., 1991;
Ghatei et al., 1993; Masuo et al., 1993; Fukuhara et al., 1997). Although PACAP
expression in neurons has been well documented, the peptide has also been shown to
be expressed in primary cultures of cortical astrocytes derived from newborn rat
cortices (Jaworski, 2000). In addition, both VIP and PACAP have been localised to
nerve fibres that innervate cerebral blood vessels (Edvinsson & Ekman, 1984;
Uddman et al., 1993).
A.l.5.2. Peripheral distribution of VIP/PACAP
Co-expression of the VIP and PACAP peptides has been well documented
in many peripheral tissues, although it is not always clear from these studies whether
the peptides are found within the innervating nerves or within non-neuronal cells of
particular organs. However, expression of both peptides has been documented
throughout the digestive tract, in the genito-urinary tract, and in multiple exocrine
glands (Aim et al., 1980; Ghatei et al., 1993; Vaudry et al., 2000). As for the CNS,
PACAP-38 has been shown to be the predominant form of PACAP expressed in
peripheral tissues and organs (Arimura et al., 1991). A particularly high
concentration of this peptide was detected in germ cells of rat testis, with the total
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concentration of PACAP-38 shown to be higher than that found in the entire rat brain
(Arimura etal., 1991).
A.l.5.3. Distribution of VIP and PACAP in the immune system
In contrast to the distinct localisation of VIP and PACAP in the CNS, the
distribution of these peptides is actually very similar in cells and tissues of the
immune system. Both VIP and PACAP have been detected in the thymus, spleen
and lymph nodes (Gaytan et al., 1994; Leceta et al., 1994; Abad et al., 2002). In
addition, the peptides are also expressed in lymphocytes and thymocytes (Delgado et
al., 1996b; Gomariz et al., 2001; Abad et al., 2002). In agreement with the general
distribution of these peptides in the body, PACAP-38 was again reported to be the
predominant form ofPACAP expressed in the immune system (Gaytan et al., 1994).
A.1.6. Conservation of VIP and PACAP
The sequences of VIP and the PACAP peptides are highly conserved
between species. The VIP amino acid sequence is identical in humans (Bunnett et
al., 1984), rats (Dimaline et al., 1984), cows (Carlquist et al., 1979), rabbits (Gossen
et al., 1990), pigs (Mutt & Said, 1974), dogs (Wang et al., 1985) and goats (Eng et
al., 1986). Both guinea pig and chicken VIP deviate from the conserved sequence by
four amino acids (Du et al., 1985; McFarlin et al., 1995). The PACAPs are similar
to VIP, with their amino acid sequences identical in human (Kimura et al., 1990),
sheep (Miyata et al., 1990; Miyata et al., 1989), rat (Ogi et al., 1990), and mouse
(Okazaki et al., 1995), with the chicken (McRory et al., 1997) and frog (Chartrel et
al., 1991) sequences differing by only a single amino acid residue. Interestingly,
PACAP has also been identified in a group of ancient protochordates - the tunicates
or sea squirts (a group that is suggested to have given rise to the vertebrates), and has
been shown to differ by only one residue when compared to the human form,
suggesting a strong evolutionary pressure to maintain the PACAP sequence (McRory
& Sherwood, 1997). The finding that PACAP has been so well conserved over 700
million years of evolution, has lead to the suggestion that it is the 'most likely
ancestral molecule for the superfamily' to which it belongs (Figure A.4; Sherwood et





































Proposed evolution of the VIP/PACAP/secretin family of
peptides (Sherwood et al., 2000).
A. 1.7. The VIP/PACAP peptide family
Due to the degree of sequence similarity with peptides such as secretin and
glucagon, VIP and the PACAP peptides have been classed as members of the
secretin peptide family, which was named after the first member of the family to be
discovered (Bayliss & Starling, 1902). As shown for VIP and PACAP (Figures A. 1 -
A.3), the precursor peptides of this family characteristically have a signal peptide, an
N-terminal peptide, 1 - 3 bioactive peptides and a C-terminal peptide (Sherwood et
al., 2000). The superfamily contains mature, linear peptides of between
approximately 25 - 50 amino acids in length (Table A. 1). In addition to sequence
homology, the majority of peptides in this family also share certain primary (C-
terminal amide) and secondary structural similarities, with disordered random coil
structures at the N-termini and extended a-helical regions at the C-termini (Clore et
al., 1986; Gronenborn et al., 1987; Theriault et al., 1991; Wray et al., 1998). There
is evidence to suggest that the structures of both the N- and C- terminal regions are
important for the biological activity of the peptides and for specific receptor
recognition (Onoue et al., 2001, 2004). For example, the NMR structure of PACAP-
27, published recently by Inooka and colleagues (2001), was shown to contain a
disordered N-terminal sequence (residues: 1 - 4) and an adjoining C-terminal a-helix
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VIP PACAP-27
(a) (b) C-terminal (c)
Figure A.5 NMR derived structures of VIP and PACAP. A superposition of
the 10 lowest energy structures (a) and the average conformation (b)
are shown for VIP, as derived from NMR studies (Tan et al., 2006).
For PACAP-27 (c), 25 NMR derived structures of the peptide are
shown superposed (Inooka et al., 2001).
(residues: 5 - 27; Figure A.5). The structure of VIP, as determined by NMR (Figure
A.5), also contains an N-terminal disordered region (residues: 1 - 6) and an a-helix
(residues: 7 - 24), with the remaining residues in the C-terminal appearing to form a
helical shape (Tan et al., 2006). For PACAP-27, the C-terminal region has been
show to be important for receptor binding, however it is not sufficient for agonist
activity as N-terminally truncated PACAPs such as PACAP(6-27), are competitive
antagonists of PACAP receptors (Gourlet et al., 1991; Robberecht et al., 1992). It
has been suggested that a hydrophobic (3-coil may form in the N-terminal region (for
which His1, Phe6 and Thr7 may be involved) and that this structure may be important
for receptor binding affinity (Inooka et al., 2001).
The peptides in this family have wide range of functions, with the majority
of these physiological actions mediated by GPCRs, as discussed below.
A.2. VIP and PACAP receptors
A.2.1. VIP and PACAP interactions with GPCR
Prior to cloning, the VIP and PACAP receptors were postulated to stimulate
AC by interacting with GTP binding proteins (G-proteins), as GTP, Gpp(nNH)p and
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GDP were all shown to inhibit VIP binding to rat prostate epithelial membranes and
rat liver plasma membranes (Ramirez-Cardenas et al., 1981; Carmena & Prieto,
1985). In addition, Couvineau et al. (1986) reported the solubilisation of a VIP
receptor complex from rat liver membranes that was associated with a GTP
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regulatory protein. Using cholera toxin to induce [ PJADP ribosylation of liver
membranes, this group suggested that the G-protein associated with the VIP
receptors was Gas (Couvineau et al., 1986). At that time, more detailed studies were
emerging regarding the control of AC activity by guanine nucleotides, with the
isolation of these proteins and the development of specific antisera allowing further
investigations of the precise mechanisms involved (Mumby et al., 1986). In 1992,
by using cross-liking methods and antisera for different G-protein subunits, Kermode
and colleagues reported a direct physical interaction between VIP, VIP receptors and
Gas subunits (Kermode et al., 1992). It is now well established that VIP and PACAP
interact with GPCRs to stimulate intracellular signalling cascades.
For VIP and PACAP, along with many other peptides and neurotransmitters,
it was not until advances in molecular biology were achieved, that the cloning of
their cognate GPCRs was reported. In the following section I will give a general
view of GPCRs, prior to specifically addressing the group B GPCR subfamily which
contains the receptors for VIP and PACAP.
A.2.2. GPCR stoichiometry and families
G-protein coupled receptors (GPCRs) are heptahelical membrane proteins
that have been described as the 'most important set of targets for research aimed at
the design of new medicines' (Horn et al., 1998), and account for 30 - 45 % of
today's drugs targets (Drews, 2000; Hopkins & Groom, 2002). The human genome
has been estimated to contain ~ 950 GPCRs (Takeda et al., 2002), which is
approximately 5 % of the total estimated protein encoding gene repertoire in the
genome (International Human Genome Sequencing Consortium, 2004;
http://ensembl.lcb.uu.se:8080/Homo_sapiens/). All of the receptors in the
heptahelical family contain 7 transmembrane (TM) hydrophobic regions, linked by
intracellular (IC) and extracellular (EC) loops, with an EC N-terminal and IC C-
terminal. 7-TM receptors are generally assigned into one of 5 - 6 families
(depending on the classification system) based on protein sequence similarities, with
the receptors in each family generally sharing over 25 % sequence identity in the 7-
TM region (Fredriksson et al., 2003b; Jacoby et al., 2006). The three main GPCR
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families (A, B and C) encompass the mammalian GPCRs and schematic illustrations
of the general structures of receptors in these families are shown in Figure A.6.
Group A or the 'rhodopsin receptor family' includes amine, chemokine and
purinergic receptors amongst others (Foord et al., 2005). This group is the largest
within the GPCR superfamily and the IUPHAR receptor database currently
recognises 282 members of this family (http://www.iuphar-db.org). The smaller
group B or 'secretin receptor family' mostly consists of peptide hormone and
neuropeptide receptors such as secretin, calcitonin, VIP and PACAP receptors, with
55 members of this group currently represented on the IUPHAR GPCR database.
The group C family is the 'metabotropic glutamate receptor family' which in
addition to mGluR, counts the GABAb, calcium-sensing receptors and some taste
receptors amongst its members. There are 19 members of this group reported in the
IUPHAR database, with all members having distinct, long N-terminal domains of
approximately 500 - 600 amino acids (Takahashi et al., 1993). Another group of
GPCRs found in mammals is the small 'frizzled' receptor family, of which 11
members are currently described in the IUPHAR database. These receptors bind
'Wnt' secreted glycoprotein ligands and are suggested to be most closely related to
receptors of the group B family, as a result of certain sequence similarities observed
between the groups (Barnes et al., 1998; Harmar, 2001). The other smaller families
ofGPCRs which have been identified are generally considered to contain pheromone
and cAMP receptors that are found only in fungi and moulds (Gether, 2000; Harmar,
2001; Fredriksson et al., 2003b). Among the three main mammalian GPCR groups
there are few similarities other than the gross structural features of 7-TM domains
and a disulphide bridge between EC loops 1 and 2 (Figure A.6). As VIP/PACAP
receptors are members of the group B GPCR family, I will focus on this sub-family,
however for excellent reviews on all GPCRs please see Gether (2000), Pierce et al.
(2002) and Kristiansen (2004).
A.2.3. Group B GPCR family
The G-protein coupled receptor for the brain/gut peptide secretin was cloned
in 1991 and subsequent sequence analysis found it had virtually no homology to any
of the other GPCRs identified at that time (Ishihara et al., 1991). Hence, the secretin
receptor became the first member of a new GPCR family, later designated as group
B. Many members of this family are activated by peptides and have the same
general structural features described in the preceding section, having ~ 30 %
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(a) Rhodopsin receptor family
(Family A)
(b) Secretin receptor family
(Family B)
(c) Metabotropic glutamate receptor family (Family C)
CQQH
Figure A.6 Schematic illustrations of the general structural features of the
three main GPCR families. Endogenous hormone ligands are
shown in orange, with conserved amino acid residues and disulphide
bridges for each family highlighted in green and yellow respectivley.
Figure taken from Jacoby et al. (2006).
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homology within the 7-TM region (McKnight & Gordon, 1998; Stacey et al., 2000).
The majority of the group B receptors also have a hydrophobic N-terminal signal
peptide, as well as an N-terminal domain of > 120 residues (Figure A.7), which has
been designated the 'hormone binding domain' and contains numerous conserved
amino acids, including several cysteines residues (Harmar, 2001; Laburthe &
Couvineau, 2002). The receptors' N-termini alone are not sufficient for ligand
binding and the binding domain is discontinuous, with contact points on both the N-
terminus and the EC loops (Unson, 2002; Lins et al., 2001). The family B GPCRs
have been further categorised into three sub-families: Bl, B2 and B3 (Harmar, 2001).
The 'BE sub-family contains the classical peptide hormone receptors such as those
for GLP, VIP, PACAP and GHRH, i.e. the secretin family of peptides described
earlier. All members of the subfamily signal through Gas and AC to increase the
production of intracellular cAMP, although coupling to additional pathways, for
example those leading to increased calcium levels, has been reported for some
receptors (Aiyar et al., 1999; McCulloch et ah, 2002). The 'B2' sub-family is the
largest of the group and encompasses several sets of receptors, including the orphan
receptors that have been described as the LN-TM7 (Zendman et al., 1999) or LNB-
TM7 family (Stacey et al., 2000). The members of this group have very long N-
terminal domains, which can be up to 2000 - 3000 residues in length (Fredriksson et
CCOh
Figure A.7 Schematic illustration of the structures of selected group B
GPCRs. The diagram shows the general structural features of six
group B receptors, with 'E' representing EGF domains, 'T'
representing thrombospondin type-1 repeats and C2 representing C2-
set IgSF domains (Stacey et al., 2000).
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al., 2003a) and a 7-TM region that is typical of the other members of the group B
GPCR family. Additional characteristics of receptors in this family include a region
consisting of- 20 % SER/THR residues and a CYS-box, both of which are found on
the EC terminal just before the start of the first TM domain (Stacey et al., 2000).
The B2 family also includes the EGF-TM7 group, which are almost exclusively
found on immune cells and have distinct long N-terminal domains which contain
variable numbers of tandemly repeated endothelial growth factor (EGF) domains
(McKnight & Gordon, 1998; Kwakkenbos et al., 2004). Despite showing significant
homology to other group B GPCRs in the 7-TM region, evidence for G-protein
coupling and transduction mechanisms for B2 receptors, akin to the B1 receptors is
scarce. Only four members of the B2 family have been reported to couple to specific
G-proteins (Lelianova et al., 1997; Foord et al., 2002). The third sub-family is the
'B3' or 'Methuselah-like' GPCRs, aptly named after the P-element insertion gene
mutation in drosophila which generates mutant 7-TM receptors that are associated
with an extended life-span (Lin et al., 1998). Methuselah receptors have some
homology to the other group B receptors in the 7-TM region, however they do not
have a SER/THR rich region or CYS-box (Stacey et al., 2000).
Over the last few years a generally accepted model of ligand binding to, and
activation of group B GPCRs has emerged. This model proposes that the C-terminus
of the activating peptide binds to the long EC N-terminal domain of the receptor,
after which the N-terminus of the ligand docks to the body of the receptor or the 'J'
domain (i.e. juxtamembrane region consisting of transmembrane regions and
intervening loops), causing a conformational change that allows intracellular loops to











Figure A.8 Suggested mechanism for peptide binding to, and activation of
the group B GPCR. In this model, the C-terminal region of the
peptide binds to the EC N-terminal of the receptor (a, b), after which
the N-terminal of the peptide binds to the TM bundle (c). A
conformational change then occurs in the receptor, leading to G-
protein activation (d). Figure modified from Hoare et al. (2005).
G-protein
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Hoare, 2005). An interesting alternative model has recently been proposed by Dong
and colleagues (Dong et al., 2006), who suggested that the hormone (secretin in this
case) may expose a hidden, built-in agonist epitope in the amino terminus of the
GPCR which interacts with specific regions in the body of the receptor (TM6 for
secretin) causing activation. However, it remains to be seen whether this mechanism
will apply to other members of this receptor family.
A.2.4. Classification ofVIP and PACAP receptors
Initial pharmacological studies of putative VIP receptors generally involved
either cAMP stimulation assays or binding studies using iodinated VIP, with these
approaches existing long before modern advances in molecular biological
techniques, such as receptor cloning. Such studies identified generic 'VIP receptors'
in a variety of tissues and cells, including guinea pig pancreatic acinar cells
(Christophe et al., 1976; Robberecht et al., 1976), various preparations of rat brain
membranes (Taylor & Pert, 1979), peripheral blood lymphocytes (Guerrero et al.,
1981a; O'Dorisio et al., 1981), rat liver membranes (Guerrero et al., 1981b), human
lymphoblasts (Beed et al., 1983), epithelial cells from human gallbladder (Dupont et
al., 1981), neonatal astrocytes (Magistretti et al., 1983), multiple areas of the adult
CNS (Staun-Olsen et al., 1985) and human colonic epithelial cells (Broyart et al.,
1981). 'VIP receptors' were also identified in various human carcinoma cell lines,
including those derived from the gut (Laburthe et al., 1978), the cervix (Prieto et al.,
1981), the lung (Laburthe et al., 1981), the breast (Gespach et al., 1988) and from the
pancreas (Estival et al., 1983). During the same period many autoradiographic
studies were published, in which iodinated VIP was used to identify the anatomical
distribution of non-specific VIP receptors in a variety of central and peripheral
tissues, from a range of species (Besson et al., 1984; Farmery et al., 1984; Leroux et
al., 1984; Carstairs & Barnes, 1986; Shaffer & Moody, 1986; Power et al., 1988).
The specific distribution of each receptor subtype shall be discussed further in
section A.2.9. (p 33).
The VIP receptors characterised in these tissues using VIP and the VIP-like
peptides available at the time, showed variations in pharmacology due, in part, to the
presence of multiple receptors and because of the lack of suitable ligands. It was not
until more selective ligands were identified and generated that the receptors could be
more clearly identified and characterised. In 1982, Raufman and colleagues
identified a bioactive peptide from the venom of the Gila monster (.Heloderma
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suspectum) that was able to stimulate AC and cAMP in guinea-pig acinar cells, in a
manner similar to VIP and secretin; hence the action of the venom was attributed to
secretin/VIP receptor activation (Raufman et al., 1982). In further studies on
intestinal epithelial cells (which are devoid of secretin receptors), new data indicated
that the action of the venom was specific for VIP receptors, interacting equally well
with both rat and human receptors (Amiranoff et al., 1983). This distinguished the
pharmacology of this ligand from other VIP like peptides, such as PHI and secretin,
which showed differences in affinity for the VIP receptors of the two species
(Laburthe et al., 1983). The active peptide in the venom, helodermin, was
subsequently isolated and purified (Vandermeers et al., 1984), which led to more
extensive analysis of its specific properties and the resultant identification of many
VIP-like physiological effects (Blank et al., 1986; Naruse et al., 1986; Koshiyama et
al., 1987). However, differences between these peptides were beginning to emerge
in terms of potency/binding characteristics, with a study by Robberecht and
colleagues (1984) clearly showing variations between helodermin, VIP and secretin
in their ability to stimulate cAMP production in membranes from several rat and
human organs. These researchers tentatively suggested that the distinct actions of
helodermin (from both secretin and VIP) may be a result of the activation of specific
helodermin receptors (Robberecht et al., 1984). Four years later, the same group
used iodinated helodermin and SUP-T1 cells, to provide further evidence for a single
population of helodermin-preferring VIP receptors in this human T-cell lymphoma
cell line (Robberecht et al., 1988). In this study, the rank order of potency (ROP) of
the various VIP-like peptides examined was distinct from that of all other VIP
receptors previously described, with helodermin shown to have an even higher
affinity than VIP (5-7 times higher) in the radioligand binding studies. In parallel
cAMP studies, the same ROP was produced, with helodermin being ~ 3 fold more
potent than VIP (Robberecht et al., 1988). Around the same time, Turner and
colleagues (1986) reported that rat basophilic leukaemia (RBL) cells produced a VIP
fragment, N-terminally truncated VIP(10-28), that was functionally distinct from
normal VIP (Turner et al., 1986). This peptide was shown to inhibit VIP binding and
VIP induced AC activity in HT-29 cells, having no effect alone on AC activity and
was therefore suggested to be a VIP receptor antagonist. More interestingly, this
peptide had no affinity for, or effect on, agonist stimulated responses from VIP
receptors in SUP-T1 cells (Robberecht et al., 1989), in contrast to its antagonist
effects in HT-29 cells. These data again suggested a degree of diversity in the VIP
receptor population.
18
The gradual accumulation of the pharmacological evidence which led to the
eventual identification of distinct VIP receptors contrasts with the rapid identification
of a selective PACAP receptor, following the isolation of PACAP-27 and PACAP-
38. Soon after the isolation of both peptides (Miyata et al., 1989, 1990), high
affinity, selective PACAP receptors were identified in the rat AR4-2J pancreatic
cancer acinar cell line (Buscail et al., 1990). Initially, PACAP was tested in this cell
line as the cells were known to express VIP receptors, and as a consequence of the
sequence similarities between the peptides, it was proposed that PACAP may interact
with the VIP receptors (Svoboda et al., 1988; Buscail et al., 1990). However,
PACAP-27 and PACAP-38 were shown to have an equally high affinity for PACAP
binding sites in these cells, with both VIP and helodermin being of much lower (~
1000 fold) affinity (Buscail et al., 1990). Similarly, these studies showed that the
PACAPs potently stimulated adenylate cyclase (EC50: 0.2 nM for both peptides) in
AR4-2J cells, with VIP and helodermin again being much less potent. In contrast to
PACAP-27 and PACAP-38, VIP and helodermin actually appeared to be partial
agonists in the adenylate cyclase assay (Buscail et al., 1990). In the same year,
similar high affinity PACAP-preferring binding sites were also identified in primary
cultures of rat cortical astrocytes (Tatsuno et al., 1990), bovine brain membranes
(Ohtaki et al., 1990), rat hypothalamus, brain stem, cerebellum and lung (Lam et al.,
1990) and in the NB-OK-1 human neuroblastoma cell line (Cauvin et al., 1990a).
Around this time, data from many studies using a combination of VIP,
PACAP-27, PACAP-38 and helodermin amongst others (e.g. secretin and PHI)
began to draw out differences in pharmacology that could clearly distinguish distinct
receptor subtypes. For example, PACAP and helodermin were found to bind with
equal affinity to the VIP-helodermin preferring receptors in SUP-T1 cells (Gourlet et
al., 1991). Autoradiography studies clearly identified two PACAP binding sites, one
of which was PACAP preferring, whereas VIP and PACAP had equal affinity at
other sites (Shivers et al., 1991). PACAP and VIP also bound equally well to
receptors in jejunal epithelial plasma membranes, with helodermin being less potent
(Salomon et al., 1993). The emerging pattern suggested there were two classes of
VIP receptors, both of which PACAP bound to with high affinity, however the two
subtypes could be distinguished by examining the potency of other ligands, such as
helodermin. In addition, a third receptor class was more easily recognisable by its
clear preference for PACAP compared to VIP. These three receptor subtypes were
later classified by IUPHAR into 'VPAC receptors' for VIP and PACAP, and 'PACi
receptors' which were the PACAP-preferring subtype (Harmar et al., 1998). The
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VPAC receptors were further distinguished into VPACiR and VPAC2R subtypes,
based upon helodermin binding/potency (VPAC2R being helodermin preferring).
A.2.5. Cloning of VPAC/PAC receptors
The VPACiR was initially cloned from a rat lung cDNA library by Ishihara
and colleagues (1991) and soon after, the human homologue was cloned from the
HT-29 colon carcinoma cell line (Sreedharan et al., 1993). The mouse sequence was
then cloned three years later from mouse lymphoid cells (Johnson et al., 1996).
When examined in stably transfected cell lines, the general agonist ROP at this
receptor (in cAMP studies) was VIP = PACAP-27 = PACAP-38 = PHM > secretin,
with the EC50 values for the former four agonists being approximately 0.01 - 0.1 nM
(Ishihara et al., 1992; Sreedharan et al., 1993). A small number of studies have
examined endogenous VPACiR function in the HT-29 cell line and have similarly
shown the VIP and PACAP peptides to be equipotent and of low nanomolar potency
at this receptor in stimulating cAMP production, with secretin being considerably
less potent (Laburthe et al., 1978; Mangeat et al., 1981; Lelievre et al., 1998;
Summers et al., 2003). Additional human cell lines in which endogenous VPACiR
function has been studied include the L0V0 (colon adenocarcinoma: Yu et al., 1992;
Gourlet et al., 1997b) and HeLa (cervical carcinoma: Laburthe et al., 1980; Prieto et
al., 1981) cell lines.
The VPAC2R was first cloned by Lutz and co-workers from a rat pituitary
cDNA library (Lutz et al., 1993). This was quickly followed by a report on the
cloning of the human receptor from SUP-T1 cells (Svoboda et al., 1994) and then the
mouse transcript from the MIN-6 insulin secreting P-cell line (Inagaki et al., 1994).
When these groups expressed the transcripts in COS-7 and CHO cells, the general
ROP from cAMP studies was VIP = PACAP-27 = PACAP-38 = helodermin >
PHI/PHM, with very little response to secretin observed even at micromolar peptide
concentrations. The majority of cell based studies examining endogenously
expressed I1VPAC2R receptors have focussed on the SUP-T1 cell line, however some
have also used human Molt-4b lymphoblastic leukaemia cells (Summers et al., 2003)
and THP-1 monocytic leukaemia cells (Chedeville et al., 1993). Prom the SUP-T1
studies, the generally observed ROP was helodermin > VIP = PACAP = PHI »
secretin, although a degree of variability is evident between studies (Robberecht et
al., 1988, 1989; Xia et al., 1996; Gourlet et al., 1997b; Igarashi et al., 2002b).
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Average EC50 values reported in these studies from the examination of cAMP
stimulations, were ~ 0.3 nM for helodermin and ~ 10 nM for VIP and the PACAPs.
Finally, the rat PACiR was simultaneously cloned by several groups within
just a few weeks of each other (Hashimoto et al., 1993; Hosoya et al., 1993; Morrow
et al., 1993; Pisegna & Wank, 1993; Spengler et al., 1993; Svoboda et al., 1993),
either from rat brain cDNA libraries or the rat AR4-2J cell line. The human
transcript was cloned in the same year, whereas the mouse variant was cloned three
years later (Ogi et al., 1993; Hashimoto et al., 1996b). Several of these groups also
expressed the transcripts in various host cell lines for functional assessment of
receptor activity, with the clear ROP from all such studies being PACAP-27 =
PACAP-38 > VIP. In terms of endogenous cell lines, PACiR pharmacology has
been examined using AR4-2J cells and the human neuroblastoma cell line NB-OK-1,
with many studies also performed using the rat phaeochromocytoma PC 12 cell line
(Buscail et al., 1990; Cauvin et al., 1990a; Deutsch & Sun, 1992). In general, the
data from human cell lines expressing PACiR (in cAMP assays) has shown the
PACAPs and VIP to have EC50 values of ~ 0.2 nM and ~ 40 nM respectively
(Cauvin et al., 1990a; Buscail et al., 1990).
From the sequences of the cloned receptors, hydropathy plots of the
individual amino acid residues were suggestive of a heptahelical transmembrane
receptor structure (Lutz et al., 1993; Morrow et al., 1993). As mentioned previously,
these receptors have since been classified by IUPHAR as GPCRs and are regarded to
be members of the group B1 GPCR family, due to the presence of characteristic
structural features as described earlier (Harmar et al., 1998).
A.2.6. VPAC/PAC receptor pharmacology
A.2.6.1. Generic ligands
Prior to cloning of the individual VPAC/PAC receptors, multiple non¬
specific VIP receptor ligands were reported, in addition to the endogenous ones
already described (VIP, PACAP, PHM etc.). Several of these ligands are VIP
receptor antagonists which have proven to be useful in defining receptor function,
although the majority of these ligands are modified analogues of existing agonists.
These analogues, discussed further below, fall into three main categories: C-terminal
fragments of VIP/PACAP, chimeric or hybrid peptides and finally, D enantiomer
substituted peptides. Some of the better characterised receptor antagonists of
VIP/PACAP action are (N-Ac-Tyr1, D-Phe2)-GRF(l-29)-NH2 (Waelbroeck et al.,
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1985), [4C1-D-Phe6, Leul7]VIP (Pandol et al, 1986), VIP(10-28) (Turner et al.,
1986), PACAP(6-27) (Robberecht et al, 1991) and PACAP(6-38) (Robberecht et al.,
1992). Most of these antagonists had relatively low affinity (pM) for VIP receptors
and over the next few years, as the individual VPAC/PAC receptors were cloned and
peptide design studies improved, these generic peptides were superseded by novel
ligands of higher potency and selectivity. Some of these ligands have proven to be
useful tools in defining the physiological functions of the VPAC/PAC receptors, with
the use of BAY 55-9837 for example, highlighting important roles for the VPAC2R
in glucose homeostasis (Tsutsumi et al., 2002). However, to date all of the ligands
reported are peptides and are mostly modified versions of VIP and the PACAPs
(sequences provided in Table A.2), with no non-peptide agonists or antagonists
described. A summary of the most potent and selective of these ligands will be
discussed briefly below, with further discussion of selected ligands in chapter one.
A.2.6.2. VPACiR selective peptides
A highly potent and selective agonist and antagonist have been described for
the VPACiR. In 1997, Gourlet and colleagues described a modified hybrid peptide
of VIP and GRF which was reported to be a VPACiR antagonist (Gourlet et al.,
1997a). This peptide, PG97-269, inhibited agonist induced cAMP responses in rat
and human VPACiR expressing cell lines with IC50 values of 15 nM and 2 nM
respectively (Gourlet et al., 1997a; Juarranz et al., 1999). When tested up to 0.3 pM,
PG97-269 had no effect alone, or on any agonist induced response in VPAC2 (human
and rat) or PACi (rat) receptor expressing cell lines (Gourlet et al., 1997a).
Three years later in 2000, the generation of a VPACiR selective agonist
1 1 97 oo
[Ala ' ' ]VIP was reported (Nicole et al., 2000), from structure-function studies of
VIP binding to VPAC receptors. In AC stimulation studies, this modified VIP
analogue was observed to have low nanomolar potency at hVPACiR (EC50: 0.4 nM)
and was more than 3000 fold selective for VPACiR over VPAC2R. To date, no
studies have examined the effect of this agonist at PAQR.
A.2.6.3. VPAC2R selective peptides
The first of the more selective and potent VPAC2R agonists were developed
by Roche in the mid 1990s, as potential bronchodilators (Bolin et al., 1995). Two
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cyclic peptide analogues of VIP, Ro25-1553 and Ro25-1392 were described, both of
which stimulated cAMP production in CHO cells expressing the VPAC2R, with EC50
values of~ 1 nM (O'Donnell et ah, 1994; Xia et ah, 1997). These peptides were 300
- 1000 fold selective for the VPAC2R, however both compounds also showed clear
agonist activity at VPACiR, when applied at micromolar concentrations (Gourlet et
ah, 1997b; Xia et ah, 1997). A number of VPAC2R agonists have been developed
by Bayer in an attempt to determine whether they could be potential therapeutic
agents for type II diabetes, with the most potent ligands being BAY 55-9837 and
R3P65 (Tsutsumi et ah, 2002; Yung et ah, 2003). Both peptides were produced
following site directed mutagenesis studies ofVIP, PACAP and Ro25-1553 and were
found to be potent VPAC2R agonists (cAMP stimulation, EC50: ~ 0.3 nM). BAY 55-
9837 was shown to be 100 fold selective for VPAC2R over VPACiR (EC50: 30 nM;
Tsutsumi et ah, 2002). R3P65, which differs from VIP by only 4 amino acids, was
slightly more selective (~ 200 fold) for VPAC2R than BAY 55-9837, however at
higher concentrations R3P65 stimulated both VPACi (EC50: 90 nM) and PACi
receptors (partial agonist at micromolar concentrations; Yung et ah, 2003).
In attempts to develop VPAC2R selective antagonists, Moreno and co¬
workers (2000) investigated how modifications of VPAC2R agonists, such as Ro25-
1553, affected peptide potency and binding to the receptor. Following acylation of
the amino-terminus of the extended VIP(1-26)KKGGT peptide by myristic acid
(CI4 fatty acid), the resulting peptide, named PG99-465 was reported as the first
selective VPAC2R antagonist (Moreno et ah, 2000). In AC stimulation studies, these
authors showed that the peptide was a potent VPAC2R antagonist (IC50: 2 nM),
however partial agonism at VPACiR was also observed (EC50: 200 nM), giving this
peptide a 100 fold selectivity (Moreno et ah, 2000). Again, to date, the effect of
PG99-465 at the PAQR has not been reported.
A.2.6.4. PACiR selective peptides
In contrast to that described above for the VPAC receptors, the peptides
which have been reported to be PACiR selective ligands have no significant
sequence homology to VIP, PACAP or any other member of this peptide family.
Maxadilan, the first truly selective PAQR agonist, was extracted from the salivary
gland of sand flies (Lutzomyia longipalpis) and was found to be a potent vasodilator
(Lerner et ah, 1991). Upon cloning, maxadilan was shown to be a 63 amino acid
peptide (Figure A.9), which is processed by C-terminal amidation to give a mature
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61 amino acid peptide. This peptide was found to have similar biological effects to
calcitonin gene-related peptide (CGRP) and was therefore evaluated for binding site
interactions on rat and rabbit brain membranes, with other members of the peptide
family, including VIP, PACAP, glucagon and secretin (Moro & Lerner, 1997). In
addition, these authors also examined functional responses induced by maxadilan in
COS cell lines transfected with the three individual VPAC/PAC receptor subtypes.
Maxadilan was shown to specifically bind to the PACiR and was equipotent with
PACAP-38 in stimulating cAMP production (EC50: 1 nM). No interactions in the
binding or functional studies were observed with maxadilan at either of the VPAC
receptor subtypes (Moro & Lerner, 1997).
From structure function studies using maxadilan, two deletion variants have
been identified as PACiR selective antagonists (Figure A.9). The first, M65, was
described by Tajima and colleagues following the deletion of amino acids 25 - 41 of
the maxadilan sequence (Uchida et al., 1998). These authors reported that M65
inhibited PACAP responses mediated by the PACiR in a concentration dependent
manner, however no IC50 values or graphical data was presented for the functional
Figure A.9 The amino acid sequence of the PACiR agonist maxadilan. The
full length maxadilan sequence is shown, prior to C-terminal
amidation to a 61 residue peptide. Deletion of the residues
highlighted in grey (25 - 41) produces M65, a PACjR antagonist.
The additional removal of two leucine resides (*) results in a peptide
named max.d.4, which is also reported to be a PACiR antagonist.
The figure shown has been modifed from Tatsuno et al. (2001).
Maxadilan
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studies discussed (cAMP) in that report. In a more recent set of studies examining
the effect of agonists on pigment dispersion in Xenopus melanophores expressing the
PACi receptors, M65 was shown to inhibit PAQR agonist responses with an IC50 of
4 nM (Reddy et al., 2006). Tajima's group also reported a second deletion variant of
maxadilan, max.d.4., with residues 24 - 42 omitted from the parent peptide, which
inhibited PACAP-38 simulated cAMP production in PAQR expressing stable cell
lines with an IC50 of~ 0.3 nM (Moro et al., 1999).
In summary, despite intensive investigation in the last 20 years only a
limited number of selective VPAC/PACR ligands have been reported in the
literature, including PG97-269, maxadilan and M65. However the majority of
compounds identified as agonists or antagonists at these receptors show some
interaction with more than one subtype (at least at higher concentrations) and
additionally, some of these ligands have not been fully characterised with all three
receptor subtypes. To date, all of the VPAC/PACR agonists and antagonists are
peptides, the majority of which are derived from the structures of the endogenous
peptides VIP and PACAP.
A.2.7. VPAC/PAC receptor signalling
In addition to the classical stimulation of Gas proteins which activate AC
and increase cAMP levels, the VPAC/PAC receptors have been observed to
stimulate the production of additional second messengers. This coupling to multiple
G-proteins has . also been observed for other members of the group B1 GPCR family,
e.g. calcitonin receptors (Aiyar et al., 1999). Prior to VPAC/PAC receptor cloning,
many groups reported elevated levels of calcium in a variety of cells types upon
exposure to VIP and PACAP. These include rat superior cervical ganglion cells
(Audigier et al., 1986), adrenal medulla cells (Malhotra et al., 1988), PC 12 cells
(Deutsch & Sun, 1992), hippocampal neurons (Tatsuno et al., 1992), pituitary cells
(Canny et al., 1992) and the SK-N-SH human neuroblastoma cell line (Oettling et
al., 1990). The specific interaction of VPAC/PAC receptors with G-proteins that
couple to pathways stimulating intracellular calcium was reported soon after the
cloning of each receptor subtype (VPACiR: Sreedharan et al., 1994; VPAC2R: Xia et
al., 1996; PACiR: Spengler et al., 1993). The receptors also couple to additional
signalling pathways, including those modulating phospholipase D (Morisset et al.,
1995; McCulloch et al., 2000), tyrosine kinases (Morisset et al., 1995) and L-type
calcium channels (Chatterjee et al., 1996). The signalling pathways mediated by the
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receptors, particularly those modulating cAMP and calcium, will be discussed more
extensively in chapter one.
A.2.8. Receptor splice variants
Although many of the mammalian genes encoding GPCRs are intronless,
the VPAC/PAC receptors are one exception, along with other group B receptors
including the calcitonin and GHRH receptors (Gentles & Karlin, 1999). The
presence of introns introduces the possibility that the genes may be processed
differently (alternative splicing, exon skipping and intron retention), thereby
generating receptor splice variants, which may lead to alterations in the
pharmacology and signal transduction of those receptors (Kilpatrick et al., 1999).
Until recently VPAC receptors splice variants were not thought to occur, which
contrasts with the multiple PACiR variants which have been identified, all of which
shall be discussed below.
A.2.8.1. VPACR splice variants
A recent report using human peripheral blood mononuclear cells and SUP-
T1 cells, described putative 5-TM variants of both the VPACiR (88 amino acid
deletion) and VPAC2R (74 amino acid deletion; Bokaei et al., 2006). Both of these
variants were postulated to lack sections of the third intracellular loop, the third
extracellular loop and the TM domains 6 - 7, as illustrated in Figure A. 10 (Bokaei et
Figure A.10 Schematic illustration comparing the structures of the wild type
VPAC receptors and the postulated 5-TM splice variants.
Sections of the wild-type receptors (a: VPACi; b: VPAC2) which are
thought to be deleted in the splice variants are indicated by lighter
shading, with arrows showing the suggested connection point of
TM-5 to the C-terminus. Figure taken from Bokai et al. (2006).
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al., 2006). These authors examined the functionality of the truncated VPACiR
variant only and found that when expressed in CHO cells, this receptor demonstrated
poor coupling to cAMP pathways in response to agonist stimulation, however
stimulation of protein tyrosine kinase activity was observed. As this is first report of
a functional VPACiR variant, and the first report of 5-TM VPAC/PAC variants,
clearly further studies will be required to determine the distribution and physiological
roles of such receptors. In addition, two naturally occurring deletion variants of the
VPAC2R have been identified in recent years by the Goetzl laboratory. The first,
VPAC2de367-380, was identified from mouse thymus and spleen and has a 42 base
pair deletion in exon 12, resulting in a 14 amino acid omission (367 - 380) at the C-
terminal of the seventh TM domain (Grinninger et al., 2004). It has been postulated
that this variant may be a 6-TM receptor with an extracellular C-terminal, however
as to how this variant arises is unknown, with its distribution and physiological
function remaining unclear (Huang et al., 2006). When transfected into Jurkat T
cells, VIP bound to the mutant receptor with the same affinity as the standard VPAC2
receptor, however modulation of intracellular signalling molecules, including cAMP
and IL-2, was not observed, in contrast to the wild type receptor (Grinninger et al.,
2004). In addition, T-cells transfected with the mutant receptor have been shown to
secrete less IL-4 upon VIP stimulation than cells transfected with the standard
VPAC2R receptor (Huang et al., 2006). The second VPAC2R variant was identified
from both a human malignant T-cell line and activated normal T-cells, and was
produced as a consequence of the deletion of exon 11, resulting in the loss of 114
amino acids from 325 - 438, with 10 new amino acids in positions 325 - 334 (Miller
et al., 2006). This created a frame shift and introduced a premature stop codon, with
the resulting VPAC2 variant (VPAC2de325-438(i325-334)), suggested to be a 5-TM
receptor. In preliminary studies these authors found that VIP had a lower affinity for
the mutant variant compared to the wild type VPAC2R and that the mutant receptor
was less sensitive to agonist-induced down regulation and showed a weaker coupling
to intracellular signalling pathways (Miller et al., 2006).
In 2001, Murthy and co-workers reported the presence of a VIP receptor in
guinea-pig smooth muscle cells that was VIP specific and for which PACAP had
very low affinity (Teng et al., 2001). The same authors have just reported the
cloning of this 'VIPs' receptor from the same cell type, and through binding and
functional studies have confirmed that PACAP has a much lower affinity
(radioligand binding) and efficacy (cAMP studies) than VIP for this receptor when
expressed in COS-1 cells (Zhou et al., 2006). The sequence of 'VIPs' was shown to
differ from the VPAC2R by only two residues, located in the N-terminal ligand
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binding domain (Zhou et al., 2006). The existence of a putative VIP selective
receptor has been previously suggested by other groups. For example Gressens and
colleagues suggested that a VIP selective receptor was responsible for mediating the
neuroprotective effects of VIP against ibotenate induced excitotoxic brain lesions in
newborn mice (Gressens et al., 1999; Rangon et al., 2006). In this model, VIP was a
potent neuroprotectant, as were other VPAC2R agonists and PHI, however VPACiR
agonists and the PACAP peptides were without effect (Rangon et al., 2006). The
presence of a 'VIPs' receptor was also described by Ekblad and colleagues when
investigating the properties of VPAC/PAC receptors in the mouse intestine (Ekblad
& Sundler, 1997; Ekblad et al., 2000). The recent cloning of the 'VIPs' receptor
may facilitate more extensive studies into the distribution and function of such a
receptor and may confirm whether it is the same VIP selective receptor described by
other groups.
A.2.8.2. PACiR splice variants
The PACiR has been described as 'one of the most extensively spliced
GPCRs known', with variants carrying changes in the intracellular loops,
transmembrane domains, and N-terminal regions (Dautzenberg et al., 1999).
Although the presence of potential splice sites in such a range of regions is not
common, a similar pattern has been reported for the calcitonin and GHRH receptors
(Kilpatrick et al., 1999). In contrast to the VPAC receptors, the first PACiR variants
were identified at the time of the initial receptor cloning by Spengler and co-workers
(1993). These authors reported the cloning of five distinct PACi receptor variants
from a newborn rat colliculi cDNA library, which were named null, hip, hopl, hop2
and hiphopl, according to the presence of two 28 amino acid cassettes (hip and hop)
in the third intracellular loop (Figure A. 11). The PACi-hopl (28 residue insertion)
and hop2 (27 residue insertion) variants were suggested to originate from the
alternative use of splice acceptor sites in the hop cassette. The null and hopl variants
were shown to be the predominant PACjR variants found in several rat brain regions
(Spengler et al., 1993). Using the same techniques, these authors subsequently
reported the cloning of the sixth and final combination of these cassettes, the PACi-
hiphop2 receptor (Journot et al., 1995). When expressed in a porcine kidney cell line
(LLC PK1), the presence of the hip cassette was generally shown to reduce agonist
induced AC stimulation and abolish calcium responses, whereas the hop cassette
appeared to have no influence on the ability of the receptor to increase cAMP or
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calcium following agonist stimulation (Spengler et al., 1993; Joumot et al., 1995).
The receptors which contained both cassettes were shown to have an intermediate
phenotype, with agonists stimulating cAMP and calcium pathways through the
PACi-hiphopl receptor with marginally reduced potency and producing a smaller
peak calcium response (compared to PACi-null; Journot et al., 1995).
One year later, the same group identified an N-terminal PACiR variant from
a mouse genomic library, with the corresponding human sequence isolated from a
fetal brain cDNA library (Pantaloni et al., 1996). They suggested this variant was
produced from alternative splicing of exons, resulting in a 21 amino acid deletion in
the N-terminal region (Figure A.l 1; residues 89 - 109). At the time, this variant was
called the 'very short' (vs) PACiR and the only apparent functional consequence was
a marginal increase in the potency with which PACAP-27 activated phospholipase C
(PLC; VIP was not tested). In a subsequent study, VIP and PACAP induced
stimulations of cAMP were compared in HEK-293 cells expressing this variant, and
in contrast to the PACAP preferring null receptors, these peptides were shown to be
equipotent (Dautzenberg et al., 1999). In later studies, a PACiR mutant equivalent to
the 21 amino acid deletion variant described above combined with the hopl cassette,
was shown to be the predominantly expressed PACjR variant in rat superior cervical
ganglion (SCG) neurons (Braas & May, 1999). In accompanying pharmacological
studies (cAMP and inositol phosphate assays) using the cultured SCG neurons, the
PACAPs had similar potencies in both assays and were over 1000 fold more potent
than VIP. In both of these assays, the maximum PACAP-27 induced responses were
slightly larger than those of PACAP-38.
Following on from the cloning of the rat hip and hop splice variants, Pisegna
and Wank identified four human homologues from a frontal cortex cDNA library
(Pisegna & Wank, 1996). As for the rat receptors, the human variants were
distinguished by the presence of two exons, SV-1 and SV-2 (corresponding to two 28
amino acid insertions), which were suggested to be equivalent to the hip and hop
cassettes respectively. In addition to the human PACi-null, the SV-1, SV-2 (two
variants potentially from alternative splice acceptor sites) and SV-3 variants were
found and when stably expressed in a mouse embryonic fibroblast cell line
(NIH/3T3), all four were shown to couple to pathways increasing cAMP and calcium
following agonist activation (Pisegna & Wank, 1996). In these studies, the PACAP
peptides were equipotent at all four variants, with an approximate 50 fold reduction
in potency observed in the calcium assay. Maximal cAMP responses were similar
for all four variants, however maximum calcium responses varied (Pisegna & Wank,
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fold higher than the null or SV-1 responses, with the SV-3 variant showing
intermediate level of calcium stimulation (measured from total inositol phosphate
accumulation/receptor). The null variant was found to be the predominant form
expressed in a human frontal cortex cDNA library, with the rank order of expression
being: null > SV-2 > SV-1 > SV-3 (Pisegna & Wank, 1996). Similar to the larger
calcium responses observed for the SV-2 receptor, further studies demonstrated that
this variant also produced a greater stimulation of immediate early gene expression
(c-fos and c-myc) compared to the other splice variants (Pisegna et al., 1996).
The final PACiR variant reported that year was cloned from rat cerebellar
cDNA and was shown to differ from the null at several residues, primarily in the
fourth TM domain and was consequently called PACAP-TM4 (Chatterjee et al.,
1996). The substitution and deletion of two amino acids in the fourth TM region
(CVTV to SA—; residues 279 - 283), was in addition to the D136N (N-terminal) and
N190D substitutions (second TM domain). When expressed in BHK-21 cells (a
hamster kidney cell line) this receptor did not mediate any effect on cAMP or
inositol phosphate levels following PACAP stimulation, although interestingly a
clear calcium influx through L-type calcium channels was observed (Chatterjee et
al., 1996).
Three years later, Dautzenberg and colleagues (1999) identified a PACiR
variant in which 57 amino acids were deleted from the N-terminus. The deleted
sequence was comprised of the 21 amino acids from the 'very short' variant
described by Pantaloni (1996), in addition to the preceding 36 residues (i.e. a
deletion of residues 53 - 109; Figure A.ll). This variant was subsequently isolated
from human cerebellar tissue and Y-79 retinoblastoma cells and was described as the
'vs' variant, with these authors referring to the receptor described by Pantaloni et al.
(1996) as the short or's' variant (Dautzenberg et al., 1999). From RT-PCR analysis,
appropriate mRNA bands for the null, short and very short variants were identified in
human cerebellar and cortical tissues, and in Y-79 retinoblastoma cells (Dautzenberg
et al., 1999). The PACAP peptides were shown to be less potent at the 'vs' receptor
(~ 40 fold; cAMP assay) compared to the null or short variants, although the 'vs'
variant remained a PACAP selective receptor with only a small VIP induced
response detected at micromolar concentrations. In fact, the maximum VIP induced
cAMP responses from both the null and 'vs' expressing cells, were reported to be
two thirds smaller than those from the short variant (in which the VIP and PACAP-
38 responses were equivalent; Dautzenberg et al., 1999).
In 2001, Daniel and colleagues described a splice variant identified from rat
testis, which had an additional 24 amino acids between exons 3 and 4 (EC ligand
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binding domain), and was consequently called PACjR(3a). The exact location of the
insert in the PAC]R sequence has not been described, but it lies in the N-terminal
region, near the deletion site for the 'vs' and 's' variants. In functional studies
(cAMP and IP3) using transfected HEK-293 cells, both PACAPs were slightly less
potent at the (3a) variant compared to the null receptor. More recently the (3a)
variant has also identified in newborn rat cortical astrocytes (Pilzer & Gozes, 2006a).
The range of PACiR variants was recently extended by Lutz and co¬
workers, who identified fourteen different human PACiR splice variants from the
SHSY-5Y neuroblastoma cell line (Lutz et al., 2006). The most abundant variants
detected were the 'short' (Pantaloni et al., 1996; referred to as 85, 6 + null), the
short-hopl (Braas & May, 1999; 85, 6 + hop) and the 'very short' variants
(Dautzenberg et al., 1999; 84, 5, 6 + null). These authors also compared the ability
of the variants to couple to cAMP and calcium signalling pathways when expressed
in COS7 cells. In cAMP and inositol phosphate studies, PACAP-38 was shown to be
~ 30 fold more potent than VIP in activating the 85, 6 + null variant, which is in
contrast to the previous data (cAMP) showing these peptides to be equipotent
(Dautzenberg et al., 1999). Although the agonist ROP for this variant was similar in
both assays, there was a shift to lower agonist potency (~ 140 fold) in the calcium
studies. For the 85, 6 + hop variant, VIP was less potent than PACAP-38 in both
assays as reported by Braas & May (1999), although the reduction in potency was
only about 50 fold, in contrast to the 1000 fold shift described previously. In
addition, there was a small shift to lower agonist potency in the calcium assay (~ 25
fold on average) which was not reported in the original studies. Finally, in cAMP
studies the 84, 5, 6 + null variant was confirmed to be a PACAP preferring receptor,
and as reported previously, agonists were less potent at this variant when compared
to the PACi-null receptor (Dautzenberg et al., 1999). The implications of these
studies shall be discussed further in chapter one.
A.2.9. VPAC/PAC receptor distribution
The distribution of VPAC/PAC receptors has now been thoroughly
investigated in several species, using a range of techniques (e.g. autoradiography, in-
situ hybridisation studies) and in varying degrees of detail. The following discussion
is a brief summary of VPAC/PAC receptor distribution, with more extensive
descriptions of the distribution available elsewhere (Usdin et al., 1994; Sheward et
al., 1995; Vertongen et al., 1998; Vaudry et al., 2000; Harmar et al., 2004).
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A.2.9.1. VPACiR distribution
Following the cloning of the VPACiR, initial studies indicated expression of
this receptor in brain, heart, lung, kidney, small intestine, hippocampus and cerebral
cortex (Ishihara et al., 1991; Sreedharan et al., 1993). More detailed studies in the
CNS have described expression of the VPACiR in the pyrifom cortex, cerebral
cortex, dentate gyrus, lateral amygdaloid nucleus, caudate putamen, supraoptic
nucleus, choroid plexus, dentate gyrus and the pineal gland (Usdin et al., 1994;
Vertongen et al., 1998; Vaudry et al., 2000). In peripheral tissues, the VPACiR has
been shown to be expressed in the mucosa of the gastro-intestinal tract, liver, spleen
and also on lymphocytes in lymph nodes (Reubi, 2000). VPACi receptors have been
shown to be expressed in almost all human epithelial tissues (Reubi, 2000).
A.2.9.2. VPAC2R distribution
Upon cloning, initial studies demonstrated that the VPAC2R was expressed
in the hippocampus, thalamus, SCN, olfactory bulb, lung and colon (Lutz et al.,
1993; Inagaki et al., 1994). Further studies of VPAC2R distribution in the CNS
revealed a high expression in the cerebral cortex, periventricular nucleus, SCN,
thalamus, hypothalamus and amygdala (Sheward et al., 1995; Vertongen et al., 1998;
Vaudry et al., 2000). Although both VPACR subtypes are reported to be co-
expressed in many areas of the CNS, several reports suggest that in the majority of
cases where this occurs, the two subtypes have a complementary distribution, being
found in different areas or layers of cells, e.g. in the olfactory bulb and cerebral
cortex (Usdin et al., 1994; Vaudry et al., 2000). In 2004, Harmar and co-workers
performed an extensive study of VPAC2R distribution in peripheral tissues of the
mouse, reporting a predominant expression in the smooth muscle layers of organs
and blood vessels. In addition, the receptor was also expressed in colonic mucosal
epithelia, pancreatic acinar cells, thyroid follicular cells, adrenal medulla, the retina,
in lung alveoli and in blood vessels from many tissues (Harmar et al., 2004).
A.2.9.3. PACiR distribution
In 1993 when the PACiR was first cloned, abundant receptor expression
was observed in the brain (Ogi et al., 1993; Hashimoto et al., 1993), with a lower
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expression detected in lung and liver (Hosoya et al., 1993). Several detailed studies
of PACiR distribution have since been reported, most of which have investigated the
expression of generic PACiR, with limited studies investigating the distribution of
specific splice variants. In the CNS, PACjR expression has been reported in the
olfactory bulb, dentate gyrus, cerebral cortex, hippocampus, cerebellar cortex,
hypothalamic nuclei, cingulate and entorhinal cortices, amygdaloid nucleus, thalamic
nuclei, hypothalamus, raphe nuclei, SCN and the area postrema (Hashimoto et al.,
1996a; Vaudry et al., 2000; Joo et al., 2004; Kalamatianos et ah, 2004). In
peripheral tissues expression of this receptor has been reported in the pituitary,
adrenal medulla, uterus, lymphoid tissue of the gut, testes and epididymis (Shivers et
al., 1991; Reubi et al., 2000; Vaudry et al., 2000).
From the few studies in which localisation of specific PACiR variants has
been investigated, the PACi-null and hop variants were shown be the predominant
variants detected in brain tissue, with a specific and high expression of PAC i-hop in
the testes, olfactory bulb and adrenal glands (Spengler et al., 1993; Zhou et al.,
2000). These studies showed the PACi-hip variant was also expressed in the
olfactory bulb and hippocampus, but at lower levels than the null or hop variants.
The PACi-TM4 mRNA transcript was detected in the cerebral cortex, cerebellum,
brainstem, vas deferens, lung and pancreatic P cells (Chatterjee et al., 1996).
Expression of the 21 amino acid 'short' deletion variant, reported by Pantaloni and
colleagues (1996), was shown to be restricted to the pituitary, adrenal gland,
hypothalamus and thalamus. The combined short and hopl variant described by
Braas & May (1999), is the predominant variant expressed in SCG neurons, however
the expression of this receptor in other tissues has not been examined. Finally, the
PACi(3a) variant was originally identified in the testes by Daniel et al. (2001), but
has very recently been detected in cultured newborn rat cortical astrocytes (Pilzer &
Gozes, 2006).
A.2.9.4. VPAC/PACR distribution in cells of the CNS
Soon after the PACAP peptides were identified and before any of the
VPAC/PAC receptors were cloned, PACAP binding sites were identified on rat
astrocytes (Tatsuno et al., 1990). Since then, several studies (RT-PCR, ISH) have
described the expression of VPACiR, VPAC2R and PACiR (null, hop-1, hop-2, and
(3a) splice variants) in cultured rat astrocytes (Ashur-Fabian et al., 1997; Grimaldi &
Cavallaro, 1999; Jaworski, 2000; Pilzer & Gozes, 2006b). Cultured rat neurons have
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also been investigated for VPAC/PAC receptor expression and have been shown to
express VPAC2 and PACi-hopl receptors (Grimaldi & Cavallaro, 1999). In
addition, microglia are reported to express VPACiR and PACiR, although the
presence of specific PAQR splice variants has not yet been investigated (Kim et al.,
2000; Delgado et al., 2002). Finally, Joo and colleagues (2004) have described the
expression of PACjR in oligodendrocytes, although this is the only study to date
where expression in this cell type has been investigated.
A.2.9.5. VPAC/PACR distribution in cancerous cells
As described in previous sections, a high expression of VPAC/PAC
receptors has been identified in a number of cancerous cell lines (VPACiR: HT-29,
L0V0, HeLa cells; VPACiR: SUP-T1, Molt-4b, THP-1; PACiR: AR4-2J, NB-OK-1,
PC 12). In addition, epithelial neoplasms originating from many organs express
VIP/PACAP binding sites (Vaudry et al., 2000), with the VPACiR being the most
commonly expressed VPAC/PACR in several cancers, including those found in the
lung, GI tract, breast, pancreas and liver (Reubi, 2000; Busto et al., 2003; Moody &
Jensen, 2006). In contrast, VPAC2R expression only predominates in a few tumours,
for example in leiomyomas (benign smooth muscle tumours; Reubi, 2000). The
PACiR has been shown to be predominantly expressed in several neuronal and
endocrine tumours including glial tumours, neuroblastoma, pituitary adenomas,
phaeochromocytomas and prostate tumours (Vertongen et al., 1996; Reubi, 2000;
Lieu et al., 2006; Mammi et al., 2006; Muller et al., 2006). Several studies have
investigated VPAC/PACR expression in neuroblastoma biopsy samples, where a
high expression of PACiR variants are generally found (Vertongen et al., 1996;
Jaworski, 2000; Lutz et al., 2006), however there appears to be a degree of
variability in such samples. A recent study from Isobe and colleagues (2004),
described a high level of VPACiR expression in all of the neuroblastoma biopsy
specimens tested, with lower frequency of expression of VPAC2R (~ 30 %) and
PACiR (~ 40 %). In immortalised cell lines derived from neuroblastomas, e.g. the
SHSY-5Y cell line, the PACiR is predominantly expressed (Vertongen et al., 1996;
Lutz et al., 2006). In the recent study by Lutz and co-workers (2006) which
identified several new PACiR splice variants from the SHSY-5Y cell line, these
authors reported that the PACiR 85, 6-null variant (21 residue deletion variant
originally identified by Pantaloni) was the predominant isoform expressed.
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A.2.9.6. VPAC/PACR distribution in cells of the immune system
As discussed earlier, prior to receptor cloning, generic VIP receptors were
identified on several types of immune cells, including lymphocytes and lymphoblasts
(A.2.4., p 17). The identity of the specific receptors present on such cell types has
since been clarified, with extensive studies performed by Delgado and colleagues
(reviewed by Gomariz et al., 2001), and shall be described here in brief. Specific
and constitutive expression of VPAQR has been described on thymocytes (CD4+,
CD8+), peripheral lymphocytes and macrophages (Delgado et al., 1996b, 1996c). In
studies by the same authors, the VPAC2R was shown only to be expressed on
lymphocytes or macrophages following bacterial or viral exposure (Delgado et al.,
1996a; Lara-Marquez et al., 2000). In addition, some of the cell types described
have been used to identify splice variants of the VPAC2R, as discussed previously
(A.2.8.I., p 27). Finally, the expression of the PACiR in the immune system appears
to be very specific, with macrophages being the only cells shown to constitutively
express these receptors (Pozo et al., 1997).
A.3. Functions and roles ofVIP/PACAP and VPAC/PAC receptors
Given the widespread distribution of VIP, PACAP and their cognate
receptors, it is not surprising to find that the range of physiological effects produced
by these peptides is extensive. Early reports suggested that VIP and PACAP exerted
a multitude of effects on cardiovascular, circulatory and respiratory systems and on
metabolic function (Said & Mutt, 1970; McCulloch & Edvinsson, 1980; Miyata et
al., 1989, 1990), whereas a number ofmore recent studies have pointed to a plethora
of putative roles in the nervous (Dickinson & Fleetwood-Walker, 1999; Harmar et
al., 2002) and immune systems (Gomariz et al., 2001; Pozo & Delgado, 2004).
Investigations into the roles of these peptides and receptors have been driven by an
extensive range of research interests. However, a large proportion of the published
work in recent years has focused upon a limited number of areas, including the roles
of the peptides/receptors in circadian function, glucose homeostasis, neuroprotection
and in modulation of the immune system. The intensive interest in these particular
areas has proven fruitful, with many exciting roles proposed for VIP/PACAP and
their receptors. These roles, amongst others, shall be discussed here with regard to
studies using transgenic animals, and in addition the roles of the peptides and
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receptors in circadian function and in neuroprotection/inflammation shall be
examined more extensively in chapter three.
A.3.1. Transgenic mice
As for many peptides and receptors, clear insights into the physiological
roles of VIP/PACAP and their cognate receptors can be gained from the creation and
study of transgenic animals. This approach has proven particularly important for the
study of VPAC/PACR function in the absence of low molecular weight, selective,
non-peptide ligands. To date, transgenic mice have been developed with altered
gene expression for VIP, PACAP, VPAC2R and PACiR. The impact of the
transgenes for each type ofmutant strain will be discussed below.
A.3.1.1. VIP transgenics
Several different types of VIP transgenic mice have been reported, ranging
from mice over-expressing (OE) the peptides to mice with reduced VIP expression
and finally to complete knock-out (KO) animals (Gozes et al., 1993; Kato et al.,
1994; Colwell et al., 2003). These studies have focussed primarily on the impact on
glucose-insulin balance and on circadian cycles, of which the major findings shall be
briefly discussed below.
To study the role of VIP in the control of secretory functions of pancreatic
islet cells, mice over-expressing the human VIP gene specifically directed to
pancreatic (3 cells (by linking the VIP gene to an insulin promoter which is active in
these cells) were created (Kato et al., 1994). The over-expression of these peptides
was found to enhance glucose-induced insulin secretion, leading to a significant
reduction in blood glucose levels. In addition, VIP over-expression abolished
glucose intolerance in mice that had a reduced functional pancreatic islet cell mass
(70 % of pancreatic tissue had been removed). From these findings, the authors
suggested that VIP-like peptides may be of therapeutic value in enhancing insulin
secretion in diabetes (Kato et al., 1994).
The first of the VIP transgenic mouse lines with a reduced peptide
expression was reported by Gozes and colleagues (1993). These mice harboured
disrupted VIP genes, leading to reduced expression of the peptide. In a line ofmice
with a 20 % reduction in VIP expression in the brain, these animals were shown to
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have learning impairments, retardation in memory acquisition and additionally, male
mice showed reduced sexual activity (Gozes et al., 1993). The first line of VIP
knock-out mice was reported in 2003 by Colwell and colleagues, with these mice
produced through targeted homologous recombination in embryonic stem (ES) cells,
leading to the complete disruption of the VIP gene. The resulting mice appeared
healthy and fertile and were used in subsequent circadian function studies to address
the impact of VIP gene disruption on the sleep/wake cycle. The intrinsic circadian
rhythms of the KO mice (determined under constant darkness) were found to be
weaker and in some cases completely arrhythmic when compared to WT littermates
(Colwell et al., 2003). In addition, the knockout mice displayed altered entrainment
patterns to light cues, with these animals appearing to show no phase shift in
response to light pulses. These studies highlight the critical involvement of VIP in
the mammalian circadian system. Some recently published data using the VIP KO
mice described by Colwell (2003), reported that the transgenic mice were more prone
to display symptoms of bronchial asthma, to develop pulmonary hypertension and
were more susceptible to die from experimentally induced endotoxemia than WT
littermates (Hamidi et al., 2006).
A.3.1.2. PACAP transgenics
Studies using PACAP transgenic mice have focussed primarily on PACAP
knock-out mice, with several groups independently generating KO mice lines
through targeted disruption of the PACAP gene in ES cells. One of the first lines of
PACAP knock-out animals was described by Gray and colleagues (2001). These
authors reported that PACAP KO mice appeared normal at birth, however the
majority of pups died in the second postnatal week (Gray et al., 2001). In most of
these cases, the death of the pups was coincident with a difficulty in gaining weight
and eventual weight loss. In addition, a role for PACAP in lipid metabolism was
suggested given the finding that there was an accumulation of lipids in the heart,
skeletal muscle and liver of the KO mice (Gray et al., 2001).
In agreement with the findings of Gray et al. (2001), pups from a similar
KO line generated by Baba and colleagues were also reported to have a high
mortality rate, with ~ 50 % dying before weaning (Hashimoto et al., 2001).
Surviving adult mice demonstrated several hyperactive behaviours, including
increased locomotor activity, novelty related exploration and explosive jumping
behaviour, leading the authors to propose a role for PACAP in the regulation of
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psychomotor behaviours. In addition, homozygous matings of KO mice generally
resulted in fewer successful pregnancies. A specific role for PACAP in the female
reproductive cycle was further delineated when these authors proceeded to examine
the reduced mating success of their PACAP -/- mice. These studies showed that the
female mice were less fertile, mated less frequently and showed reduced crouching
behaviour (Shintani et al., 2002). The same group also examined circadian function
in their PACAP null mice (Kawaguchi et al., 2003). The mice were shown to have
an intact SCN, no developmental complications and in addition, had a similar free
running period to their WT littermates. These findings suggested that PACAP was
unlikely to be necessary for the generation of endogenous circadian rhythms.
However, further studies highlighted an important role for PACAP in the light
induced phase advance mechanism of the circadian clock (Kawaguchi et al., 2003).
This group has also investigated the role that PACAP plays in neuroprotection, by
examining the extent of damage in WT, heterozygous and homozygous PACAP mice
following permanent middle cerebral artery occlusion (pMCAO; Ohtaki et al., 2006).
The infarct volume and neurological damage observed following pMCAO was
significantly higher in the null mice, suggesting a role for endogenous PACAP in the
prevention of neuronal damage. Further studies indicated that the neuroprotective
effect of PACAP may result from modulation of cytochrome C release through the
regulation of mitochondrial bcl-2 expression, via a mechanism involving IL-6
(Ohtaki et al., 2006). Baba's group also examined the role of PACAP in pancreatic
function by generating another PACAP transgenic mouse line which over-expressed
the peptide specifically in the p-cells of the pancreas, akin to the transgenic VIP mice
described earlier (Kato et al., 1994; Yamamoto et al., 2003). In contrast to the VIP
over-expressing mice, glucose levels were normal in these PACAP mutants,
suggesting a differential role for the peptides in pancreatic function. In further
extensive analyses of these mice, this group have suggested roles for PACAP in
stimulating feeding and energy homeostasis (Nakata et al., 2004) and in the
processes leading to inflammatory and neuropathic pain states (Mabuchi et al.,
2004).
In a third line of PACAP null mice, Hamelink and colleagues (2002)
investigated the function of the adrenal glands, in which PACAP had been proposed
to act as co-transmitter with acetylcholine. This group found that despite basal
adrenaline secretions appearing normal, the mice were unable to survive following
exposure to a metabolic stress (insulin induced hypoglycaemia) that should stimulate
a prolonged adrenaline secretion (Hamelink et al., 2002). The authors suggested that
the mice were unable to recover from the initial hypoglycaemia and proposed a role
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for PACAP as an emergency response hormone during prolonged episodes of
metabolic stress (Hamelink et al., 2002).
Following on from their studies of circadian cycles in VIP null mice (2003),
Colwell and colleagues examined circadian function in another PACAP null mouse
strain (Colwell et al., 2004). These mice were observed to show less robust phase
shifts (approximately 50 % reduction compared to WT) in response to light pulses.
These studies highlighted a specific role for the peptide in modulating advances and
delays in the sleep/wake cycle in response to light, in agreement with the findings
described earlier by Baba and colleagues (Kawaguchi et al., 2003).
In summary, multiple studies using PACAP transgenic mice have shown
that these mice display hyperactive psychomotor behaviours, high early mortality
rates, abnormalities in lipid and glucose homeostasis, impaired reproductive
function, a reduced ability to resynchronise sleep/wake cycles in response to light
cues and reduced neuroprotective mechanisms in response to pMCAO. These
studies suggest important and complex roles for this peptide in a multitude of
physiological processes.
A.3.1.3. VPAC2R transgenics
The first VPAC2R transgenic animals were described in 2000 by Harmar
and colleagues, who generated transgenic mice over-expressing the human VPAC2R
(Shen et al., 2000). The pattern of receptor expression was reported to be similar to
that in WT mice, with the highest levels of expression detected in the SCN. In
circadian function studies, a role for the receptor in controlling circadian cycles was
suggested, with these mice observed to adjust more rapidly than their WT littermates
to an 8 h phase advance in the light/dark cycle (OE: 3.86 days; WT: 5.4 days).
Additionally, these mice displayed a shorter circadian free running period (OE: 23.36
h; WT 23.59 h) when assessed under conditions of constant darkness (Shen et al.,
2000).
The following year, Voice and colleagues (2001) reported the generation of
another hVPAC2R transgenic mouse line, in which the T-cells of the mice
constitutively expressed I1VPAC2R. This expression is in contrast to WT mice, in
which VPAC2R are normally only detected upon T-cell stimulation (see section
A.2.9.6, p 37; Lara-Marquez et al., 2000). The highest levels of I1VPAC2R
expression were detected in the spleen and thymus, with splenic T-cells showing a
higher expression than B-lymphocytes or macrophages (Voice et al., 2001).
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Elevated serum levels of IgE, IgGl and eosinophils were detected in these mice and
were attributed to an increase in the effective ratio of functional Th2 and Thl T-cells
and the associated cytokines which these cells express. These authors showed that
this altered balance in cytokine production resulted in a depression of delayed
hypersensitive reactions (Voice et al., 2001).
The first VPAC2R null animals were described by Harmar and colleagues in
2001, with the initial studies involving these mice reporting altered immune
responses (Goetzl et al., 2001). The mice were described as appearing normal in
general health, social behaviour and in breeding patterns. However, when delayed
type hypersensitive responses were induced in these mice (through subcutaneous
administration of the hapten NP OSu), enhanced reactions were observed, in contrast
to the VPAC2R transgenics described above (Voice et al., 2001). This observation
was suggested to result from an inability ofVIP to increase the level of Th2 cells and
associated cytokines (relative to Thl) in these mice. From these studies and those
described by Voice and colleagues, the VPAC2R clearly has an important role in
hypersensitive immune responses.
Further studies of this particular mouse line examined their circadian
characteristics and identified critical roles for the VPAC2R in the maintenance and
expression of normal circadian activity patterns (Harmar et al., 2002). Under a 12 h
light/dark cycle, these null mice were shown to have a similar pattern of activity to
WT mice, despite their overall activity levels being lower. When exposed to a phase
advance in the light/dark cycle the null mice entrained to the new cycle much faster
than WT animals (KO: 2.4 days; WT: 6.7 days). In addition, when exposed to brief
periods of darkness during the daytime, the KO mice were active, in contrast to WT
littermates. This demonstrated that masking by light was the principal factor
governing the activity cycles of these mice. This finding was emphasised by the
observation that under constant darkness the null mice expressed only very weak
endogenous rhythms and lacked coordinated clock gene expression. Subsequent in
vitro electrophysiological studies using these mice indicated that there was a loss of
electrical activity rhythms, an observation that could be mimicked in WT mice upon
application of the putative VPAC2R antagonist PG99-465 (Cutler et al., 2003).
Further support for disruption to the normal function of the SCN at the cellular level
in these null mice has also been gained from immunohistochemical studies in which
the null mice were shown to have no rhythmic expression of p-ERK or c-fos in SCN
cells, in contrast to WT animals (Hughes et al., 2004).
Following the original description in 2001 of VPAC2R null mice (Goetzl et
al., 2001), a second line of receptor null mice were independently generated by
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Asnicar and colleagues (2002). These authors investigated the role of the VPAC2
receptor in energy balance and glucose homeostasis using their transgenic mice. The
KO animals described were deletion mutants, in which multiple sections of the
receptor were predicted to be deleted, thus disrupting normal receptor function.
These mice were shown to have reduced levels of body fat and became significantly
leaner than WT littermates as they became older. These authors also report reduced
fertility rates in older male mice, due to a degeneration of the seminiferous tubules.
In contrast, these effects have not been reported for the original colony of VPAC2R
null mice (Goetzl et al., 2001).
A.3.1.4. PACiR transgenics
The first colony of PACiR null mice reported, were created by Jamen and
colleagues in 2000, following targeted homologous recombination in embryonic
stem cells. In this initial report the authors examined insulin secretion and glucose
homeostasis, and found that the KO mice had impaired glucose-induced insulin
secretion responses and increased glucose intolerance. The null mice were also
shown to weigh significantly less (~ 10 %) than their WT littermates, with these
studies highlighting the importance of PACiR mediated responses in glucose
homeostasis. Interestingly, although the null mice appeared normal at birth, ~ 60 %
died at around one month old from unknown causes (Jamen et al., 2000). The same
line of null mice were also examined in various behavioural tasks to determine any
effect of null PAQR expression in the hippocampus (Sauvage et al., 2000). In these
studies, the null mice displayed no deficits in accuracy during water maze tasks, with
the authors suggesting that PACiR in the hippocampus do not have a critical or
major role in memory formation. However, a more subtle role for this receptor was
identified, with minor differences observed in contextual fear conditioning studies.
The circadian activity cycles of these mice have also been examined (Hannibal et al.,
2001). In a 12 h light/dark cycle, the circadian pattern of activity in the null mice
was similar to WT, however in constant darkness, the null mice showed a
significantly shorter period length (KO: 23.3 ±0.1 h; WT: 23.7 ± 0.1 h). In response
to light pulses in the early night, the null mice demonstrated large phase delays,
which were twice as pronounced than in WT mice, suggesting that the SCN of the
null mice was more sensitive to light stimulation. Additionally, the normal increase
in clock genes (e.g. c-fos, mPer2) in response to light was not observed following
light stimulated phase shifts in the null mice, indicating that altered cycles of clock
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gene expression are not always observed in response to phase shifts in the sleep/wake
cycle (Hannibal et al., 2001).
In 2001, Otto and co-workers also reported the generation of two PACiR
transgenic mouse lines to study the involvement of the receptor in synaptic plasticity.
The first was a fully receptor null mutant and the second was a novel mutant in
which only the PACiR receptors in the forebrain/hippocampus were inactive (under
the control of the Cre/loxP recombination system). In hippocampal slices prepared
from the null and WT mice, post tetanic stimulation was observed in the mossy fibre
pathway, although interestingly sustained stimulation i.e. long term potentiation
(LTP), was only observed in slices from WT mice (Otto et al., 2001). These findings
suggest an essential role for the PACiR in the expression of LTP in this neural
pathway. In addition, both lines of transgenic mice showed impairments in
contextual fear conditioning paradigms, but no deficits in spatial learning were
observed, consistent with the earlier findings of Sauvage and co-workers (2000).
These authors also reported differences in body weight between the receptor null
mice and WT littermates, with most of the transgenic animals dying within the
second postnatal week (Otto et al., 2004). These observations are similar to those
originally described by Jamen et al. (2000). Furthermore, the cause of death in these
mice was suggested to be selective right heart failure, as these animals were shown to
have a high incidence of cardiac hypertrophy, with a particularly pronounced
dilatation of the right ventricle observed (Otto et al., 2004).
The most recent studies of PACiR transgenic animals have pointed to a
putative involvement of the receptors in the development of hydrocephalus (Lang et
al., 2006). In three lines of transgenic mice over-expressing the receptor to different
degrees, an enlargement of the ventricles and reduced cerebral cortex mass was
observed, the severity of which was proportional to the degree of receptor over-
expression. PACiR over-expression was associated with a decrease in neuronal
proliferation and an increase in apoptosis in the developing embryo. The presence of
abnormal cilia (shorter and more disorganised than in WT) in the ventricular
ependyma were also observed and were suggested by these authors to be partially
responsible for the hydrocephalus-like effects seen in the transgenic mice.
Interestingly, the PACiR OE mice demonstrated growth retardation and high pre-
weaning death rates, two observations which were also reported for the PACiR null
mice (Jamen et al., 2000; Otto et al., 2004).
The creation and investigation of the VIP/PACAP and VPAC/PACR
transgenic mice described in this section has proven to be extremely useful in
delineating some of the physiological roles for the peptides and receptors. Further
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examination of the behaviour and physiology of these transgenic mice may yet
provide more extensive insights into VIP/PACAP and VPAC/PACR function.
A.4. Summary
As discussed in this introduction, a large field of research has developed
since the discovery of VIP and PACAP. Cloning of specific receptors for the
peptides in the early 1990's has greatly advanced our knowledge regarding the
functions of the peptides, with the development of useful peptide ligands and
transgenic mouse models. These advances have led to the identification of many
important roles for the peptides/receptors under normal physiological conditions, and
consequently the modulation of the activity of these peptides and receptors has
emerged as an attractive prospect in the treatment ofmany disease states. However,
a key limiting factor to research in this field is the paucity of truly receptor selective
ligands, particularly non-peptides.
To address some of these issues, this thesis will begin by describing an
extensive and systematic characterisation of human VPAC/PAC receptor
pharmacology using two standardised, high-throughput (HT) amenable, cell-based
assays (chapter one). In these studies several peptide ligands were examined,
ranging form the classical endogenous peptides (VIP and PACAP) to more recently
described and less well studied peptides (e.g. R3P65, PG99-465, M65). Following
on from these characterisation studies I will report the development of an HT-assay
to detect potential VPAC/PAC receptor selective ligands from the compound
collections of Astellas Pharma Inc., formerly the Fujisawa Pharmaceutical Company
(chapter two). The use of this assay in subsequent screening studies as well as a full
evaluation of hit compounds will be presented. Finally (chapter three), I shall
describe the establishment and outcomes of studies performed to explore particular
roles and functions of central VPAC/PAC receptors, using both in vivo (circadian
activity studies) and in vitro (primary cortical cultures) techniques.
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MATERIALS AND METHODS
B.l. General molecular biology and stable cell line production
In order to perform a systematic characterisation of human VPAC/PAC
receptor pharmacology using cell-based functional assays, it was necessary to
generate mammalian cell lines stably expressing the individual hVPAC/PAC
receptors. The production of such cell lines first requires the preparation of suitable
DNA constructs containing the receptor DNA sequences and the identification of an
appropriate host cell line. The procedures involved in this process are described
below for the specific generation of CHO-K1 cells stably expressing the hVPAC2
receptor.
B.l.l. Sub-cloning of the hVPACzR
The Invitrogen Ultimate human VPAC2R ORF (IOH9624) is a sequence
verified clone that includes the open reading frame (ORF) of the I1VPAC2R (NM
003382, 1317 nucleotides), supplied in the Gateway® pENTR™221 vector (2546
nucleotides; kanamycin resistance). The Gateway® entry vector is not suitable for
expression in mammalian cell lines, therefore the insert was sub-cloned into the
standard mammalian expression vector, pcDNA3.1™(+) (5428 nucleotides;
ampicillin resistance). Restriction enzyme sites were identified on both plasmids that
could be used to excise the insert from the Gateway® vector and ligate the sequence
into pcDNA3.1™(+). The clone was supplied transformed into DH10B™ E. coli as
a frozen culture in LB media (-80 °C; 8 % glycerol), consequently it was necessary
to isolate colonies and purify plasmid DNA before manipulation of sequences.
B.l.1.1. Isolation and purification of plasmid DNA
Prior to DNA manipulation, agar plates were prepared containing
appropriate antibiotics to allow the selection of different plasmids. The plates were
prepared (in a laminar flow hood) from sterile LB agar (35 g/1 in distilled water;
autoclaved), which was heated until molten, with antibiotics added during cooling
and finally poured into sterile Petri dishes (10 cm diameter).
In order to isolate single colonies from the DH10B™ E. coli glycerol stock,
an innoculum of the bacteria was removed from the frozen sample using a sterile
plastic loop and streaked out over an agar plate (kanamycin: 50 pg/ml) which was
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then sealed, inverted and kept overnight at 37 °C. After the overnight incubation,
three distinct colonies were picked and used to inoculate aliquots (10 ml) of LB
media (20 g/1 in distilled water; autoclaved) containing kanamycin (50 pg/ml). The
cultures were then left overnight at 37 °C and continuously shaken (200 rpm), prior
to plasmid DNA purification using the Promega Wizard® Plus SV Minipreps DNA
kit. Briefly, 3 ml of each sample was centrifuged in a Micro Centaur MSE centrifuge
(5 min, 13,000 g), after which the supernatant was decanted, with excess media
removed from the top of the eppendorf by blotting on a paper towel. The bacterial
pellets were then re-suspended in cell re-suspension solution (250 pi; 50 mM Tris-
HC1 (pH 7.5), 10 mM EDTA, 100 pg/ml RNase A), followed by the addition of a
cell lysis solution (250 pi; 0.2 M sodium hydroxide, 1 % SDS), prior to mixing (4x)
by inverting the eppendorfs. The bacterial suspensions were then left for 3 - 5 min at
room temperature (RT) whilst the lysates cleared and then an alkaline protease
solution was added (10 pi, ~ 250 pg) to inactivate endonucleases and other proteins
released during lysis; the suspensions were again mixed by inverting and were
incubated for 5 min at RT. A neutralisation solution (350 pi; 4.09 M guanidine
hydrochloride, 0.759 M potassium acetate, 2.12 M glacial acetic acid; final pH 4.2)
was then added to the samples and each tube mixed by inverting, prior to
centrifugation (10 min, 13,000 g). The cleared lysates were decanted into spin
columns (placed in 2 ml collection tubes) and centrifuged (1 min, 13,000 g), trapping
the DNA on the column membranes and allowing the flow through to be discarded.
A wash solution (750 pi; 60 mM potassium acetate, 8.3 mM Tris-HCl (pH 7.5), 0.04
mM EDTA (pH 8.0), 60 % ethanol) was then added to each column, the samples
centrifuged (1 min, 13,000 g) and again the flow through disposed of. This step was
repeated with a further 250 pi of column wash solution and the empty columns were
then spun for an extra 2 min (13,000 g) before being transferred to new eppendorfs.
Plasmid DNA was eluted from the membranes by the addition of nuclease free water
(100 pi), followed by centrifugation (1 min, 13,000 g) and stored at -20 °C. The
DNA content of the samples (10 pi diluted to 0.5 ml with nuclease free water) was
determined by measuring the absorption at 260 nM (A26o), using a spectrophotometer
(DU 800, Beckman Coulter). DNA concentrations (pg/ml) were calculated by
multiplying the A26o by 50 (dilution factor) and then by 50 again, to account for the
fact that an A26o of 1 corresponds to the presence of 50 pg/ml of double stranded
DNA (Qiagen Bench Guide, p 16; http://www.qiagen.com).
From a limited stock of pcDNA3.1™(+) plasmid DNA, 5 pi was
transformed into chemically competent One Shot® TOP 10 E. coli (50 pi), for which
the full procedure is described in a later section (B. 1.1.5., p 52). Between 50 - 150 pi
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of the transformation reaction was spread onto pre-warmed (37 °C) agar plates
(ampicillin; 100 pg/ml), which were then inverted and incubated overnight (37 °C).
The following day selected colonies (six in total) were chosen to inoculate LB media
cultures, from which DNA was extracted and quantified as described in the above
paragraph. The DNA content of all six DNA preparations was very similar, at
approximately 320 pg/ml (mean: 324 ± 11 pg/ml). These were the pcDNA3.1™(+)
samples that were used in all subsequent studies.
B.l.1.2. Restriction enzyme digests
To remove the hVPAC2R insert from the pENTR™221 plasmid, two pairs
of restriction enzyme sites (Aflll and EcoRV; Nhel and EcoRV) were identified that
could be used to excise the entire insert from the plasmid (Figure B.l). These
enzymes were selected as they should facilitate ligation of the insert directly into
pcDNA3.1™(+) (also digested with the enzymes to linearise the plasmid and
generate compatible ends; Figure B.l). Double enzyme digests of purified DNA
were generally performed in a total volume of 20 pi, incorporating the restriction
enzymes (1 pi each; 8 - 20 units depending on the enzyme), bovine serum albumin
(BSA; 0.1 mg/ml), purified DNA (volume dependent on concentration utilised) and
nuclease free water (to make up the total volume). Digests were typically conducted
for 1 h, with samples incubated in a water bath at 37 °C. The resulting DNA
fragments were then visualised on 1 % agarose gels, which is an optimal
concentration for visualising DNA fragments in the 0.5 to 10 kb range (Qiagen
Bench Guide, p 12; http://www.qiagen.com). To prepare gels, solid agarose was
added to Tris-acetate-EDTA (TAE) buffer (lx) and the mixture heated until the
agarose had fully dissolved. After the solution had cooled, ethidium bromide was
added (0.3 pg/ml), the solution gently mixed and poured into gel moulds to set. Prior
to use, gels were placed in the electrophoresis chambers and submerged in TAE
buffer (lx). Samples of DNA digests (2 - 20 pi, depending on gel size) were mixed
with blue/orange loading dye (2 pl/sample, 6x dye) and, along with a KiloBase DNA
marker (1 pl/well), added to the wells of a gel and exposed to an electric current (100
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Figure B.l Schematic of the initial cloning strategy. The initial cloning
strategy attempted to excise the I1VPAC2R insert from the
pENTR™221 vector (with Aflll and EcoRV) and directly ligate it
with the compatible ends following double digestion of
pDNA3.1™(+).
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B.l.1.3. Gel purification ofDNA fragments
To isolate the digested DNA fragments, gel purification was performed
using the QIAquick Gel Extraction Kit. Briefly, using a UV light box to visualise the
bands, the DNA fragment of interest was cut from the gel with a sterile scalpel blade
and placed in a sterile, pre-weighed eppendorf. The mass of the sample was
calculated and 3 'gel volumes' of buffer QG added to solubilise the gel; the 'gel
volume' was calculated using the assumption that 100 pg = 100 pi. The gel
solutions (pH < 7.5) were placed in a heating block (50 °C, 10 min) to ensure the
agarose gel was dissolved, after which isopropanol (1 gel volume) was added to
precipitate the DNA. The sample was then mixed and decanted into a QIAquick spin
column (held in a 2 ml collection tube) and centrifuged to bind the DNA to the
membrane of the column (1 min; 13,000 g). To remove all traces of agarose, buffer
QG was added to the column (0.5 ml), and the sample again centrifuged (1 min;
13,000 g). The flow through was disposed of and the process repeated with an
ethanol containing buffer (PE; 0.75 ml) to wash the bound sample. The flow through
was discarded once more and the column centrifuged for a further 1 min (13,000 g),
to remove any residual buffer. Spin columns were placed in fresh, sterile eppendorf
tubes and the DNA was eluted from the membrane by the addition of nuclease free
water (50 pi), followed by centrifugation (1 min, 13,000g). All DNA samples were
stored at -20 °C as described previously.
B.l.1.4. DNA Ligation reactions
To ligate the compatible ends of the digested I1VPAC2R insert and
pcDNA3.1™(+) plasmid (Figure B.l), reactions were performed using E. coli
bacteriophage T4 DNA ligase. Standard ligations were performed in a total volume
of 10 pi, containing T4 DNA ligase enzyme (1 pi; 1 - 3 units), T4 DNA ligase lOx
buffer (1 pi) and DNA from the insert and vector, with the volumes of the latter two
being dependent on both the abundance of DNA in the solutions and the vector to
insert ratio required (8 pi total volume). Nuclease free water was added, as
necessary, to bring the final reaction volume to 10 pi, with the reactions gently
mixed and incubated overnight in a water bath (16 °C), prior to storage at -20 °C.
B.l.1.5. Transformation of DNA into competent E. coli
The ligation reactions were transformed using chemically competent One
Shot® TOP 10 or DH5a™ E. coli strains, in accordance with the manufacturer's
protocol. Briefly, the ligation reactions were gently mixed and kept on ice, whilst
one vial of One Shot® TOP 10 E. coli (50 pi) was thawed for each ligation. The
ligation mix (5 pi) was added to the E. coli and the suspension mixed by gentle
tapping. This was followed by a 30 min incubation on ice, prior to a 30 s heat-shock
in a 42 °C water bath. The reactions were then returned immediately to ice and 250
pi of SOC medium (RT) was added to each tube. The vials were then secured into
an eppendorf rack, which was then shaken (on its side) at 225 rpm for 1 h (37 °C).
Between 50 - 150 pi of the ligation reactions were spread onto pre-warmed (37 °C)
agar plates (ampicillin; 100 pg/rnl), which were then inverted and incubated
overnight (37 °C). Colony growth was examined the next day and selected colonies
were chosen, as previously described (B. 1.1.1., p 47), to inoculate LB media cultures
from which DNA was extracted and subsequently analysed to determine whether
transfer of the insert had been successful. For transformations using DH5a™
competent E. coli, one vial of cells was thawed and 100 pi aliquots were apportioned
into eppendorfs (one aliquot per transformation reaction). Ligation mixes were
added (5 pi per reaction) and the reactions incubated for 30 min on ice, before a 20 s
heat-shock in a 37 °C water bath. The eppendorfs were then returned to the ice for 2
min, followed by the addition of SOC medium to each reaction (0.9 ml/eppendorf;
RT). The DH5a™ transformations were shaken, spread onto agar plates, colonies
selected and DNA extracted and analysed as described above for the One Shot®
TOP 10 cells.
B.l.1.6. TOPO-TA cloning®
As the direct transfer of the hVPAC2R insert from the pENTR™221 vector
to the pcDNA3.1™(+) vector proved challenging, a second PCR-based strategy was
adopted which utilised the TOPO-TA cloning® system. Using this system, the
hVPAC2R insert was transferred into an intermediate TOPO® vector before finally
being sub-cloning into pcDNA3.1™(+) (Figure B.2). The procedure involved PCR
amplification of the insert to produce abundant copies of the sequence that were
modified (by Taq DNA polymerase) by the addition of single deoxyadenosine tails to
the 3' ends of the sequences (Figure B.2). These PCR products were then ligated
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Figure B.2 TOPO TA cloning® strategy. The cloning procedure involved
PCR amplification of the IYVPAC2R insert and sub-cloning into
pCR2.1®-TOPO®. The insert was then excised by enzymatic
digestion and ligated into pcDNA3.1™(+).
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into a linearised TOPO® plasmid which had single thymidine overhangs to aid
ligation. The forward (Fl: AAGCTTGGCACCATGCGGACG) and reverse (Rl:
GGGTCTAGATGACCGAGGT) primers were designed to amplify the full
I1VPAC2R ORF insert from the pENTR™221 plasmid, and included two restriction
enzyme sites (Hindlll and Xbal). Additional forward (F2:
TACAGCAAAGCAGGAAACATAA) and reverse (R2:
CAGGAGGGTGTGGAGGTAG) primers were designed to amplify short sequence
fragments. Primers were reconstituted in nuclease free water to generate master
stocks (50 pM) from which working solutions of 5 pM were prepared (stored at -20
C). PCR reactions were carried out using the Expand High Fidelity PCR system
(Roche). Reaction mixes were prepared containing PCR buffer with magnesium
chloride (5 pi; lOx buffer), PCR nucleotide mix (0.25 mM), forward and reverse
primers (0.5 pM each), High Fidelity polymerase enzyme mix (0.75 pi) and PCR
water to generate a total volume of 49 pi. Finally, the DNA to be amplified
(pENTR™221 plus I1VPAC2R insert) was added (1 pi) and the complete 50 pi
reaction was mixed. The reactions were placed in a thermocycler (Thermo Hybaid
PCR express) and the following protocol utilised: 94 °C (5 min), 30 cycles of 94 °C
(30 s), 60 °C (1 min), 72 °C (1 min) and finally 72 °C for 7 min. Samples of the
resulting PCR products were loaded onto agarose gels (1 %) and the DNA bands
visualised. The band produced from the amplification of the full length insert
sequence (using Fl/Rl primers) was excised from the gel and purified as described
previously (B. 1.1.3., p 51). Ligation reactions (5 pi total volume) between the
pCR®2.1-TOPO® vector (1 pi) and the gel purified insert (1 - 4 pi) were set up
(Figure B.2), with PCR water added as required to achieve a final reaction volume of
5 pi. The solutions were mixed gently and left for 5 min at RT, followed by the
addition of 6x TOPO cloning® Stop Solution (1 pi). Samples of the ligation
reactions (2 pi) were transformed into One Shot® TOP 10 E. coli as described
previously (B. 1.1.5., p 52), with 20 and 50 pi of each transformation reaction spread
onto ampicillin-containing agar plates. Following an overnight incubation at 37 °C,
selected colonies were picked and used to inoculate aliquots of LB broth, prior to
DNA extraction the following day. Restriction digests were performed on the DNA
using enzymes (Hindlll and Xbal) that should excise the insert (if present), with the
digest products visualised on an agarose gel (1 %). Bands corresponding to the
appropriate insert size were gel purified, the DNA extracted and used in a ligation
reaction with double digested vector (pcDNA3.1™(+)), using T4 DNA ligase
(B.l.1.4., p 51). The ligation reactions were transformed into One Shot® TOP 10 E.
coli, individual colonies isolated and propagated and DNA prepared using the
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standard protocols previously described (B. 1.1.1., p 47; Bl.1.5., p 52). Finally,
restriction digests (Hindlll and Xbal) were used to determine whether the
pcDNA3.1™(+) plasmid contained the I1VPAC2R insert.
B.1.2. Stable cell lines expressing human VPAC/PAC receptors
Whilst producing a plasmid containing the hVPAC2R insert for the
generation of stable cell lines, I was fortunate to find that Astellas Pharma Inc.
(formerly the Fujisawa Pharmaceutical Company) had previously generated stable
cell lines expressing the human VPACi, VPAC2 and PACi receptors. These cell
lines were kindly transferred to our laboratory and have been used in the studies
described. The generation of CHO cell lines stably expressing the VPAC/PACR was
performed by Dr I. Aramori (Astellas, Japan) and will be described here in brief.
Following the design of sequence specific primers, cDNA clones encoding the
hVPACiR, I1VPAC2R, and hPAQR were obtained by PCR, from a Clontech human
brain cDNA template. The resultant PCR products were individually sub-cloned into
pBluescript SK(-), with the identities of the resultant clones confirmed by nucleotide
sequence analysis, using an automated sequence analyser. CHO cell lines expressing
the hVPAC/PAC receptors were established in a manner similar to that described
previously (Aramori & Nakanishi, 1992). Briefly, individual hVPAC/PAC receptor
cDNAs were sub-cloned into a eukaryotic expression vector (pMH009) containing
the simian virus 40 early promoter and the mouse dihydrofolate reductase (dhfr) gene
as a selective marker, with the resultant plasmids transfected into CHO(dhfr-) cells
using calcium phosphate precipitation (Aramori et al., 1997). CHO cells were
chosen as it is known that phospholipase C/[Ca2"]i stimulation can occur via either
Gaq or Gaj proteins in this cell line and that these cells do not constitutively express
VPAC or PAC receptors (Ciccarelli et al., 1994; Van Rampelbergh et al., 1997).
Cell lines expressing hVPAC/PAC receptors together with dihydrofolate reductase
were selected in a-MEM lacking ribonucleosides and deoxyribonucleosides, but
supplemented with 10 % dialysed FBS. From the selected cell populations, clonal
lines were isolated by single cell cloning, and the resultant CHO cell lines expressing
hVPACjR, hVPAC2R, and hPACiR were maintained in culture as described below.
The hPAC] cell line generated was the hPACi-null variant described by Pisegna &
Wank (1996). The three stable cell lines examined produced equivalent maximum
responses in the [cAMP]j (~ 60 nM, ~ 25x basal) and [Ca2+], (~ 7x basal) assays,
following stimulation with a saturating concentration of ligand (VIP or PACAP).
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Vertongen et al. (2004) have shown that this level of cAMP correlates with a
receptor density of approximately 1 pmol/mg and moreover, that cAMP and [Ca2 ]i
levels are linearly correlated with a receptor density up to 5 pmol/mg (Langer &
Robberecht, 2005).
B.2. Cell culture
B.2.1 Cell stock storage and resuscitation
Aliquots of all immortalised cell lines were stored in liquid nitrogen (-170
°C) and resuscitated, as required, by loosening the vial cap slightly and warming the
vial, in a water bath (37 °C), for 1 - 2 min. The cell suspension was then added drop
wise, into a flask of appropriate, pre-warmed media. All cell lines underwent at least
two passages after resuscitation before use in the assays and with the exception of the
SHSY-5Y cell line, were sub-cultured for an additional 20 passages before a new
aliquot of cells was resuscitated. SHSY-5Y cells were only used over a 5 passage
period (PI3 - 18) as there is an obvious change in morphology after this point.
B.2.2. Maintenance of immortalised cell lines
CHO-K1 host cells (Figure B.3a) were maintained in culture in Flam's F-12
media, containing FBS (10 %) and gentamicin (1 %). The CHO-K1 cell lines stably
expressing the hVPACiR, hVPAC2R and hPACiR were grown in a-MEM
supplemented with dialysed FBS (10%), L-glutamine (2 mM), penicillin (100 U/ml)
and streptomycin (100 pg/ml). HEK-293 cells (Figure B.3b) were cultured in MEM,
with the addition of FBS (10 %), L-glutamine (2 mM) and non-essential amino acids
(1 %). FiT-29 cells (Figure B.3c) were grown in McCoy's 5A media supplemented
with FBS (10 %), and L-glutamine (2 mM). SUP-T1 cells were maintained in RPMI
1640 supplemented with FBS (10 %), L-glutamine (2 mM), sodium pyruvate (1
mM), HEPES (10 mM; filter sterilised, 0.2 pm filters) and 1.25 g glucose (dissolved
in 10 ml of the RPMI 1640 and filter sterilised (0.2 pm filters) before addition to the
complete media). SHSY-5Y cells (Figure B.3d) were cultured in DMEM containing
FBS (10 %), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100
pg/ml). All of the cells described are adherent cell lines (except SUP-T1) and were
generally sub-cultured when observed to be ~ 90 % confluent. To sub-culture these
cells, the media was first removed from the flasks and the cells rinsed with pre-
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Figure B.3 Morphology of the adherent immortalised cell lines. The
photographs illustrate the different morphologies of the following
adherent cell lines: CHO-K1 (a), HEK-293 (b), HT-29 (c) and
SHSY-5Y (d). The cells are shown at a high density, with the scale
bar representing 100 pm. The images are modified from the ATCC
website (http://www.lgcpromochem.com/atcc).
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warmed HBSS. Trypsin-EDTA solution (0.25 %, pre-warmed) was then added to
the cells and the flasks returned to the incubator for 3 - 5 min. After the majority of
cells had detached from the surface of the flask, an equivalent volume of the
appropriate media (pre-warmed) was added to neutralise the trypsin-EDTA, and the
resulting cell suspension was centrifuged in a Thermo IEC centrifuge (5 min, 850
rpm). The supernatant (media and trypsin-EDTA) was removed by pipette and the
remaining cell pellet re-suspended in 5 ml of media (1 ml initially, followed by a
further 4 ml). Cells were then seeded into new flasks containing media, at a 1:5, 1:10
or 1:20 dilution (depending on cell usage requirements) and the media changed twice
weekly. For the SUP-T1 cell line, sub-culturing was performed once per week. Cell
suspensions were removed from culture flasks and pelleted by centrifugation (5 min,
850 rpm). As described for the adherent cell lines, the supernatant was gently
removed and the cell pellet re-suspended in media before dilution into fresh media in
new culture flasks. An equivalent volume of fresh media was added to each flask 3 -
4 days after seeding.
B.2.3. Rat primary cultures
B.2.3.1. Generation and maintenance of rat primary cultures
In order to isolate primary astrocytes, a mixed cell culture was initially
prepared from the cortices of rat pups, following the procedures outlined by
McCarthy and colleagues (McCarthy & de Vellis, 1980; Kuhlow et al., 2003). Prior
to the preparation of the cortical cultures, all necessary instruments and glass Petri
dishes were wrapped in tin foil, sealed and sterilised overnight at 200 °C, with the
required media and DNase solutions prepared on the day. Complete media for the
primary cultures consisted of BME supplemented with FBS (10 %; heat inactivated
at 48 °C for 35 min), dextrose (0.5 % w/v; added from a 30 % w/v stock prepared in
water and filter sterilised, 0.2 pm filters), L-glutamine (2 mM), penicillin (100 U/ml)
and streptomycin (100 pg/ml). DNase solutions were prepared by dissolving the
contents of a 10,000 unit bottle of DNase in 3 ml of HBSS, of which 2 ml was
subsequently added to 8 ml of media and the remaining 1 ml was added to 4 ml of
trypsin solution (12.5 mg trypsin dissolved in 4 ml of HBSS). The media/DNase and
typsin/DNase solutions were both filter sterilised (0.2 pm filters) immediately and
pre-warmed before use. The primary cultures were prepared from the cortices of
Sprague-Dawley rat pups (P0 - P2), which were decapitated and the heads
immediately submerged in 50 ml of HBSS (on ice). Using sterile scissors, a midline
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cut was made through the skin on the dorsal surface of the head (caudal —> rostral),
with the skin peeled back to expose the skull. Using a second pair of sterile scissors,
a caudal-rostral incision was gently made along the midline of the skull, directing the
points of the scissors away from the surface of the brain. To expose the entire brain,
both sides of the skull were peeled away from the midline using sterile curved
tweezers (with the tips submerged in 70 % ethanol between dissections). The
cerebellum was detached using tweezers and discarded, whilst the rest of the brain
was gently removed from the skull and placed directly into a sterile Petri dish
containing HBSS (on ice). For dissection, each individual brain was moved to a
second sterile glass Petri dish, containing HBSS. Using sterile curved and straight
tweezers, the olfactory bulbs were removed (if present), as was the inner brain,
meninges and associated surface blood vessels. The remaining cortex was
transferred to a universal tube, containing 5 ml of HBSS (on ice). When all of the
dissections were complete, the HBSS containing the cortices was transferred into a
third sterile glass Petri dish and the tissue finely chopped with a sterile scalpel blade.
The chopped cortex/HBSS preparation was taken up into a 15 ml pipette, the tissue
allowed to settle in the tip and then only the tissue (not the excess HBSS) was added
to a universal tube containing the trypsin/DNase combination (5 ml) and placed in a
water bath (37 °C). After 30 min, 5 ml of the media/DNase mixture was added and
the solution was gently mixed with a 15 ml pipette. The remaining volume of
media/DNase mixture (5 ml) was added and the solution was centrifuged (10 min,
850 rpm). The majority of the supernatant was gently removed (taking care not to
disturb the cells as the pellet is very fluid) and the pellet re-suspended in
approximately 4 ml of media, using a 15 ml pipette. The cell suspension was then
filtered through sterile nylon gauze (125 prn mesh opening) to remove any remaining
clumps of tissue. The appropriate volume ofmedia was added to the cells to allow 1
ml of cell suspension per two cortices and the suspension gently mixed with a 15 ml
pipette. The cells were then aliquoted into culture flasks (80 cm2) containing 11 ml
of media (1 ml of cell suspension per flask). The flasks containing the primary
cultures were kept in a separate incubator from the immortalised cell lines (to reduce
any risk of contamination) and were maintained at 37 °C in a humidified atmosphere
(with 5 % CO2), with the media changed every 2 - 3 days. To isolate the astrocytes
used in the assays, the flasks were left for 14 - 18 days in culture, removed from the
incubator, the lids covered with parafilm and the flasks wrapped in tin foil. The
flasks were then shaken (90 min, 300 rpm), after which the media containing mostly
microglia was removed. The remaining adherent cells (predominantly astrocytes)
were washed with HBSS, trypsinised (0.25 % trypsin-EDTA solution) and
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centrifuged (5 min, 850 rpm,). The astrocyte pellet was re-suspended in media and
the cells counted and prepared for seeding into the appropriate assay plates (section
B.2.4, p 61). To determine the purity of the cultures (see below) samples of
microglia were retained and used in immunohistochemical studies alongside the
astrocytes. Following removal of the microglia from the shaken flasks, the cell
suspension was centrifuged (10 min, 850 rpm), the media removed from the
microglia pellet and the cells were then re-suspended in 2 - 3 ml of the same media
(conditioned media). The microglia were then counted and seeded into wells of the
microscope slide as described in the following section.
B.2.3.2. Immunohistochemistry of rat primary cultures
To confirm the purity of the primary cultures, microglia and astrocytes were
isolated as described above, counted and seeded into separate chambers of a multi-
welled glass microscope slide (microglia: 1 x 104 cells/well; astrocytes: 2 x 104
cells/well). Following an overnight incubation (37 °C), the media was aspirated and
the cells rinsed in phosphate buffered saline (PBS; 3x 3 min washes). The cells were
then fixed in cold 4 % paraformaldehyde (10 min), rinsed in PBS as before,
permeabilised in 0.1 % Triton X (5 min) and rinsed again (PBS). The slides were
then incubated in 3 % hydrogen peroxide (prepared in methanol; 5 min), to block
endogenous peroxidase activity. The cells were then rinsed (PBS) and blocked for 1
h with normal horse serum (2 % in PBS), prior to incubation (overnight; 4 °C) with
appropriate primary antibodies. For microglia and astrocyte identification, the
primary antibodies used were mouse anti-rat CD lib (1:100 dilution in blocking
solution) and mouse anti-pig glial fibrillary acid protein (GFAP; 1:200 dilution in
blocking solution), respectively Following the incubation with primary antibodies,
the cells were rinsed with PBS and incubated with a biotinylated anti-mouse
antibody (30 min to 1 h) from an anti-mouse Vectastain ABC kit. The cells were
then rinsed in PBS, the kit avidin/biotinylated peroxidase enzyme complex (ABC)
added (30 min) and following another rinse with PBS, antigen staining was
visualised with the Vector stain VIP substrate. The proportion of astrocytes and
microglia present in the samples was then assessed in order to determine the purity of
the isolated cells.
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B.2.4. Cell plating for assorted assays
B.2.4.1. FlexStation® assays
2_|_In the [Ca ]j assay, fluorescence readings are measured by scanning the
bottom of the assay plates; as a result it is recommended that cells in the 96-well
assay plates are seeded at an appropriate density to form an adherent monolayer. An
excess or insufficient number of cells or the presence of poorly adhered cells could
lead to a number of artefacts and inconsistencies in the data generated. Following
cell density studies using the CHO-hVPAC/PACR lines (chapter one, section 1.2.2.2,
p 96), 1 x 105 cells per well was selected as the optimum overnight seeding density
for both the FlexStation® [Ca2+]j and [cAMPjj assays. This density was also used
for all of the other adherent cell lines (including astrocytes from the primary cultures)
in these two assays, with the exception of SHSY-5Y cells which were seeded
overnight at 1.25 x 105 cells per well to obtain an adherent monolayer. In general,
flasks of cells were washed with pre-warmed HBSS, trypsinised (0.25 %) and
centrifuged at 850 rpm for 5 min. The cell pellets were then re-suspended in the
appropriate media, the cell number determined using a haemocytometer, and if
required, additional media was added to obtain the desired cell density. The cell
lines were seeded overnight (0.1 ml per well) into 96-well flat clear bottom, black
([Ca2+]j assay) or clear plates ([cAMPjj assay). The assay plates had been pre-treated
for 2 h (minimum) with poly-D-lysine, (20 pg/ml in H2O; 0.1 ml/well) in order to aid
cell adhesion. Previous work in our laboratory has shown that SHSY-5Y cells
adhere sufficiently well to untreated plates. As SUP-T1 cells grow in suspension,
cell seeding procedures were modified accordingly and performed on the assay day.
2~FFor the [Ca ]i assay, cells were pelleted as described (section B.2.2., p 56), re-
suspended in calcium assay cell buffer (5 ml) and counted. The volume of the cell
suspension was adjusted to achieve the correct density and cells were seeded into
poly-D-lysine treated, black-walled plates (1 x 105 cells, 0.1 ml). The cell plates,
were then centrifuged (4 min, 1000 rpm) to ensure the cells settled on the bottom of
the wells, with the rest of the assay performed as described for adherent cells (section
B.3.I.2., p 64). For the [cAMPjj assay, SUP-T1 cells were pelleted as before
(section B.2.2., p 56) on the assay day, re-suspended in PBS (pre-warmed) and
counted. The cell suspension was centrifuged again and the pellet re-suspended in
pre-warmed [cAMPjj assay stimulation buffer to generate the required cell density.




For the FLIPR® [Ca2+]; assay, flasks of CHO-hVPAC2R cells were rinsed
with pre-warmed PBS, detached by trypsinisation (0.25 %) and pelleted by
centrifugation (4 min, 1000 rpm). Pelleted cells were re-suspended in media (5 ml
total) and counted, with further media added to generate the required cell density (3 x
105 cells/ml). Cells were seeded into flat clear bottom, black 384-well plates (1.5 x
104 cells/well; 50 pi) and left overnight to adhere. In contrast to the FlexStation®
assays, plates were not pre-treated with poly-D-lysine, with the degree of cell
adhesion deemed satisfactory for this 384-well plate assay.
B.2.4.3. Cytokine ELISAs
RCA were isolated and counted as previously described (section B.2.3.I., p
58), and the volume of the suspension was adjusted with media to provide the desired
density. Cells were seeded into 24-well plates (5 x 105 cells/well, 0.5 ml) overnight.
The following day the media was aspirated from the cells and the wells were gently
washed (3x) with HBSS. After the final wash step, 200 pi ofHBSS was added to the
cells followed by the addition of 50 pi of peptide solution (5x final assay
concentration; FAC). Following peptide treatment for 1 h, the supernatants were
removed to eppendorfs, centrifuged to remove any cell debris (5 min, 10,000 g) and
finally transferred to fresh eppendorfs which were stored at -20 °C until use.
B.3. In vitro assay procedures
B.3.1. FlexStation® assays
The FlexStation® is a bench top scanning fluorometer with an integrated
fluid transfer system (Figure B.4a). For the studies described, the FlexStation® was
used in the 96-well plate format with the integrated 8-channel pipettor able to
transfer drugs from 8 wells of a compound plate to an assay plate (containing cells),
whilst continuously monitoring the fluorescence levels in those 8 wells. In addition,
the FlexStation® was also used to perform endpoint reads of fluorescence levels
across an entire 96-well plate.
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B.3.1.1. Intracellular cAMP assay
[cAMPji was quantified using an ELISA kit (CatchPoint® Cyclic-AMP,
MD). Cell seeding for the individual cell lines was performed as described
previously (section B.2.4.I., p 61). On the assay day, media was aspirated from
wells containing adherent cells, and the wells rinsed with 0.25 ml of pre-warmed
Krebs-Ringer bicarbonate buffer with glucose (KRBG). KRBG (pH 7.4) was
composed of D-glucose (9.1 mM), anhydrous magnesium chloride (0.49 mM),
potassium chloride (4.56 mM), sodium chloride (0.12 M), anhydrous sodium
phosphate dibasic (0.70 mM), anhydrous sodium phosphate monobasic (1.5 mM) and
sodium bicarbonate (15 mM). Following removal of the KRBG, 0.1 ml of pre-
warmed stimulation buffer was added and the plates incubated for 10 min in the
FlexStation® at 37 °C. Stimulation buffer consisted of KRBG (10 ml per plate)
containing 9.4 pi of 800 mM 3-isobutyl-l-methylxanthine (IBMX) in 100 %
dimethyl sulfoxide (DMSO), bringing the final IBMX and DMSO concentrations to
0.75 mM and 0.094 % respectively. For the SUP-T1 cell line, cells re-suspended in
stimulation buffer were seeded into wells as described (section B.2.4.1., p 61), and
the 10 min incubation period started immediately. To evaluate agonist potencies (or
antagonists alone), 50 pi of peptide solutions (3x FAC in PBS, containing 1 mg/ml
BSA) were added to the 96-well plate (using the FlexStation®), which was gently
mixed and then incubated at 37 °C for 15 min. The reaction was terminated by
addition of pre-warmed lysis buffer (50 pi) to individual wells and the plate shaken
(10 min, 450 rpm). Lysates (40 pi; a maximum of 84 per plate) were then transferred
to wells in columns 3 - 12 of a second 96-well flat clear bottom, black plate, pre-
coated with Goat anti-Rabbit IgG (excess lysates were stored at -20 °C). cAMP
standards were prepared from the serial dilution a 30 pM stock (diluted in 3 parts
assay buffer: 1 part lysis buffer), producing final in-well concentrations of 3300, 33,
11, 3.7, 1.2, 0.41 and 0.14 mM, which (in addition to a zero standard) were added to
duplicate wells in columns 1 and 2 of the plate (40 pl/well). Rabbit anti-cAMP
antibody (40 pi) was added to all wells and the plate shaken for 5 min, prior to the
addition of HRP-cAMP conjugate (40 pi) to each well. The plate was mixed for a
further 5 min and left for 2 h at RT, protected from light. Individual wells were then
rinsed (4x with 250 pi wash buffer) before addition of Stoplight Red Substrate (0.1
ml per well; 15 ml of substrate buffer containing 0.15 ml Stoplight Red Substrate and
1 mM hydrogen peroxide). The plate was again protected from light and left at RT
(10 min), prior to the measurement of fluorescence levels (excitation, 530 nm;
emission, 590 nm; cut-off, 570 nm). For inhibition studies, the KRBG was replaced
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with 75 (4.1 of stimulation buffer and the plate incubated at 37 °C for 5 min prior to
addition of antagonist (25 pi; 6x FAC in PBS with 1 mg/ml BSA). The cells were
then pre-incubated with antagonist for a further 10 min prior to agonist (50 pi)
addition in the FlexStation® and the procedure followed as above.
B.3.1.2. Intracellular calcium assay
[Ca2+]i responses were monitored fluorometrically using the Calcium Plus
Kit and FlexStation®. The day after cell seeding (section B.2.4.1., p 61), the media
was aspirated from the black-walled cell plates, followed by the addition of freshly
prepared cell buffer (0.1 ml per well, pH 7.4). The cell buffer was composed of
HBSS (with Ca2+ and Mg2+) containing 20 mM HEPES and 0.25 mM sulfinpyrazone
(diluted 1 in 100 from a freshly prepared 25 mM solution, dissolved in 1 M sodium
hydroxide). Calcium Plus dye, prepared from lyophilised dye reconstituted in cell
buffer (10 ml/vial), was added to each well (0.1 ml), the plates were protected from
light and left for 1 h at 37 °C, followed by 30 min at RT. Before drug addition, all
wells of the assay plates were scanned simultaneously for baseline fluorescence
levels (to monitor dye loading) using the endpoint read option on the FlexStation®.
To determine compound potencies, peptides were added (50 pl/well; 5x FAC in cell
Figure B.4 The FlexStation® and FLIPR® workstations (Molecular
Devices). Both of these workstations are fluorometric imaging plate




buffer containing 1 mg/ml BSA) and fluorescence levels measured (for 90 s unless
otherwise stated) by the FlexStation®, with excitation, emission and cut-off
wavelengths set at 485, 525 and 515 nM respectively. For inhibition studies, the
procedure was followed as above, except the volume of cell buffer initially added to
wells was reduced to 50 pi, with the addition of 50 pi of antagonist (5x FAC in cell
buffer, plus 1 mg/ml BSA) to appropriate wells, 10 min before the end of the RT
incubation period. Agonist addition (approximately EC50 concentration) and
fluorescence measurements were then performed by the FlexStation®, as previously
described. For intracellular calcium assays performed in calcium free conditions,
HBSS without Ca and Mg" was used to prepare the cell buffer (dye and drug
buffer).
B.3.2. FLIPR® assays
The FLIPR® workstation (Figure B.4b) is similar in principle to the
FlexStation®, with both machines being fluorometric imaging plate readers with
integrated liquid handling systems. However, and in contrast to the FlexStation®,
the FLIPR® has the added capability of measuring fluorescence levels and
transferring compounds to all wells of a 96- or 3 84-well plate simultaneously. This
allows for a much higher assay throughput, making the FLIPR® ideally suited for
use in HT-screening studies.
B.3.2.1. Intracellular calcium assay for HTS
The calcium assay procedure using the FLIPR® is very similar to that of the
FlexStation®, but is constructed to be ultra HT-compatible by allowing simultaneous
drug transfer and fluorescence measurement over all wells of either 96- or 384-well
plates. In this case, the assay was miniaturised to a 384-well plate format (total
volume: 80 pi) with the cell and agonist plates prepared as before, but in the FLIPR®
assay the addition of pre-incubated compounds was performed by the fluidics
module of the machine. Instead of performing two additions to the cell plate of cell
buffer and calcium dye (see FlexStation® calcium assay, B.3.I.2., p 64), the
FLIPR® assay was simplified to a single step addition of Calcium 3 dye assay
solution, composed of cell buffer and calcium dye. This step was taken to reduce the
risk of dislodging the cells with multiple additions to the wells and to reduce the time
65
taken when preparing the cell plates. For each 384-well assay plate, 20 ml of
Calcium 3 dye assay solution was prepared using a sterile inorganic salts buffer (ISB;
supplemented with 0.175 g sodium bicarbonate per 500 ml), containing 2 ml of
Calcium 3 dye concentrate (2x recommended concentration) and 0.11 ml of 500 mM
probenecid/sodium hydroxide (2.75 mM). Calcium 3 dye concentrate was prepared
from lyophilised stock, reconstituted in 10 ml of inorganic salts buffer (ISB) per vial
and stored at -20 °C (1 ml aliquots). On the day following cell seeding (section
B.2.4.2., p 62), the media was removed from the wells by gently tapping the plates
onto a paper towel. The Calcium 3 dye assay solution was added to each well (50
pl/well) and the plates incubated for 1 h at 37 °C, followed by 45 min at RT. 384-
well compound plates containing samples (2 pl/well) from the 4-mix Fujisawa 'F'
and 'M' compound libraries were prepared and kept at -70 °C until use. Library
stocks were stored at -70 °C in 96 deep-well plates with four compounds per well,
each of which was present at a concentration of 0.25 mg/ml, in 100 % DMSO. Each
384-well compound plate (clear bottom, clear plate) was designed to contain 160 4-
mix samples, resulting in 640 individual compounds being tested per plate (in
duplicate). From preliminary studies (chapter two, section 2.2.2.5, p 166), the
maximum strength ofDMSO that could be added to cells was 2 % (FAC: 0.5 % after
in-well dilution), so the library compounds (2 pl/well, 100 % DMSO) were diluted in
ISB on the day of assay (1 in 50 dilution to 100 pl/well, 2 % DMSO, 5
pg/ml/compound). To stimulate the receptor of choice an agonist plate was freshly
prepared on each assay day, containing VIP (800 nM; 8x FAC) diluted in ISB with
BSA (1 mg/ml). A single agonist plate could be used sequentially for up to 10 assay
plates (10 pi added per plate, 125 pi well capacity). The additions of library
compounds, VIP and the simultaneous measurement of fluorescence levels was
performed by the FLIPR® in accordance with the manufacturer's instructions. As
for the FlexStation® calcium assay, the excitation and emission wavelengths used in
the FLIPR® were 485 and 525 nm respectively (cut-off 515 nM). The FLIPR® was
programmed to provide a 2 min pre-incubation with library compounds, prior to the
addition of VIP, with fluorescence levels recorded for a total of 5 min. The size of
the VIP response from each well was calculated (max - min analysis), averaged for
duplicate wells and expressed as a percentage of the control VIP response. The four
compounds contained in each 'hit' well were then tested separately, using
concentrated samples (1 mg/ml in 100 % DMSO) from the 'F' and 'M' libraries in
which compounds are stored individually. Samples from selected compounds were
transferred to eppendorfs (1.5 pl/tube) and stored at -20 °C until use. On the day of
testing, each sample was diluted in ISB (1 in 200 dilution to 300 pi, 0.5 % DMSO, 5
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pg/ml) and added to 384-well plates (5 wells per compound). If appropriate,
additional studies of hit compounds were performed using powder samples, which
were dissolved in DMSO (to 10 mM), diluted in buffer and tested in both the
FLIPR® and FlexStation® assays.
In a number of assays performed during screening (section 2.2.3.2., p 168),
FLIPR® tips were trialled which had been coated with silicon. Using a 16-channel
multi-pipette, 30 pi of the silicon solution (Sigmacote) was taken up into the tips and
held for 10 s. The silicon solution was then removed from the tips and replaced with
30 pi of distilled water to remove any excess silicon. The tips were rinsed in this
way 3x before being left either in an oven or at RT to dry. These tips were used in
the standard FLIPR® calcium assays.
B.3.3. Quantikine® cytokine ELISAs
The Quantikine® cytokine assays (IL-ip, TNF-a, IL-6, RANTES) were
enzyme immunoassays in a 96-well plate format. The kit assay plates were supplied
pre-coated with an immobilised monoclonal antibody that specifically bound to the
cytokine of interest. All controls and standards were prepared in accordance with the
protocols supplied. Briefly, assay diluent (50 pi; RD1-40) was added to wells of a
96-well assay plate, followed by the addition of standards, controls or samples. The
plate was mixed gently (1 min) by tapping the frame, covered with an adhesive plate
sealer and incubated for 2 h (RT). The supernatant and hence any unbound
substances were removed by aspiration and the wells rinsed (5x) with wash buffer
(400 pl/well), with the plate blotted on a paper towel after each step to remove
excess buffer. The kit conjugate solution, which contains an enzyme-linked
polyclonal antibody specific for the cytokine, was then added to each well (100 pi)
and the plate covered and left at RT for a further 2 h. As before, any unbound
substances were then removed by aspiration and the wells washed (5x). A substrate
solution was then added to each well (100 pi), after which the plate was protected
from light and left at RT (30 min). Finally, a Stop Solution (100 pi) was added to
each well and the plate gently tapped to ensure mixing. The binding of the enzyme-
antibody reagent produced a blue product, which in the presence of Stop Solution
turned yellow. The intensity of this colour was determined from optical density
(OD) readings at 450 nm (measured using a microplate reader; Dynex Technologies)
and was proportional to the amount of bound cytokine.
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B.3.4. Data analysis (in vitro studies)
Data collection and analysis were performed using SoftMax Pro 4.7 and
SigmaPlot 8.0. For the [cAMP]; assay, standard curve and regression analysis were
performed using a four parameter logistic equation to determine intracellular cAMP
2_|_concentrations (nM) and ligand potencies (EC50 values). In the [Ca ]j assay the
minimum fluorescence level was subtracted from the maximum response and
compound potencies determined as above; the concentration of [Ca2+]j produced
following agonist stimulation could not be determined with the chosen calcium kit.
The data from both functional assays are presented in the form of representative
concentration effect curves. Agonist EC50 values and antagonist IC50 values are
expressed as mean ± S.E.M, for a minimum of 3 separate experiments (unless
otherwise stated), with each data point representing the mean value obtained from
duplicate wells. Where appropriate, data was analysed using one-way ANOVA, with
significant results interpreted after post-hoc analysis with the Holm-Sidak test
(SigmaStat 3.0).
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B.4. In vivo studies
B.4.1. General
C57BL/6J adult male mice (~ 8 weeks of age, ~ 25 g) were individually
housed in clear polycarbonate cages (length: 425 mm, width: 266 mm, height: 185
mm), given ad libitum access to food and water, and subjected to a strictly controlled
12 h light/dark cycle (lights off: 1900 to 0700 h). During the dark phase of the cycle,
a dim red light was permanently on, to aid animal husbandry procedures. Animals
were inspected daily, in accordance with UK Home Office regulations, following a
randomized entry time schedule. Each cage was equipped with a running wheel (240
x 80 mm) which had four small magnets fitted to the outside, at 90° intervals. Upon
wheel rotation, the magnets passed a reed relay switch on the cage lid, causing the
switch to close transiently, with the frequency of closures or counts per minute
recorded using Dataquest ART software. Each count was equivalent to a horizontal
distance of 189 mm. From analysis of the activity patterns, the mice were
demonstrably habituated to their environment and stably entrained to the 12 h
light/dark cycle before any further studies ensued.
B.4.2. Effects of displacement and surgery on activity patterns
As drug studies were to involve the central administration (i.e.v.) of test
compounds under anaesthesia, the effects of physically displacing the mice from
their home cages and anaesthesia/surgery were examined. In this study, sixteen mice
were randomly divided into three groups; moved (6 mice), sham surgery (6 mice)
and the not moved group (4 mice). The twelve mice in the former two groups were
removed from their home cages and transferred to a well-lit procedure room during
the 12 h Tights on' period when the mice were typically inactive (1030 to 1400 h).
Six mice were left in an incubator (the moved group) and the other six (the sham
surgery group) were individually subjected to halothane anaesthesia (3 % halothane
in 30 % oxygen/70 % nitrous oxide) for 2 - 3 min in a Perspex box, prior to surgery.
Under anaesthesia, the mice were transferred to a Kopf stereotaxic frame, with
anaesthesia (1.5 % halothane) maintained through a snout mask. Throughout the
surgical procedure, rectal temperature was monitored and body temperature
maintained at 37 °C by means of heating pads. A small midline incision was made in
the scalp to expose the surface of the skull, after which a small burr hole was drilled
in the skull (stereotaxic co-ordinates: - 0.22 mm posterior to bregma, 0.9 mm lateral
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from the midline (AP - 0.22 and L 0.9); from the mouse brain atlas of Paxinos and
Franklin, 2001). An empty, blunt-ended needle attached to a 2 pi Hamilton syringe
was slowly lowered into the lateral ventricle to a depth of 1.8 mm from the dural
surface. The lateral ventricle was selected as the location for drug administration in
these studies as it was hypothesised that once injected into the ventricle, the
compound would diffuse through the CSF to the fourth ventricle and be taken up into
the suprachiasmatic nucleus (SCN; Figure B.5). After 10 min, the needle was slowly
withdrawn and the skin was sutured. The anaesthesia was then withdrawn and all of
the mice (moved and surgery groups) were placed back into their home cages within
4 h and their sleep/wake cycles were monitored as before.
Figure B.5 Coronal section of a C57BL/6J mouse brain. The coronal section
shown was taken from the Mouse Brain Library
(http://www.mbl.org) and represents a slice taken - 0.82 mm from
Bregma. For the in vivo studies described, the approximate location
of the needle tip is indicated in the ventricles by the asterisk. The
location of the SCN are also highlighted by the dashed circle.
B.4.3. Phase shifts
A second group of mice (16 adult C57BL/6J males, as before) were
entrained to a 12 h light/dark cycle (lights off: 1900 to 0700 h) as described above.
The effects on activity of introducing an 8 h phase advance, i.e. lights off: 1100 to
2300 h, were determined. The re-entrainment period was defined as the number of
24 h cycles that the animals took to entrain to the new light/dark cycle. The presence
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of activity bursts within the first 2 h of the novel dark cycle was also assessed. The
mice were subsequently re-entrained to the original light dark cycle (lights off: 1900
to 0700 h), following which the ability of the mice to adapt to a slightly shorter phase
advance (6 h; lights off: 1300 to 0100 h) was determined, with performance
measured as before. A 6 h phase advance was evaluated as its use would facilitate
the planned surgical intervention in the following study. This protocol would allow
for a 4 h treatment period during the animals inactive cycle, followed by a minimum
of 1 h in the home cage before the proposed phase-advanced lights off period began.
Following successful demonstration of stable entrainment to this shorter phase
advance, mice were re-entrained to a third light/dark cycle (lights on: 2000 - 0800 h),
in preparation for surgery.
B.4.4. Effect of PG99-465 on responses to phase shifts
Surgery was limited to 7 - 8 animals within the 4 h period. Therefore, on
the first treatment day, 7 mice were transferred from the holding room to the surgery
room, 1 h into their inactive cycle. The remaining subjects (9 mice) were maintained
on the pre-surgery light/dark cycle in a separate holding room. Surgery was
performed with administration of anaesthetic and insertion of a Hamilton
syringe/needle into the ventricle as described previously (section B.4.2., p 69). Prior
to insertion of the needle, the barrel of the syringe was filled with PG99-465 (0.1
mM; 8 mice) or vehicle (saline; 8 mice). During surgery, 1 pi of drug/vehicle was
injected into the lateral ventricle at a rate of 0.1 pl/min. Mice were returned to their
home cages at least 1 h before the onset of the dark phase of the new light/dark cycle
(lights off: 1400 - 0200 h). A three day gap was enforced between the two surgery
sessions (7 and 9 animals on day 1 and 2 respectively) to allow the initial group of
animals to respond to treatment with minimal disturbance.
B.4.5. Data analysis (in vivo studies)
The data output from the running wheels, i.e. number of magnet passes per
minute, was collected using Dataquest ART software. The data was subsequently
exported into MS Excel for analysis, where the intensity and timing of activity
patterns was analysed. Where appropriate, data were analysed using two-way
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ANOVA, with significant results interpreted after post hoc analysis with Tukey's test
(SigmaStat 3.0).
B.5. Materials
The following lists detail all of the chemicals and reagents used in the
studies described in this thesis, with the supplier of each chemical, in addition to its
reference number (where applicable) shown in parenthesis. Additional laboratory
resources (plasticware, cell lines etc.) and specific computer software utilised are
also described.




[Alau'22'28]VIP Tocris, UK (1386)
Anti-mouse Vectastain ABC kit Vector Laboratories (PK - 4002)
BME Sigma-Aldrich (B1522)
BSA Sigma-Aldrich (A7906)
CD1 lb antibody (mouse anti-rat) Serotec, UK (MCA 275G)
DMEM Sigma-Aldrich (D5671)
DMSO Sigma-Aldrich (D2650)
DNase (10, OOOU/bottle) Sigma-Aldrich (D4527)
F12 Hams media Sigma-Aldrich (N6658)
Fetal bovine serum Invitrogen (10106-169)
Fetal bovine serum (dialysed) Invitrogen (26400-044)
Forskolin Sigma-Aldrich (F3917)
Gentamicin Invitrogen (15710-049)
GFAP antibody (mouse anti-pig) Abeam, UK (Ab 8136)
Glucose (dextrose) Sigma-Aldrich (G5146)
HBSS (without Ca2+ or Mg2+) Sigma-Aldrich (H6648)
HBSS (lOx; with Ca2+ and Mg2+) Invitrogen (14065-049)
HEPES Sigma-Aldrich (H4034)
Horse serum Vector Laboratories (S - 2000)
Human brain cDNA template Clontech, USA
Hydrogen peroxide (30 %) Sigma-Aldrich (HI009)
IBMX Sigma-Aldrich (17018)




KiloBase DNA marker Amersham (27-4004-01)
Krebs-Ringer bicarbonate buffer Sigma-Aldrich (K4002)
LB agar Sigma-Aldrich (L2897)




McCoy's 5A media Sigma-Aldrich (M8403)
Mouse anti-rat CD1 lb Serotec, UK (MCA 275G)
Mouse anti-pig GFAP Abeam, UK (Ab 8136)
Non-essential amino acids Sigma-Aldrich (M7145)
PACAP-27 Synpep, USA or NeoMPS France
PACAP-38 Synpep, LTSA or NeoMPS, France
Paraformaldehyde Sigma-Aldrich (HT153020)
PG99-465 Albachem, UK (custom synthesized)
PG97-269 Phoenix Pharmaceuticals, USA (064-25)
pBluescript SK(-) Stratagene, USA
pcDNA3.1™(+) Invitrogen (V790-20)
Penicillin/streptomycin Sigma-Aldrich (P0781)
Phosphate buffered saline Invitrogen (20012019)
Poly-D-lysine Sigma-Aldrich (P6407)
Primers for PCR Invitrogen (custom synthesized)
Probenecid Sigma-Aldrich (P8761)
R3P65 Albachem, UK (custom synthesized)
RPMI 1640 Sigma-Aldrich (R0883)
Restriction enzymes Promega or New England Biolabs
Saline Ivex Pharmaceuticals
Sigmacote silicone solution Sigma-Aldrich (SL2)
Sodium bicarbonate Sigma-Aldrich (S6297)
Sodium hydroxide pellets Sigma-Aldrich (S8405)
Sodium pyruvate Sigma-Aldrich (S8638)
T4 DNA ligase Promega (Ml 801)
Triton X-100 Sigma-Aldrich (XI00)
Trypsin-EDTA solution Sigma-Aldrich (T4049)
Trypsin powder Sigma-Aldrich (T4665)
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Sulfinpyrazone Sigma-Aldrich (S9509)
Vector stain VIP substrate Vector Laboratories (SK - 4600)
VIP (for screening) Sigma-Aldrich (V3628)
VIP Synpep, USA or NeoMPS, France
B.5.2. Additional equipment and resources
24-well flat clear bottom clear plates
96-well flat clear bottom black plates
96-well flat clear bottom clear plates
384-well flat clear bottom clear plates
384-well flat clear bottom black plates
Running wheels, cages and magnets
Sprague-Dawley rat pups
(from an in-house breeding colony)
C57BL/6J adult male mice
Nylon gauze (125 pm mesh opening)
FlexStation® tips (96/box; clear)
FLIPR® tips (384/box; clear)
FLIPR® Calcium Plus Kit
FLIPR® Calcium 3 kit
Multi-welled glass microscope slides
CatchPoint® Cyclic-AMP Kit
Expand High Fidelity PCR Kit
Quantikine® ELISAs kits
TOPO TA Cloning® kit
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PHARMACOLOGY OF hVPAC/PAC RECEPTORS
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1.1. Introduction
1.1.1. VPAC/PACR coupling to signal transduction pathways
As described in the general introduction, one of the main characteristics of
GPCRs in the group B family, including VPAC/PAC receptors, is a ligand induced,
Gets dependent increase in intracellular cAMP ([cAMP];; Figure 1.1.1; Harmar,
2001). However, as is common for many GPCRs, including (32 adrenoceptors and
calcitonin receptors amongst others (Zhu el al., 1994; Aiyar el al., 1999; Xiao et al.,
1999), no exclusive signalling pathway exists. In addition to pathways that modulate
cAMP levels, VPAC/PAC receptor activation has also been observed to stimulate
phospholipase D (PLD) activity and intracellular calcium ([Ca2+]i; Figure 1.1.1)
production in both human and rat stable cell lines (Spengler et al., 1993; Sreedharan
et al., 1994; Pisegna & Wank, 1996; Xia et al., 1996; McCulloch et al., 2000). Only
a limited number of studies have described VPAC receptor mediated increases in
[Ca2+], in cells endogenously expressing hVPAC receptors (HT-29, Sreedharan et al.,
















Schematic of the main intracellular transduction pathways
stimulated by G-protein coupled receptors. The figure illustrates
the principal signalling pathways activated by 7-TM receptors
coupled to heterotrimeric G-proteins containing Gaq, Gas and Ga,
subunits (Jacoby el al., 2006).
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et al., 1994; CHO, Xia et al., 1997; Langer et al., 2002a). The transduction
mechanisms which contribute to the rise in [Ca2+]i reportedly include both G(Xj and
Gaq coupled pathways, with the Ga\ pathway reported to account for ~ 40 % of the
total [Ca2 ]i response in VPAC receptor expressing stable cell lines (for human and
rat receptors; MacKenzie et al., 1996; Langer & Robberecht, 2005). In contrast,
although hPACiR mediated stimulation of [Ca2+]j has also been reported in native
(SHSY-5Y: Eggenberger et al., 1999; NB-OK-1: Delporte et al., 1993) and
recombinant cell lines (CHO: McCulloch et al., 2000), this calcium transduction
pathway appears to be exclusively mediated via Gaq (MacKenzie et al., 1996; Van
Rampelbergh et al., 1997). The complex and differential coupling of VPAC/PACR
to pathways stimulating [Ca2+]i is paralleled in the mechanisms involved in
VPAC/PACR stimulation ofPLD activity. VPAC and PACi-hopl receptor mediated
elevations in PLD activity have been shown to be dependent on the small G-protein
ARF (ADP-ribosylation factor; McCulloch et al., 2000). In contrast, PLD
stimulation resulting from PACi-null receptor activation was shown to be entirely
independent of ARF, with a component of the response identified as PLC dependent
(McCulloch et al., 2000).
1.1.2. VPAC/PACR Iigand potencies in activating transduction pathways
In general, although cAMP, calcium and PLD can all be modulated by
VIP/PACAP stimulation of CHO cells over-expressing VPAC/PAC receptors,
production of the former second messenger occurs more readily than the latter two.
In the few studies in which PLD responses have been examined, VPAC/PAC
receptor agonists were on average ~ 70 fold less potent in stimulating PLD activity
than cAMP production in CHO cells expressing the rat VPACi, VPAC2 and PACi
receptors (McCulloch et al., 2000, 2001). However, for VPAC receptors even in the
presence of a considerable agonist induced cAMP response, sometimes no alteration
in calcium is observed (McCulloch et al., 2000; McCulloch et al., 2001). Moreover,
when an VPAC receptor mediated calcium signal can be detected, the EC50
concentration of agonist required to elicit this response varies considerably, ranging
from at least one to two orders of magnitude greater than that required for cAMP
(Sreedharan et al., 1994; Xia et al., 1996; Langer et al., 2001; MacKenzie et al.,
2001). This difference in agonist potency in stimulating cAMP and calcium
responses can also be seen for PACi receptors (Deutsch & Sun, 1992; Spengler et al.,
1993; McCulloch et al., 2001). As discussed below, assay methodologies and
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receptor expression levels have varied considerably in studies of VPAC/PAC
receptor pharmacology and it is therefore difficult to conclude exactly what underlies
the different agonist potencies for the various VPAC/PAC receptor transduction
pathways (Ciccarelli et al., 1994; Laburthe & Couvineau, 2002). Finally, species
differences for the individual receptor subtypes further complicates the interpretation
of published studies, when comparing different transduction pathways and receptor
pharmacology (Deutsch & Sun, 1992; Spengler et al., 1993; Gourlet et al., 1997;
Laburthe & Couvineau, 2002).
1.1.3. Functional studies characterising VPAC/PACR pharmacology
A diverse range of assay methodologies has been used to examine
VPAC/PACR pharmacology, particular in studies examining cAMP and calcium
production. Coupling of VPAC/PACR to Gas pathways has generally been
investigated using radioactive and non-radioactive assays to measure either AC
activity or [cAMPji production (Xia et al., 1997; Langer et al., 2003). In addition,
the varying use of whole cells or membranes adds a further complexity to the
methodologies adopted, with the majority of studies to date utilising membrane-
based approaches. Importantly, in recent years it has been shown that the potency of
VIP to induce cAMP production can vary as much as 30-fold between assays, on
switching from membranes to whole cells (Langer et al., 2002a). A range of
techniques can also be found upon examination of the methods used to measure
VPAC/PACR coupling to signaling pathways which stimulate calcium production.
In addition to directly monitoring calcium levels with fluorescent indicators such as
fura-2 and fluo-4 (Delporte et al., 1995; Masmoudi et al., 2003), luminescence based
approaches have been utilized (aequorin/coelenterazine assay; Langer et al., 2002a),
as have more indirect measures, such as the accumulation of inositol phosphate
which is often associated with calcium stimulation (MacKenzie et al., 2001). In
contrast, the assays that have been reported for investigating PLD activity show very
little variation (quantification of radiolabelled phosphatidylalcohol), perhaps because
only three groups have examined VPAC/PACR modulation of PLD (Morisset et al.,
1995; McCulloch et al., 2000; Dejda et al., 2006). Further variation emerges in
VPAC/PAC receptor cell based studies with regard to the specific characteristics of
the expression system utilised. Whether in cell lines in which the receptors are
endogenously expressed or in cells in which the receptors are stably transfected,
changing levels of receptor expression may influence the characteristics of the
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responses observed (Langer et al., 2002b; Langer & Robberecht, 2005).
Furthermore, in transfected cell lines, the nature of the host cell line may alter the
repertoire of agonist induced responses observed following VPAC/PAC receptor
activation. For example, hVPACiR have been shown to mediate calcium responses
via coupling to Gaq and Ga, (pertussis toxin sensitive) proteins in stably transfected
CFIO cells (Langer & Robberecht, 2005), however in HEK-293 cells expressing the
hVPACiR, no coupling to pertussis toxin sensitive G-proteins (GaO was observed
(Shreeve et al., 2000). This was despite the demonstration of agonist induced
calcium responses in that cell line (Sreedharan et al., 1994). These findings indicate
that the G-protein and second messenger complement of the cell line being examined
may introduce a further source of variation into the transduction
pathways/pharmacology observed for VPAC/PAC receptors (Laburthe & Couvineau,
2002; Langer et al., 2002b). Further variability in VPAC/PAC pharmacology of
different cell types may also involve the interesting interactions between these
receptors and receptor activity-modifying proteins (RAMPs). The RAMPs are single
transmembrane proteins which are reported to alter the trafficking, pharmacology,
and signalling characteristics of GPCRs (Hay et al., 2006). Sexton and colleagues
have shown that the VPACiR strongly interacts with RAMPs, with the specific
interaction with RAMP2 shown to augment VIP induced phosphatidylinositol (PI)
hydrolysis with no effect on cAMP responses (Figure 1.1.2; Christopoulos et al.,
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Figure 1.1.2. The modulation of VPACiR signalling by RAMP2. Co-
expression of hVPACiR and RAMP2 in COS cells enhances the
agonist induced hydrolysis of PI with no change in the cAMP
stimulation. This figure was modified from Sexton et al. (2006).
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interaction of VPAC2R with RAMPs (Sexton et al., 2006) and no examination of the
PACiR was reported. With the RAMPs shown to have a widespread distribution
throughout the nervous system and peripheral tissues, their potential influence on
VPAC/PACR pharmacology and signalling merits future consideration (Hay et al.,
2006). In addition, several studies of VPAC/PAC receptor pharmacology and
signaling mechanisms have only utilised rat receptors (McCulloch et al., 2001).
With differences in compound potencies observed in studies in which human and rat
receptors have been compared (Laburthe et al., 1983; Gourlet et al., 1998), it is
clearly not appropriate to extrapolate ROPs determined using rat VPAC/PAC
receptors to the human homologues. For this reason, caution must be applied when
comparing data from studies of multiple species, which adds further difficulty to the
complex task of clearly defining human VPAC/PAC receptor pharmacology from
published studies. Finally, even between reports from the same group, in which the
same cell line and assay methodology have been followed, potency differences arise.
For example in a membrane AC stimulation assay, VIP induced responses from the
same CHO-I1VPAC2R cell line were 6 fold different between published studies from
the Robberecht group (Vertongen et al., 2001; Nachtergael et al., 2003).
1.1.4. Systematic characterisation of VPAC/PACR pharmacology
To date, there is still no single study that systematically investigates
functional responses at all three human VPAC/PAC receptor subtypes, using a broad
range of agonists and antagonists. To provide a comprehensive characterisation of
human VPAC/PAC receptor pharmacology and eliminate variability arising from the
use of different assay and expression systems, CHO-K1 cell lines stably expressing
the three individual human receptor subtypes were generated, and standardised whole
cell, non-radioactive, HT-amenable, fluorescence based assays established to
measure [cAMPjj and [Ca2+]j. Agonist profiles for the transfected cell lines were
generated using the endogenous peptides VIP, PACAP-27 and PACAP-38, in
addition to the putatively VPACi ([Ala"l22'28]VIP; Nicole et al., 2000), VPAC2
(R3P65; Yung et al., 2003) and PACi (maxadilan; Moro & Lerner, 1997) receptor
selective agonists. The potency and selectivity of the reportedly receptor specific
antagonists, PG97-269 (VPACi; Gourlet et al., 1997a), PG99-465 (VPAC2; Moreno
et al., 2000), and M65 (PACi; Uchida et al., 1998) were also thoroughly examined.
Furthermore, using the same repertoire of peptide ligands, the pharmacology of the
hVPAC/PAC receptors were evaluated in cell lines which endogenously express the
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1.2.1. Sub-cloning of hVPAC/PACR
In order to generate mammalian cell lines stably expressing the three
hVPAC/PAC receptors, it was necessary to incorporate the receptor DNA sequences
into an appropriate mammalian expression vector prior to transfection. This process
was attempted first for the I1VPAC2R, as a commercially available, sequence verified
clone was identified, which encompassed the entire ORF (IOH9624 Invitrogen; 1317
nucleotides). The I1VPAC2R ORF was supplied in the pENTR™221 vector (2546
nucleotides), with the DNA construct provided already expressed in DhlOB™ E.
coli. As pENTR™221 has no promoter for mammalian expression, the hVPAC2R
was sub-cloned into pcDNA3.1™(+) vector (5428 nucleotides), which has the CMV
promoter.
1.2.1.1. Preparation of hVPAC/PACR cDNA for stable cell line generation
The initial cloning strategy involved the direct transfer of the insert into the
pcDNA3.1™(+) vector and a schematic of this procedure is illustrated in Figure B.l
(methods section, p 50). To prepare plasmid DNA, an innoculum of DhlOB™ E.
coli, expressing the pENTR™221-hVPAC2R clone, was streaked out onto agar
plates (overnight; 37 °C; kanamycin: 50 pg/ml) and three individual colonies were
picked to innoculate LB media. Plasmid DNA (MP 1-3) was then extracted and
purified using the Promega Wizard® Plus SV Minipreps DNA kit and eluted in
nuclease free water (100 pi). Elsing spectrophotometric analysis (A260), the
concentration of DNA in the minipreps MP1, MP2 and MP3 was calculated to be
157, 155 and 153 pg/ml, respectively. Restriction enzyme sites (for Aflll and
EcoRV) were identified on the pENTR™221 plasmid, which flanked either side of
the I1VPAC2R insert, with compatible recognition sequences also present in the
multiple cloning site of the pcDNA3.1™(+) plasmid. Digests with these enzymes
would therefore produce an I1VPAC2R insert and pcDNA3.1™(+) expression vector
sequences with compatible DNA ends for subsequent ligations. Single and double
enzyme digests with Aflll and EcoRV were performed (~ 2 pg DNA, 1 h, 37 °C)
using the three minipreps and pcDNA3.1™(+), with the digest products run on
agarose gels (1 %) and the DNA bands visualised under UV light (Figure 1.2.1).
Single digests of MP 1-3 produced DNA band sizes of just under 4 kb, consistent
with the expected size of linearised plasmid and insert (3863 nucleotides), with two
84
bands clearly visible following the double digest. The first band corresponded to the
excised insert (~1.5 kb) and the second, to linearised pENTR™221 plasmid sequence
(-2.3 kb; Figure 1.2.1). The single digests of pcDNA3.1™(+) generated bands on
the gel between 5 - 6 kb, consistent with the presence of linearised plasmid (5428
nucleotides), with the products from double digests being of a similar size, which
was as expected, given the proximity of the enzymes' recognition sequences within
the multiple cloning site (Aflll - 909 and EcoRV - 965). The bands corresponding
to the I1VPAC2R insert and linearised pcDNA3.1™(+) vector produced from the
double digests, were excised from the gel and the DNA extracted and purified.
Following extraction, the DNA was again visualised on a gel (Figure 1.2.2), with
fragments of the expected size present. Ligation reactions (T4 DNA ligase; 10 pi
reaction volume) were performed using the double digested, gel purified hVPACiR
insert and pcDNA3.1™(+) vector (ligated overnight; 16 °C). The ligation reaction
was then transformed into One Shot® TOP 10 E. coli and the bacteria were cultured
overnight on agar plates (ampicillin; 100 pg/ml). Individual colonies were used to
inoculate samples of LB media and following an overnight incubation (37 °C), the
DNA was extracted and double digested using Aflll and EcoRV. Digest products
from 6 of the cultures (1.1 - 1.6) are shown in Figure 1.2.3, where the absence of a
DNA band at approximately 1.5 kb indicated that none of these colonies contained
the ligated DNA. Despite several attempts to directly transfer the insert from
pENTR™221 into pcDNA3.1™(+), which included using other E. coli strains
(DH5a™) and different restriction enzymes (Nhel and EcoRV), none were
successful despite almost 50 colonies being examined. Throughout the process,
bacterial colonies grew as expected and all control reactions were successful,
suggesting that the transformation step had worked efficiently and leaving the
ligation reaction as the most likely point of failure in the process.
1.2.1.2. TOPO-TA cloning®
Due to the failure of the standard sub-cloning procedures, a TOPO-TA
cloning® strategy was adopted. This involved PCR amplification of the hVPAC2R
fragment and its insertion into a TOPO-TA cloning® vector (pCR®2.1-TOPO®),
before finally sub-cloning into pcDNA3.1™(+) (Figure B.2, p 53). Two primer pairs
were designed for PCR amplification of the hVPACaR insert; Fl/Rl and F2/R2 (see
methods for sequences, p 54). F1 and R1 were designed to amplify the entire length
of the I1VPAC2R insert and also contained restriction enzyme sites (F1 - Xbal; R1 -
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Hindlll), to facilitate the sub-cloning into pcDNA3.1™ (+). F2 and R2 were internal
primers and were used to check the integrity of the insert. PCR reactions were
performed using purified DNA from MP3 as described in the methods section (p 54).
PCR products were visualised on an agarose gel (Figure 1.2.4), with the full length
primers Fl/Rl producing an intense band of approximately 1.3 kb, correlating well
with the expected insert size; all other bands were as expected. The PCR product
containing the full length hVPAC2R insert was gel purified and ligated with the
pCR®2.1-TOPO® vector (TOPO-TA cloning®). As PCR amplification of DNA
using Taq polymerase generates a product with single deoxyadenosine overhangs at
the 3' ends, the pCR®2.1-TOPO® vector is supplied linearised with single
thymidine residue overhangs and is ideal for ligation. The ligation products were
then transformed using One Shot® TOP 10 E. coli, with colonies selected and
propagated and the DNA extracted as described previously. Restriction digests were
then performed with EcoRI, as it was expected to cut twice (residues 284 and 302),
on either side of the pCR®2.1-TOPO® cloning site (Figure B.2, p 53). Almost two
thirds of the colonies selected for analysis contained the PCR amplified I1VPAC2R
insert (1.3 kb; Figure 1.2.5). Five were selected for digestion with the restriction
enzymes Xbal and Hindlll, and the digest products visualised on an agarose gel.
This resulted in digest products which contained the full length insert sequence (-1.3
kb) and the remaining empty pCR®2.1-TOPO® plasmid (-3.9 kb; Figure 1.2.6a).
Parallel restriction digests were run with samples of pcDNA3.1™(+), to linearise the
plasmid and generate compatible ends for ligation with the hVPAC2R insert (Figure
1.2.6b). Three of the bands containing the I1VPAC2R insert were gel purified, as was
the linearised pcDNA3.1™(+) vector, with the recovered, gel purified products
visualised on a gel (Figure 1.2.7). Finally, samples of the gel purified, double
digested I1VPAC2R insert and pcDNA3.1™(+) vector were ligated, transformed (One
Shot® TOP 10 E. coli) and the DNA extracted as described previously. Restriction
digests (Xbal and Hindlll) were then carried out to determine if the ligation had been
successful. In the majority (13/15) of DNA samples examined (Figure 1.2.8) it
appeared that the hVPAC2R insert (~ 1.3 kb) had been successfully sub-cloned into
the pcDNA3.1™(+) expression vector (~ 5.4 kb). Therefore, a construct was created
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A: AfIII digest E: EcoRV digest DD: Aflll & EcoRV digest
Figure 1.2.1 Restriction enzyme digests of the pENTR™221 vector containing
the I1VPAC2R insert and the pcDNA3.1™(+) plasmid. DNA
from MP 1-3 (hVPAC2R-pENTR™221 construct) was digested with
Aflll and EcoRV to excise the I1VPAC2R insert from the entry
vector. In addition, products are shown from single digests with
each enzyme, with the equivalent digests of the pcDNA3.1™(+)
vector also presented.
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Figure 1.2.2 Gel purified I1VPAC2R inserts and linearised pcDNA3.1™(+)
plasmid. The inserts and plasmid (previously digested with Aflll
and EcoRV) were extracted from the gel in Figure 1.2.1 and run on a
second gel, confirming successful purification of the resultant DNA.
88
Figure 1.2.3 Double digests of DNA extracted from bacterial colonies
transformed with hVPAC2R-pcDNA3.1™(+) ligation reactions.
Products from the ligation of the I1VPAC2R insert and
pcDNA3.1™(+) vector were transformed into One Shot® ToplO E.
coli and bacterial cultures were prepared from the resulting colonies
(1.1 - 1.6). DNA was extracted from the cultures, enzyme digested
(with Aflll and EcoRV) and the DNA bands visualised on a gel to
determine the whether the insert (-1.3 kb) was present.
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F1/R1 F2/R2 GP PCR product
(F1/R1)








Figure 1.2.4 PCR amplification of the I1VPAC2R insert from the
pENTR™221 vector. Primers F1 and R1 were designed to amplify
the full length I1VPAC2R sequence (~1.3 kb), whereas F2 and R2
were designed to amplify a short section (0.5 kb) within the
sequence (a). The amplified insert was then gel purified and the
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Figure 1.2.5 Restriction enzyme digests of DNA extracted from One Shot®
TOPIO E. coli colonies, transformed with the TOPO-TA
cloning® reaction. DNA from the ligation reaction of the
pCR®2.1-TOPO® vector and the PCR amplified I1VPAC2R insert
was transformed into One Shot® TOPIO E. coli, cultured on agar
plates and selected colonies used to innoculate LB media cultures
(2.1 - 2.12). The DNA was extracted and purified from the cultures
and digested with EcoRI to evaluate the presence of the I1VPAC2R
insert (~1.3 kb), which was apparent in 8 of the DNA preparations.
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Figure 1.2.6 Enzyme digests of hVPAC2R-pCR®2.1-TOPO® and
pcDNA3.1™(+). Utilising the restriction sites incorporated into the
Fl/Rl primer sequences, hVPAC2R-pCR®2.1-TOPO® construct
samples were digested with Xbal and Hindlll to isolate the insert (a).
Parallel digests were run using pcDNA3.1™(+), in order to linearise
the plasmid and create compatible ends for the subsequent ligations
(b).
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Gel purified inserts and pcDNA3.1™(+)
hVPAC2R inserts pcDNA3.1 ™(+)
Figure 1.2.7 Products from gel purification of I1VPAC2R insert and linearised
pcDNA3.1™(+) vector. Xbal and Hindlll double digested
I1VPAC2R insert and pcDNA3.1™(+) plasmid DNA were extracted
from the agarose gel shown in Figure 1.2.6. Purified DNA samples
are shown above, confirming successful extraction from the agarose.
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Figure 1.2.8 Successful production of DNA constructs consisting of the
I1VPAC2R insert in the pcDNA3.1™(+) mammalian expression
vector. DNA from the ligation reaction of the I1VPAC2R insert and
pcDNA3.1™(+) vector was transformed into One Shot® TOP 10 E.
coli and cultured on agar plates. Selected colonies were used to
innoculate LB media cultures (3.1 - 3.15), and following an
overnight incubation (37 °C), the DNA was extracted and purified
from the cultures and enzyme digests were performed (Xbal and
Hindlll). The hVPACiR insert (~1.3 kb) was present in 13/15
colonies examined.
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1.2.1.3. Identification of a suitable host cell line
On examination of the literature, it appeared that CHO-K1 or HEK-293 cells
were suitable host cell lines in which to stably express VPAC/PACR, as the G-
protein complement of these cell lines included those subunits to which
VPAC/PACR couple (Gs, Gi, Gq; Van Rampelbergh et al., 1997; Wietfeld et al.,
2004). To ensure that these cell lines were appropriate host cells for transfection
with the hVPAC2R-pcDNA3.1™(+) construct, the presence of endogenous
VPAC/PACR was examined by stimulating the cells with an excess concentration of
PACAP-27 and monitoring both [cAMP]i and [Ca2+]j levels, with forskolin and ATP
respectively used as positive controls (Figure 1.2.9). The responses were compared
with those from SHSY-5Y cells, a human neuroblastoma cell line that is known to
express native VPAC/PACR (Vertongen et al., 1996). In the CHO-K1 cells,
PACAP-27 (1 pM) had no stimulatory effect in either assay, suggesting that these
cells do not express endogenous VPAC/PACR. In contrast, PACAP-27 (1 pM)
induced small responses in HEK-293 and SHSY-5Y cells, indicating the presence of
native VPAC/PAC receptors in these cell lines. These results indicated that CHO-K1
cells were the most suitable host cell line in which to stably express the hVPAC2R
construct. However, at this stage it was identified that three CHO-K1 cell lines
stably expressing human VPAQR, VPAC2R and PACiR had been generated
previously by Fujisawa (Japan) and were kindly gifted to our laboratory by Dr I.
Aramori. These three cell lines are the stable hVPAC/PACR cell lines described in
all the subsequent pharmacological studies, with the hPACiR being the PACi-null
variant described by Pisegna & Wank (1996).
1.2.2. Establishment and characterisation of [cAMP]j and [Ca2+]i assays for
the examination of human VPAC/PAC receptor pharmacology
The FlexStation® (Molecular Devices) is a bench-top fluorimeter with an
integrated system of optics, fluidics and temperature control. It is capable of running
96-well plates and is suitable for rapid characterisation of receptor pharmacology.
9+
Although routinely used for measuring [Ca ]j and membrane potential, at the outset
of these studies a 96 well plate, FlexStation® compatible [cAMPJj kit became
available from MD. As the [cAMPJi assay for the FlexStation® was new and we
were one of the first laboratories in the UK to use it, the protocol was optimised
before embarking on the hVPAC/PACR characterisation studies.
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1.2.2.1. Optimisation of [cAMP]j assay incubation period
The initial assay protocol recommended that cells be exposed to test
compounds for 15 min prior to cell lysis and measurement of [cAMPjj. To establish
whether 15 min was the optimal assay time, the time-course of agonist induced
[cAMP]i production was investigated using VIP (100 nM) and the CHO-I1VPAC2R
cell line (1 x 105 per well), with the assay then conducted as described in the methods
section (p 63). [cAMPjj concentrations in the cell lysates increased in a time-
dependent manner, peaking at 15 min of agonist exposure (Figure 1.2.10a),
confirming that this time-point was optimal. The second parameter verified was the
time at which fluorescence levels could be measured on the final assay plate. The
assay protocol stated that the final reading could be taken at any point between 10
min and 24 h following the addition of the substrate solution. In order to verify this,
a cAMP standard curve was generated and fluorescence levels compared over a
range of time points (Figure 1.2.10b). Fluorescence levels appeared to increase in a
time dependent manner up to 18 h following substrate addition, reaching a plateau
thereafter. Although the signal size increased, the shape of the standard curves
remained consistent with only a minimal increase in the EC50 for the standard curve
over the course of the experiment (t = 0, EC50: 5.23 nM; t = 48 h, EC50: 8.7 nM).
This result verified that fluorescence measurements to determine [cAMPjj could be
made up to 48 h.
1.2.2.2. Optimisation of cell densities for the [cAMP]i and [Ca2+]j assays
9+
The protocols for the [cAMPjj and [Ca ]j assays suggested that the
optimum cell density for a 96-well plate, was likely to fall between 0.2 and 1 x 105
cells per well, with the optimum number ultimately being dependent on the size and
growth characteristics of the cell line being tested. To establish optimal assay
conditions for the hVPAC/PAC stable cell lines, cells were seeded overnight at a
range of densities (0.5 - 1.5 x 105 cells per well) and agonist responses in the
[cAMP]j and [Ca2+]i assays measured using the FlexStation®. In the [Ca2+]j assay,
the response to a saturating concentration of agonist for each of the cell lines
increased with cell density, plateauing around 1 x 105 cells per well (Figure 1.2.11a-
c). Similarly in the [cAMPj; assay, the increasing cell density corresponded with a
rise in [cAMPjj, reaching a maximum at around 1.25 - 1.5 x 105 cells per well
(Figure 1.2.1 ld-f). For direct comparability, the cell number utilised in all
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subsequent experiments was set at 1 x 105 cells per well, as this density produced
consistent and near maximal responses in both assays.
1.2.2.3. Analysis of calcium traces
The final parameter to be established was the generation of a standardised
method for data analysis. For the [cAMPJj assay, this was straightforward, with the
standard curve used to define [cAMPJi in test wells using endpoint fluorescence
readings from those wells. The [cAMPJi levels measured were then plotted against
drug concentrations, giving concentration-response curves from which EC50/IC50
values could be determined. However, in the calcium assay the options for data
analysis are more numerous, and include maximum to minimum (max-min), area
under the curve (AUC), peak, slope and time to maximum. An example of the traces
produced following agonist stimulation of the CHO-hVPAC/PACR cell lines is
shown in Figure 1.2.12. Although the raw data sets associated with the individual
measures cannot be directly compared, processing the raw values into concentration-
response curves allowed a comparison of EC50 values to be calculated and provided a
parameter with which the different methods of analysis could be compared. Agonist
concentration-response curves in the calcium assay were compared with the three
most common measures (max-min, AUC and peak), for each of the hVPAC/PACR
cell lines (Figure 1.2.13: a - hVPACiR with VIP; b - hVPAC2R with PACAP-27; c -
hPACiR with PACAP-38). When the EC50 values for VIP, PACAP-27 and PACAP-
Table 1.2.1 Agonist potencies (EC50 values) from concentration response
curves produced from analysing calcium assay traces with max-
min, AUC and peak analyses.
hVPACiR with VIP hVPAC2R with PACAP-27 hPAC^ with PACAP-38
EC50 (nM) EC50 (nM) EC50 (nM)
Max-min 16.5 23.1 5.7
Peak 18.9 24.2 5.9
AUC 26.1 33.5 7.5
Values shown were produced from the concentration response curves shown in
Figure 1.2.13, for the agonist stimulation of CHO-hVPACiR, -hVPACiR and -
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Figure 1.2.9 [cAMP]i and [Ca2+]i responses following PACAP-27 application
to CHO-K1, HEK-293 and SHSY-5Y cells. The three cell lines
(cells per well: CHO-K1, HEK-293 - 1 x 105; SHSY-5Y - 1.25 x
105) were stimulated with buffer, PACAP-27 (1 pM) and either
forskolin (10 pM; [cAMP]j assay) or ATP (10 pM; [Ca2+]j assay),
which served as positive controls. The responses shown are
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Figure 1.2.10 Effect of altering the agonist exposure period and the final plate
read time on levels of cAMP detected. The concentration of
cAMP released from CHO-I1VPAC2R cells after VIP stimulation
(100 nM) increased with time and peaked at 15 min (a; n = 1).
Increasing the time prior to the final reading of the assay plate
produced a rise in fluorescence for all samples, although the overall
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Figure 1.2.11 Effect of hVPAC/PACR seeding density upon response size to
agonist. The hVPAC/PACR stable cell lines were seeded into 96-
well plates (0.5 - 1.5 x 105 per well) and stimulated with saturating
concentrations of agonists (hVPACR: VIP - 1 pM; hPACjR:
PACAP-27 - 1 pM) in the [cAMP]j and [Ca2+]j assays. The figures
shown are representative of three independent experiments.
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Figure 1.2.12 An example of the data traces produced in the calcium assay
following addition of increasing agonist concentrations to CHO-
hVPAC/PACR cells. CHO-hVPAC2R cells (1 x 105 per well) were
seeded overnight and stimulated with PACAP-38 (as indicated by
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Figure 1.2.13 Agonist concentration response curves for the calcium assay
generated using different data analysis methods. hVPACiR (a),
I1VPAC2R (b) and hPAQR (c) stable cell lines were stimulated with
VIP, PACAP-27 and PACAP-38 respectively. The resultant
fluorescence responses were measured using max-min, peak and
AUC analyses, and concentration response curves generated from
the data produced (n = 1). The EC50 value from each curve is
presented in Table 1.2.1.
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38 were compared for each receptor, it was evident that the different methods of
analysis did not greatly alter EC50 values in all three stable cell lines (Table 1.2.1).
As the different methods of analysis did not obviously affect the agonist potencies
calculated from the concentration response curves, additional factors were
considered when selecting the most appropriate measure to use for data analysis in
the [Ca2+]j assay. In these preliminary studies, baseline fluorescence levels in wells
were similar for individual cell lines, however well to well variation was observed
between baselines when different cell lines were used. The measurement of peak
values from such traces cannot accommodate this variation and may have reduced
the accuracy of the data, hence this measure was deemed unsuitable for data analysis.
In addition, as trace shape changed on progression from low to high agonist
concentrations (Figure 1.2.12) and between cell lines (section 1.2.3.3., p 106), the
use of AUC analysis may not have provided a fair comparison between data sets.
Therefore, max-min appeared to be the most accurate and reproducible measure with
which to process the data for comparison between different compounds and cell
types.
1.2.3. Pharmacology of hVPAC/PACR expressing stable cell lines
The pharmacology of human VPAC/PACR was systematically characterised
'y 1
using the CHO-K1 stable cell lines and the optimised [cAMPJj and [Ca ]i assays
described above. The potency of the classical agonists VIP, PACAP-27 and
PACAP-38 was determined, in addition to three reportedly receptor selective
agonists [Ala11'22'28]VIP (VPAC,R; Nicole et al., 2000), R3P65 (VPAC2R; Yung et
al., 2003) and maxadilan (PAQR; Moro & Lerner, 1997). The pharmacological
properties of the putatively receptor selective antagonists PG97-269 (VPACiR;
Gourlet et al., 1997a), PG99-465 (VPAC2R; Moreno et al., 2000) and M65 (PACiR;
Uchida et al., 1998) were also thoroughly investigated.
1.2.3.1. hVPAC/PACR agonist pharmacology - [cAMP], assay
The three endogenous agonists VIP, PACAP-27 and PACAP-38 increased
[cAMPji in all three stable cell lines in a concentration dependent manner (Figures
1.2.14a, 1.2.15a and 1.2.16a). These peptides were approximately equipotent at the
hVPACiR (Figure 1.2.14a; EC50 values: VIP = 0.109 ± 0.026 (7) nM; PACAP-27 =
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0.127 ± 0.018 (3); PACAP-38 = 0.218 ± 0.039 (4) nM) and at the hVPAC2R (Figure
1.2.15a; EC50 values: VIP - 0.628 ± 0.187 (6) nM; PACAP-27 = 0.383 ± 0.094 (3);
PACAP-38 = 0.528 ± 0.136 (4) nM), with all three marginally less potent at the latter
receptor (Table 1.2.2). At the hPACiR (Figure 1.2.16a), both PACAP-27 and
PACAP-38 exhibited picomolar potencies with EC50 values of 0.026 ± 0.003 (7) nM
and 0.049 ± 11 (3) nM respectively, resulting in these peptides being ~ 4 and ~ 10
fold more potent than at the hVPACiR and hVPAC2R. VIP however was ~ 40 times
less potent than the PACAP peptides, with an EC50 of 15.1 ± 2.76 (4) nM (Table
1.2.2). The reportedly VPACiR selective agonist [Alau'22'28]VIP was confirmed as a
potent sub-nanomolar peptide agonist at that receptor (EC50: 0.057 ±0.015 (4) nM).
In addition, this peptide was also a full agonist at the hPACiR, albeit at micromolar
concentrations (EC50: 1.49 ± 0.208 (3) pM), with a negligible effect at the
hVPAC2R. R3P65 (putatively VPAC2R selective) was a full agonist at the
hVPAC2R, demonstrating a similar potency (EC50: 1.75 ± 0.4 (4) nM) to the
endogenous agonists at this receptor (Table 1.2.2). However, in our hands R3P65
was not selective, eliciting full agonist responses at both hVPACi and hPACi
receptor expressing cell lines, with its highest potency (EC50: 0.268 ± 0.006 (4) nM)
at the former receptor subtype. In contrast, maxadilan was a highly selective and full
hPACiR agonist (EC50: 0.054 ± 0.009 (3) nM; Table 1.2.2), being equipotent with
both PACAPs, whilst eliciting no response at either of the hVPAC receptors. In all
three CHO-K1 cell lines expressing the hVPACiR, hVPAC2R or hPACiR, the
maximal concentrations of [cAMP]; produced from agonist stimulation were all
similar at around 50 nM and were approximately 25x basal levels (Figure 1.2.17),
suggesting comparable receptor expression levels.
In short, all agonist potencies generated using the [cAMP]j assay were
similar at hVPAC iR (excluding maxadilan), a trend also observed for hVPAC2R
(except [Ala11'22'28]VIP]), albeit with about a 4-fold lower potency at the latter
subtype (Table 1.2.2). As a result, agonist ROPs for these two cell lines in the
[cAMP]j assay were as follows: - hVPACiR: VIP = PACAP-27 = PACAP-38 =
[Ala11'22'28]VIP = R3P65, and - hVPAC2R: VIP = PACAP-27 = PACAP-38 =
R3P65. In contrast, at hPACiR, PACAP-27 and PACAP-38 were more potent than
at hVPAC iR and hVPAC2R (~ 4 fold) receptors, whereas VIP and R3P65 were more
than 100 times less potent compared to hVPACiR (Table 1.2.2). [Alan'22,28]VIP, the
most potent hVPAC iR agonist, was more than 4 orders of magnitude less potent at
hPACiR (EC50 = 1.49 ± 0.208 (3) pM), whereas maxadilan had sub-nanomolar
affinity at the latter receptor and even greater selectivity over both hVPACiR and
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I1VPAC2R. The resulting ROP for the hPACiR in the [cAMP], assay was therefore:
PACAP-27 = PACAP-38 = maxadilan > VIP = R3P65 > [Ala1 ''22'28]VIP.
1.2.3.2. hVPAC/PACR agonist pharmacology - [Ca2+]j assay
In the three stable cell lines expressing hVPAC/PACR (Figures 1.2.14b,
1.2.15b and 1.2.16b), the endogenous peptides VIP, PACAP-27 and PACAP-38 all
produced a concentration dependent increase in [Ca2+];. All three peptides had
similar potencies to each other at both hVPAC receptors (Table 1.2.2), with EC50
values ranging from 14 - 37 nM at the hVPACiR (VIP = 14.1 ± 0.9 (6) nM, PACAP-
27 = 22.6 ± 5.3 (8) nM, PACAP-38 = 37.4 ± 7.9 (10) nM) and 19 - 50 nM at the
I1VPAC2R (VIP = 49.6 ± 7.9 (10) nM, PACAP-27 = 23.9 ± 2.4 (6) nM, PACAP-38 =
19.4 ± 2.3 (8) nM). In agreement with the [cAMP]j assay, PACAP-27 and PACAP-
38 were potent hPACiR agonists (EC50 values of 5.0 ± 1.1 (9) nM and 4.7 ± 1.2 (6)
nM respectively; Table 1.2.2), whereas VIP was considerably less potent at this
receptor subtype when compared to the hVPAC receptors (~ 10 fold; EC50 = 405 ±
36.3 (5) nM). These three peptides were clearly less potent in the [Ca2+]j assay than
in the [cAMP]j assay, with EC50 values being approximately 100 fold less (Table
1.2.2). [Ala"'22'28]VIP was a potent hVPACiR agonist in the calcium assay (EC50:
26.8 ± 2.0 (5) nM; Figure 1.2.14), however it had no effect at the hVPAC2R (Figure
1.2.15) or the hPACiR (Figure 1.2.16). The lack of effect of [Ala11'22'28]VIP at the
hPACiR (EC50 = 1.49 ± 0.2.8 (3) pM in the [cAMP]; studies; Table 1.2.2), may have
been due to an insufficient concentration of compound being added. R3P65 was
once more not hVPAC2R selective, being slightly more potent at hVPAC iR (EC50
values of 108 ± 18.4 (6) nM and 86.1 ± 1.3 (4) nM respectively; Table 1.2.2). R3P65
was a full agonist at the hPACiR (Figure 1.16b; EC50 = 0.59 ± 0.089 (6) pM),
although it was 5 fold less potent than at the hVPAC receptors. In agreement with
the [cAMP]j data, maxadilan was equipotent with PACAP-27 and PACAP-38 at the
hPACiR (EC50 = 12.6 ± 2.3 (12) nM), whilst being highly receptor selective with no
agonist effects in the hVPACR cell lines (Table 1.2.2). The resulting ROPs for each
9+
VPAC/PAC receptor in the [Ca ]j assay were consistent with those generated from
the [cAMP]i assay, being: - hVPAQR: VIP = PACAP-27 = PACAP-38 =
[Ala"'22'28]VIP > R3P65, - hVPAC2R: VIP = PACAP-27 = PACAP-38 > R3P65 and
- hPACiR: PACAP-27 = PACAP-38 = maxadilan > VIP = R3P65. The calcium dye
9+
used in the FlexStation® [Ca ]j assay is non-ratiometric and although it was not
9+
possible to determine the exact [Ca ];, the average maximal response elicited from
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the three stable cell lines following exposure to a saturating concentration of agonist
produced comparable levels of fluorescence (~ 17,000 RFU), all of which were
approximately 7x basal levels (Figure 1.2.17a-c). This is consistent with the
equivalent levels of agonist induced [cAMP]i observed in all three cell lines.
In short, the peptides VIP, PACAP-27, PACAP-38 and R3P65 all had
similar potencies in CHO-K1 cells expressing either hVPACiR or I1VPAC2R. This
finding was similar in both the [cAMP]j and [Ca ]j assays, although there was
approximately a two order of magnitude difference in the EC50 values generated in
the two assays (Table 1.2.2). At the hPACjR, PACAP-27, PACAP-38 and
maxadilan were again the most potent agonists, despite the 100-fold reduction in
potency (Table 1.2.2). This is clearly illustrated in Figure 1.2.18, which shows a
correlation of the agonist potencies from the [cAMPJj and [Ca2+]j assays, for all three
hVPAC/PACR subtypes. Regression analysis (r2 = 0.85) confirmed that the agonists
were approximately 100 fold less potent in the calcium assay.
1.2.3.3. hVPAC/PACR agonists - [Ca2+]j assay traces
In contrast to the [cAMPJi assay, which uses an endpoint fluorescence
7+
reading, the data generated using the [Ca ]j assay is produced in a 'real-time'
format, with a reading taken from each well every 1.27 s. In addition to measuring
max-min responses, the overall shapes of traces can be analysed, thereby providing
an alternative source of information to compare the different cell lines and the effects
of compounds. Figure 1.2.19 shows representative sets of fluorescence traces
produced by agonist stimulation of the three CHO-hVPAC/PACR cell lines. The
traces were produced using a range of agonist concentrations, with fluorescence
levels generally monitored for up to 90 s. In general, the agonist induced responses
at hVPACiR and I1VPAC2R were very similar, consisting of an initial rapid increase,
which gradually declined to approximately 40 % of the peak response at the end of
the 90 s period (Figure 1.2.19). However, the traces produced for the hPACiR were
more complex, with the various agonists inducing responses that appeared to decline
at a slower rate than those observed from the hVPAC receptors (Figure 1.2.19). To
quantitatively compare these observations, the magnitude of the agonist response at
the end of the 90 s period was measured for all of the agonist assays performed
during the current studies of CHO-hVPAC/PACR pharmacology (Figure 1.2.20),
with data presented as the percentage of the peak response for each agonist. As
predicted, agonist induced responses at 90 s for both hVPAC receptor cell lines were
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Figure 1.2.14 Characterisation of hVPAC,R using the [cAMP], and [Ca2+],
assays. CHO-hVPAC,R cells (1 x 105 per well) were stimulated
with a range of VPAC/PACR agonists and [cAMP], (a) and [Ca2+]j
(b) responses measured. The concentration response curves shown
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Figure 1.2.15 Characterisation of hVPAC2R using the [cAMPJj and [Ca2+]i
assays. CHO-hVPAC2R cells (1 x 105 per well) were stimulated
with a range of VPAC/PACR agonists and [cAMPJj (a) and [Ca2+]j
(b) responses measured. The concentration response curves shown













































Figure 1.2.16 Characterisation of hPACiR using the [cAMP], and [Ca2+]j
assays. CHO-hPACiR cells (1 x 105 per well) were stimulated with
a range of VPAC/PACR agonists and [cAMP], (a) and [Ca2+]i (b)
responses measured. The concentration response curves shown are
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Figure 1.2.17 Maximum peptide induced [cAMP]i and [Ca +]j responses from
CHO-hVPAC/PACR cells. Agonist responses shown are the mean
maximum responses (± SEM) taken from the top of each
concentration response curve which contributes to the EC50 values
shown in Table 1.2.2. [cAMPJj and [Ca2+]j stimulations in response















Figure 1.2.18 Correlation of agonist EC50 values for stimulation of [cAMP]j
and [Ca2+]j responses in CHO cells expressing hVPACj, hVPAC2
and hPACi receptors. Mean EC50 values for the agonists VIP,
PACAP-27, PACAP-38, [Ala11'22'28]VIP, R3P65 and maxadilan were
taken from Table 1.2.2, generating a correlation coefficient (r2) of
0.85 using a linear regression analysis (95 % confidence levels are
represented by the dashed lines). The receptor subtypes are

















Figure 1.2.19 FlexStation® calcium assay traces from agonist stimulation of
CHO-hVPAC/PACR cells. Representative traces shown are from
agonist stimulation of the three stable cell lines (1 x 105 cells per






















































Figure 1.2.20 Magnitude of agonist evoked calcium responses from CHO-
hVPAC/PACR cells at 90 s. From each concentration response
curve used to generate the data in Table 1.2.2, response sizes at 90 s
were measured from fluorescence traces produced from stimulation
of CHO-hVPACiR (a), -hVPAC2R (b) and -hPACiR (c) cells. The
traces selected for analysis were generated from stimulation of the
cell lines with agonist concentrations that produced maximal


































Figure 1.2.21 Magnitude of agonist evoked calcium responses from
hVPAC/PACR expressing cell lines at 200 s. The three cell lines
were stimulated with VIP, PACAP-27 and PACAP-38 and the
maximum responses (a) and the responses at 200 s (b) were
measured from the fluorescence traces. Peptides were tested at 1 pM
for the hVPACR cell lines and at 3 pM (VIP) and 0.1 pM (PACAP)

















































Figure 1.2.22 Magnitude of agonist induced [Ca2+]j responses from
hVPAC/PACR expressing cell lines, using calcium free assay
conditions. hVPAC/PACR cells were stimulated with saturating
concentrations of agonist and the maximum responses (a) and the
responses at 200 s (b) were measured. Peptides were tested at 1 pM
for the hVPACR cell lines and at 3 pM (VIP) and 0.1 pM (PACAP)
for the hPACiR cell line.
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of a similar magnitude, being approximately 40 - 50 % of the peak fluorescence
response (Figure 1.2.20). In contrast, at the hPACiR fluorescence measurements at
90 s were as large as 70 - 80 % of the peak response. To examine these findings in
greater depth, agonist induced responses for all three cell lines were examined at 200
s. With compound stocks limited, only VIP, PACAP-27 and PACAP-38 induced
responses were examined. All three agonists were used at a concentration of 1 pM
for the hVPACR cell lines, with the concentration of VIP increased (3 pM) and the
PACAP peptides decreased (0.1 pM) when examining hPAQR responses. The peak
fluorescence response produced with the agonists for all three cell lines were, as
expected, of a similar magnitude (18,000 - 20,000 RFU; Figure 1.2.21a). After 200
s the response size from the hVPACR cell lines was negligible for all three agonists,
being less than 10 % of the peak response. In contrast, the responses from the
hPACiR cell line remained elevated after 200 s, however the magnitude of this event
was ligand dependent (Figure 1.2.21b). VIP induced responses from hPACiR were ~
30 % of the peak response at 200 s, whereas the PACAP-27 and PACAP-38
responses remained high at ~ 80 % of the peak response. To examine the possibility
that the enhanced signal sizes observed for the hPACiR (at 200 s) with the PACAP
peptides were a result of extracellular calcium entry during the assay, a similar
experiment was conducted using a 'calcium free' assay, with calcium free buffers
used throughout. Once again, the maximal response for each cell line was
comparable, although the magnitude was reduced by almost 50 % (9,000 - 13,000
RFU) when compared to previous studies using calcium containing buffers (Figure
1.2.22a). The responses produced by VIP, PACAP-27 and PACAP-38 for all three
cell lines were of a similar magnitude at 200 s, being approximately 20 % of the peak
'calcium free' response. This finding suggests that the slower rate of decline of
PACAP peptide induced responses at hPACiR may be due to an additional
component involving extracellular calcium influx.
1.2.3.4. hVPAC/PACR antagonist pharmacology
The pharmacological characteristics of the three putatively receptor
selective antagonists PG97-269, PG99-465 and M65 were examined using the
hVPAC/PAC stable cell lines. Representative concentration effect curves for each
antagonist (in both assays) are shown in Figures 1.2.23 - 1.2.25, with the appropriate
quantitative measures (IC50/EC50) summarised in Table 1.2.3.
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When tested alone at concentrations up to 3 pM, neither PG97-269 or M65
had any significant effect on [cAMP]j or [Ca2+]i in the three hVPAC/PACR stable
cell lines (Figures 1.2.23 - 1.2.24, 1.2.17). However, the reportedly VPACiR
selective antagonist PG97-269 did produce a concentration dependent inhibition of
the VIP induced [cAMP], and [Ca2+]j responses in cells expressing hVPACiR (IC50
values: 80.0 ±3.2 (3) nM and 9.9 ± 2.1 (7) nM respectively), although with slightly
less potency in the former assay (Figure 1.2.23; Table 1.2.3). PG97-269 was
selective, having no effect on agonist induced responses at either I1VPAC2R or
hPACiR in both second messenger assays (Figure 1.2.29). M65 was as receptor
selective as PG97-269, inhibiting PACAP-27 induced [cAMPJi and [Ca2+]j responses
at hPACiR with a similar potency (IC50 values: 149 ± 13 (3) nM and 282 ± 55 (5) nM
respectively), whilst having no effect on agonist activity at hVPAC receptors
(Figures 1.2.24, 1.2.29; Table 1.2.3). Typical calcium assay traces showing the
reduction of the agonist stimulated responses by PG97-269 (at the hVPACiR) and
M65 (at the hPACiR) are shown in Figure 1.2.29. In contrast to PG97-269 and M65,
the pharmacological activity of PG99-465, the supposedly hVPAC2R selective
Table 1.2.3 Comparison of IC50 (and EC50) values for antagonist inhibition
of agonist induced [cAMPh and [Ca2+]j responses in CHO-K1
cells stably expressing hVPACi, hVPAC2 and hPACi receptors
PG97-269 PG99-465 M65
IC5o/*EC50 ± SEM (nM)
[cAMP], 80.0 ± 3.2 (3) *8.04 ± 1.9 (5) NE
hVPAC^
[Ca2+]j 9.90 + 2.1 (7) - NE
[cAMP]| NE 22.9 ± 5.7 (4) NE
hVPAC2R
*4.9 ± 0.4 (3)
partial agonist (10-20 % max)
[Ca2+]j NE 4.4 ± 0.8 (6) NE
[cAMP]i NE *71.3 ±9.6 (6) 149 ± 13 (3)
hPACiR
[Ca2+]i NE -- 282 ± 55 (5)
IC5o/*EC5o values are shown as the mean ± SEM, with the number of
independent experiments given in parenthesis. NE is no effect at 3 pM. In the
calcium assay, PG99-465 had no clear or reproducible effect on the agonist
induced responses from CHO-hVPACiR or -hPACiR cell lines.
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antagonist, was considerably more complex.
At the hVPAC2R, PG99-465 produced a concentration dependent inhibition
of the VIP induced [cAMPJj response (IC50: 22.9 ±5.7 (4) nM), plateauing at 80 %
inhibition (Figure 1.2.25a, Table 1.2.3). This is most likely explained by the
observation that when tested alone, this putative VPAC2R antagonist acted as a
partial agonist at the I1VPAC2R in the [cAMPJj assay, inducing a response that was
10-20 % of the maximum, with an EC50 of 4.9 ± 0.4 (3) nM (Figure 1.2.17 and
1.2.25a; Table 1.2.3). However, PG99-465 did produce a complete inhibition of the
agonist induced [Ca2+]j response at the hVPAC2R (see Figure 1.2.29 for illustrative
fluorescence traces), having a marginally higher potency (IC50: 4.4 ± 0.8 (6) nM;
Figure 1.2.25b), when compared with its EC50 value in the [cAMPji assay (Table
1.2.3). In the [cAMPji assay, PG99-465 acted as a potent, full agonist at hVPACiR
(EC50 = 8.04 ± 1.9 (5) nM) and hPACiR (EC50 = 71.3 ± 9.6 (6) nM), with nanomolar
potency (Figure 1.2.26; Table 1.2.3). Studies examining PG99-465 inhibition of
agonist induced responses at hVPACiR and hPACiR in the [cAMPJj assay were
therefore complicated, with the stimulatory effects of PG99-465 appearing to act
synergistically with the EC50 concentration of agonist (illustrated for the hVPACiR
in Figure 1.2.27). In the [Ca2+]i assay, PG99-465 did not have any clear or consistent
effects on agonist stimulated responses at hVPACiR and hPACiR, and when applied
alone at concentrations of up to 3 pM, this peptide had no effect in any of the three
hVPAC/PACR stable cell lines (Figure 1.2.17). The agonist activity of PG99-465
was specific to the CHO-hVPAC/PACR cells, as this peptide did not stimulate
[cAMPJj or [Ca2+]j responses in CHO-K1 host cells (Figure 1.2.28). These findings
clearly emphasize the complex and variable actions of this peptide at hVPAC/PACR.
In summary, PG97-269 and M65 were found to be selective hVPACiR and
hPACiR antagonists respectively in both second messenger assays. Whilst the
reportedly selective I1VPAC2R antagonist PG99-465 did antagonise agonist induced
responses at I1VPAC2R (both assays), this peptide also displayed agonist activity at
all three hVPAC/PACR when applied alone in the [cAMPji assay. However, these
2d"effects were not observed in the [Ca ]j assay.
1.2.4. VPAC/PACR pharmacology in cell lines endogenously expressing the
receptors
Having systematically characterized the pharmacology of human
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[Ca2+];: IC50 = 9.9 ± 2.1 nM (n = 7)
Buffer ■
VIP •
VIP plus PG97-269 □
PG97-269 alone V
-vn
Buffer VIP -10 -9 -8 -7 -6 -5 -4
[PG97-269] Log M
Figure 1.2.23 Inhibition of agonist evoked [cAMP]j and [Ca2+]j responses by
PG97-269 in CHO-hVPACiR cells. Representative inhibition
curves are shown for both assays ([cAMP],: a; [Ca2+]j: b), in which
cells (1 x 105 per well) were pre-incubated (10 min) with PG97-269,
prior to the addition of VIP ([cAMPJj: 0.3 nM; [Ca2+]j: 30 nM).
























[cAMPJi: IC50 = 149 ± 13 nM (n = 3)
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PACAP-27 plus M65 O
M65 alone ®
Buffer P-27 -10 -9 -8
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Figure 1.2.24 Inhibition of agonist evoked [cAMP]j and [Ca2+], responses by
M65 in CHO-hPACiR cells. Representative inhibition curves are
shown for both assays ([cAMP]j: a; [Ca2+]j: b), in which cells (1 x
105 per well) were pre-incubated (10 min) with M65, prior to the
addition of PACAP-27 ([cAMP]i: 0.1 nM; [Ca2+]i: 30 nM). Mean
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[Ca2+]j: IC50 = 4.4 ± 0.8 nM (n = 6)
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Figure 1.2.25 Inhibition of agonist evoked [cAMP]j and [Ca2+]i responses by
PG99-465 in CHO-hVPAC2R cells. Representative inhibition
curves are shown for both assays ([cAMP]j: a; [Ca2+]j: b), in which
cells (1 x 105 per well) were pre-incubated (10 min) with PG99-465,
prior to the addition of VIP ([cAMPJj: 3 nM; [Ca2+]i: 300 nM).
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Figure 1.2.26 Concentration response curves showing VIP, PG99-465 or
PACAP-27, induced stimulation of [cAMP]j in hVPACi and
hPACi receptor expressing cell lines. The hVPACiR (a) and
hPACiR (b) cell lines (1 x 105 cells/well) were exposed to the
peptides for 15 min before cells were lysed and [cAMP]j levels
determined. Mean EC50 values ± SEM (n > 3) are shown for PG99-













VIP plus PG99-465 <$>
0
Buffer VIP -11 -10 -9 -8 -7 -6 -5
[PG99-465] Log M
Figure 1.2.27 Synergism of VIP and PG99-465 stimulated [cAMPjj responses
from CHO-hVPACjR cells. CHO-hVPAQR cells (1 x 105 per
well) were pre-incubated (10 min) with increasing concentrations of
PG99-465, prior to the addition of VIP (0.3 nM; ~ EC50
concentration). The graph shown is representative of four
































Buffer -9 -8 -7 -6 ATP
[PG99-465] Log M
Figure 1.2.28 PG99-465 has no stimulatory effect on [cAMP]i and [Ca2+]j levels
in CHO-K1 host cells. In both the [cAMP]j (a) and the [Ca2+]i (b)
assays, PG99-465 (up to micromolar concentrations) failed to
stimulate responses from CHO-K1 host cells (1 x 105 per well; n =
1). The positive controls forskolin (F; 10 pM) and ATP (10 pM) are






Figure 1.2.29 Traces illustrating the effects of VPAC/PACR antagonists on
agonist induced calcium responses from CHO-hVPAC/PACR
cells lines. Representative traces are shown for the antagonism of
VIP (hVPACiR; 30 nM, hVPAC2R: 100 nM) and PACAP-27
(hPACiR: 30 nM) induced responses from the hVPAC/PACR stable
cell lines. Antagonists (0.01 nM - 3 pM) were pre-incubated with
the cells for 10 min, prior to agonist addition and fluorescence
measurement (90 s recording) in the FlexStation®.
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then performed using cell lines that endogenously express the receptors to ensure that
the observed findings were not a consequence of altered expression levels or G-
protein complement as discussed in the introduction to this chapter (p 77). SHSY-
5Y cells which natively express PACiR were the primary focus of these studies,
although the pharmacological characteristics of hVPAC receptors expressed in HT-
29 (hVPAC iR) and SUP-T1 (I1VPAC2R) cells were also partially characterised.
1.2.4.1. hVPAC/PACR agonist pharmacology in SHSY-5Y cells
For SHSY-5Y cells, the pharmacology of VPAC/PAC receptors was
examined using the same six agonists and three antagonists used with the
hVPAC/PACR stable cell lines. All of the agonists induced a concentration
11 22 28
dependent increase in [cAMPJi, except [Ala ' ' ]VIP although this was probably
due to its low micromolar potency (Figure 1.2.30a). PACAP-27 (EC50 = 0.13 ± 0.02
(3) nM), PACAP-38 (EC50 = 0.56 ± 0.11 (4) nM) and maxadilan (EC50 = 0.37 ± 0.05
(3) nM) were highly potent, sub-nanomolar agonists with similar EC50 values in the
[cAMPJi assay (Table 1.2.4). The remaining full agonists, VIP (EC50 = 26.2 ± 6.6
(5) nM) and R3P65 (EC50 = 13.4 ± 0.98 (3) nM), were approximately 60 fold less
potent, with [Ala11'22'28]VIP being more than 5,000 fold weaker (Figure 1.2.30a;
Table 1.2.4). Therefore, the agonist ROP determined for SHSY-5Y cells in the
[cAMPJi assay was consistent with the CElO-hPACiR cells (PACAP-27 = PACAP-
38 = maxadilan > VIP = R3P65 > [Alan'22'28]VIP). In the [Ca2+]i assay, an identical
Table 1.2.4 EC50 values for peptide induced [cAMP]i and [Ca2+]j stimulation
in SHSY-5Y cells
VIP PACAP-27 PACAP-38 [Ala11,22,28]VIP
EC50 ± SEM (nM)
R3P65 Maxadilan
26.2 ±6.6 0.13 ±0.02 0.56 ±0.11 Agonist from 13.4 ±0.98 0.37 ±0.05
[cAMP]i
(5) (3) (4) 1 |jM (3) (3)
[Ca2+]i
544 ± 57 12.7 ± 1.6 9.57 ± 1.3 1.49 ± 0.28 16.2 ±2.55
NE
(7) (14) (9) (JM(7) (10)
EC50 values are shown as the mean ± SEM, with the number of independent
experiments given in parenthesis. NE is no effect at 3 pM.
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rank order of potency was observed for the agonists, albeit with a decrease in
potency of about 100 fold (Figure 1.2.30b; Table 1.2.4). The increasing fluorescence
responses observed with each agonist are illustrated in Figure 1.2.31. Interestingly,
both PACAP-27 and PACAP-38 appeared to produce maximum responses in the
calcium assay that were almost double the size of those produced by the other
agonists (Figure 1.2.30b), therefore further investigation of the maximum agonist
induced responses was performed with both assays.
When maximum [cAMPJj responses were calculated using the data for all
the agonist concentration response curves, the levels produced from SFISY-5Y cells
proved to be variable. Indeed, separate assays using the same ligand yielded
maximum responses that were up to four fold different (for VIP: 2.2 to 8.8 nM). For
this reason, a comparison of agonist induced maximal responses in these cells was
directly compared, using saturating concentrations of all six agonists on one assay
plate (values shown are an average from three independent experiments; Figure
1.2.32a). From this study, all of the agonists (except [Ala11'22'28]VIP) induced similar
maximal [cAMPJj responses, ranging from 12.6 to 15.1 nM (4 - 5x basal). Although
these values were marginally higher than the average maximal responses from all
combined SHSY-5Y experiments (5.1 nM and 10 fold lower that that observed for
the stable cell lines), this study confirmed that the ligands used all induced a similar
maximal response (Figure 1.2.32a). When tested at concentrations of up to 3 pM,
the hVPACiR agonist [Ala"'22'28]VIP was only capable of stimulating a [cAMPJj
response that was approximately two thirds smaller than that detected with the other
five agonists, probably as a consequence of the low potency of this agonist. In
2+ 11 22 28similar experiments performed using the [Ca ]; assay, [Ala ' ' ]VIP did not elicit
any calcium response (as expected from the concentration response studies), whereas
VIP, R3P65 and maxadilan evoked changes in fluorescence of ~ 3 fold above basal
levels and with the overall fluorescent signal being ~ 3 fold less than that observed
with the stable cell lines (Figure 1.2.32b). Interestingly, in the same experiments
PACAP-27 and PACAP-38 induced a [Ca2+]i response which was almost double that
observed for VIP, R3P65 and maxadilan (Figure 1.2.32b), as had been indicated by
the representative concentration response curves in Figure 1.2.30b. In a small
number of experiments in which PACAP stimulated calcium responses were
examined, there was an indication of agonist activity at two sites (as illustrated by the
dashed line in Figure 1.2.33). Attempts were made to investigate this phenomenon,
with twice the number of agonist concentrations used in the standard assays.
However, the biphasic response was not always evident and as a consequence it was
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Figure 1.2.30 Characterisation of hVPAC/PACR in the SHSY-5Y cell line
using the [cAMPJj and [Ca2+]j assays. SHSY-5Y cells (1.25 x 105
per well) were stimulated with a range of VPAC/PACR agonists and
o | #
[cAMPJj (a) and [Ca ]j (b) responses measured. The concentration
response curves shown are representative, with mean EC50 values ±
SEM (n > 3) shown in Table 1.2.4.
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Figure 1.2.31 FlexStation® calcium assay traces produced from VPAC/PACR
agonist stimulation of SHSY-5Y cells. Representative traces
shown are for agonist stimulation of SHSY-5Y cells (1.25 x 105 cells
































Figure 1.2.32 Maximum peptide induced [cAMPJi and [Ca ]i responses from
SHSY-5Y cells. Maximum [cAMP]j responses (a) from SHSY-5Y
cells were determined from three independent experiments, in which
cells (1.25 x 105 per well) were stimulated with saturating
concentrations of peptides (3 pM or 0.3 pM for maxadilan and the
PACAP peptides). Mean [Ca2+]j responses (b) were calculated from
the upper plateau of the concentration response curves used to
calculate the potencies in Table 1.2.4 (n > 3). In both assays,
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Figure 1.2.33 Biphasic PACAP-38 induced calcium responses in SHSY-5Y
cells. On some occasions the PACAP peptides stimulated a biphasic
calcium response from SHSY-5Y cells. The figure shows a
representative example of this response (dashed line), compared
against a typical maxadilan concentration response curve for this cell
line. This biphasic nature of the PACAP response was not always


























Magnitude of agonist evoked calcium responses from SHSY-5Y
cells at 90 s. From each concentration response curve used to
generate the data in Table 1.2.4., response sizes at 90 s were
measured from the fluorescence traces produced from stimulation of
SHSY-5Y cells. The traces selected for analysis were generated
from stimulation of the cells with agonist concentrations that
produced maximal responses (see Figures 1.2.30b).
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general, the agonist potencies in SHSY-5Y cells for both assays (Table 1.2.4) were
very similar (3.3 fold lower) to that observed for the hPACiR stable cell line (Table
1.2.2). In addition, and as observed with the hPACiR stable cell, agonist potencies
2_|_
were consistently lower in the [Ca ]j assay (~ 60 fold), irrespective of the
considerably lower levels of hPACiR expression (Table 1.2.4).
As the agonist pharmacology indicated that SHSY-5Y cells expressed
endogenous hPACiR (predominantly), the traces produced following agonist
2+stimulation in the [Ca ]j assay were examined in more detail, to investigate whether
PACAP induced calcium responses had both an intracellular and extracellular
component (as described earlier for the CHO-hPACiR cell line, p 117). As before,
fluorescence levels at 90 s were expressed as a percentage of the maximum response
for each agonist (Figure 1.2.34). From this data, PACAP-27, PACAP-38 and
maxadilan stimulated responses (at 90 s) were approximately 60 % of their peak
values, whereas VIP and R3P65 induced responses had declined to approximately 40
%. Unfortunately the analysis was not extended to 200 s for SHSY-5Y cells as
response sizes became too small and variable. Flowever, the slower rate of decline of
the PACAP responses at 90 s is consistent with the effects described (at 200 s) for
the agonist traces produced using the hPACiR stable cell line (Figure 1.2.21).
Moreover, due to limited compound stocks, it was not possible to test maxadilan at
200 s, therefore it remains to be determined whether there is a reduced rate of decline
with this peptide.
1.2.4.2. VPAC/PACR antagonist pharmacology in SHSY-5Y cells
The pharmacological properties of the reportedly selective PACiR
9+
antagonist M65, were examined in the [cAMP]i and [Ca ]i assays using the SHSY-
5Y cell line. M65 fully inhibited PACAP-27 (~ EC50 concentration) induced
responses from SHSY-5Y cells, in a concentration dependent manner, being
equipotent in both assays with IC50 values of 37.5 ± 5.6 (4) nM ([cAMP]g Figure
1.2.35a) and 13.6 ± 2.1 (5) nM ([Ca2+]j; Figures 1.2.35b, 1.2.36; Table 1.2.5). As the
PACAP induced calcium responses in SHSY-5Y cells were almost double the size of
those stimulated by the other agonists (Figures 1.2.30 and 1.2.32), the ability of M65
to fully inhibit the maximum PACAP induced response (in contrast to the standard
EC50 PACAP-27 induced response) was subsequently evaluated (Figure 1.2.37).
M65 fully inhibited the PACAP-27 induced calcium responses from SHSY-5Y cells,
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Agonist from 1 uM
[cAMP], NE 37.5 ± 5.6 (4)
Antagonist from 0.1 gM
[Ca2+]i NE NE 13.6 ±2.1 (5)
IC50 values are shown as the mean ± SEM, with the number of independent
experiments given in parenthesis. NE is no effect at 3 pM.
when the agonist was used at either an EC50 (~ 30 nM) or saturating concentration
(300 nM), with similar IC50 values of 6.7 and 8.4 nM (n ~ 1).
Although SHSY-5Y cells appear to predominantly express hPACiR, the
hVPACR selective antagonists, PG97-269 and PG99-465, were also examined.
PACAP-27 evoked responses in SHSY-5Y cells were completely insensitive to the
hVPACiR antagonist PG97-269 (up to 3 pM), in both assays (calcium assay traces
are presented in Figure 1.2.36; Table 1.2.5). Similarly, PG99-465 had no effect
alone or on agonist induced responses in the calcium assay (Figure 1.2.36; Table
1.2.5), however this peptide did exhibit some activity in the [cAMPjj assay. When
applied alone, PG99-465 induced a small, concentration dependent increase in cAMP
at concentrations greater than 100 nM (Figure 1.2.38; Table 1.2.5). At the maximum
PG99-465 concentration tested (3 pM) the average [cAMPjj concentration was
approximately 3 nM (n = 2; Figure 1.2.38a). A full PG99-465 concentration
response curve could not be generated due to compound availability and solubility of
the peptide. In preliminary inhibition studies using SHSY-5Y cells, PG99-465
application at concentrations associated with agonist activity in these cells, coincided
with a reduction in the PACAP-27 (1 nM) induced response (n = 1; Figure 1.2.38b).
This contrasts with the effects observed for hVPACiR and hPACiR stable cell lines
([cAMPj] assay), where PG99-465 stimulatory responses appeared to act
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Figure 1.2.35 Inhibition of agonist evoked [cAMPJj and [Ca2+]j responses by
M65 in SHSY-5Y cells. Representative inhibition curves are shown
for both assays ([cAMP]*: a; [Ca2+]j: b), in which cells (1.25 x 105
per well) were pre-incubated (10 min) with M65, prior to the
addition of PACAP-27 ([cAMP]i: 1 nM; [Ca2+]j: 30 nM). Mean IC50
values ± SEM (n > 3) are shown (see Table 1.2.5).
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Figure 1.2.36 Traces illustrating the effects of VPAC/PACR antagonists on
PACAP-27 stimulated calcium responses in SHSY-5Y cells.
Representative traces shown are from SHSY-5Y cells (1.25 x 105
cells per well) that have been pre-incubated with antagonist (10
min), prior to PACAP-27 stimulation (90 s recording; [antagonist]
range: 0.01 nM - 3 pM).
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[PACAP-27]: 300 nM, IC50 = 8.4 nM (n = 1)
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Figure 1.2.37 M65 antagonism of maximal PACAP-27 induced [Ca2+]j
responses in SHSY-5Y cells. Inhibition curves from the same
[Ca +]j assay plate are shown, in which cells (1.25 x 105 per well)
were pre-incubated (10 min) with M65, prior to the addition of





















Buffer PG P27 -10 -9 -8 -7 -6
[PG99-465] Log M
Figure 1.2.38 PG99-465 modulation of [cAMP]j in SHSY-5Y cells. Alone,
PG99-465 increased [cAMP]i in SHSY-5Y cells (1.25 x 10s per
well) at micromolar concentrations (a; n = 2). The inhibitory action
of PG99-465 on agonist induced [cAMPJi responses was determined
in SHSY-5Y cells that had been pre-incubated (10 min) with PG99-
465, prior to the addition of 1 nM PACAP-27 (b; n = 1).
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1.2.4.3. hVPAC/PACR pharmacology in HT-29 and SUP-T1 cells
The pharmacology of VPAC/PACR in the HT-29 and SUP-T1 cell lines was
also investigated. From preliminary studies, it was evident that neither cell line was
particularly suitable for use in the calcium assay. With HT-29 cells generally
growing in clumps (Figure B.3, p 57) and SUP-T1 cells growing in suspension, it
proved difficult to obtain the even monolayer of cells on the assay plate that is
required for the calcium assay. Several [Ca2+]j assays were performed with both cell
lines, in which the cells were either seeded overnight, or on the day of assay with the
cell plate centrifuged as described (B.2.4.1., p 61). However, the responses observed
with both seeding procedures, upon agonist addition, were extremely variable and
non-reproducible, indicating that these cell lines were not suitable for analysis with
this assay. In contrast, the [cAMPJj assay does not depend upon an even distribution
of cells and as result, it was possible to evaluate VPAC/PACR pharmacology in HT-
29 and SUP-T1 cells using this assay. As no comparative studies were possible with
the calcium assay, these two cell lines were only partially characterised with the
[cAMPJj assay with a limited range of peptides.
In HT-29 cells, VIP, PACAP-27 and PACAP-38 were equipotent agonists,
evoking concentration dependent increases in [cAMPJj (Figure 1.2.39a), with low
nanomolar potency (EC50 values of 0.13 ± 0.02 (4) nM, 0.12 ± 0.02 (5) nM and 0.17
± 0.02 (3) nM respectively; Table 1.2.6). These potencies are almost identical to
those determined for the CHO-hVPACiR cell line using this assay (Table 1.2.2, p
110). However, in contrast to the CHO-hVPACiR data, [Alall 22,28]VIP and R3P65
were ~ 25 fold less potent than VIP or the PACAP peptides (Figure 1.2.39; Table
1.2.6). The agonist ROP for the HT-29 cell line was therefore: VIP = PACAP-27 =
Table 1.2.6 Comparison of EC50 values for agonist stimulation of [cAMP] j
responses in HT-29 cells
VIP PACAP-27 PACAP-38 [Ala11,22,28]VIP R3P65
EC50 ± SEM (nM)
0.13 ± 0.02 0.12 ± 0.02 0.17 ± 0.02 2.88 ± 0.75 4.15 ± 0.63
[cAMP]i (5) (3) (6) (3)
EC50 values are shown as the mean ± SEM, with the number of independent
experiments given in parenthesis. Maxadilan was not tested with these cells as

















































VIP plus PG97-269 □
PG97-269 alone V
BufferVIP -12 -11 -10 -9 -8 -7
[PG97-269] Log M
-6 -5 -4
Figure 1.2.39 Characterisation of VPAC/PACR in HT-29 cells. Using the
[cAMP]j assay, HT-29 cells (1 x 105 per well) were stimulated with a
range of VPAC/PACR agonists and concentration response curves
produced (a). The antagonist action of PG97-269 was also
determined in the cells (b), which were pre-incubated (10 min) with
PG97-269, prior to the addition of VIP (0.3 nM). The concentration
response curves shown are representative, with mean EC50/IC50



















Figure 1.2.40 Maximum peptide induced [cAMPJi responses from HT-29 cells.
Mean [cAMPJi responses from the HT-29 cell line (1 x 105 per well)
were calculated from the upper plateau of the agonist concentration
response curves used to calculate the ligands potencies in Table 1.2.6
(n > 3). Antagonists were tested at a concentration of 3 pM.
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Table 1.2.7 Comparison of IC5o/*EC5o values for antagonist inhibition of
VIP induced [cAMP]j responses in HT-29 cells
PG97-269 PG99-465
IC50/*EC5o ± SEM (nM)
*53.0 ±7.65 (4)
[cAMPJi 0.34 ± 0.08 (5)
partial agonist (10 % max)
IC5o/*EC5o values are shown as the mean ± SEM, with the number of
independent experiments given in parenthesis. It was not possible to test M65
with these cells, as stocks of this peptide were limited.
PACAP-38 > [Ala"'22'28]VIP - R3P65. The potency of the VPAQR selective
antagonist, PG97-269, was also evaluated using the HT-29 cells. PG97-269
inhibited VIP induced [cAMP]j responses in a concentration dependent manner, with
an IC50 of 0.34 ± 0.08 (5) nM (Figure 1.2.39b; Table 1.2.7), which is over 200 fold
more potent than in the CHO-hVPACiR cell line (IC50: 80.0 ± 3.2 (3); Figure 1.2.23,
p 120; Table 1.2.3, p 118). In addition, the stimulatory effects of PG99-465, which
was shown to be a full agonist in the CHO-hVPACiR [cAMP]i assays, were
evaluated. This peptide produced a very small increase in cAMP in HT-29 cells
which was equivalent to ~ 10 % of the maximum VPAC/PAC agonist induced
responses (EC50: 53.0 ± 7.65 (4) nM; Table 1.2.7). From all of the agonist
concentration response curves (Table 1.2.6), maximum responses produced with
saturating concentrations of the peptides were evaluated, with all of the agonists
evoking a similar peak [cAMPJi response of approximately 80 nM (Figure 1.2.40).
The peak partial agonist response of ~ 10 nM observed from PG99-465 stimulation is
also shown.
Table 1.2.8 VPAC/PACR ligand potencies from the partial characterisation
of SUP-T1 cells in the [cAMP]j assay
VIP [Ala11,22,28]VIP PG99-465
EC50± SEM (nM) IC50±SEM (nM)
[cAMP]i 7.6 ±1.2 (3) NE 51.0 (1)
IC5o/*EC50 values are shown as the mean ± SEM, with the number of
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PG99-465 alone <>
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[PG99-465] Log M
Figure 1.2.41 Partial characterisation of VPAC/PACR in SUP-T1 cells. SUP-
T1 cells (1 x 105 per well) were stimulated with VIP and
[Ala11'22'28]VIP for 15 min and [cAMP]j determined (a). In addition,
the antagonist action of PG99-465 was determined using the cells,
which were pre-incubated (10 min) with the antagonist, prior to the
addition of 30 nM VIP (b). EC50/IC50 values ± SEM (n > 1) are
shown in Tables 1.2.8.
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In the VPAC2R expressing SUP-T1 cell line, VIP induced a concentration
dependent increase in cAMP with a maximum response of 21 ± 1.9 (3) nM [cAMP]j
(Figure 1.2.41a). VIP was of nanomolar potency in this cell line with an EC50 of 7.6
± 1.2 (3) nM (Figure 1.2.41a; Table 1.2.8), making it ~ 10 fold more potent than in
the CHO-hVPAC2R cell line (Table 1.2.2, p 110). To confirm that SUP-T1 cells do
not express VPAQR (Igarashi et al., 2002b), the stimulatory effects of
[Ala"'22'2S]VIP were evaluated and as expected, this potent VPAQR agonist
produced no change in [cAMPJi (Figure 1.2.41a). Finally, PG99-465 was observed
to fully inhibit VIP induced [cAMPJj responses from SUP-T1 cells with an IC50 of
51.0 nM (n = 1; Figure 1.2.41b; Table 1.2.8), which is a similar potency to the
inhibitory action of this peptide in the CHO-hVPAC2R cell line (Table 1.2.3).
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1.3. Discussion
1.3.1. Functional evaluation of hVPAC/PAC receptor pharmacology
To date, comprehensive studies directly comparing the pharmacology of
human VPAC/PAC receptors across multiple functional assays remains limited. In
addition, comparison between data from different research groups is complicated by
the variation in protocols used (receptor expression system, species of receptor, assay
type). To address these limitations, stable cell lines expressing the three human
VPAC receptor subtypes (hVPACiR, hVPAC2R and hPACiR) were generated and
two simple, non-radioactive, HT-amenable [cAMP], and [Ca ]j assays were
established and characterised. Although VPAC/PAC mediated enhancement of PLD
activity has been reported in a limited number of studies (McCulloch et al., 2000;
Dejda et al., 2006), there have been no studies to date exploring the physiological
relevance of this coupling. Therefore, we sought to characterise hVPAC/PAC
receptor pharmacology by comparing the agonist/antagonist modulation of [cAMPJj
and [Ca2+]j pathways, both of which have been associated with a number of
physiological roles (Masmoudi et al., 2003; Perez et al., 2005; Zizzo et al., 2005).
These assay platforms were used to evaluate the pharmacology of a selection of
agonists and antagonists, including endogenous as well as new and reportedly
receptor selective ligands.
For the endogenous peptides VIP, PACAP-27 and PACAP-38, the agonist
ROP was identical in both assays for the three human receptor subtypes, although
EC50 values in the [Ca2+]j assay were approximately 100 fold less (range: 26 - 174
fold). In the [cAMPJj studies, the agonists [Ala"'22'28]VIP and maxadilan showed
considerable selectivity for hVPACiR and hPACiR respectively (> 25,000 fold), and
whilst R3P65 was not hVPAC2R selective in our hands, all three peptides were
comparably less potent in the [Ca2+]j assay. With the reduction in agonist potency in
the [Ca2+]j assay also observed in SHSY-5Y cells, which endogenously express
hPACi receptors, this effect is unlikely to be a consequence of receptor over-
expression. In contrast to the agonists, the reportedly selective VPACiR (PG97-269)
and VPAC2R (PG99-465) antagonists had slightly lower IC50 values and hence
greater potency in the [Ca2+]j assay at their respective receptor subtypes, whereas the
hPACiR selective antagonist M65 was almost equipotent in both assays. With
PG99-465 alone acting as a partial (hVPAC2R) and full (hVPACiR and hPACiR)
agonist in the [cAMPJj assay, this compound is clearly not a selective antagonist.
These studies reiterate that there remains a paucity of VPAC/PAC receptor selective
drugs, in particular non-peptides, and that functional responses both in vitro and in
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vivo will critically depend upon the range of ligand concentrations tested and the
cellular complement of intracellular messengers, as well as other factors outlined in
the introduction (p 78).
1.3.2. hPACiR pharmacology
In the current study, the EC50 values of PACAP-27, PACAP-38 and
maxadilan at the hPACi-null receptor (Pisegna & Wank, 1996; equivalent to rat
PACAP-R, Spengler et al., 1993) were similar within assays, however a 1 - 200 fold
2"hloss in potency was observed on going from the [cAMP]; to the [Ca ]j assay.
Although limited, previous studies have shown that the three peptides have a similar
affinity/potency in radioligand binding (Moro & Lerner, 1997) and [cAMP]j assays
(Eggenberger et al., 1999), with the former study also demonstrating considerable
selectivity for maxadilan at PACi receptors, as shown in Table 1.2.2 (p 110).
Consistent with our observations, Pisegna and Wank (1996) had reported PACAP-27
and PACAP-38 to be equipotent at the human PACi-null variant expressed in
NIH/3T3 cells using a [3H]cAMP and [3H]IP assay, with both peptides being 60 fold
less potent in the latter assay. Moreover, in the human neuroblastoma cell line, NB-
OK-1, that endogenously expresses a PACi receptor variant, Delporte and colleagues
(1993) showed that PACAP-27 and PACAP-38 were considerably less potent in
2_|_
stimulating [Ca ], release when compared to [cAMP],. Importantly, we confirmed
and extended these observations using an alternative human neuroblastoma cell line,
SHSY-5Y (Table 1.2.4, p 127), which also endogenously expresses PACi receptors
(Vertongen et al., 1996). Both [Ca2+]i and [cAMPJj were elevated in response to
agonists in the SHSY-5Y cells, with identical ROPs and similar potencies to the
CHO-hPACiR cell line (Table 1.2.2 and 1.2.4). More significantly, in our SHSY-5Y
studies, there was a clear reduction in agonist potency in the [Ca2+]i assay, despite
[cAMPjj levels in these cells being 10 fold lower than in the stable cell lines. The
recent findings of Lutz and colleagues (2006) support these data, with PACAP-38
and VIP producing a similar fold increase in a [3H]cAMP assay, however no [3H]IP
data was presented for SHSY-5Y cells, despite comparing both second messengers
for some of the new, individual hPACi splice variants. These data support the
assertion that the reduction in agonist potency is not a consequence of receptor over-
expression (MacKenzie et al., 2001), but could reflect inefficient coupling (Langer et
al., 2002b). These observations are not unique to human PAC receptors; in CHO
cells expressing rat type I PACAP-R (Delporte et al., 1995) the potency of PACAP-
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27 (cAMP, 0.01 nM; [Ca2+]i, 1.1 nM) and the fold difference (110) was almost
identical to our human data. Although Spengler et al. (1993) reported a smaller 40-
fold reduction in potency for PACAP-38 at the same rat receptor (PACAP-R), these
authors showed that PACAP-27 did not stimulate inositol phosphate (IP) production
(despite a robust production of cAMP), suggesting species differences in PACi
receptor pharmacology and supporting a similar observation in PC 12 cells (Deutsch
& Sun, 1992).
In our hands, VIP was approximately 300x less potent than PACAP-38 in
the CHO-hPACiR [cAMP]j assay, which is consistent with some published data
(Spengler et al., 1993). However, Pisegna and Wank (1996) have shown that VIP at
concentrations lOOOx in excess of the PACAP EC50 had no effect on adenylate
cyclase. In the present hPACiR [Ca2+]j studies, VIP was only 25x less potent than in
the [cAMPJi assay, resulting in this peptide only being about 75x less potent than the
PACAPs (rather than 300x), and possibly why it was possible to determine an EC50
value of about 400 nM for VIP (Table 1.2.2, p 110). This is however consistent with
the recent data from Lutz and colleagues (2006), with IC50 values for VIP of 55 nM
([3H]cAMP) and approximately 1.5 pM ([3H]IP) giving a ratio of 27. The
pharmacological properties of R3P65 (Yung et al., 2003) at hPACiR were akin to
VIP, with only a 10 fold difference in potency in the two assays (Table 1.2.2, p 110).
This peptide's sequence differs from VIP by only 4 amino acids (2 within the VIP
sequence; Table A.2, p 23), and it is not inconceivable that both peptides induce
[Ca2+]j production more readily than the PACAPs (relative to [cAMPJj) at human
PACiR, akin to that described for PACAP-38 at rPAQ receptors (Spengler et al.,
1993).
In the calcium studies with the SHSY-5Y cell line, the PACAP peptides
evoked a considerably larger response (~ 30 %) than maxadilan, VIP and R3P65
(Figure 1.2.30, p 129). This larger response was not linked to the potency of the
peptides as maxadilan, which was equipotent to the PACAPs, did not produce a
similarly enhanced calcium response. This finding extends a preliminary observation
made by Eggenberger et al. (1999), who showed that peak maxadilan induced
calcium responses in SHSY-5Y cells were only ~ 25 % of the size of those induced
by PACAP-27 (both peptides tested at 100 nM), despite the cAMP responses to these
peptides being similar in magnitude. Furthermore, the tentative suggestion from our
data, of a biphasic concentration response relationship for the PACAP induced
calcium elevations (Figure 1.2.33, p 132), introduces the possibility that this peptide
may act via another group of PACAP sensitive receptors in the SHSY-5Y cell line.
The current characterisation of PACAP receptors in the SHSY-5Y cells suggests that
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this additional population of receptors would be PACAP sensitive, maxadilan
insensitive and M65 sensitive. Although multiple variants of the PACiR have been
described, a receptor with the specific pharmacological characteristics presented here
has not yet been reported. However, Lutz and colleagues (2006) have recently
identified up to 14 splice variants of the human PACj receptor, all of which were
cloned from the SHSY-5Y cell line. In future studies it would be of interest to
examine calcium responses from the individual splice variants cloned from the
SHSY-5Y cells, in an attempt to identify the receptor variant responsible for the
PACAP (and M65) sensitive, maxadilan insensitive response. Furthermore, it is
intriguing to note that these differential agonist responses are specific for the calcium
signalling pathway, with the targeting of this specific receptor variant being
potentially useful to delineate the functional significance ofPACiR splice variants.
In the calcium studies using the stable cell lines, there was a clear difference
in the kinetics of the responses from the VPACR and PACiR expressing cells, with
PACiR mediated responses appearing to show a prolonged duration of calcium
stimulation (Figure 1.2.19, p 113). Upon further examination of PAQR mediated
calcium responses to the PACAPs and VIP, the prolonged calcium elevation was
found to be particularly pronounced in response to PACAP treatment. In contrast to
our data, VPAQ receptor mediated calcium responses have been previously shown
to have a sustained phase following the initial peak response (Sreedharan et al.,
1994), however these studies also suggested that the kinetics of the response may be
dependent on the cell type utilised. As all of the stable cell lines used in the current
studies were generated using the same parent cell line, this excludes the possibility
that the differences between the VPAC and PAC traces were a result of host cell
type. Furthermore, agonist induced responses from the PAQR expressing SHSY-5Y
cell line also demonstrated differential rates of decline, with responses to the
PACAPs and maxadilan appearing to decline at a slower rate than those produced
with VIP or R3P65 (Figure 1.2.34, p 133). As only VIP and R3P65 responses
declined at a faster rate, these effects do not appear to correlate with the reduced
magnitude of response observed for certain agonists in these cells (as discussed in the
preceding paragraph), however these effects may be dependent on the potency of the
agonist tested. The agonist induced calcium responses mediated by endogenous
VPAC and PACiR have been shown to be biphasic in nature, with an initial peak
response followed by a lower, sustained elevation in calcium (NB-OK-1 cells:
Delporte et al., 1993; AR4-2J: Barnhart et al., 1997; polymorphonuclear neutrophils:
Harfi & Sariban, 2006; intracardiac neurons: Dehaven & Cuevas, 2004). From these
studies the initial peak of the response has been shown to result from mobilisation of
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intracellular calcium stores, with the subsequent sustained response attributed to an
influx of extracellular calcium, consistent with observations for other GPCR
mediated calcium responses (Edelman et al., 1994). Indeed, in the current studies the
larger sustained phase of the PACAP induced calcium response through PAC|R was
abolished upon removal of extracellular calcium (Figures 1.2.21 and 1.2.22, p 115 -
116). The precise route of entry for this calcium influx into the cell remains to be
determined. A direct comparison of the kinetics of VPAC and PAC receptor
mediated calcium responses has not been previously reported, however the apparent
receptor and agonist specificity of the sustained phase of the response in the current
studies is intriguing. Future studies comparing the kinetics of PACiR mediated
calcium responses (post 200 s), with all of the agonists described will be useful to
determine if the prolonged responses are unique to the PACAPs, given the sustained
responses produced by maxadilan and the PACAPs in SHSY-5Y cells. In addition,
elucidating the route of calcium influx for the enhanced second phase of the PACiR
mediated PACAP responses will also prove interesting.
1.3.3. hVPACR pharmacology
In contrast to the data showing that PACi receptor activation is associated
with downstream production of both [cAMPJi and [Ca2+]j, studies fully examining
VPAC mediated stimulation of the latter second messenger have been more limited
and variable (Dehaven & Cuevas, 2004). The three endogenous peptide ligands,
VIP, PACAP-27 and PACAP-38 all exhibited similar, sub-nanomolar potencies in
the [cAMP], assay in the two cell lines stably expressing either hVPACi or hVPAC2
receptors (Table 1.2.2, pi 10). For the VPAQR, this pharmacological profde was
also observed in the initial [cAMPJj studies using the HT-29 cell line. In the stable
cell lines, the maximal amount of cAMP produced (~ 50 nM) and the fold
stimulation above basal levels (~ 25 fold) was the same for all three ligands at both
hVPAC receptor subtypes (and hPACi). Sreedharan et al. (1994), reported similar
EC50 values for VIP at hVPAC 1 receptors expressed stably in either HEK-293 or
CHO cells, although the same group reported a considerably lower potency (70 fold)
for VIP at hVPAC2 in both SUP-T1 and transfected cells (Xia et al., 1996, 1997). In
studying cAMP responses at hVPACiR, Langer and colleagues (2002a)
demonstrated that the potencies of VIP (3Ox) and PACAP-27 (lOx), were higher in
intact cells when compared to membranes, with the former values (EC50: VIP = 0.1
nM; PACAP-27 = 0.3 nM) similar to those described in these studies (Table 1.2.2, p
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110). Similarly, the EC50 values ofVIP and PACAP-38 for recombinantly expressed
rat VPAC/PAC receptors in a whole cell cAMP assay (MacKenzie et al., 2001;
McCulloch et al., 2001), were consistent with the present data using human receptors
(Table 1.2.2, p 110). Therefore, it is clear that for the endogenous peptide ligands
such as VIP and the PACAPs, the use of membrane preparations may result in an
underestimate of their potencies, and that the variation in use of whole cell and/or
membrane preparations could contribute to the inconsistencies seen in the literature.
In the [Ca24 ]j assay, VIP, PACAP-27 and PACAP-38 were again almost equipotent
at hVPACi and I1VPAC2 receptors, although the agonist EC50 values were
approximately lOOx greater than those in the [cAMPJj studies (Table 1.2.2). The
maximal response induced by agonists was about 7x that of basal fluorescence levels
for all three VPAC/PAC stable cell lines. Although EC50 values were not
determined, Sreedharan et al. (1994) had shown in an earlier study, that in cells
stably (CHO and HEK-293) or endogenously (HT-29) expressing hVPACiR, VIP
could elicit an increase in [Ca2']i, albeit at higher concentrations than that required
for [cAMP]j. Using a luminescence based calcium assay, Langer and colleagues
(2001, 2002b) have reported similar EC50 values for VIP and PACAP-27 in CHO
cells expressing hVPACiR. In further studies, the same authors have since shown
that the enhanced VPACi coupling is due to a small number of residues in the third
intracellular loop, whilst also suggesting that their absence underlies the inefficient
VIP induced [Ca2+]j response at VPAC2 receptors (Langer et al, 2002b; Langer &
Robberecht, 2005).
In human T-lymphoblast cells (SUP-T1) that endogenously express
hVPAC2 receptors (Xia et al., 1996), the concentration of VIP (EC50 = 30 nM)
required to induce [Ca2+]j production was very similar to the current study (Table
1.2.2, p 110). Xia et al. (1997) also reported, but did not fully characterize a [Ca2+]j
response in CHO-cells expressing hVPAC2, although the present data are consistent
with that of Langer et al. (2002b), who reported a comparable EC50 value for VIP at
hVPAC2R. In COS7 cells expressing rat VPAC2R, the EC50 of PACAP-38 was also
similar (37 nM) in an [3H]IP assay (MacKenzie et al., 2001), however it must be
noted that when the same authors expressed either rat VPACi or VPAC2 receptors in
CHO cells, no stimulation of IP was observed, despite similar data for rat PACi
(McCulloch et al., 2000, 2001).
The rightward shift in potency (~ 100 fold) that we observed for VIP,
PACAP-27 and PACAP-38 between the cAMP and calcium assays for all three
human VPAC/PAC receptors (Figures 1.2.14 - 1.2.16, p 107 - 109), is therefore
consistent with the other study using cloned human VPAC/PAC receptors which
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compared cell-based assays (Langer et al., 2002a), with lower ratios observed when
[cAMPji responses were determined in membrane based assays (Langer et al., 2001;
Langer & Robberecht, 2005). A similar change in potency between these assay types
has also been shown for rat VPAC2 (~ 100 fold) (MacKenzie et al., 2001) and PACi
(~ 170 fold) receptors (McCulloch et al., 2001). In contrast, Xia et al. (1996) only
reported a 2 fold difference in potency for VIP between cAMP and calcium assays,
using SUP-T1 cells, perhaps as a consequence of the low potency of VIP in their
cAMP assay, as discussed previously (p 150). Although the [Ca2+]j/[cAMP]i and
phospholipase D/[cAMP]j, ratios were of a comparable magnitude (100 - 300x) for
rat PACi (McCulloch et al., 2000, 2001), no [Ca2+]i response was found for VPACi
and VPAC2, despite a similar phospholipase D/[cAMP]j ratio for these two subtypes.
It remains unclear whether these variations are due to expression level (Van
Rampelbergh et al., 1997; Langer et al., 2002b; Ciccarelli et al., 1995), as
MacKenzie et al. (2001) clearly showed there was no difference in the
[Ca2+]i/[cAMP]j potency ratio for PACAP-38 on comparing transfected and
endogenously expressed VPAC2 receptors. In contrast, Langer et al. (2002b) do
show that the magnitude of the cAMP and calcium responses may be dependent upon
the level of receptor expression, however they do not discuss what impact this has
upon agonist EC50 values. However, it is important to stress that the VPAC/PAC
induced increase in calcium is of physiological importance (Delgado et al., 2003a;
Dehaven & Cuevas, 2004; Zizzo et al., 2005).
1.3.4. Pharmacology of putatively receptor selective ligands
1.3.4.1. VPACiR selective peptide ligands
Using a combined approach of alanine scanning and molecular modeling
Nicole et al. (2000), identified [Ala11,22,28JVIP as the first highly selective human
VPACi receptor agonist. In agreement with these observations, our [cAMP]j data
also established [Ala11'22'28]VIP to be as potent as VIP at the hVPACi receptor,
whilst having no demonstrable agonist effect at I1VPAC2, at concentrations up to 3
pM. [Ala"'22'28]VIP also induced a concentration dependent increase in [Ca2+]j in
the hVPAC)R cell line, with an EC50 value which was in excess of 2 orders of
magnitude greater than that observed for [cAMP];. To our knowledge this is the first
11 22 28
report to show that [Ala ' ' ]VIP stimulates the production of [cAMPji in cells
expressing hPACi, albeit at micromolar concentrations, which are approximately
25,000x higher than that required to activate hVPACiR. The general reduction in
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agonist potencies in the [Ca ], assay, meant we were unable to test a sufficient
concentration of [Ala1''22'28]VIP to evaluate whether this peptide stimulates [Ca2+]i
production at hPACiR.
Although a range of approaches have resulted in some moderately selective
VPAC/PAC agonists, to date there is still a paucity of suitable receptor antagonists
(Laburthe & Couvineau, 2002). One notable exception is PG97-269, which was
reported to be a VPACiR selective antagonist (Gourlet et al., 1997a). Alone, PG-97-
269 had no effect on [Ca2+]i in any of the three human VPAC/PACR cell lines (Table
1.2.3, p 118), however there was a small (up to 5 % of the maximal VIP response),
but non-quantifiable, increase in [cAMPJj in the hVPACiR cell line. Although
PG97-269 produced a concentration dependent inhibition of both the [cAMPJj and
2 I
[Ca ]j responses in hVPACiR expressing cells, its potency was slightly reduced in
the [cAMPJj assay, perhaps as a consequence of the small agonist-like response.
However, the IC50 value in the [Ca2+]j assay is consistent with that observed by
Gourlet et al. (1997a). Interestingly, this peptide has recently been shown to act as
an inverse agonist at the C-terminally truncated form of VPACiR, which is a
constitutively active form of the receptor (Vertongen et al., 2004).
1.3.4.2. VPAC2R selective peptide ligands
Using an HT-mutagenesis approach, Yung et al. (2003) generated a
comprehensive range of VIP-related peptides that resulted in a series of putatively
receptor selective VPAC2 agonists, including R3P65 (Table A.2, p 23). R3P65 was
reported to exhibit at least 80 (radioligand binding) and 500 fold (cAMP) selectivity
over human VPACi and PACi receptors. Such ligands would be advantageous, as
the existing VPAC2 peptide agonists e.g. Ro25-1392 and Ro25-1553 (Moreno et al.,
2000), are difficult to synthesize (Yung et al., 2003) and can act as partial agonists at
VPACi and PACi receptors (Akesson et al., 2005). Although the EC50 values of
VIP, PACAP-27 and PACAP-38 for [cAMP]j production, at the three human
VPAC/PAC (Table 1.2.2) receptors were very similar to those reported by Yung et
al. (2003), we could provide no evidence to support their assertion that R3P65 is a
selective hVPAC2 agonist. Although our EC50 value for R3P65 at hVPAC2 receptors
in the [cAMP]j assay (Table 1.2.2, p 110) was consistent with Yung et al. (EC50 ~ 0.4
nM; 2003), we found this peptide to be slightly more potent at hVPACi, in addition
to acting as a full hPACi agonist, albeit with lower potency. In our [Ca2+J; studies,
the pharmacological profile of R3P65 was as observed for [cAMPJj, with the
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compound again having a lower potency in the former assay, consistent with the
trend observed for the other peptides (Table 1.2.2, pi 10). These data contrast with
the published 80 - 500 fold selectivity for R3P65 over hVPACi receptors and with its
negligible effect at hPACiR (Yung et al., 2003). As both studies used a CHO-based
cell line to express human VPAC/PAC receptors, the differences between the two
studies are intriguing, although these authors did introduce the promiscuous G-
protein Gai6 into their cell lines (Yung et al., 2003). In both our assays, for all three
human VPAC/PAC receptor subtypes, R3P65 was on average 3x less potent than
VIP. Compared to the VPAC2R agonist Ro25-1553, the amino acid sequence of
R3P65 is remarkably similar to VIP (Table A.2, p 23), and it is interesting to note
that of the four key residues identified by Yung et al. (2003), neither V19A (R3P47)
or L27K (R3P42) alone, which lie within the VIP sequence, alter selectivity in the
binding or functional assays; even the double (R3P49) mutant is only functionally
selective (30 fold). Although the further addition ofK29 and R30 resulted in R3P65,
the authors comment that any reduction in the number of mutations did not produce
peptides with comparable selectivity, with no data shown even for the triple mutant
without the R30 addition (Yung et al., 2003). It is also interesting to note, that these
authors have not published any further studies involving this peptide, instead
returning to study BAY 55-9837, a VPAC2R agonist that was reported by the same
group prior to R3P65, in an attempt to improve the poor stability of this compound
(Tsutsumi et al., 2002; Pan et al., 2006).
In 2000, Robberecht and colleagues developed PG99-465, which was
reported to be the first potent and selective VPAC2R antagonist (Moreno et al.,
2000). In the present investigation, PG99-465 was indeed a potent hVPAC2 receptor
antagonist in both the [cAMP]j and [Ca2+]i assays, with low nanomolar potency
observed (Table 1.2.3, p 118), consistent with the findings ofMoreno et al. (IC50 = 2
nM; 2000). Alone, PG99-465 had no effect on the hVPAC2R [Ca2+]i response,
however it did display partial agonist activity in the [cAMPJi assay, perhaps
accounting for the 5 fold reduction in potency between assays when added prior to
VIP (Table 1.2.3, p 118). This finding contrasts with the original publication which
showed that PG99-465 had no effect alone at the I1VPAC2 receptor (Moreno et al.,
2000), although in two more recent studies there is a suggestion of a small increase
in cAMP for both human (Langlet et al., 2004) and rat VPAC2 receptors (Vanneste et
al., 2004); with the latter study reporting an EC50 similar to that in our present study
(30 nM; maximum response ~ 10 % VIP induced response). At both hVPACi and
hPACi, PG99-465 was a full agonist in the [cAMPji assay (Figure 1.2.26, p 123;
Table 1.2.3, pi 18), with no effect again on the [Ca2+]j response. Moreno et al.
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(2000), and more recently Vanneste et al. (2004), have reported PG99-465 to be a
partial agonist of human and rat VPACi receptors respectively, however this is the
first description of an agonist effect of PG99-465 at human PACi receptors. As our
EC50 value for PG99-465 at hVPACi, was more than 25x lower than that ofMoreno
et al. (2000), the increased sensitivity in the current study may account for the further
agonist observations at hVPAC2 and hPACi receptors. Furthermore and in
agreement with the current observations for PG99-465, Langer and colleagues
(2002a), showed that the putative antagonist VIP(4-28) (Ciccarelli et al., 1994) had
no detectable effect alone in an adenylate cyclase assay using CHO-hVPACi
membranes, however it was a full agonist in a whole cell based cAMP assay. These
findings suggest that the full agonism observed for PG99-465 may only be detectable
in whole cells (rather than membranes) with an appropriate G-protein complement.
Indeed in preliminary studies using HT-29 cells, which endogenously express
hVPACi (Sreedharan et al., 1994), we have continued to examine the properties of
PG99-465. Although cAMP concentrations produced were higher in these cells at an
equivalent cell density (~ 80 nM), implying at least an equivalent receptor density to
our stable cell lines, agonist potencies (VIP, PACAP-27 and PACAP-38) were
identical to those seen for the hVPACi stable cell line (Figure 1.2.39, p 141; Table
1.2.6, p 140). However, and most importantly, PG99-465 had no agonist effect
despite the higher levels of cAMP (Figure 1.2.40, p 142), which would again suggest
the agonist effects observed for PG99-465 in the CHO-stable cell lines are a
consequence of their particular receptor/G-protein complement and the use of a cell
based assay rather than just simply receptor density. These findings do however add
further credence to the assertion of Laburthe and Couvineau (2002), who suggest that
PG99-465 is not a satisfactory I1VPAC2 receptor antagonist, with these observations
perhaps complicating the interpretation of some recent in vitro studies that use this
peptide (Itri & Colwell, 2003; Piggins & Cutler, 2003; Akesson et al., 2005).
1.3.4.3. PACiR selective peptide ligands
Maxadilan is a vasodilatory peptide isolated from the salivary glands of sand
flies (Lerner et al., 1991). This peptide was reported to be a PACiR selective
agonist, stimulating receptor mediated cAMP production at low nanomolar
concentrations (Moro & Ferner, 1997; Moro et al., 1999). We were able to confirm
the high selectivity of this peptide for PACiR and report a similar EC50 value for
maxadilan stimulation of [cAMPJj to that reported previously (EC50 = 0.3 nM; Moro
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et al., 1999). Although maxadilan induced calcium responses have been described in
the literature using pancreatic P cells (Yamada et al., 2004) and SHSY-5Y cells
(Eggenberger et al., 1999), full concentration response curves have never been
previously described. In the current studies, we have fully characterised the
maxadilan evoked [Ca2+]i response at hVPAC/PACR, with the compound clearly
acting as a full and selective hPACiR agonist. As discussed in earlier sections, in the
current studies PACAP induced calcium responses in SHSY-5Y cells consisted of a
component that was insensitive to maxadilan, yet sensitive to M65 (p 149). Whether
the atypical responses to maxadilan and M65 are mediated by a specific PACiR
splice variant or are not mediated by VPAC/PACR, remains to be determined.
Studies assessing the PACi receptor antagonist M65 (Uchida et al., 1998),
are even more limited than those examining the putative VPAC antagonists. M65
alone had no effect in either assay at any of the VPAC/PAC receptors, nor did it
exhibit any antagonism of agonist evoked responses at hVPACi or I1VPAC2. It did
however produce a concentration dependent inhibition of agonist evoked responses
at the hPACi receptor, exhibiting similar potencies (-210 nM) in both of the in vitro
assays. These IC50 values (Table 1.2.3, p 118) are lower than those reported in a
radioligand binding assay for rat PACi, however they are close to the potency of the
closely related antagonist max.d.4 (Moro et al., 1999).
1.3.5. Summary
The generation of cell lines stably expressing human VPAC/PAC receptors,
combined with the establishment of two simple, non-radioactive, HT-amenable
[cAMP]j and [Ca2+]j assays, facilitated a systematic characterisation of receptor
coupling, clearly demonstrating that all three receptor subtypes can activate more
than one downstream messenger in a single cell type. However, with agonist
potencies being approximately 100 fold different in the two assays, despite a similar
ROP, and with antagonist effects being complex, it is clear that any new compound
should be examined in both assays, as the final functional outcome in vitro/in vivo
will be dependent upon the receptor and second messenger complement of the cell or
tissue being examined. This may be of considerable physiological importance as a
range of VIP/PACAP cAMP-independent effects have been noted (Gressens et al.,
1999; Laburthe & Couvineau, 2002; Delgado et al., 2003a; Dehaven & Cuevas,
2004). As VPAC/PAC receptor activation has also been shown to activate the small
G-protein ARF and stimulate PLD activity, it would be interesting in future studies
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to perform similar receptor characterisation studies using a whole cell, HT-amenable
PLD assay. This would allow a comprehensive comparison of VPAC/PAC receptor
pharmacology to be made using all three second messengers, which may prove
pertinent as the physiological roles, if any, for VPAC/PACR activation of PLD are
clarified. Finally, there still remains a distinct lack of truly selective non-peptide
agonists and antagonists to examine the functional role of VPAC/PAC receptors both
in vitro and in vivo.
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CHAPTER TWO
HT-SCREENING FOR hVPAC2R ANTAGONISTS
2.1. Introduction
2.1.1. VPAC/PAC receptors as drug targets
As discussed in the introduction and chapter one, no truly selective non-
peptide antagonists or agonists of the VPAC/PAC receptors have been reported to
date. The only selective ligands available are peptides, which are generally modified
analogues or chimeric peptides derived from endogenous VPAC/PACR ligands; for
example [Ala"'22'28]VIP and PG97-269 (Nicole et al., 2000; Gourlet et al., 1997a).
However, even some of the putatively selective peptides, such as R3P65 (Yung et al.,
2003) and PG99-465 (Moreno et al., 2000), are not truly specific for the individual
VPAC/PACR subtypes, as was clearly demonstrated in the characterisation studies
described in chapter one. For example, PG99-465 (the reportedly VPAC2R
antagonist) had a particularly complex pharmacological profile, with different effects
at the individual VPAC/PAC receptor subtypes and variable responses between the
two functional assays used in the characterisation studies (calcium and cAMP).
Therefore, to fully delineate the precise physiological roles and functions of the
individual receptors, VPAC/PACR ligands which are truly selective, potent and
ideally non-peptide must be found. The need to identify such compounds has been
recognised by many researchers in the field (Vaudry et al., 2000; Voice et al., 2001;
Laburthe & Couvineau, 2002).
2.1.2. Selection of the VPAC2R as a target for HT-screening
As VPAC/PAC receptors are thought to be involved in a variety of
physiological processes in both normal and disease states, all three subtypes are
therefore potentially attractive targets for HT-screening, with the principal aim of
identifying potent, non-peptide, selective modulators of receptor function. Within
our institute, the VPAC2R was of particular interest as colleagues in our group had
previously been involved in collaborative studies investigating the role of this
receptor in the control of circadian activity rhythms using receptor transgenic mice
(Shen et al., 2000; Harmar et al., 2002). As described previously (general
introduction, p 42), these studies examined running wheel activity of VPAC2R
knock-out mice under various lighting regimes and clearly demonstrated an essential
role for this receptor in maintaining normal circadian rhythms of activity (Harmar et
al., 2002). In the absence of a strong endogenous circadian'rhythm (determined
under constant darkness), the activity profiles of these VPAC2R null mice were
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shown to be exquisitely controlled by the lighting schedule. The in vivo data
identifying a role for the VPAC2R in circadian rhythm control has been reinforced by
in vitro electrophysiological brain slice studies, comparing the responses of circadian
clock (SCN) neurons from the knock-out and wild-type mice to various VPAC2R
ligands (Reed et al., 2002; Cutler et al., 2003). As indicated from these studies,
VPAC2R selective ligands can modulate the normal activity of SCN neurons. We
therefore hypothesised that VPAC2R selective antagonists, may be of therapeutic
value in treating circadian rhythm disorders, such as advanced and delayed sleep
phase syndromes, shift work sleep disorder and jet lag. Traditional pharmacological
treatments for such disorders include benzodiazepines and melatonin (Turek &
Gillette, 2004). The use of benzodiazepines to treat such disorders has proven to be
problematic as a consequence of the side effects associated with their long term use,
including increased tolerance and dependence (Ebert et al., 2006). Although
melatonin treatment has been shown in several studies to help control sleep/wake
cycles, the effectiveness of this treatment is often associated with a large degree of
variability (Arendt, 1998; Turek & Gillette, 2004). In addition, melatonin
modulation of the sleep/wake cycle is usually only observed when it is taken in large
doses and its effectiveness appears to be critically dependent on the time of
administration in the circadian cycle (Turek & Gillette, 2004; Pandi-Perumal et al.,
2005). More recently several new agonists have been developed that selectivity
target melatonin receptors, surpassing the potency, selectivity and stability of
melatonin itself. Examples of such drugs include the Takeda compound Ramelteon
(TAK-375), LY156735 and agomelatine (Turek & Gillette, 2004). Of these drugs,
Ramelteon was licensed by the FDA in 2005 and is currently in clinical use. In the
absence of a diversity of treatments, investigations into the potential use of VPAC2R
antagonists as treatments for circadian rhythm disorders could provide a novel
mechanism that may prove more effective than existing treatments.
2.1.3. Industrial interest in the VPAC2R as a drug target
The selection of the VPAC2R as a target for drug discovery is by no means
unusual, given that it is a member of the GPCR superfamily (general introduction, p
12) and as such, is part of one of the most 'druggable' target groups in current drug
discovery programmes. The pharmaceutical industry's focus on GPCRs has
generally proven productive, with approximately one third of all the small molecule
drugs available targeting these receptors (Figure 2.1.1). However, upon examination
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Figure 2.1.1 Pie chart representation of the proportions of marketed small-
molecule drug targets by biochemical class (Hopkins & Groom,
2002).
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of successful industrial projects that have targeted the Group B GPCRs specifically,
novel non-peptide ligands have been developed for only a small proportion of these
receptors (Table 2.1.1).
The identification of selective VPAC2R ligands has proven in recent years to
be attractive to some industrial companies, with Hoffman La Roche and more
recently Bayer, attempting to develop VPAC2R selective ligands (Xia et al., 1997;
Yung et al., 2003). However, the VPAC2R ligands identified were all peptides and
although potent, showed relatively low selectivity over the other VPAC/PAC
receptors, especially when compared to existing ligands such as maxadilan (see
chapter one results). From published studies and results presented in this thesis,
there is still a clear paucity of truly selective VPAC2R antagonists, which contrasts
with the VPACi and PACi receptors, for which PG97-269 and M65 respectively are
selective, potent, but peptide antagonists. The only reportedly specific antagonist for
the VPAC2R is the peptide PG99-465 which in our hands was not selective,
potentially compromising its value as a tool with which to modulate and study
receptor activity and function. Therefore we undertook a collaborative study with
Astellas Pharma Inc. (formerly the Fujisawa Pharmaceutical Company), to develop
and carry out an HT-screening project in order to identify potential VPAC2R
antagonists from the company's compound libraries.
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Name Peptide Company Status
Peptide ligands
Calcitonin Osteoporosis Agonist Miacalcin Salmon calcitonin Novartis On market
Paget's disease Agonist Cibacalcin Human calcitonin Novartis On market
Hypercalcemia Agonist Calcimar Salmon calcitonin Rhone-Poulenc Rorer
and Aventis
On market
PTH Osteoporosis Agonist Forteo PTHO-34) Lilly On market
PREOS PTHO-84) NPS Phase III
GLP-I Type II diabetes Agonist Exenatide Exendin-4 Amylin and Lilly Phase III
Liraglutide GLP-1 analogue Novo Nordisk Phase III
CJC-1131 6LP-1 analogue ConjuCliem Phase I and II
Secretin Autism Agonist RG1068 Porcine secretin RepliGen Unknown
Nonpeptide ligands
CGRP Migraine Antagonist BIBN4096BS NA Boehrlnger Ingelheim Phase II
CRF, Depression, anxiety, IBS Antagonist Numerous NA Numerous Phase l/ll
Glucagon Type II diabetes Antagonist Numerous NA Numerous Unknown
'Abbreviation?
PTH Darathvn
i:CGRP, calcitonin gene-related peptide. CRF. cc
>id hormone
irticotropin-releasing factor. GLP, glucagon-like peptide. IRS. irritable boi,vel syndrome, NA. nc
Table 2.1.1 Summary of non-peptide ligands identified for group B GPCRs
from the pharmaceutical industry and their stage of progress in
the drug discovery pipeline (Hoare, 2005).
2.1.4. HT-screen selection
Following the identification of the VPAC2R as a target for HT-screening,
the normal process would include pharmacological characterisation of the receptor.
Clearly, extensive characterisation of this receptor subtype, in addition to the VPAC]
and PACi receptors, had already been performed with a range of peptide agonists
and antagonists (chapter one). Additionally, as the characterisation studies had been
performed using cell based, 96-well format, functional assays (cAMP and calcium)
on the FlexStation®, both assays were amenable to miniaturisation to a 384-well HT
format for the FLIPR® workstation. The pharmacological outputs (agonist ROP,
antagonist potencies) from both assays were consistent and indicated that monitoring
either intracellular messenger would be possible when establishing screening studies
for the VPAC2R. From examination of the protocols for both assay types, the
calcium assay was selected as the most appropriate screening assay for these studies,
due to the simplicity of the procedure, the shorter duration of the assay and the lower
cost of this assay. In addition, measurement of intracellular calcium fluxes in
FLIPR® assays has a proven track record in successful HT-studies, being described




As will be discussed in this chapter the calcium assay was miniaturised and
optimised from the 96-well FlexStation® format to the 384-well format for the
FLIPR® workstation of the Astellas laboratories in Tsukuba (Japan). Using the
CHO-I1VPAC2R cell line characterised in chapter one, HT-screening of a large
proportion of the company's compound library (~ 100,000 compounds) was
performed and potential VPAC2R antagonists identified. A counter-screening assay
for the FLIPR® was also established using the CHO-hVPACiR cell line. Further
evaluation of the potency and selectivity of hit compounds was performed using both
the FLIPR® and the FlexStation®.
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2.2. Results
2.2.1. HT-screening for I1VPAC2R antagonists
From the results presented in chapter one, although a clear shift to lower
potency was observed for agonists in the 96-well FlexStation® calcium assay when
compared to the cAMP assay, no differences were found in agonist ROPs for any of
the VPAC/PAC cell lines. This suggests that measuring either second messenger is
potentially appropriate for HT-screening of hVPAC2 receptors. However, for
I1VPAC2R antagonist screening of the Fujisawa compound libraries, the calcium
assay was selected as the most appropriate assay to utilise due to the fact it is a
simpler, less time consuming and more cost effective assay to run. HT-screening
was performed using the Calcium 3 dye and the FLIPR® workstation. In principle,
the FLIPR® calcium assay is identical to its FlexStation® counterpart, however the
FLIPR® assay has the added advantage of being ultra HT-compatible, due to the
ability of the workstation to simultaneously perform compound additions across an
entire 384-well assay plate, whilst reading fluorescence levels in every well.
2.2.2. [Ca2+k assay miniaturisation and optimisation for the FLIPR®
2.2.2.1. Cell density
Miniaturisation and optimisation of the I1VPAC2R FLIPR® assay involved
identifying a suitable cell density, as well as defining the optimal concentrations of
calcium dye, agonists and library compounds. Following the standard Fujisawa
protocol for calcium assays using transfected CHO cell lines, the CHO-
hVPAC/PACR cells were seeded at a density of 1.5 x 104 cells per well. Initially, all
assay characterisation studies (using VIP and PG99-465) were performed using the
recommended dye concentration (lx) and then the optimum concentration was
determined. The concentration of the calcium dye can either be increased in an
attempt to enhance a small response or, in the case of large fluorescent signals, it can
be reduced for economic purposes.
2.2.2.2. Agonist concentration
In the first FLIPR® study CHO-I1VPAC2R cells were exposed to increasing
concentrations of VIP. The consistency in response size for each VIP concentration
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can be seen when the fluorescence traces produced by each concentration are
compared; Figure 2.2.1 shows responses to each VIP concentration, tested in 8-well
replicates. For each concentration, the responses produced were averaged on the
FLIPR® and the resulting composite traces are shown superimposed in Figure
2.2.2a. The average response to each VIP concentration was calculated (max-min
reduction) and a concentration response curve produced (EC50 = 20.7 nM (n = 1);
Figure 2.2.2b). This value was almost identical to the VIP EC50 generated in the
CHO-I1VPAC2R calcium assay using the FlexStation® (14.1 ± 0.9 nM (n = 6);
chapter one, Table 1.2.2, p 110). For screening purposes, the most appropriate
agonist concentration should produce a maximal response without saturating the
receptor, therefore a VIP concentration between 50 and 100 nM was generally
utilised.
2.2.2.3. Antagonist studies
In inhibition studies with PG99-465, the reportedly selective VPAC2R
antagonist (Moreno et al., 2000), two concentrations of VIP (60 and 100 nM) were
tested. Using the averaged responses for each set of replicate wells, inhibition curves
were generated for PG99-465 antagonism of VIP induced responses from the CHO-
I1VPAC2R cell line (Figure 2.2.3). PG99-465 inhibited the VIP stimulated
fluorescent responses in a concentration dependent manner, with the higher
antagonist concentrations (> 1 pM) producing almost complete inhibition. The IC50
values of 116 nM (60 nM VIP) and 150 nM (100 nM VIP) generated from the
inhibition curves were very similar for both VIP concentrations. In the FlexStation®
calcium assay, PG99-465 had an IC50 of 4.4 ± 0.8 nM (n = 6) for the I1VPAC2R
(chapter one , Table 1.2.3, p 118), which was approximately 30 times more potent
than that observed using the FLIPR® assay. One possible explanation which could
have accounted for the change in antagonist potency was the difference in pre¬
incubation time. Routinely in the FlexStation® assays, antagonists were pre-
incubated with cells for 10 min prior to agonist addition, whereas in the FLIPR®
assay, this was reduced to 2 min due to constraints associated with the established
FLIPR® protocol. To determine if shortening the pre-incubation period contributed
to the change in antagonist potency, the effect of changing the pre-incubation time
(from 2 - 20 min) on the level of inhibition of the VIP response was investigated. As
the duration of the pre-incubation period increased, so did the extent to which PG99-
465 (10 nM) inhibited the VIP (100 nM) induced calcium response (Figure 2.2.4a).
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Following a 2 min pre-incubation, PG99-465 had reduced the VIP response by 51 %.
The level of inhibition increased in a time dependent manner, with the 20 min pre¬
incubation period completely ablating the VIP response. To further ascertain
whether the difference in incubation times between assays was responsible for the
change in PG99-465 potency, a full inhibition curve was run on the FlexStation®
using a reduced antagonist pre-incubation period of 2 min. The resulting curve had
an IC50 of 8.9 nM for PG99-465 (Figure 2.2.4b), which was marginally less potent (2
fold) than the IC50 generated using the 10 min pre-incubation (4.4 ± 0.8 nM (n = 6)
nM; Table 1.2.3, p 118). Therefore, although the shorter pre-incubation appeared to
partially contribute to the reduction in PG99-465 potency, it was not fully sufficient
to explain the 30 fold shift between the FlexStation® and FLIPR® assays.
2.2.2.4. Calcium dye concentration
For a number of cell lines it is possible to alter the concentration of calcium
dye added to the cells in order to maximise the signal. To investigate the effect of
calcium dye concentration on agonist response sizes using CHO-hVPACaR cells,
fluorescence responses to VIP (100 nM) were measured for a range (0.75x - 2x) of
dye concentrations (Figure 2.2.5a). The magnitude of the VIP response increased
with dye concentration, with 2x dye producing a 3 fold larger signal than the
recommended dye concentration. In this particular assay, the response to VIP (100
nM) with lx dye (~ 2,000 RFU) was approximately 5 times smaller than in the
previous experiments (Figures 2.2.2 and 2.2.3). As a consequence of this potential
variability, the 2x dye concentration was selected for screening, to maximise the
signal produced.
2.2.2.5. Concentration of library compounds
The final factor that was assessed before screening commenced was the
vehicle in which the library compounds were stored. With the library compounds
prepared in 100 % DMSO (0.25 mg/ml), the final concentration of the compounds
that could be used was ultimately dependent upon the percentage of DMSO that
could be added to the cells without causing any toxic effects. The effect of DMSO
concentration on the size of the VIP (100 nM) response from CHO-hVPAC2R cells
was examined over a 20 fold range from 0.1-2 % (Figure 2.2.5b), which covers the
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lower and upper extremes generally used during screening. No major alteration in
the VIP induced response was apparent with any of the DMSO concentrations tested
(Figure 2.2.5b). As a compromise between DMSO strength and compound
concentration, 0.5 % was chosen as the final in-well DMSO concentration to be used
during screening. Consequently 4-mix library compounds (0.25 mg/ml per
compound in 100 % DMSO) were diluted in inorganic salts buffer (1 in 50) prior to
use, generating a 2 % DMSO containing solution which was then diluted during
screening (1 in 4 dilution), to give the defined DMSO concentration of 0.5 % and
ultimately a compound concentration of 1.25 pg/ml.
In summary, the calcium assay for screening library compounds on the
FLIPR® was performed using 3 84-well clear bottom, black walled plates containing
CHO-hVPACoR cells (1.5 x 104 cells per well; 50 pi) seeded on the previous day.
The assay was performed as described in the methods (section B.3.2., p 65), with 100
nM VIP selected as the optimal agonist concentration for screening, as the potency of
the reference antagonist PG99-465 was unaltered, and the signal size was larger than
that obtained with 60 nM VIP. This was expected to facilitate the identification of
antagonists during screening of the compound libraries. The calcium dye was used
at 2x the recommended concentration (50 pl/well) and library compounds diluted
before addition to the cells (20 pl/well), to give a final in-well concentration of 1.25
pg/ml/compound in 0.5 % DMSO. Library compounds were pre-incubated with the
CHO-hVPAC2R cells for 2 min before agonist addition, after which fluorescence
levels were monitored for a further 3 min.
2.2.3. Screening results
2.2.3.1. Screening data and hit identification
HT-screening for hVPACiR antagonists was performed using the Fujisawa
'F' and 'M' libraries, which contained a total of 98,240 compounds. The initial
screening was performed using library compounds stored in a 4-mix format (4
compounds per well), with compounds tested in duplicate. On each 384-well assay
plate, 640 compounds were tested in total, with individual columns designated for
VIP alone and vehicle only. For each plate, fluorescence levels were recorded in
every well for the entire duration of the 5 min assay. An example of the data
generated from a single 384-well assay plate, along with the corresponding
fluorescence traces for each well is shown in Figure 2.2.6. Changes in fluorescence
from each well (max-min; Figure 2.2.6a) were converted to show the percentage
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change from the average VIP response (Figure 2.2.6b) and finally, the percentages
from duplicate wells were averaged (Figure 2.2.6c). On the plate shown,
fluorescence responses of the CHO-hVPACaR cells to VIP alone, following pre¬
incubation with compound buffer (ISB containing 2 % DMSO), were consistent at
6098 ± 234 (mean ± SEM; RFU) and demonstrated a low level of variability of 3.8
% (Figure 2.2.6, column 21). The minimal responses to the VIP buffer (ISB with
BSA; 1 mg/ml) following a pre-incubation with compound vehicle, were similarly
low between wells (1841 ± 92 RFU), showing 5.0 % variability (Figure 2.2.6,
column 22). Prior to screening, it was decided that hit compounds identified from
the 4-mix library would be split into 'first' and 'second' priority compounds. 'First
priority' compounds were those that demonstrated an average inhibition of the VIP
response of more than 60 %, whereas the 'second priority' compounds were those
which produced an average inhibition between 50 - 60 %. From the particular assay
plate shown in Figure 2.2.6 no hit compounds were identified.
2.2.3.2. Consistency of responses
As the number of plates screened increased, the magnitude of the VIP
response varied, as is illustrated in Figure 2.2.7 which shows the fluorescence traces
from a CHO-hVPAC2R cell plate treated only with VIP (100 nM). The percent
deviations from the average VIP response (for the whole plate (RFU): 7730 ± 78; 1
%) are shown for all wells in Figure 2.2.7b, with negative values indicative of a
response below the average. On this particular plate, although the overall variability
appeared small (1 %), this masked the fact that the size of the VIP response ranged
from 87 % above the average (well D9) to 65 % below (well PI8), with the most
variable responses produced in the outer wells of the plate. At first, it was proposed
that the variability may have arisen from inefficient liquid transfer as a consequence
of the re-use of the same FLIPR® tips for 6 - 8 plates. In an attempt to address this
issue, the use of new tips with every assay plate was tested (Figure 2.2.8a), as was
the use of silicone coated tips (Figure 2.2.8b). However, neither of these measures






















Figure 2.2.1 Fluorescence traces from the FLIPR® produced following
stimulation of CHO-I1VPAC2R cells with VIP. Cells were seeded
into 384 well plates (1.5 x 104 per well) and left overnight.
Following the removal of medium and addition of calcium assay
dye (40 pi), cells were stimulated with a range of VIP
concentrations (0.1 nM - 10 pM; 20 pi per well; 3 x final assay
concentration).
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[VIP] Log M
-6 -5
Figure 2.2.2 VIP produced a concentration dependent increase in
fluorescence in CHO-hVPACzR cells. VIP solutions were added
to CHO-ITVPAC2R cells and the resulting fluorescence levels
measured by the FLIPR®. From max-min analysis of the data
traces shown in (a), a concentration response curve for VIP was


















[VIP] = 60 nM ICso = 116 nM
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[VIP] = 100 nM ICso = 150 nM
Buffer VIP -10 -9 -8 -7
[PG99-465] Log M
-6 -5 -4
Figure 2.2.3 Inhibition of VIP induced hVPAC2R mediated calcium
responses by PG99-465. Using the FLIPR® calcium assay, PG99-
465 (FAC: 0.1 nM to 10 pM) was added to CHO-hVPAC2R cells
(1.5 x 104 per well) and pre-incubated for 2 min. VIP was then
added to the appropriate wells at a concentration of either 60 nM (a)
or 100 nM (b). Responses (max-min) were averaged for each set of
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ICso = 8.9 nM
Buffer VIP -10 -9 -8
[PG99-465] Log M
-7
Figure 2.2.4 Effect of the duration of the PG99-465 pre-incubation period on
VIP induced calcium responses in CHO-I1VPAC2R cells. Using
the FlexStation® calcium assay, the effect of the length of the pre¬
incubation period on the potency of PG99-465 (10 nM) to inhibit
VIP (100 nM) induced responses (from CHO-hVPAC2R cell) was
determined (a). PG99-465 (0.1 - 300 nM) was pre-incubated with
the cells for 2 min, followed by the addition of VIP (100 nM) and
































Buffer VIP 0.1 0.2 0.5 1.0 1.5 2.0
[DMSO] % final assay volume
Figure 2.2.5 Effect of calcium dye and DMSO concentration on the VIP
stimulated calcium response in CHO-I1VPAC2R cells using the
FLIPR®. Cells were stimulated with VIP (100 nM) in the presence
of increasing calcium dye concentrations (a). DMSO (0.1 - 2 %
final concentration) had no effect on the VIP (100 nM) induced





Fie = C 1RlPR2©3fa^Louise\J4 26-11-03\4MF0001-0002
Statistic = Max-Min
Start Sample = 33 End Sample = 122
Positive Staferg = OFF Negative Correction =OFF
Sufctrad Ete Value = Spatial UnifbnnityCorrections OFF
Bias Sample = 122
t 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 ^
A 7429 8253 7307 7441 7160 7585 8022 84 86 9017 8402 8770 9472 10765 0089 7014 7565 6155 6990 7855 6581 9270 2093
B 7822 5765 6835 5996 7431 6438 6861 5730 7845 6787 6733 6037 8381 6961 7007 8008 6341 6479 7374 6910 6549 1762
C 7682 8498 8269 8399 8227 8744 9071 8255 8432 8088 7313 7135 9578 8919 7847 8533 9023 9134 6746 7185 8366 1538
D 7560 7641 6266 7419 6925 8499 8130 6088 5858 6587 7790 7299 8230 6552 8666 6521 7011 7187 7896 8453 7520 1483
E 8724 6227 7845 7267 8393 7865 9188 9520 7704 8188 6874 7819 7235 9135 9531 7916 7542 8094 8094 8342 7477 1812
F 8392 8431 9872 10389 9222 9056 9921 8519 8460 8026 7619 8698 7492 5479 7161 6743 9487 9392 7641 7801 7826 1559
G 8332 8347 7062 8450 7744 8080 10018 8726 9364 9182 8503 8083 8015 7692 7726 7472 7192 8003 8216 8302 6828 1222
H 8503 7932 8172 8548 8702 9270 9147 9954 7394 8186 8261 9026 9274 8856 10750 9354 9659 9998 8211 8639 7535 1997
4751 6788 6773 7138 7638 7174 8090 8064 6271 6578 5282 5548 7310 8211 5881 5735 8801 7670 6300 8281 7057 1444
J 5524 6806 7221 7700 8207 7953 10631 8557 8846 8647 9968 8147 8386 8065 8442 8557 9423 8763 8875 9289 8949 1090
K 4912 6156 8006 6033 7531 7491 7367 7903 7500 7323 7530 7936 7810 7657 8385 6997 5714 6341 7744 7948 6542 2072
I 9730 5753 7892 5128 6881 8573 8368 7624 9659 9192 9641 8693 7888 6955 8600 8436 9238 8447 9435 9563 9637 2357
M 5172 7525 7932 7414 10691 10591 9210 8364 7992 7560 7666 9924 8762 8396 9259 6562 7934 7270 8267 8952 8358 2192
N 666S 7287 7586 7200 7111 7112 10237 9731 9159 8407 8886 9556 9779 0669 9603 7866 7136 7640 9626 7744 8332 1853
0 6493 7618 7615 8665 8103 6580 9006 9796 7618 7053 8701 7930 8674 8048 9704 8934 8390 8846 8776 10127 8528 2619
p 4821 7859 6057 7566 7572 8103 9590 8375 9344 9594 9346 9589 8043 9716 9711 8373 9121 8942 7578 8361 8237 1759
7939 1841 *
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 \
A 8.4 -52 10.4 8.2 12.8 59 -1.4 -9.0 -17.7 -79 -13.6 -25.1 -46.4 -35 3 15 2 6.1 29.3 159 1.4 22.3 -22.0 95.9
B 19 359 18.1 31.9 8.3 24.6 17.7 362 15 18.9 19.8 312 -7.3 16.0 15.3 -1.1 262 23.9 9.3 16.9 22.8 101.3
C 42 -92 -5.4 -7.5 -4.7 -132 -18.6 -52 -8.1 -2.4 10.3 132 -26.9 -18.1 1.5 -9.7 -17.8 -199 19.6 12.4 -7.0 105.0
D 62 4.9 27.1 89 16.6 -92 -3.1 30.4 34.1 222 2.4 105 -4.8 -10.1 -119 232 152 129 0.7 -8.4 6.9 105.9
E -12.9 28.1 19 11.0 -7.4 12 -20.7 -25.9 3.8 ■4.1 17.5 2.0 115 -19.6 -26.1 0.4 65 -29 -2.5 -8.6 76 100.5
F -7.4 -8.1 -31.7 -40.2 -219 -183 -32.5 -9.5 -8.6 -1.4 52 -125 7.3 40 3 129 19.6 -25.4 -23.8 4.9 2.3 IB 1049
G -65 -6.7 14.4 -8.4 32 -2.4 -34.1 -129 -7.0 -20.4 -9.2 -2.4 -19 40 39 79 12.2 -1.1 -4.6 -6.0 182 110.1
H -92 0.1 -3.8 -10.0 -12.5 -21.8 -19.8 -33.0 8.9 -4.1 -5.3 -17.8 -21.9 -15.0 -46.1 -23.2 -282 -33.8 -4.5 -11.5 6.6 97.4
52.3 18.9 19.1 13.1 4.9 12.5 -2.5 -2.4 27.4 22.3 43.8 39.2 10.3 -4.5 33.8 36.1 -14.1 4.4 26.9 -59 14.5 106.5
J 39.8 18.6 11.8 39 -4.4 -02 -442 -10.1 -14.9 -11.6 -339 -3.4 -79 -2.1 -82 -10.1 -249 -139 -15.4 -22.2 -169 102.5
K 499 292 31.7 21.4 6.7 79 9.4 0.6 7.2 10.1 6.7 0.0 2.1 49 25 5 15.4 365 262 3.2 -02 229 962
L 362 35.8 09 46.1 17.3 -104 -7.0 52 -28.2 -20.6 -27.9 -12.4 0.8 16.1 -109 -82 -21.3 -8.3 -24.5 -269 -279 91.5
M 45.4 6.8 0.1 8.6 -45.1 -435 -20.8 -7.0 -0.9 62 4.5 -329 -135 -7.5 -21.7 229 0.1 11.0 -5.4 -169 -6.9 942
N 200 10.7 5.0 12.1 13.8 13.0 -37.7 -29.4 -20.0 -7.7 •15.5 -265 -302 -44.8 ■21.3 12 132 4.9 -27.7 3.2 -6.4 99.8
O 23.7 59 52 -119 -2.7 223 -179 -30.3 59 149 -129 0.1 -12.1 -1.8 -29 0 -169 -7.4 -14.0 -13.7 -35.9 -9.7 87.2
P 51.1 1.3 30.9 6.1 6.0 -2.7 -26.9 -7.2 -23.0 -27.1 -23.1 -27.1 -1.7 -29.2 -29.1 -7.1 -19.4 -16.4 5.9 -6.9 -4.9 101.3 J
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
A 1.6 9.3 9.3 -5.2 -12.6 -19.4 ■40.8 109 22.4 11.8
e 189 25.0 16.5 26.9 102 25.5 4.4 7 1 25.1 13.1
c -29 -6.5 -9.0 -119 -5.3 11.7 -215 -4.1 -18.7 16.0
D 59 17.8 3.7 13.6 28.1 6.5 -7.4 5.7 138 -3.9
E 7.6 8.3 -3.1 -23.3 -0.1 9.7 -4.0 -129 20 •4.6
F -7.8 -35.9 -19.7 -219 -5.0 -39 23.8 18.2 -249 39
G -6.6 3.0 0.4 -23.5 -13.7 -58 1.4 59 5.6 -5.3
H -4 6 -6.9 -172 -26.4 2.4 -11.6 -18.5 -34.7 -31.0 -8.0
35.6 16.1 8.7 -2.4 24.8 41.4 2.9 34.9 -4.9 10.6
J 29.1 7.8 -2.3 -27.1 -13.2 -18.3 -4.7 -9.2 -18.9 -18.8
K 394 26.6 7.0 5.0 8.6 14 3.4 20 5 31.3 15
L 36.0 23.4 39 -09 -24.4 -20.1 85 -95 -149 -259
M 26.1 4.4 -449 -139 2.7 -14.0 -10.5 09 5.5 -11.0
N 15jB 9.0 13.6 -33.5 -13.8 -21.0 -37.5 -13.0 9.0 -122
0 149 -3.3 9.8 -23.9 9.9 -62 -6.9 -229 -11.1 -24.8
P 262 18.5 1.7 -17.0 -25.1 -25.1 -15.4 -18.1 -17.9 -0.5 y
















































Figure 2.2.6 An example of 384-weIl data generated from the screening of an
individual compound library plate. Raw fluorescence counts
(from max-min analysis) are shown (A), followed by the values
expressed as a percentage (B) of the VIP alone response (column
21). The average levels of inhibition from duplicate wells were also
calculated (C). Finally, the traces generated from the individual
wells are shown in the lower section (D).
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(a)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
(b) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
A 27 -10 -23 -26 4 -16 -21 -21 -20 -22 -23 -16 -33 -33 -29 -20 -41 -46 -39 -42 -38
B 61 4 19 14 3 1 7 4 8 5 2 4 -7 8 3 -13 -9 -13 -16 -15 -14
C -9 10 11 15 6 -1 2 -7 4 3 0 -1 -6 2 0 5 -18 -15 -6 -9 -12
D -4 15 18 6 14 11 15 24 87 23 18 18 19 11 23 17 6 3 11 12 9
E -23 1 11 2 9 0 3 2 8 4 8 12 8 6 17 1 -3 -11 -5 -4 14
F -20 1 9 3 14 7 10 11 8 8 6 7 -2 3 10 7 -5 -2 -5 -9 -3
G -7 4 9 13 11 9 10 10 17 22 16 20 13 15 17 2 -3 4 5 8 6
H -8 6 19 7 13 11 13 15 8 17 11 21 7 11 19 6 3 1 8 6 8
1 -23 4 8 3 10 11 13 20 41 14 14 19 9 18 23 21 12 -1 11 5 12
J -26 8 3 10 13 15 18 17 18 15 12 19 12 18 15 22 11 5 12 0 8
K -44 -21 11 13 6 14 15 14 22 17 17 20 4 20 13 26 7 8 9 7 9
L -23 -30 -2 3 7 3 9 9 17 14 10 17 8 6 0 13 -2 0 9 9 1
M -32 -47 -7 2 -6 6 -9 7 7 5 5 8 1 9 7 10 -3 1 0 -6 -9
N -50 -28 -3 5 -1 8 -12 -1 3 12 -2 1 3 8 5 13 -5 -6 10 -13 -9
0 -33 -25 -15 1 7 3 -8 -16 6 1 4 4 -7 -6 -5 -5 -17 -15 -10 -26 -31
P -26 -27 -33 -26 -37 -40 -37 -47 -33 -48 -45 -25 -29 -26 -52 -39 -53 -65 -60 -56 -35
Figure 2.2.7 Variation in response size to VIP stimulation of CHO-I1VPAC2R
cells. In an individual 384-well plate, CHO-WPAC2R cells were
stimulated with VIP (100 nM) and the resulting change in
fluorescence measured (a). The percentage change in response size,






































Figure 2.2.8 Compound plates assayed on the FLIPR® using new tips and
silicone-coated tips. In an attempt to reduce the variation in the
VIP response on the assay plate, a new box of tips were utilised
(a) as were silicone-coated tips (b). However, the resulting VIP
responses remained small and variable, with the average VIP
alone response being 1800 ± 223 (a) and 5008 ± 203 (b).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
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2.2.3.3. Reproducibility studies of hit compounds
As a result of variability in the VIP response size, a large number of first
and second priority hits compounds were identified from the initial round of library
screening (153 assay plates in total). From the 4-mix 'F' library, 69 first priority
and 45 second priority hits were identified (from 68 plates). Consequently, a total of
456 'F' library compounds were then re-tested in reproducibility studies to verify the
initial hit categorisation. First and second priority hits identified from the 4-mix 'M'
library totalled 132 and 136 respectively (from 85 plates). For reproducibility
studies, this would mean 1072 individual compounds would need to be tested. The
large numbers of'hits' identified in the 'M' library coincided with the increase in the
degree of variability associated with the VIP response elicited from the CHO-
IWPAC2R cells. For this reason a number of the 4-mix 'M' plates had to be re-
screened, which was ultimately performed at a later stage by colleagues in Japan, so I
will focus on the data from the 'F' library alone. As discussed in the materials and
methods (section B.3.2.1, p 66), in preparation for reproducibility studies, samples
were taken from the 'individual compound' libraries (1 mg/ml; 100 % DMSO) and
stored at -20 °C until use (1.5 pl/eppendorf). On the assay day, samples were diluted
(1 in 200) with inorganic salts buffer (5 pg/ml; 0.5 % DMSO) and added to 384-well
compound plates (5 replicates per sample). Individual compounds were then tested
for their ability to inhibit VIP (100 nM) induced responses from CHO-hVPAC2R
cells, using the same FLIPR® calcium assay. The majority of the first priority
compounds from the 'F' library (276 in total) were then tested in 2 - 3 independent
experiments depending on sample availability, with the average percentage inhibition
for each compound shown in Table 2.2.1. From these studies, the twelve compounds
(highlighted in Table 2.2.1) which produced the strongest and most consistent
inhibition of the VIP induced response were characterised more fully in subsequent
studies (see below). As can be seen from Table 2.2.1, a number of compounds which
produced similar levels of inhibition to the weaker of the twelve highlighted
compounds were not selected for further analysis. This was because only a limited
number of compounds could be fully evaluated in the following studies due to time
restrictions.
Compounds from the second priority group (180 in total) were tested only
once, as most of the 'hits' proved to be false positives (Table 2.2.2). Although a
small number of the second priority compounds (F0443-C09, F0466-F09 and F0466-
G05) produced a reasonably strong inhibition of the VIP induced response, these
compounds were not examined further in these studies.
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2.2.3.4. Hit compound analysis
Following reproducibility studies, twelve compounds which showed
consistent hVPACaR antagonism were selected for further analysis (FR169879,
FR174736, FR228725, FR049554, FR180868, FR134709, FR236314, FR237277,
FR237276, FR239478, FR238897 and FR240725). Although one of the twelve
compounds was unavailable (FR238897), lyophilised samples of the other eleven
were used in FLIPR® assays to generate approximate IC50 values. Compound
solubility proved to be a problem at high concentrations and as a result, only a
limited range of concentrations was examined in these studies (6 concentrations per
compound over the range 1 x 10"9 to 1 x 10"3; 4 replicate wells per concentration).
Figure 2.2.9 shows representative FLIPR® traces generated from the inhibition of
the VIP response by FR134709, which was one of the more potent compounds
identified. Representative inhibition curves for 10 of the compounds (excluding
FR044954) are shown in Figure 2.2.10(i) and (ii), with the approximate IC50 values
for each sample, where calculable, shown in Table 2.2.3. Approximate IC50 values
ranged from 3 pM for FR169879 to 65 pM for FR228725, with a ROP of FR169879
= FR134709 = FR180868 > FR147436 = FR239478 > FR240725 » FR228725.
Clearly, even some of the hits identified from the reproducibility studies were false
positives with FR236314, FR237276 and FR237277 (Figure 2.2.10(h) f - h) showing
no antagonism of the VIP response. As described above, compound solubility
proved problematic when trying to prepare sufficiently high compound
concentrations, with the presence of a precipitate observed in some of the 0.1-1 mM
solutions. For FR169879, FR174736 and FR239478 (Figure 2.2.10(i): a, b;
2.2.10(h): i) this may have contributed to the inability of the compounds to inhibit
the VIP response at these higher compound concentrations. The particular responses
in which this reversal of inhibitory action was observed, were not included in the
data used to determine compound IC50 values. Although compound FR044954,
appeared to be a potent antagonist in the initial round of screening and in subsequent
reproducibility studies (Figure 2.2.11a), the effects of this compound were variable
and as a result no consistent inhibition curves could be generated. In further studies
when applied alone to CHO-hVPAC2R cells, this compound appeared to stimulate a
large calcium response in the cells, which probably accounts for the subsequent
reduction in the VIP response (Figure 2.2.1 lb). This is supported by the observation
that when VIP (100 nM) is added to CHO-hVPAC2R cells, following a previous




Figure 2.2.9 FR134709 inhibition of VIP stimulated responses from CHO-
hVPAC2R cells. Using the FLIPR®, FR134709 (1 x 10"4 M to 1 x
10"9) inhibited in a concentration dependent manner the VIP (100
nM) induced increase in fluorescence in hVPAC2R cells, with an
IC50 of approximately 4 pM.
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VIP -9 -8 -7 -6 -5 -4 -3
[FR174736] Log M
IC50: ~ 5 pM
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VIP -9 -8 -7 -6 -5 -4 -3
[FR236314] Log M
Figure 2.2.10(i) Inhibition of VIP induced calcium responses from CHO-
hVPAC2R cells by Fujisawa library compounds.
Representative inhibition curves are shown for the following
compounds: (a) FR169879, (b) FR174736, (c) FR228725, (d)
FR180868, (e) FR134709 and (f) FR236314. The IC50 values
presented for each compound were determined from two
independent FLIPR® experiments, with mean values presented in
Table 2.2.3. Continued in Figure 2.2.10 (ii).
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IC50: ~ 15 pM
JL
-8 -7 -6 -5 -4 -3
[FR240725] Log M
Figure 2.2.10(ii) Inhibition of VIP induced calcium responses from CHO-
hVPACiR cells by Fujisawa library compounds, continued
from Figure 2.2.10(i). Representative inhibition curves are
shown for the compounds: (g) FR237277, (h) FR237276, (i)
FR239478 and (j) FR240725. The approximate IC50 values
presented for each compound were again determined from two







Figure 2.2.11 FR044954 has complex effects on calcium signalling in CHO-
I1VPAC2R cells. Using the FLIPR®, FR044954 was initially
observed to strongly inhibit VIP induced calcium responses
mediated by hVPAC2R (a). Flowever, upon further examination
FR044954 alone induced a large increase in fluorescence in these




Figure 2.2.12 Multiple additions of VIP to CHO-I1VPAC2R cells decreases the
evoked calcium response. Using the FLIPR® (a) and FlexStation®
(b), CHO-hVPAC2R cells were stimulated with VIP (100 nM) and
after 2 min (FLIPR®) or 10 min (FlexStation®), a second addition
of VIP (100 nM) was made. The evoked fluorescence response
following the second addition of VIP was dramatically reduced






Buffer -10 -9 -8 -7 -6 -5 -4
[VIP] Log M
Figure 2.2.13 VIP produced a concentration dependent increase in calcium in
CHO cells stably expressing hVPACiR. In the FLIPR® assay, VIP
stimulated an increase in fluorescence from the CHO-hVPACiR cells
in a concentration dependent manner (a), with the resulting sigmoidal












Buffer VIP -10 -9 -8 -7 -6 -5
[PG99-465] Log M
Figure 2.2.14 PG99-465 did not inhibit VIP induced calcium responses from
CHO-hVPACiR cells. PG99-465 was pre-incubated with CHO-
hVPACiR cells for 2 min prior to the addition of VIP (100 nM), with
no subsequent reduction in fluorescence levels observed in the
FLIPR® assay.
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2.2.4. Establishment of the CHO-hVPACiR counter-screen
In parallel to the CHO-hVPAC2R primary screen, I also established a CHO-
hVPACiR counter-screen in which the selectivity of hit compounds was
subsequently evaluated. These assays were performed on the FLIPR® in a similar
manner to those for CHO-hVPAC2R cells, with 1.5 x 104 cells per well seeded
overnight and the 2x calcium dye concentration used. To establish the pharmacology
of the hVPACiR using the FLIPR® assay, a concentration response curve to VIP
was generated (0.1 nM to 10 pM; 8 replicates per concentration), which gave an
EC50 value of 18.8 nM (Figure 2.2.13). This value is consistent with the EC50 of 14.1
± 0.9 nM (n = 6) that was generated for VIP stimulation of CHO-hVPAC2R cells
using the FlexStation® calcium assay (Table 1.2.2, p 110). To verify that this was a
VPACiR mediated response, the effect of the VPAC2R antagonist PG99-465 was
examined. PG99-465 had no overt effect on the VIP response, perhaps marginally
reducing the magnitude of the response at micromolar concentrations (Figure 2.2.14).
As the pharmacological data generated for the hVPACiR receptor using the FLIPR®
was consistent with the FlexStation® data (Table 1.2.2, p 110), the counter-screen
was deemed ready for use. However, as a consequence of personal time restraints
regarding my secondment to Japan, all subsequent hit analysis and counter-screening
studies were performed in Edinburgh (see below) using the FlexStation®.
2.2.5. Analysis of hit compound pharmacology using the FlexStation®
On returning to Edinburgh, samples of FR049554, FR169879, FR174736,
FR180868 and FR134709 were sent over from the Fujisawa laboratories in Japan for
a full pharmacological characterisation, including receptor selectivity studies, using
the FlexStation® assay. In addition, the pharmacological properties of FR300771,
FR149534 and FR035321 were also characterised, as these compounds had been
identified as hits by colleagues in Fujisawa on screening of the 'M' library. The
FlexStation® assays were performed as detailed in the materials and methods, with
cells seeded overnight (1 x 105 cells per well) and the addition of cell buffer and
calcium dye solution as previously described (section B.3.I.2., p 64). The effects of
each compound alone and on the VIP stimulated response are shown for the three
cell lines (a: CHO-hVPAC2R; b: CHO-hVPAC^; c: CHO-hPAC,R) in Figures
2.2.15 - 2.2.22 (2.2.15: FR169879; 2.2.16: FR174736; 2.2.17: FR180868; 2.2.18:
FR134709; 2.2.19: FR300771; 2.2.20: FR149534; 2.2.21: FR035321, 2.2.22:
188
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IC50 > 10 nM
Vehicle VIP -10 -9 -8 -7
[FR169879] Log M
IC50 = 28 pM
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Potency/selectivity of FR169879 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR169879 alone
and on VIP induced responses was determined using CHO-VPAC2
(a; VIP = 100 nM), -VPAC, (b; VIP = 30 nM) and -PAC, (c; VIP =
1000 nM) receptor expressing cells. The graphs shown are
representative, with approximate IC50 calculated from three


























































































IC50 = 7.6 pM
Vehicle VIP -10 -9 -8 -7 -6
[FR174736] Log M
ICso > 30 pM
Vehicle VIP -10 -9 -8 -7
[FR174736] Log M




Vehicle VIP -10 -9 -8 -7 -6 -5
Figure 2.2.16
[FR174736] Log M [FR174736] Log M
Potency/selectivity of FR174736 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR174736 alone
and on VIP induced responses was determined using CFIO-VPAC2
(a; VIP = 100 nM), -VPAC, (b; VIP = 30 nM) and -PAC, (c; VIP =
1000 nM) receptor expressing cells. The graphs shown are
representative, with approximate IC50 calculated from three























































































IC50 = 7.2 juM
IC50 > 30 pM
IC50 = 17 pM
Vehicle VIP -10 -9 -8 -7 -6
[FR180868] Log M
Vehicle VIP -10 -9 -8 -7 -6 -5
[FR180868] Log M
Vehicle VIP -10 -9 -8 -7 -6 -5
[FR180868] Log M [FR180868] Log M
Figure 2.2.17 Potency/selectivity of FR180868 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR180868 alone
and on VIP induced responses was determined using CHO-VPAC2
(a; VIP = 100 nM), -VPAQ (b; VIP = 30 nM) and -PAC, (c; VIP =
1000 nM) receptor expressing cells. The graphs shown are
representative, with approximate IC50 calculated from three























































































Vehicle VIP -10 -9 -8 -7
[FR134709] Log M
Vehicle VIP -10 -9 -8 -7
[FR134709] Log M
IC50 - 8.9 pM
I *




Potency/selectivity of FR134709 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR134709 alone
and on VIP induced responses was determined using CHO-VPAC2
(a; VIP - 100 nM), -VPAC, (b; VIP = 30 nM) and -PAC, (c; VIP =
1000 nM) receptor expressing cells. The graphs shown are
representative, with approximate IC50 calculated from three
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Figure 2.2.19 Potency/selectivity of FR300771 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR300771
alone and on VIP induced responses was determined using CHO-
VPAC2 (a; VIP = 100 nM), -VPAC, (b; VIP = 30 nM) and -PAC,
(c; VIP = 1000 nM) receptor expressing cells. The graphs shown
are representative, with approximate IC50 calculated from three







































































IC50 = 22 pM
Vehicle VIP -10 -9 -8 -7 -6
[FR149534] Log M
ICso > 30 pM
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Vehicle VIP -10 -9 -8 -7 -6 -5
Figure 2.2.20
[FR149534] Log M [FR149534] Log M
Potency/selectivity of FR149534 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR149534 alone
and on VIP induced responses was determined using CHO-VPAC2
(a; VIP = 100 nM), -VPAC, (b; VIP = 30 nM) and -PAC, (c; VIP =
1000 nM) receptor expressing cells. The graphs shown are
representative, with approximate IC50 calculated from three
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IC50 > 30 pM
ICso > 30 pM
Vehicle VIP -10 -9 -8 -7
[FR035321] Log M
I n„n
Vehicle VIP -10 -9 -8 -7 -6 -5
Figure 2.2.21
[FR035321] Log M [FR035321] Log M
Potency/selectivity of FR035321 at hVPAC/PAC receptors.
Using the FlexStation® calcium assay, the effect of FR035321
alone and on VIP induced responses was determined using CHO-
VPAC2 (a; VIP = 100 nM), -VPAC, (b; VIP = 30 nM) and -PAC,
(c; VIP = 1000 nM) receptor expressing cells. The graphs shown
are representative, with approximate IC50 calculated from three
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[FR044954] Log M [FR044954] Log M
FR044954 is an agonist in the CHO-hVPAC/PACR cell lines. In
all three hVPAC/PACR stable cell lines, FR049554 alone produced
a concentration dependent increase in calcium (a: VPACi; b:
VPAC2; c: PACi). The EC50 values shown here and in Table 2.2.3
are from one or two independent experiments. Pre-incubation (10
min) of FR044954 with the cells prior to VIP addition resulted in
reduced responses to the peptide as a result of the initial agonist
effect of FR049554.
197
FR044954). The IC50/EC50 values (where applicable) are summarised for each
compound in Table 2.2.3. When tested alone at concentrations from 0.1 nM to 10
pM, none of the compounds, excluding FR044954, elicited an obvious effect on
basal levels of calcium in any of the three hVPAC/PACR stable cell lines (Figures
2.2.15 - 2.2.22). In contrast, FR044954 demonstrated clear agonist properties when
tested alone with all three CHO-hVPAC/PACR cell lines (Figure 2.2.22). FR049554
had EC50 values of 4.7 pM (CHO-hVPAC2R), 3.2 pM (CHO-hVPAC,R) and 2.4 pM
(CHO-hPAC]R), appearing to be an equipotent, non-selective agonist for these
receptor subtypes (Figure 2.2.22). The maximum responses produced by FR049554
in all three cell lines were similar to those produced with the peptide agonists
described in chapter one (section 1.2.3.2., p 105). Although FR049554 inhibited the
VIP response in each of the three stable cell lines (Figure 2.2.22), this was probably a
consequence of its agonist properties as discussed previously (see Figures 2.2.12a
and 2.2.12b, from the FLIPR® and FlexStation® respectively). Of the remaining
seven compounds, FR169879, FR174736, FR180868, FR134709 and FR149534 all
produced a concentration dependent inhibition of agonist evoked calcium signalling
at hVPAC2R (Figures 2.2.15-2.2.22), with approximate IC50 values ranging from 2.3
to 22.1 pM, which was consistent with data generated using the FLIPR® (Table
2.2.3). The ROP for these compounds was FR169879 = FR134709 > FR174736 =
FR180868 > FR149534. FR300771 and FR035321 were less potent than the other
compounds and as a result no IC50 values could be determined as the concentration
range required could not be achieved in these assays; estimated IC50 values were
expected to be at least greater than 10-30 pM. The receptor selectivity of the
compounds was also examined using the hVPACiR and hPACiR stable cell lines,
with the most potent VPAC2R antagonist FR169879, being at least 5 fold less potent
at VPACiR, whilst exhibiting 10-fold selectivity over PACiR. All of the five non-
peptide antagonists that were observed to have micromolar potency at the VPAC2R,
exhibited some degree of selectivity over the other receptors (Table 2.2.3), although
none of the compounds were as potent or as selective as the peptide antagonist
PG99-465 (Table 1.2.3, p 118).
198
2.3. Discussion
2.3.1. HT-screening to identify VPAC2R antagonists
The VPAC2R receptor is critical in the maintenance and control of normal
circadian rhythms of activity and consequently, we hypothesised that antagonists of
this receptor may be beneficial in treating circadian rhythm disorders in which the
sleep/wake cycle is disrupted. In collaboration with Astellas Pharma Inc., I have
performed a high-throughput screening study to identify selective, non-peptide
VPAC2R antagonists from the company's compound libraries.
Both of the functional assays (cAMP and calcium assays) performed using
the FlexStation® (chapter one) provided sensitive and robust assays with which to
characterise the pharmacology of this particular GPCR. However, due its simplicity,
increased throughput and cost-effectiveness, the calcium assay was selected for use
in the HT-screening process and was miniaturised and optimised accordingly for use
in a 384-well format on the FLIPR®. Miniaturisation of the assay involved
investigating several factors, including the optimal concentration of calcium dye,
agonist and library compounds to use in the assay, in order to maximise the response
and facilitate the detection of hit compounds.
2.3.2. Potency and selectivity of hit compounds
Following the successful miniaturisation of the I1VPAC2R assay to the 384-
well format, approximately 100,000 compounds, in 4-mix cocktails from the small-
compound libraries were evaluated in the initial round of screening. Hit wells were
identified and the compounds comprising the appropriate 4-mix cocktails were tested
individually and hit compounds identified. From the 'F' library alone, 456
compounds were identified as potential hits and were subsequently re-evaluated to
confirm antagonist action. In further studies, the concentration dependence of
inhibition was determined for a dozen of the most potent and consistently active
compounds, of which five were selected for characterisation in potency and
selectivity studies using the FlexStation® assay (FR169879, FR174736, FR044954,
FR180868, FR134709). Three additional compounds were selected by colleagues in
Astellas for evaluation in these studies (FR300771, FR149534, FR035321). Of these
eight compounds, FR169879 was the most potent at the hVPAC2R, inhibiting agonist
induced responses with an IC50 value of 2.3 ± 0.8 pM (n = 3). However, as also
observed for the other less potent compounds, FR169879 was not highly specific for
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the hVPAC2R, demonstrating only 5-10 fold selectivity over the hVPACi and
hPACi receptors. When compared to the VPAC2R peptide antagonist PG99-465
(Moreno et al., 2000), which was demonstrated to be both potent (IC50 = 4.4 ± 0.8
nM, n = 6) and selective in the calcium assay (Table 1.2.3, p 118), the non-peptide
compounds identified during screening were considerably less potent (at least 500
fold), as well as exhibiting little selectivity. As a consequence, these compounds do
not exhibit sufficiently good pharmacological properties to allow them to be
classified as potent and selective I1VPAC2R antagonists. The structures of several of
the hit compounds identified from screening were examined by colleagues in
Astellas Pharma Inc. with a view to improving their potency and selectivity for the
hVPAC2R, however none were thought to be amenable to chemical modification.
Although FR049554 originally appeared to be an I1VPAC2R antagonist, this
effect was subsequently shown to be a result of the agonist activity of this compound.
As shown in both the FLIPR® and FlexStation® calcium assays, the fluorescence
response induced by an agonist can be almost completely ablated if it follows the
pre-incubation of another compound which also behaves as an agonist (Figure
2.2.12). Data generated from the FLIPR® during screening was focussed upon the
magnitude of the VIP response and as a result it was not possible to perform detailed
retrospective analyses of potential agonist activity of the library compounds, prior to
VIP addition. Without the specific evaluation of possible stimulatory effects during
the pre-incubation period, such compounds could easily be mistaken for antagonists.
FR049554 was found to be an equipotent (EC50 = 2.4 - 4.7 pM), non-selective
agonist of all three hVPAC/PAC receptor subtypes. Although demonstrating full
agonist activity when tested with the three cell lines, FR049554 is clearly much less
potent than any of the VPAC/PAC receptor peptide agonists characterised using the
calcium assay in chapter one. Therefore, despite being a non-peptide, this compound
is again of limited use as a VPAC/PACR agonist given its weak potency. In future
studies, this compound would clearly have to be evaluated using VPAC/PACR
antagonists and in CHO-K1 host cells to determine if it is truly a selective agonist of
receptors in the VPAC/PACR sub-family.
2.3.3. Challenges encountered during screening
As described in the results section, as the screening of library compounds
progressed, the fluorescence signals generated in response to VIP using the CHO-
hVPAC2R cell line became increasing variable between wells of individual assay
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plates and consequently between assay plates. As a result, a large number of false
positive hits were identified during screening, particularly from the 'M' library. In
an attempt to rectify this situation, silicone coated FLIPR® tips and a new box of tips
for each plate were systematically trialled, but neither resulted in any significant
improvement in the consistency of response. The occurrence of this variability
meant several compound plates had to be re-screened at a later date.
Although the agonist induced calcium responses from the CHO-I1VPAC2R
cell line were large enough (in the FlexStation® and initial FLIPR® assays) to
justify the use of this assay in HT-screening, the use of the cAMP assay may have
proven to be more reliable. When comparing the two assays in the FlexStation®,
maximum agonist induced cAMP responses from the stable cell lines were 3-4 fold
greater than the corresponding calcium responses (~ 25x basal compared to ~ 7x
basal; chapter one, p 104 and p 106). Therefore, the use of the cAMP assay during
screening may have reduced the impact of the well-to-well variability and decreased
the number of false positive hits. A further drawback of the calcium assay became
evident in the reproducibility studies, as discussed previously for FR049554. If a
particular library compound alone stimulated a calcium response from the hVPAC2R
cell line, it would reduce the subsequent response to VIP and appear to be an
antagonist, giving a false positive result. This reduction in agonist induced calcium
response following an initial stimulation event with agonist has been described for
other GPCRs, including VPACR (Porter et al., 2001; Harfi & Sariban, 2006). In our
CHO-I1VPAC2R studies, this effect may have been a consequence of receptor
desensitisation or of a limited availability of calcium in the intracellular stores of the
host cell line, as a result of the initial calcium stimulation. In contrast, this effect did
not appear to be an issue in the FlexStation® cAMP assay. In preliminary studies
using the hVPAQR and hPAQR cell lines, in which PG99-465 (which was shown
to be a full agonist at these receptors in this assay; chapter one, p 119) was pre-
incubated with the cells prior to VIP addition (EC50 concentration), the resulting
cAMP levels were found to be additive (Figure 1.2.27, p 124). This suggests that
when stimulated by these receptors, the Gas-adenylate cyclase pathway in CHO-K1
cells was perhaps less susceptible to desensitisation than the calcium stimulating
pathways, or that larger pools of cAMP were available in these cells relative to
calcium. As a result, the use of the cAMP assay for screening may again have
reduced the number of false positives detected. The possible advantages of the
cAMP assay over the calcium assay in our screening studies are speculative at this
stage and both assays would need to be compared in a 3 84-well format on the
FLIPR® before this could be verified. Prior to the selection of the screening assay
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we intended to perform a pre-screening trial of both assays on the FLIPR®, however
as the calcium assay was less time consuming and more cost-effective than the
cAMP assay, our colleagues in Astellas Pharma Inc. selected the former assay as the
most appropriate to use for this I1VPAC2R screening project. In an industry where
the cost of developing one drug from the laboratory into clinical use is estimated to
be in the region of $802 million, reducing expenditure during development is of
prime importance (Dickson & Gagnon, 2004; O'Connell & Roblin, 2006). The
necessity of economical pre-clinical studies is further emphasized when it is
considered that only 1 out of every 5 - 10,000 compounds evaluated in pre-clinical
testing proceeds to clinical use (Figure 2.3.1; Preziosi, 2004). In addition, the
average success rate for CNS targets specifically, has been estimated to be 3 - 5 %
(Kola & Landis, 2004; Hurko & Ryan, 2005). The high attrition rates in the drug
discovery process are a result of multiple factors, however in most cases (~ 40 %), a
lack of efficacy of lead compounds at the clinical trial stage of development is
responsible (Preziosi, 2004; Kola & Landis, 2004). Furthermore, there are an
emerging number of critics who suggest that the introduction of target based drug
discovery and HT-screening is the predominant cause of the declining numbers of
new chemical entities (NCE) reaching the clinic (Flilbush et al., 2005; Macarron,
2006).
When multiple assay types are deemed suitable for screening a particular
drug target, the logical selection for HT-screening would be the most cost-effective,
Launch of NCE (Y
Figure 2.3.1 Estimated proportions of compounds proceeding to various
stages in the drug development process. The diagram illustrates
hypothetical ratios of compounds that successfully proceed through
the stages of drug development. Figure from Preziosi (2004).
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high-throughput and simplest assay. However, for GPCRs which activate multiple
signalling pathways, selecting a single assay for screening may be limiting. As
discussed recently by Gurwtiz & Haring (2003), a more effective strategy may be to
utilise multiple assays for a range of second messengers, hence providing a more
extensive and thorough (high-content) screening programme. The possible benefits
of this approach have been discussed with particular reference to cevimeline
(Evoxac), a Mi receptor agonist that is currently marketed by Daiichi-Sankyo Inc. as
a treatment for symptoms associated with Sjogren's Syndrome (Gurwitz & Haring,
2003; Jacoby et al., 2006). This drug has been shown to have remarkably different
pharmacological activities at Mi receptors in vitro, depending on the second
messenger investigated; being an antagonist in AC assays, a partial agonist in PLC
assays and a 'super-agonist' in calcium mobilisation con-focal microscopy studies
(Fisher et al., 1996). The use ofmultiple assays in this case clearly helped identify a
therapeutically useful compound, the efficacy of which could otherwise have been
overlooked if only AC studies had been utilised to evaluate its pharmacology.
Additionally the use of multiplex assays may be an even more attractive alternative
to improving the HT-screening process (Jacoby et al., 2006). In these assays the
parameters of a single screen are adjusted and modified to facilitate the identification
of different types of ligands (agonists, antagonists etc.) from compound libraries,
with this approach already implemented into FLIPR® based screening platforms in
pharmaceutical companies such as Novartis (Jacoby et al., 2006). Although these
approaches produce much more extensive data from screening, they are inevitably of
lower throughput and higher cost than the simpler, single assay screens. However
there are no advantages to running an ineffective screen, solely for the reason that is
fast and economical. A balance between the resources required to run an effective
screen and the quality of the data produced should be investigated for each HT-
screening study performed.
2.3.4. HT-screening studies of group B GPCR
As discussed in the introduction to this chapter, HT-screening to identify
novel ligands for the group B GPCR family has proven challenging for the
pharmaceutical industry and consequently, this receptor family is deemed to be a
difficult target for drug discovery, with only a few non-peptide antagonists and no
potent, non-peptide agonists reported to date (see Table 2.1.1, p 162; Hoare, 2005).
Indeed, when the success rates of compounds proceeding from HT-screening to lead
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Target class Success rate: FITS to
tractable hit (%)
G-protein-coupled Family A 54







Table 2.3.1 Success rates of compounds proceeding from HT-screening
studies to lead compound (tractable hit) status for a range of
drug targets utilised by GSK over a three year period
(Macarron, 2006).
compound status are compared between target types utilised in HT-screening at
GlaxoSmithKline (GSK; from 2001 to 2004), the group B (and C) GPCR families
are clearly lagging behind the group A GPCRs and other classes of target (Table
2.3.1). It has been suggested that structural differences in the transmembrane
domains between the group A and B GPCRs may account for the contrasting success
rates of HT-screening studies and why it appears to be so difficult to find non-
peptide ligands for the group B receptors (Macarron, 2006). The chemical and
molecular basis for this hypothesis warrants further consideration as more data
becomes available regarding the mechanisms of ligand binding to the group B
GPRCs (Hoare, 2005). Such data may facilitate the identification and design of
novel non-peptide ligands for this group of receptors in the future, including the
VPAC/PAC receptor family. In addition, the poor success rates of group B GPCR
screening studies may also be due to a lack of appropriate chemicals in the
compound libraries examined. This simple explanation has proven to be pertinent in
recent years, as can be clearly seen upon examination of the success rates in lead
compound identification from the compound libraries at GSK. Following the merger
of GlaxoWellcome and SmithKline Beecham in 2000, the amalgamation of the
respective compound libraries led to the identification of lead compounds for almost
a third of the targets for which screening studies prior to the merger had proven
unsuccessful (Macarron, 2006). Similarly, the merger of the Fujisawa and
Yamanouchi Pharmaceutical Companies to form Astellas Pharma Inc., which took
place after the current screening studies were performed, has resulted in a much
larger and more diverse compound library for the new company. In the future, this
could provide a new opportunity to identify novel VPAC2R specific ligands.
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CHAPTER THREE
CENTRAL ROLES FOR VPAC/PAC RECEPTORS
205
3.1. Introduction
In the final chapter of this thesis I will consider some of the roles of
VPAC/PAC receptors in the central nervous system and describe studies
investigating such actions, using both in vitro and in vivo techniques. As discussed
in the general introduction, a plethora of potential roles have been described for VIP,
PACAP and their cognate receptors, with a large proportion of these studies focusing
on glucose homeostasis, neuroprotection, modulation of the immune system and
control of circadian function. In this section, I will explore some of the central roles
that are potentially mediated via VPAC/PAC receptors, with a primary focus on
neuroprotection/immunomodulation and circadian rhythms of activity.
3.1.1. VPAC/PACR in neuroimmunomodulation and neuroprotection
The first descriptions of a neuroprotective action for VIP were published
almost twenty years ago by Brenneman and colleagues (Brenneman & Eiden, 1986;
Brenneman et al., 1987). In these studies, VIP application to cultures of mouse
dorsal root ganglion neurons was reported to increase the survival of the cells
(maximal protection observed with nanomolar VIP concentrations) in response to co-
treatment with the well established neurotoxin, tetrodotoxin (TTX). In the years
following, evidence in support of a neuroprotective role for VIP and PACAP grew
considerably, with publications reporting the use of a wide variety of in vitro and in
vivo models, which shall be discussed in depth in the following sections.
3.1.1.1. VIP and PACAP mediated neuroprotection
In agreement with the findings of Brenneman (see above), Kaiser & Lipton
(1990) reported that VIP was able to rescue rat retinal ganglion cells from TTX
induced cell death, with maximal protection observed with micromolar
concentrations of the peptide. Furthermore these authors suggested that the survival
promoting effects of VIP involved a cAMP dependent pathway (Kaiser & Lipton,
1990). Using rat cultured cortical neurons, PACAP-38 was subsequently shown to
reduce glutamate induced cell death (by approximately 50 %), with the peak of this
protective effect observed at considerably lower (picomolar) concentrations (Morio
et al., 1996). Comparable protection against glutamate excitotoxicity has also been
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demonstrated in rat retinal neurons (with micromolar peptide concentrations) and
was reported to occur through a pathway involving cAMP, PKA and MAPK (Shoge
et al., 1998, 1999). In rat and murine mixed cortical cultures, the PACAPs have also
been shown to protect against neuronal death following an inflammatory insult
generated using LPS, which is a major constituent of the cell wall of gram-negative
bacteria (Kong et al., 1999; Li et al., 2005). Once again PACAP proved to be
neuroprotective even when used at very low (picomolar) concentrations, however its
effectiveness appeared to have a biphasic concentration dependence. Furthermore,
these studies suggested that the neuroprotective action of PACAP was mediated
through PACjR and that at least two pathways were involved. One component was
reported to involve the stimulation of cAMP (nanomolar peptide concentrations),
whereas the second involved stimulation of MAPK (subnanomolar peptide
concentrations; Kong et al., 1999; Li et al., 2005). The protective effects of VIP and
PACAP are not restricted to neurons and further studies from Brenneman and
colleagues demonstrated that in rat cortical astrocytes (RCA), VIP and PACAP-38
could protect against toxicity induced by gpl20 derived peptides (glycoprotein
envelope of the HIV virus; Brenneman et al., 1999, 2002). As illustrated in Figure
3.1.1, the concentration response relationship for both peptides was biphasic,
however the peaks of protective action were different for the individual peptides,
indicating different potencies. Vaudry and colleagues have also investigated the
neuroprotection of PACAP using rat cerebellar granule cells and have shown that
this peptide can protect these cells against ethanol induced apoptosis and cell death
from oxidative stress (Vaudry et al., 2002a, 2002b). The authors suggested that the
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Figure 3.1.1 VIP and PACAP-38 protect rat cortical astrocytes against gpl20
induced cell death. These figures are adapted from Brenneman et
al. (1999,2002).
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consequence of caspase-3 inhibition, which occurred downstream of PACiR
activation. Consistent with these findings, Onoue and co-workers have used rat
PC 12 cells (endogenously express PACiR) to show that VIP and PACAP-27 were
protective against (3-amyloid and prion protein induced neurotoxicity, involving a
PKA-MAPK pathway, again as a result of caspase-3 inhibition (Onoue et al., 2002a,
2002b). Similar to the effects described for gpl20 toxicity (Figure 3.1.1), these
studies demonstrated that the peptides had quite different potencies, with significant
protection detected with picomolar and nanomolar concentrations of PACAP-27 and
VIP respectively. This is consistent with the potency of these peptides at the PACiR
(chapter one). From the studies described above and others showing VIP/PACAP
cellular protection in vitro, the protective effects generally appear to be biphasic with
regard to their concentration dependence and are partly mediated by pathways
involving MAPK and cAMP. In addition, several of the studies described in this
section have implied that the PACiR mediates the neuroprotective actions ofVIP and
PACAP. A very recent study exploring the role of specific PACiR splice variants
demonstrated that the PACi-hop2 receptor can protect transfected COS cells from
hydrogen peroxide induced oxidative stress (Pilzer & Gozes, 2006b). These authors
suggested that cAMP may mediate these effects and also discussed the possible
involvement of receptor mediated calcium signals.
Within the last ten years, the neuroprotective properties of VIP and PACAP
have been examined in a range of animal models, including models of stroke,
Parkinson's disease and traumatic brain injury (TBI). In models of both global and
focal ischemia, administration of PACAP-38 (i.e.v. or i.v. injection) has been shown
to have remarkable effects on the infarct volume and the integrity of hippocampal
neurons (Uchida et al., 1996; Reglodi et al., 2000, 2002). Indeed, even when given 4
h post-insult (transient MCAO) PACAP-38 produced a 50 % reduction in infarct size
(Figure 3.1.2; Reglodi et al., 2000). In addition, PACAP was demonstrated to
protect hippocampal neurons from ischemic damage even when given up to 24 h
post-insult, with these effects suggested to be mediated by astrocytes (Uchida et al.,
1996). In further studies these authors suggested that the anti-apoptotic effects
involved increased IL-6 release from astrocytes and the modulation of MAPK
activity (Shioda et al., 1998). Recent studies using transgenic mice have also
confirmed that PACAP can have a number of protective effects. As discussed in the
general introduction, PACAP null mice had significantly higher neuronal damage
following pCMAO when compared with WT mice (Ohtaki et al., 2006). In addition,
these studies also showed that PACAP-38 was not neuroprotective in IL-6 null mice,



















Figure 3.1.2 Effects of PACAP-38 administration on infarct size following
transient MCAO. MCAO was performed for 2 h and was followed
four hours later by the administration of vehicle or PACAP-38
through osmotic mini-pump. The reduction in infarct size with
PACAP-38 is evident in both the upper graph and from the
representative brain slices. Figures taken from Reglodi et al. (2000).
neuroprotection (Ohtaki et al., 2006). In general the doses of peptides that have
been shown to be effective in vivo are relatively low, in comparison to the doses
required to induce a significant increase in cerebral blood flow. This led Reglodi and
colleagues to speculate that although the exact mechanism underlying PACAP
induced neuroprotection is not clear, the effects may only be partially due to a
peptide induced increase in cerebral blood flow (Reglodi et al., 2000). These authors
have also used an animal model of Parkinson's disease to examine PACAP induced
neuroprotection (Reglodi et al., 2004). In these studies, the neurotoxin 6-
hydroxydopamine was used to induce lesions of the substantia nigra in rats and the
neuroprotective effects ofPACAP-38 pre-treatment were evaluated. PACAP-38 was
shown to rescue ~ 50 % of the dopaminergic neurons from death, with a reduction in
behavioural deficits. Delgado & Ganea (2003a) have used the MPTP model of
Parkinson's disease and reported that VIP administration was also able to reduce
neuronal degeneration in the substantia nigra. Again, the mechanism of the VIP
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action in this model is not entirely clear, however it was suggested that anti-apoptotic
and anti-inflammatory actions of the peptide may be involved. The putative impact
of VIP/PACAP and their receptors in TBI has also been explored in a small number
of relatively recent studies. In 1999 Skoglosa et al., using the weight drop technique
in rats, demonstrated that an insult to the cerebral cortex produced an increase in
PACAP mRNA expression in the ipsilateral cortex (for up to 72 h post insult) and
hippocampus (peaked at 12 - 48 h post insult; Skoglosa et al., 1999). In contrast,
using the stab wound injury model, which induces a much lower inflammatory
response, Jaworski and colleagues (2000) found that PACAP mRNA was not up-
regulated post insult. However, and perhaps in support of the data from Skoglosa et
al. (1999), following a TBI insult in rats (weight drop technique), Hang and
colleagues (2004) demonstrated that the concentration of VIP in the plasma and gut
tissue of the rats was significantly elevated 72 h after the insult. The observed
increase in VIP levels was coincident with elevations in other brain-gut peptides, and
was suggested to be involved in the gastric dysfunction observed in many patients
following TBI (Hang et al., 2004). Furthermore, using the same TBI model Farkas
et al. (2004) have shown that in contrast to i.v. administration of PACAP pre-insult
which was ineffective, i.e.v. administration post-insult reduced the density of
damaged neurons, re-iterating the potential therapeutic value of PACAP like
peptides. Although much attention has focused on the role of the PACiR in
mediating these neuroprotective effects, results from a recent study have shown that
the VPAC2 receptor may be involved. Using VPAC2R null mice, Rangon and
colleagues (2006) have shown, in contrast to WT mice, that VIP was not protective
against ibotenate induced cerebral white matter lesions. In addition, the
neuroprotective effect ofVIP in the WT mice was shown to be independent of cAMP
levels, but dependent on PKC activity (Rangon et al., 2006). From both the in vitro
and in vivo studies discussed, although the exact mechanisms underlying the
protective effects of VIP/PACAP remain unclear, anti-apoptotic and anti¬
inflammatory actions are likely to be involved given the involvement of caspases and
cytokines. As shall be discussed in the following section, several factors have now
been identified which may mediate the neuroprotective effects ofVIP and PACAP.
3.1.1.2. VIP and PACAP secretagogue activity
The neuroprotective effects of VIP and PACAP are suggested to occur
through several mechanisms, involving both direct and indirect actions (Dejda et al.,
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2005). The direct effects are thought to be mediated by the VPAC/PAC receptors
expressed on neurons and to involve both cAMP/PKA and PLC/IP3 signalling
pathways leading to modulation ofMAPK activity. It is interesting to note that these
direct protective effects are not always evident, as the early studies of Brenneman
showed that enriched neuronal cultures were not protected by VIP following TTX
treatment, in contrast to observations from mixed astrocyte/neuronal cultures
(Brenneman et al., 1987). However, this may reflect the different types of neurons
that have been examined and the receptor expression levels on those neurons. In
addition, some of the indirect protective effects of VIP and PACAP have been
attributed in recent years to anti-inflammatory effects mediated by microglia
(Delgado et al., 2002). The peptides have been demonstrated to reduce the release of
pro-inflammatory cytokines (TNF-a, IL-ip, IL-6) from microglia and hence have
been termed 'microglia deactivating factors' (Delgado et al., 2002, 2003b). Much of
the research into the protective effects of VIP and PACAP has focused on the
indirect effects mediated through VIP/PACAP activity on astrocytes. The role of
astrocytes has been well documented since the very first studies of VIP/PACAP
neuroprotective effects, in which Brenneman and colleagues (1987) reported that 'a
diffusible substance that exhibits neuronal survival-promoting activity is detectable
after treatment of non-neuronal cultures with VIP'. Although the exact mechanism
underpinning VIP/PACAP neuroprotection via astrocytes is unclear, peptide induced
production and release of a number of factors, including cytokines and highly potent
neurotrophic factors is involved (Brenneman et al., 1987; Dejda et al., 2005). The
secretion of these factors has been demonstrated in vitro following stimulation of
primary cultures ofRCA with VIP and PACAP, and is discussed below.
Much of the research into cytokine release from astrocytes upon
VIP/PACAP treatment has come from the Brenneman laboratory, although other
groups have also contributed to the existing knowledge (Gottschall et al., 1994;
Grimaldi et al., 1994). VIP and PACAP have been shown to stimulate the release of
multiple cytokines from RCA including IL-la, IL-P, IL-3, IL-6, MlP-la, MIP-ip,
RANTES, TNF-a, M-CSF and G-CSF (Brenneman et al, 1995, 1999, 2002, 2003).
These studies have shown that the concentration of peptide, and the specific peptide
used, will greatly alter the composition of the pool of cytokines released from the
RCA (Figure 3.1.3). Furthermore, the involvement of cAMP dependent and cAMP
independent mechanisms has been demonstrated in this peptidergic modulation of
cytokines (Brenneman et al., 2003). The release of these cytokines is likely to
contribute to the neuroprotective effect through modulating the inflammatory
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Figure 3.1.3 VIP and PACAP stimulated release of cytokines from RCA. The
composition of the cytokine pool released from RCA in response to
VIP/PACAP is critically dependent on which peptide (a) is applied
to the cells and at what concentration (b). Figures taken from
Fukuhara et al. (1997) and Brenneman et al. (2002).
neuroprotection observed at very low peptide concentrations. These effects have
been attributed to a very exciting group of neurotrophic factors, the first of which -
'activity-dependent neurotrophic factor' (ADNF), was purified 10 years ago from rat
cortical astrocyte cultures following stimulation with VIP (0.1 nM; Brenneman &
Gozes, 1996). These authors reported that ADNF and an active fragment of this
factor, ADNF-14 were able to potently reduce neuronal death in cerebral cortical
cultures treated with TTX, gpl20, NMDA and (3-amyloid (Figure 3.1.4), and
suggested that these factors may do so by influencing calcium mobilisation.
Structure-activity studies of ADNF revealed that a shorter derivative ADNF-9 (9
amino acid residues: SALLRSIPA) was actually even more potent than the parent
peptide and was effective over a broader concentration range (Brenneman et al.,
1998). In addition the conferred neuroprotection was relatively long lasting, with a 2
h treatment protecting neurons from TTX induced death for 4 days. The potency of
this peptide was shown to be increased by -10,000 fold in mixed neuron/glial
cultures compared to neuronal cultures alone, suggesting that in addition to a direct
action on neurons, ADNF-9 was able to stimulate the release of additional protective
factors from astrocytes. An ADNF-like factor called ADNP (activity-dependent
neurotrophic protein) was also identified from a mouse carcinoma cDNA library and
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Figure 3.1.4 ADNF neuroprotection of cerebral cortical cultures. ADNF
derived peptides were shown to potently protect neurons from TTX
(a) and P-amyloid (b) induced cell death. The dashed lines indicate
the number of neurons in control cultures. Figures from (Brenneman
& Gozes, 1996; Cagampang et al., 1998a)
was subsequently shown to have similar in vitro protective properties to the ADNF
factors and in some cases, was even more potent (Bassan et al., 1999; Gozes &
Brenneman, 2000). The protective actions of NAP have also been demonstrated in
several in vivo models including stroke, TBI and fetal alcohol syndrome (Beni-Adani
et al., 2001; Leker et al., 2002; Vink et al., 2005). These factors are proposed to
work in part though cGMP pathways and are thought to target tubulin, a component
of the cytoskeleton (Ashur-Fabian et al., 2001; Divinski et al., 2004). The
remarkable neuroprotective activity of NAP therefore provides an exciting
opportunity for drug development, with the peptide currently entering into phase II
clinical trials (Gozes et al., 2005). The mechanisms which link VIP and PACAP to
ADNP release from astrocytes, including the exact VPAC/PAC receptors and the
downstream signalling pathways involved, remain to be clarified although the
VPAC2R is suggested to be involved (Zusev & Gozes, 2004). The precise
mechanisms will depend on the expression levels of VPAC/PAC receptors in the
astrocytes, as discussed in the following section.
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3.1.1.3. VPAC/PAC receptor expression in RCA
Multiple studies have demonstrated that primary cultures of rat astrocytes
(RCA) express several subtypes of VPAC/PAC receptors (Ashur-Fabian et al., 1997;
Grimaldi & Cavallaro, 1999; Jaworski, 2000). However, the range of subtypes
expressed and their relative expression levels appear to vary considerably between
reports. VPAC/PAC receptor expression in astrocytes has been suggested to be
developmentally regulated, therefore the expression levels in cultured astrocytes may
depend on the age of the animals from which the cells were derived and on the length
of time the cells have been maintained in culture (Jaworski, 2000). In general
PACiR variants have been shown to be the predominant subtype expressed in RCA,
with the expression of the null, hop2 and hopl variants shown (Ashur-Fabian et al.,
1997; Grimaldi & Cavallaro, 1999; Jaworski, 2000; Hashimoto et al., 2003).
Furthermore, the recently described PACi(3a) variant has also been shown to be
expressed in rat astrocyte cultures (Pilzer & Gozes, 2006a). The presence of both
VPAC receptor subtypes has also been described in these cells, although the
expression levels appear to vary, with VPACjR expression suggested to be very
weak and with VPAC? levels differing between reports (Ashur-Fabian et al., 1997;
Grimaldi & Cavallaro, 1999; Jaworski, 2000; Hashimoto et al., 2003). The
complement of receptors expressed in the RCA at any given time will regulate
downstream signalling, and the potencies with which they are activated by
VPAC/PACR agonists may influence the levels of neuroprotective factors secreted
by the cells.
3.1.1.4. VPAC/PAC receptor signalling pathways in RCA
As discussed in chapter one, VPAC/PAC receptors have been demonstrated
to couple to G-proteins stimulating intracellular pathways that increase cAMP,
calcium and PLD levels. In RCA, the VPAC/PAC receptor modulation of these
intracellular messengers is poorly characterised, as is the pharmacology of the
receptors present. Further investigation into both of these areas could prove useful to
our understanding of the mechanisms linking VPAC/PACR activation to the
secretion of neuroprotective factors from astrocytes. The concentration dependent
stimulation of cAMP by PACAP in astrocytes has been demonstrated in only a small
number of studies (Hashimoto et al., 1993; Grimaldi & Cavallaro, 1999; Masmoudi
et al., 2003; Li et al., 2005). The most extensive characterisation was performed by
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Hashimoto and colleagues (1993) who compared PACAP-27, PACAP-38 and VIP
potencies for cAMP stimulation in RCA, generating an ROP that was consistent with
the expression of the PACjR. Regarding the other intracellular messengers, only one
study has demonstrated a concentration dependent increase of calcium in response to
PACAP-38 (Masmoudi et al., 2003), although Dejda and colleagues (2006) have
recently reported the characterisation of cAMP, calcium and PLD responses in RCA
in response to VIP, PACAP-38 and PHI/PHM. These authors reported that cAMP
levels were stimulated by all the agonists examined, with calcium and PLD pathways
only sensitive to VIP and PACAP-38. However, no concentration response curves
were shown from these studies and no quantification of potency was reported,
limiting the interpretation of the results (Dejda et al., 2006).
3.1.1.5. Characterisation of VPAC/PACR pharmacology in RCA and the
correlation with cytokine release
Given the highly important roles of astrocyte derived factors in
neuroprotection and the poorly characterised VPAC/PACR pharmacology in these
cells, we sought to fully investigate the pharmacology of VPAC/PAC receptor
mediated intracellular cAMP and calcium responses in primary cultures of rat
cortical astrocytes. The characterisation studies were performed using the same
FlexStation® assays that were utilised in chapter one. Furthermore, we attempted to
determine if any correlation was evident between cAMP and/or calcium signalling
and the release of cytokines from the astrocytes upon VPAC/PACR stimulation.
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3.1.2. The role of VPAC/PACR in the control of circadian rhythms
As discussed in the general introduction, the generation of mouse lines
harbouring transgenes for VIP, PACAP and their receptors, has provided significant
insights into the important roles of these peptides and their cognate receptors in
circadian function. The basic physiology of circadian rhythm generation and its
control shall be discussed here in brief, prior to a more in-depth review of current
knowledge regarding VPAC/PACR control of circadian rhythms, with particular
reference to the VPAC2R.
3.1.2.1. The mammalian circadian clock
Circadian rhythms are biological cycles of behaviour or physiology which
have a period of approximately 24 h. The principal regulator of these cycles in
mammals is the suprachiasmatic nucleus (SCN), a small collection of neurons which
is located at the base of the brain. The initial identification of this brain area as the
circadian pacemaker or clock was reported simultaneously by two groups in 1972
(Moore & Eichler, 1972; Stephan & Zucker, 1972). In these studies, both groups
examined circadian rhythms in rats in which the SCN had been lesioned and they
found that the rats' activity and drinking rhythms, in addition to rhythms of
corticosterone production in the adrenal glands, were severely disrupted. Oscillatory
cycles within this nucleus were subsequently demonstrated through evaluation of
neuronal activity and glucose utilisation, both of which were demonstrated to be
generally high during the day and low during the night (Schwartz & Gainer, 1977;
Shibata et al., 1982). Further confirmation of the role of the SCN in the control of
circadian cycles was demonstrated through multiple SCN transplant studies
(Drucker-Colin et al., 1984; Sawaki et al., 1984; Lehman et al., 1987; Ralph et al.,
1990). These studies involved the transplantation of fetal SCN cells into
rats/hamsters in which the SCN had been lesioned and which had disrupted circadian
cycles. Following surgery, the recipient animals were observed to express normal 24
h cycles of activity. Furthermore, the transplantation of SCN cells from the tau
hamster mutant which had a short circadian period (~ 22 h), demonstrated that the
characteristics of the circadian cycles expressed by recipient animals were governed
by those of the donor (Ralph & Menaker, 1988; Ralph et al., 1990).
Since these early studies a wealth of knowledge has been produced to
demonstrate how the SCN controls and maintains circadian cycles. The SCN
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receives environmental cues principally from the retino hypothalamic tract (RHT), a
neural tract which projects from retinal ganglion cells (RGC) to VIP containing
neurons in the ventral region of the SCN (Moore & Eichler, 1972; Ibata et al., 1989).
The contribution of additional input pathways to the SCN has also been described,
for example the geniculo-hypothalamic tract (GHT) which projects from the
intergeniculate leaflet, however these pathways appear to have a more minor role
compared to the RHT (Piggins & Cutler, 2003). Transmission of photic information
from the RHT to the SCN is suggested to principally involve the peptide PACAP and
glutamate, the release of which are modulated by retinal signals (Ebling, 1996; Chen
et al., 1999; Hannibal, 2002). Within the retina the presence of a photosensitive
GPCR termed melanopsin, in a subset of PACAP containing RGC, has been
suggested to control the integration of environmental lighting cues into transmitter
signals in the RHT (Provencio et al., 2000; Hannibal et al., 2004). Photic
information received by the SCN is used to entrain and finely tune the periodicity of
the clock, which can then coordinate peripheral oscillators (Hastings et al., 2003).
The molecular mechanism of rhythm generation in SCN has cells has been
intensively researched in recent years and the generation of rhythmic activity has
been shown to involve feedback loops between two pairs of molecules,
CLOCK/BMAL1 and CRY/PER (reviewed in detail elsewhere: Albrecht & Eichele,
2003; Ko & Takahashi, 2006).
3.1.2.2. VIP/PACAP and VPAC/PACR expression in the SCN
As discussed above, both VIP and PACAP have been localised to specific
areas within the SCN. From both in situ hybridisation studies and enzyme
immunoassays, expression of VIP and PACAP in their respective areas has been
shown to be low during the day and higher at night (Figure 3.1.5; Shinohara et al.,
1993, 1999; Ban et al., 1997; Fukuhara et al., 1997). These studies demonstrated
that the rhythmic expression of the peptides is not detected under conditions of
constant darkness, suggesting that their expression is controlled by light stimulation
and thus may be involved in entrainment. Following on from the demonstration of
VIP binding sites in the SCN (Besson et al., 1984; Shaffer & Moody, 1986) and the
identification of VIP/PACAP receptor subtypes (described in the general
introduction), the expression of individual VPAC/PACR in the SCN was
investigated. As discussed previously (p 34), the VPAC2R has been shown to be
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Expression of VIP and PACAP mRNA in the rat SCN. The
expression levels of VIP (a/b) and PACAP (c/d) in the SCN under a
light/dark cycle (a/c) and constant darkness (b/d) are shown. Figures
taken from Ban et al. (1997) and Cagampang et al. (1998a, 1998b).
throughout the day (Cagampang et al., 1998b). The first examination of the temporal
expression of VPAC2R in the SCN was reported by Cagampang and colleagues
(1998b). Using in situ hybridisation techniques, these authors showed that daily
VPAC2R expression was biphasic in the SCN, with peak expression levels detected
midway through the light cycle (ZT6) and towards the end of the dark cycle (ZT22)
(Cagampang et al., 1998b). This rhythm was reported to be sustained in constant
darkness with similar peaks of expression (CT10 and CT22; Cagampang et al.,
1998b). In contrast, one year later Shinohara et al. (1999) used similar techniques
and reported that expression of this receptor was generally low during day and high
at night. In this study the authors also reported negligible expression of VPAC]R in
the SCN. Finally, PAQR expression in the SCN has also been investigated and was
reported to peak in the middle of the light and the dark cycles (Cagampang et al.,
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Figure 3.1.6 VPAC2 and PACiR mRNA expression in the rat brain. The
arrows indicate the location of the SCN. Figures taken from
Cagampang et al. (1998a, 1998b).
1998a). The expression of different splice variants was also reported, with only the
null and hop variants being detected in SCN cells (Ajpru et al., 2002).
3.1.2.3. VPAC/PACR modulation of circadian time-keeping
With the combined expression of VIP, PACAP, VPAC2R and PACjR in the
SCN, many groups have investigated the effects of modulating VPAC/PACR
function on circadian rhythms both in vitro and in vivo. Hannibal and colleagues
(1997, 1998) have reported that the neuronal activity of the rat SCN (brain slice
preparations) could be phase advanced by PACAP-38 application in the daytime
(CT6), in a concentration dependent manner. These effects were shown to be
mediated by PACiR, with VIP being 1000 fold less potent in inducing similar phase
shifts (Hannibal et al., 1997, 1998). Consistent with the studies of Hannibal (1997,
1998), Harrington and colleagues also reported that PACAP application to hamster
brain slices could induce phase shifts when applied during the daytime (Harrington
& Hoque, 1997; Harrington et al., 1999). These authors reported that daytime
application ofPACAP (10 nM to 1 pM) induced phase shifts in SCN neuronal firing
rate activity, an effect that was suggested to be cAMP mediated (Harrington et al.,
1999). Interestingly, lower doses (~ 1 nM) of the peptide produced phase delays
when administered during the night, through glutamate mediated pathways.
Furthermore, PACAP has been demonstrated (via a pathway involving PACiR and
cAMP) to alter the magnitude of the phase shifts produced from nocturnal glutamate
application to the SCN in vitro (Chen et al., 1999). In contrast to the effects of
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PACAP on the SCN which appear to be PAQR mediated, the effects of VIP on SCN
activity in vitro have been reported to depend on VPAC2R involvement (Reed et al.,
2001, 2002). The neuronal firing rhythms of rat SCN cells in vitro were shown to be
significantly phase advanced by VIP application during the night (ZT19), in a
concentration dependant manner (Reed et al., 2001). These effects were very similar
to those produced by application of the VPAC2R agonist Ro25-1553 (100 nM), thus
indicating a role for VPAC2R in the resulting phase advance. The phase shifting
effects of PACAP were also examined in these studies and in contrast to the results
of Harrington and colleagues (1999), no phase shift was observed. These authors
suggested that photic stimuli may stimulate the release of VIP in the SCN, which
through the activation of VPAC2R may then play a role in resetting the clock (Reed
et al., 2001). These studies were subsequently extended, with the effects of PG99-
465, the reportedly selective VPAC2R antagonist (Moreno et al., 2000), on VIP
activity examined in SCN neurons (Moreno et al., 2000; Reed et al., 2002). When
applied alone, PG99-465 (100 nM) had no effect on the neuronal firing rates,
however co-application with VIP resulted in a reduced agonist response.
Furthermore, the PAQR selective agonist maxadilan was shown to modulate
neuronal activity in the SCN, which was insensitive to PG99-465. Therefore a
number of in vitro studies have investigated the phase shifting properties of VIP and
PACAP in the SCN and the involvement of the VPAC2 and PACiR receptors in
mediating these effects.
A small number of studies have also examined the effects of VIP and
PACAP on circadian rhythms in vivo. The first of these investigations was
conducted by Albers and colleagues in 1991, with the effects of SCN microinjected
peptides (VIP, PHI, GRP) examined. Individually, none of the peptides were shown
to produce any phase shift in activity patterns, however when these peptides were co-
injected (at the beginning of activity onset), large progressive phase delays were
subsequently observed (Albers et al., 1991). In contrast to these results, Piggins et
al. (1995) reported that when individual peptides (VIP, PHI and GRP) were
microinjected into the SCN of hamsters, they could in fact cause phase shifts in
activity patterns. Furthermore no synergism of phase shifting effects was observed
when the peptides were co-injected. Analysis of the phase shifting activity of VIP
(150 pmol), demonstrated that the peptide induced phase delays at CT12-14 and
phase advances at CT20-24 (Piggins et al., 1995).
In summary, these studies show that the effects of VIP and PACAP in the
SCN appear complex, with the time of administration and concentration of peptide
contributing to the observed outcome in SCN activity. VIP and PACAP clearly have
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considerable effects on SCN rhythmicity, highlighting their importance in the normal
function of the SCN and the expression of circadian rhythms.
3.1.2.4. Circadian rhythms of VPAC/PACR transgenic mice
The importance of VIP/PACAP and VPAC/PAC receptor activity in the
control of circadian rhythms of activity has been further demonstrated through the
use of transgenic mice. The behaviours of such mice were extensively discussed in
the general introduction (section A.3.1., p 38) and shall be briefly summarised here
with reference to circadian activity rhythms.
The generation of VIP and PACAP null mouse lines re-iterated the
particularly important role of these peptides in the phase-resetting of circadian
activity rhythms, with both types of transgenic mice showing significantly reduced
responses to lighting cues that would normally cause phase shifts (Colwell et al.,
2003, 2004; Kawaguchi et al., 2003). Furthermore, the VIP null mice had intrinsic
activity rhythms that were considerably weaker and more arrhythmic than those of
wild-type mice (Colwell et al., 2003). This is in contrast to the PACAP null mice,
which demonstrated a similar but slightly shorter free running period than their wild-
type littermates (Kawaguchi et al., 2003).
The use of VPAC/PAC receptor transgenic mice has also proven
particularly important in contributing to our understanding of their roles in SCN
function and circadian rhythm generation. As discussed in the introduction, the
behaviours of two VPAC2R transgenic mouse lines (I1VPAC2R receptor over-
expressing and VPAC2R null) produced by Harmar and colleagues have been crucial
in delineating the important role of this receptor in SCN function (Shen et al., 2000;
Harmar et al., 2002). The over-expressing mice were observed to have a shorter free
running period than wild-type mice and additionally they were also able to adjust
more rapidly to an 8 h advance in the light-dark cycle (Shen et al., 2000). Further
insights into the role of the VPAC2R were gained from examination of the behaviour
of the null mice. These mice were shown to re-entrain to an 8 h phase advance in the
light cycle in about a third of the time taken by wild-type mice (Harmar et al., 2002).
When in constant darkness, these mice were shown to have only weakly rhythmic
intrinsic cycles of activity and clock gene expression. Furthermore exposure to brief
dark bursts during the lights on period resulted in sudden activity bursts from these
mice, demonstrating that the major influence on the timing of activity patterns was
light. The disruption to normal SCN activity in the null mice was further explored in
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subsequent electrophysiological and immunohistochemical studies, which showed a
loss of normal rhythmic physiological patterns (Cutler et al., 2003; Hughes et al.,
2004).
The role of PACi receptors has also been investigated through the use of
transgenic mice (PACiR null). These knock-out mice were shown to have a similar
activity pattern to wild-type mice under light-dark cycles, however in constant
darkness the null mice were observed to have a considerable shorter free running
period (Hannibal et al., 2001). The SCN of the null mice appeared to be more
sensitive to light stimulation, because upon exposure to brief light pulses in the early
stage of the dark cycle, the null mice responded with much larger phase delays than
their wild-type littermates. These mice also failed to show increased clock gene
expression in response to light stimulated phase shifts (Hannibal et al., 2001).
3.1.2.5. Pharmacological modulation of VPAC2R in vivo
It is now clear that VIP/PACAP and VPAC/PAC receptors play an
important role in the normal function of the SCN and thus the control of circadian
rhythms. Several studies have highlighted a particularly important role for the
VPAC2R in SCN function, through the use of transgenic mice lines and also via
pharmacological modulation of the receptors (in vivo and in vitro). The data from
these studies, as discussed in chapter two, indicates that pharmacological modulation
of this receptor may be of therapeutic value in controlling circadian rhythm cycles
and increasing re-entrainment rates to phase shifts. Indeed, the use of VPAC2R
selective antagonists may mimic the behavioural characteristics of the VPAC2R null
mice, which could be important therapeutically. In brain slices from wild-type mice,
the reportedly VPAC2R selective antagonist PG99-465 mimicked the
electrophysiological characteristics observed in brain slices from the VPAC2R null
mice. However, although the impact of exogenous administration of non-selective
VPAC/PACR ligands (agonists) has been investigated in vivo, no similar studies
have been performed to date using PG99-465. With the current interest in the
VPAC2R as a target for therapeutic intervention in the treatment of circadian rhythm
disorders, we therefore sought to evaluate if the use of this VPAC2R antagonist could
indeed mimic the phenotype of the null mice and reduce re-entrainment times to a
phase advance.
Prior to PG99-465 studies, a new set of cages and mouse running wheels
were established and linked to a computer to monitor running wheel activity.
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Consistent with the previous in vivo studies examining the effects of VIP/PACAP on
circadian rhythms, it was decided that PG99-465 should be injected directly into the
brain to maximise the delivery of the peptide to the area surrounding the SCN. This
also avoids potential complications regarding the inability of the peptide to cross the
blood-brain-barrier. As the fluid filled ventricles within the brain come into close
proximity with the SCN, i.c.v. injection was selected as the most appropriate route of
administration for PG99-465. The potential effect on mouse circadian activity of the
planned surgical procedures was first evaluated. The re-entrainment of the mice to a
standard 8 h phase advance was subsequently evaluated as was the ability of the mice
to entrain to a shorter 6 h phase advance, which would facilitate future surgical
procedures. The effect of PG99-465 on re-entrainment time was then evaluated.
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3.2. Results
3.2.1. In vitro studies using brain derived astrocytes
3.2.1.1. Purity of rat cortical astrocyte cultures
Rat cortical astrocytes were isolated from a mixed primary cell culture
prepared from the cortices of Sprague Dawley rat pups (PI - P2), as described in the
methods section (p 58). In preliminary studies to determine the purity of the
astrocyte cultures, samples of the isolated cells were fixed in paraformaldehyde and
stained using cell-specific antibodies. Astrocytic cells were stained using a glial
fibrillary acidic protein (GFAP) antibody and in the representative field shown
(Figure 3.2.1a), astrocytes were clearly the predominant cell type in the cultures.
The presence of contaminating microglial cells was assessed with a CD1 lb antibody
(Figure 3.2.1b) and whilst this marker stained a few cells, a similar proportion of
cells were identified using the secondary antibody (biotinylated anti-mouse antibody)
alone (Figure 3.2.1c). This suggests that the level ofmicroglial contamination of the
astrocyte cultures was low and indistinguishable from background levels of non¬
specific staining. Therefore, as the majority of cells in the isolated cultures appeared
to be astrocytic (which is in agreement with previous studies performed in our
institute) and as the availability of the cultures was limited, such cultures were used
in all of the following studies.
3.2.1.2. Peak agonist induced [cAMPji and [Ca2+h responses from RCA
2"F
In order to compare the peak agonist stimulated [cAMP]; and [Ca ]j
responses from RCA, the maximum responses from all agonist concentration
response curves included in Table 3.2.1 (p 226) were averaged. The collated peak
responses produced with the VPAC/PACR ligands in each assay are presented in
2_|_
Figure 3.2.2 ([cAMPJj: panel a; [Ca ],: panel b). Averaged maximal responses for
VIP and maxadilan were similar in the [cAMPji assay (approximately 50 nM
cAMP), whereas PACAP-27, PACAP-38 and R3P65 responses appeared larger (100
- 120 nM cAMP), however no significant differences in response size were detected
between the peptides (p = 0.203). [Ala11,22'28]VIP which was previously shown to be
a selective VPAQR agonist (section 1.2.3., p 103) had no effect on [cAMPji levels
9+
in the rat astrocytes (Figure 3.2.2a). In the [Ca ]j assay, the PACAPs, VIP and
maxadilan were the only agonists that produced full concentration response curves in
the astrocytes, with the average maximum PACAP responses being similar, but -30
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% larger than the maxadilan and VIP induced fluorescent responses (Figure 3.2.2b).
Indeed, from analysis of this data set, VIP responses were significantly smaller than
those induced by PACAP-27 (p = 0.038). Upon further examination of the average
peak responses and the individual assay values, a considerable level of variability
between, but not within assays, was evident in the magnitude of responses produced
from the astrocytes. The observed variability may have been a result of several
potential factors, including the age and health of the pups and the length of time the
cells were in culture. To reduce this variability and provide a more relevant
comparison, relative peak responses to each agonist were calculated as a percentage
of the maximum PACAP-27 response determined on each experimental day (Figure
3.2.3). This method of analysis was applied to all the agonist responses for which
complete concentration curves were generated (Figure 3.2.4). When expressed as a
percentage of the PACAP-27 response, the maximum responses produced from VIP,
PACAP-27, PACAP-38, R3P65 and maxadilan stimulation of RCA in the [cAMP];
assay, were all similar (90 - 110 % of the PACAP-27 response; Figure 3.2.3a) with
no significant differences detected (p = 0.462), indicating that these peptides were all
full agonists; a finding that was previously masked by the variability when the raw
data were compared (Figure 3.2.2). From the raw data for these five agonists, the
average maximum [cAMPjj response was ~ 90 nM (32x basal). Normalised peak
agonist responses in the calcium assay were consistent with the profile of response
sizes calculated using the raw data (Figures 3.2.2b, 3.2.3b), with PACAP-27 and
PACAP-38 inducing similar maximum fluorescence levels (average response: 8650
RFU; 2.1x basal). The PACAP induced responses were significantly larger (p <
0.001) than the maxadilan and VIP evoked responses (average response: 6156 RFU;
1.5x basal). As concentration response curves could not be produced for
[Ala1 U2'28]VIP and R3P65 in the [Ca2+]j assay, it was not possible to include the
maximum responses from these agonists in Figure 3.2.3.b.
3.2.1.3. VPAC/PACR agonist pharmacology in RCA
The peptides VIP, R3P65, PACAP-27, PACAP-38 and maxadilan were full
agonists in RCA, increasing [cAMP]j levels in a concentration dependent manner,
with a ROP: PACAP-27 = PACAP-38 = maxadilan > VIP = R3P65 (Figure 3.2.4a).
The PACAP peptides and maxadilan were of similar nanomolar potency (EC50 range:
0.43 - 2.2 nM; Table 3.2.1) and were ~ 150 fold more potent than VIP and R3P65
(EC50 values of 179 and 154 nM respectively; Table 3.2.1). This is consistent with
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Table 3.2.1 Agonist EC50 values for the stimulation of |cAMP|i and [Ca2+]j






























Agonist EC5q values were generated using the standardised [cAMP]j and [Ca2+li
assays. Ligand potencies are presented as: EC50 (nM) ± SEM, with the number
of independent experiments shown in parenthesis. NE is no effect at 3 pM.
data from the CHO-hPAC|R expressing cells and the SHSY-5Y cell line, where the
former agonists were also considerably more potent than VIP and R3P65 (sections
1.2.3.1. and 1.2.4.1., p 103 and p 127). [Alan'22'28]VIP had no effect on [cAMP]i
levels in the rat astrocytes, suggesting that VPAQR were either not expressed or
expressed at very low levels in these cells. In the calcium assay, complete
concentration response curves were evoked by PACAP-27, PACAP-38, maxadilan
and VIP (Figure 3.2.4b). Akin to the [cAMPJi data, the first three peptides were of
similar potency in the [Ca2+]j assay (EC50 range: 3.85 - 9.34 nM; Table 3.2.1),
however as indicated by the maximum responses shown in Figure 3.3.3b, the
maxadilan concentration response curves were ~ 30 % smaller than either of the
PACAP curves. VIP mediated responses were only detected at the upper limit of the
peptide concentration range and as a consequence complete concentration response
curves for this agonist were not always produced. On the occasions (n = 4) were the
upper plateau of the curve was present and a sigmoidal curve fit possible, the
maximum VIP induced responses were found to be smaller than those induced by
PACAP, which is in agreement with the observation made for maxadilan. This
finding was consistent with the differential maximum calcium responses induced by
these peptides in the hPACiR expressing SHSY-5Y cell line (section 1.2.4.1., p 127).
In the RCA, VIP was over 100 fold less potent (EC50: 0.7 pM) than the PACAP
peptides or maxadilan in the calcium assay, which is consistent with the [cAMPJj
data produced using these cells (Table 3.2.1). Although R3P65 evoked a calcium
response in rat astrocytes, this stimulatory effect was only detected at or above
micromolar concentrations, and consequently full concentration response curves
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11 22 28could not be generated for this peptide. [Ala ' ' ]VIP had no stimulatory effect on
calcium levels in rat astrocytes, which is again consistent with the [cAMP]j data. As
reported for the VPAC/PACR expressing stable cell lines and SHSY-5Y cells
(section 1.2.4.1., p 127), agonist potencies determined using the astrocytes were
lower in the calcium than the cAMP assay, although the fold shift between assays
was less pronounced in these cells when compared with the stable cells lines (RCA:
~ 10 fold, CHO-hPAQR: ~ 100 fold).
3.2.1.4. Agonist stimulated calcium traces from RCA
Fluorescence traces produced from agonist stimulation of RCA in the
calcium assay are illustrated in Figure 3.2.5. On examination of the fluorescence
traces in RCA, the responses appeared to remain elevated over the 90 s recording
period, akin to that observed in the hPACiR expressing stable cell line and in SHSY-
5Y cells, but in contrast to the CHO-hVPACR expressing cells (sections 1.2.3.3., p
106; 1.2.4.1., p 127). To examine this observation further, the fluorescence levels
after 90 s in response to a saturating concentration of peptide were determined and
expressed as a percentage of the peak response observed for each peptide (Figure
3.2.6). At 90 s, agonist evoked fluorescence levels from PACAP-27, PACAP-38 and
maxadilan stimulation were similar at ~ 75 % of the peak response. In contrast, the
VIP response at this time point was significantly lower, at approximately 50 % of the
peak response (p < 0.001). The differences observed are consistent with hPACiR
mediated responses in SHSY-5Y cells (90 s analysis; Figure 1.2.34, p 133) and with
the slower rate of decline reported for PACAP responses in CHO-hPACiR
expressing cells (200 s analysis; Figure 1.2.21, p 115). Further examination of the
magnitude of agonist responses at 200 s (as was reported for the CHO-hPACiR cell
line; section 1.2.21., p 115), was not performed with the astrocytes due to the limited
amount of primary cultures which could be generated.
3.2.1.5. Antagonism of agonist induced responses in RCA
The ability of M65, the PAQR antagonist, to inhibit PACAP-27 induced
functional responses from RCA was examined. When tested alone in the astrocytes,
M65 had no effect in either assay at concentrations up to 3 pM (Figure 3.2.7). M65
fully inhibited PACAP-27 evoked [cAMPJj and [Ca2+]i responses from RCA, in a
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concentration dependent manner, with equipotent IC50 values of 37.3 and 22.0 nM,
respectively (Figure 3.2.7; Table 3.2.2). These values are almost identical to the IC50
values determined for M65 antagonism of PACAP-27 stimulated responses from the
SHSY-5Y cell line ([cAMPJj: 37.5 ± 5.6 nM (4) and [Ca2+];: 13.6 ±2.1 nM (5);
section 1.2.4.1., p 127), and slightly more potent than the values determined using
the CHO-hPACiR cell line (section 1.2.3.4., p 117).
In a similar set of experiments the effects of the putatively VPAC2R
selective antagonist PG99-465 were examined in the [cAMPJi and [Ca2+]j assays,
using rat astrocytes. In the [cAMP]; assay, PG99-465 alone (1-3 pM) had no
effect, however this peptide significantly reduced the PACAP-27 stimulated [cAMP]j
response (50 - 75 %) when pre-incubated with the astrocytes at low micromolar
concentrations (p < 0.001; Figure 3.2.8a). The concentration dependence of this
inhibition was examined, but as can be seen from Figure 3.2.8 although significant
effects of PG99-465 were observed in both experiments, the extent of the inhibition
varied between assays (p < 0.001; Figure 3.2.8a, b). Therefore, no true IC50 value
could be determined for PG99-465 inhibition of [cAMP]; responses in RCA. In the
calcium assay, PG99-465 had no effect when tested at or below 1 pM, however at 3
pM a significant fluorescence response equivalent to ~ 30 % of the maximum
PACAP-27 response was observed (p = 0.017; Figure 3.2.9a). When PG99-465 was
pre-incubated with the astrocytes prior to agonist addition, both at concentrations of
1 and 3 pM, the PACAP-27 induced response was reduced by ~ 50 %, however this
Table 3.2.2 Potency of VPAC/PACR antagonists to inhibit agonist induced
[cAMP]j and [Ca2+]j responses from RCA
M65 PG99-465
IC50±SEM (nM)
[cAMP], 37.3 ±0.15 (3) Variable inhibition
Inhibition at micromolar
[Ca2+]i 22.0 ±2.16 (4)
concentrations
Following a 10 min pre-incubation with antagonist, responses to PACAP-27
from RCA were determined in both assays. Potencies are presented as IC50 ±
SEM, with the number of independent experiments shown in parenthesis. The
VPACiR antagonist PG97-269 was not tested as the presence of these receptors
was shown (from the agonist studies) to be negligible in the astrocyte cultures.
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reduction was not found to be statistically significant (p > 0.06; Figure 3.2.9b).
These findings were not extensively pursued, due to the complexities of PG99-465
pharmacology described in chapter one (section 1.2.3.4., p 117) and the limited
availability of astrocytes. The fluorescence traces produced in the calcium assay
from antagonism of PACAP-27 induced responses with M65 and PG99-465 are
11 22 28
shown in Figure 3.2.10. As the use of the selective agonist [Ala ' ' ]VIP had
indicated that the presence of VPACiR in the RCA was negligible (Figure 3.2.4), the
effects of the VPACiR selective antagonist, PG97-269, on agonist evoked responses
were not examined.
3.2.1.6. VPAC/PACR mediated cytokine production from RCA
Preliminary studies were performed to examine the effect of VPAC/PACR
stimulation on the secretion of key inflammatory cytokines from primary cultures of
rat astrocytes. Briefly, RCA were stimulated with VIP and PACAP-27 for 1 h, the
supernatants collected and IL-ip and TNF-a levels determined by ELISA (section
B.3.3., p 67). Both VIP and PACAP-27 increased IL-1(3 secretion from astrocytes in
a complex biphasic manner. There were significant peaks in secretion with
picomolar and nanomolar concentrations of both peptides (p < 0.001; Figure 3.2.11).
Although the pattern of stimulation observed over the peptide concentration range
examined was the same for both peptides, the total amount of IL-ip released was two
to three times larger for VIP when compared to PACAP-27. In the TNF-a ELISA,
PACAP-27 induced an initial peak in cytokine secretion at picomolar concentrations,
in a similar manner to the IL-ip assay (Figure 3.2.12a). The agonist also appeared to
induce a secondary stimulation of TNF-a release, with a large increase in TNF-a
production at the 100 nM concentration of PACAP-27. However, the peaks in TNF-
a secretion were not found to be significantly greater than those detected with buffer
alone (p = 0.16), perhaps as a consequence of the limited data set available and the
level of variation observed. When tested with the same ELISA kit, VIP produced no
clear stimulation of TNF-a secretion (Figure 3.2.12b). VPAC/PACR modulation of
the cytokines IL-6 and RANTES was also examined, however no consistent














(a) GFAP F 50 nm
(b) CDllb 50 jurn
(c) Biotinylated anti-mouse antibody 50fim
Figure 3.2.1 Immunohistochemical staining of purified rat cortical astrocyte
cultures. Following isolation of cortical astrocytes, the presence of
contaminating microglia was determined. Cell samples were stained
with GFAP (a) and CDllb (b) primary antibodies to detect the
presence of astrocytes and microglia respectively. Binding of these
primary antibodies was visualised using a biotinylated anti-mouse
secondary antibody. Non-specific staining with the secondary








































Figure 3.2.2 Agonist induced maximum [cAMP]j and [Ca2+]i responses from
RCA. Peak responses are shown from agonist stimulation of RCA
in the [cAMP]; (a) and [Ca2+]j assays (b). Raw data values are
shown, averaged from the peaks of the concentration curves detailed
in Table 3.2.1 (n > 3). The relatively large error bars, particularly in
the [cAMPJi assay, indicate the degree of inter-experiment
variability observed with these cells. The asterisk indicates relevant

















































Figure 3.2.3 Maximum agonist induced [cAMP]j and [Ca2+|j responses from
RCA, normalised to control PACAP-27 responses. Peak
responses are shown for the agonists for which complete
concentration response curves were produced (Figure 3.2.4),
following stimulation of RCA in the [cAMPJj (a) and [Ca2r]j (b)
assays. Peak responses are expressed as a percentage of the
maximum PACAP-27 response on each individual day. The
asterisks indicate responses which were significantly smaller than





















































-14 -13 -12 -11 -10 -9 -8 -7
[Peptide] Log M
-4
Figure 3.2.4 VPAC/PACR agonist concentration response curves produced
using RCA in the [cAMP]j and |Ca2+]i assays. Using primary
cultures of rat astrocytes (1 x 105 per well), agonist concentration
response curves were produced in the [cAMPji (a) and [Ca2+]j (b)
assays. The graphs shown are representative, with EC50 values for




Figure 3.2.5 Agonist stimulated fluorescence traces from rat cortical
astrocytes in the [Ca2+]j assay. The representative traces shown are
for the stimulation of RCA with the agonists for which complete
concentration curves were produced (as shown in Figure 3.2.4b).
The traces presented for the individual agonists show the changing
fluorescence levels over a 90 s period (with agonist addition at 20 s)
and cover the full range of concentrations used to determine agonist
potencies (Table 3.2.1). As illustrated by the traces, the magnitude
of the fluorescence responses increased with agonist concentration,





































Figure 3.2.6 Agonist stimulated fluorescence responses from RCA cultures,
90 s after peptide addition. The fluorescence responses 90 s after
peptide addition are expressed as a percentage of the peak response
observed for each trace. Each agonist was tested at a concentration
which was at the upper limit of the respective concentration response
curves from Figure 3.2.4b. The data are shown as the mean ± SEM,
calculated using each concentration response curve used to
determine the potencies in Table 3.2.1 (n > 3). The asterisk indicates
that the VIP induced response (at 90 s) was significantly smaller than



















































[Ca ]p 22.0 ± 2.2 (n = 4)
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Figure 3.2.7 M65 inhibition of PACAP-27 induced [cAMP]j and |Ca2+]i
responses from primary cultures of rat cortical astrocytes.
Astrocytes (1 x 105 per well) were pre-incubated with M65 for 10
min prior to PACAP-27 addition, which was used at approximately
EC50 concentrations (a: [cAMPJj - 1 nM; b: [Ca2+]j - 10 nM). IC50
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Figure 3.2.8 Comparison between assays of the inhibitory actions of PG99-
465 on agonist induced [cAMP]j responses in RCA. PG99-465
activity (at micromolar concentrations) in astrocytes (1 x 105 per
well) was determined alone and on the PACAP-27 (1 nM) induced
response (a; n = 1, samples run in duplicate). The concentration
dependence of the observed inhibition was subsequently determined,
but PG99-465 was less potent in this assay, indicating a degree of
inter-experiment variability (b; n = 1, samples run in duplicate). In
each figure, the asterisks indicate responses which were significantly






































Buffer P27 P27/PG P27/PG
Figure 3.2.9 PG99-465 modulation of [Ca2+]j levels in RCA. The activity of
PG99-465 alone in rat astrocytes was examined in the [Ca2+]j assay
(a; n = 1, samples run in duplicate). The asterisk indicates
significant responses to PG99-465 alone (p = 0.017), relative to
buffer. Inhibitory effects of PG99-465 addition were also
determined, by pre-incubating the peptide with the astrocytes for 10
min prior to PACAP-27 (10 nM) addition (b; n = 1).
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Figure 3.2.10 PG99-465 and M65 inhibition of agonist induced responses in
RCA. Representative calcium assay traces are shown for PG99-465
and M65 antagonism of PACAP-27 induced fluorescence responses
from rat cortical astrocytes. The cells were pre-incubated with
PG99-465 or M65 for 10 min prior to PACAP-27 (10 nM) addition
and fluorescence measurement in the FlexStation® (over 90 s). In
each panel the largest response illustrates the PACAP-27 response
alone, with subsequent decreasing responses produced from pre¬
incubation with increasing concentrations of antagonist, ranging
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Figure 3.2.11
[VIP] Log M
VPAC/PACR agonist induced stimulation of IL-ip from RCA.
RCA cells (5 x 105 per well) were incubated with PACAP-27 (a) and
VIP (b) for 1 h, prior to the determination of IL-1 p concentrations in
the supernatants by ELISA. The data shown is from an individual
experiment, with each agonist concentration tested in duplicate
wells. The asterisks indicate responses which were significantly
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Figure 3.2.12 PACAP-27 and VIP induced TNF-a responses from rat cortical
astrocytes. Following a 1 h incubation with PACAP-27 (a) or VIP
(b), supernatants were removed from wells containing RCA (5 x 105
per well) and TNF-a levels in the samples determined. The data
shown is from a single assay, in which each agonist concentration
was tested in duplicate wells.
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3.2.2. In vivo behavioural studies using C57BL/6J
3.2.2.1. Entrainment of mice to standard 12 h light/dark cycles
To detect and monitor mouse running wheel activity, 16 cages were
equipped with new running wheels, each of which was connected to a computer.
Rotations produced from activity in the wheels resulted in the transient closure of a
relay switch (produced via magnets attached to the wheels), with the number of
closures per minute recorded on a computer. As this was a new system, the first task
was to establish that the equipment was assembled and connected correctly and that
the behaviour of mice using this system was as expected. Mice were initially
subjected to a 12 h light/dark cycle, with lights off from 1900 to 0700 h. As
expected for nocturnal rodents, the mice were predominantly active during the dark
cycle and at rest during the light cycle (Figure 3.2.13). In general, the mice showed
intense bursts of activity within the first hour of the dark cycle, the frequency of
which gradually declined over the following 6-8 hours, as can be seen from the
actogram and 24 h activity profile for an individual mouse presented in Figures
3.2.13 and 3.2.14a. In addition, these figures demonstrate that further bursts of
activity were generally seen within the last 3-4 hours of the dark cycle. This pattern
of activity was consistently observed for this mouse, as can be seen from the
averaged activity profile over a 7 day period (Figure 3.2.14b). Furthermore, the
other mice also displayed a similar and consistent pattern of activity, as clearly
presented in Figure 3.2.15, which shows the averaged running wheel counts for all
16 mice over a 7 day period. For these mice, the average activity counts (magnet
passes) were 371 ± 54 and 33815 ± 1469, during the light and dark cycles
respectively (measured for the 7 day period prior to the study in section 3.2.2.2;
Table 3.2.3). Following the stable entrainment of these 16 mice, they were used in
the study described below. In all of the following studies, mice were always shown
to be stably entrained and expressing consistent activity patterns in an appropriate
light/dark cycle prior to treatment or phase alteration.
3.2.2.2. Impact of displacement and surgery on activity patterns
Prior to examining the effect of PG99-465 on circadian cycles of activity,
we examined the effects of re-locating the mice and anaesthesia/surgery (for i.e.v.
compound administration) on activity levels. Three groups of mice (moved, n = 6;
surgery, n = 6; not moved, n = 4), were analysed over a 13 day period under a normal
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12 h light/dark cycle, with the challenge on day 7. Representative actograms for the
groups are shown in Figure 3.2.16, with all 16 actograms available in appendix I, p
285. Representative activity patterns from each group measured over a 4 day period
(days 6-9) are shown in Figure 3.2.17, in which the reduction in activity post-
treatment can clearly be seen for the moved and surgery groups. The average total
activity for each group in the light and dark cycles is illustrated in Figure 3.2.18. As
expected, over the 13 day experimentation period the mice were mostly inactive
during the daytime, with the exception of the 5th light cycle, in which a relatively
small amount of activity (compared to the dark cycle) was observed for all three
groups of mice (Figure 3.2.18a). Two-way ANOVA of total light cycle activity
demonstrated a significant effect of cycle number (p < 0.001), but not of treatment
group (p = 0.285). The effect of cycle number was exclusively due to a rise in
overall activity of the mice, as a consequence of essential animal husbandry
procedures on day 5. Analysis of total dark cycle activity (prior to treatment)
showed that there was a significant difference in the level of activity between the
groups, despite the random allocation of mice to the treatment groups (two-way
ANOVA, p < 0.001; Figure 3.2.18b). Consequently, data from this study were
expressed as proportionate changes from baseline, which was defined as the average
activity from the 5 cycles prior to the challenge day (Figure 3.2.19). Two-way
ANOVA of proportionate dark cycle activity showed a significant effect of day (p <
0.001) and group (p = 0.003), with post-hoc analysis indicating that activity during
the 1st and 2nd dark cycles post procedure was significantly reduced. There was no
significant difference (p = 0.958) between 'moved' and 'surgical' groups overall,
however activity levels from both of these group were shown to be significantly
different from the 'not moved' group (p < 0.005 for both). As group activities during
the 3rd dark cycle post procedure were not different from those in any of the cycles
prior to treatment, this demonstrated that the disruptive effects of relocation and
anaesthesia were absent and group activity levels had returned to normal. No
significant interactions were observed between the individual groups and dark cycle
number. This challenge demonstrated that movement of mice from their home cages
caused a marked decrease in subsequent activity, with full recovery 2 - 3 days later.
As no difference was observed in activity between the moved and surgical groups,
recovery from anaesthesia does not appear to contribute to the observed reduction in
activity, leaving movement alone as the major disruptive factor.
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3.2.2.3. Re-entrainment of mice in response to phase advances
Following the successful re-entrainment of a second group of 16 mice to a
stable 12 h light/dark cycle, as described before, the responses of the mice to an 8 h
phase advance in the cycle were determined, with a representative actogram
presented in Figure 3.2.20 and all 16 actograms available in appendix II (p 288). As
can be clearly seen from the actograms, the mice gradually entrained to the advance
in the light/dark cycle, with a progressively earlier onset time of their activity
periods. The leftwards shift in activity onset can also be seen in Figure 3.2.21, where
the activity patterns over 24 h are compared during the entrainment period following
the phase advance. On average, the mice re-entrained to the new light/dark schedule
in 5.9 ± 0.2 full cycles (Table 3.2.3). Analysis of the number of mice that showed
activity early in the onset of the new light/dark cycle showed 25 % of mice were
active within one hour of the phase shift, which increased to ~ 75 % of mice by the
second cycle (Figure 3.2.22a). When only activity was analysed that was greater
than or equal to the average activity (per hour) in the 5 dark cycles prior to the phase
advance, no mice were active within the first 2 h of the novel lights off period
(Figure 3.2.22b).
The same group of 16 mice were then stably entrained to a 12 h light/dark
cycle (lights off: 1900 - 0700 h), following which they were subjected to a 6 h phase
advance (lights off: 1300 - 0100 h; Figure 3.2.23; appendix III, p 290). A 6 h phase
advance was assessed in addition to the standard 8 h advance as it would facilitate
the timing of the planned surgical intervention in the subsequent studies. As
observed for the 8 h advance, in the days following the 6 h advance there was a
Table 3.2.3 Characteristics of circadian wheel running activity
Mean SEM
Wheel running activity - dark cycle (magnet passes) 33815 1469
Wheel running activity - light cycle (magnet passes) 371 54
Re-entrainment to 8 h phase advance (days) 5.9 0.2
Re-entrainment to 6 h phase advance (days) 5.9 0.3
Re-entrainment to 6 h phase advance (days) + saline 7.0 0.5
Re-entrainment to 6 h phase advance (days) + PG99-465 7.9 0.4
The running wheel activity shown for the light and dark cycles is the average
activity of the 16 mice used in the study described in section 3.2.2.2., from the 7
days period prior to treatment. For the phase advances, the average number of
days taken to re-entrain was estimated from the onset of activity from the
actograms (appendices II - IV).
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progressive leftwards shift in the onset of activity as can be seen in the representative
actogram (Figure 3.2.23) and the 24 h activity patterns following the advance (Figure
3.2.24). On average, the mice re-entrained to the novel cycle in approximately 5.9 ±
0.3 days, which was consistent with that previously reported for the 8 h phase
advance (5.9 ± 0.2 days; Table 3.2.3). A number of the mice (n = 6) failed to re-
entrain completely to the 6 h advance within a week of the shift and were not
included in the calculation of average re-entrainment time. Further inspection of the
activity profiles, revealed that half of the mice demonstrated a persistent low level of
activity during the first six hours of the dark cycle on the first day of the phase
advance (Figure 3.2.25a). As observed in the activity profiles following the 8 h
advance, by the second cycle the majority of mice (~ 85 %) were active within the
first hour of the novel dark period (Figure 3.2.25a). Excluding activity which was of
a lower amplitude to that observed during the 5 dark cycles prior to the phase
advance (mean activity per hour), demonstrated that no mice were active within the
first two hours of darkness in the novel cycle (Figure 3.2.25b). Following the
successful demonstration of a stable entrainment to this 6 h phase advance, the mice
were re-entrained to a third light dark cycle (lights on: 0800 - 2000 h), in preparation
for surgery and the 6 h phase advance.
3.2.2.4. PG99-465 modulation of responses to phase advances
When the potencies of PG99-465 solutions were examined in the previous in
vitro studies, BSA was included in the assay to reduce any non-specific interactions
of the peptide (B.3.I., p 62 and B.3.2., p 65). Flowever, as injection of BSA into the
mouse brain could induce an immunological response (Anisman et al., 2003), BSA
had to be removed from the peptide containing solution for the in vivo studies. To
determine whether BSA removal affected the potency of PG99-465, the ability of the
peptide (± BSA) to inhibit VIP induced calcium responses in the CHO-hVPAC2R
cell line was examined (Figure 3.2.26). The potencies of PG99-465 were directly
compared in an individual experiment and were found to be similar under both
conditions (IC50 + BSA: 2.8 nM; - BSA: 5.5 nM), and to previous values (IC50: 4.4 ±
0.8 nM (n = 6); chapter one, Table 1.2.3, p 118), therefore BSA was not included in
the injected peptide solution.
During surgery (0800 - 1200 h), PG99-465 (1 pM) or vehicle (saline) was
administered to the mice through i.e.v. injection (1 pi; injection rate: 0.1 pl/min).
Immediately following the injection of PG99-465 in vivo, the potency of the solution
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was verified in the intracellular calcium assay (Figure 3.2.27). PG99-465 inhibited
VIP induced fluorescence responses in the CHO-hVPAC2R cell line in a
concentration dependent manner (IC50: 6.5 nM; Figure 3.2.27), with a potency
similar to the previously established values (IC50: 4.4 ± 0.8 nM (n = 6); chapter one,
Table 1.2.3, p 118) and those described above. Following surgery, the mice were
returned to their home cages by 1300 h, to allow a full hour in these cages before the
onset of the novel dark cycle (lights off: 1400 - 0200 h) as can be seen in the
representative actograms in Figure 3.2.28. The leftwards shift in the onset of dark
cycle activity and general activity levels following surgery and the 6 h phase advance
are shown in Figure 3.2.29. The activity profdes from both groups of mice were
identical, with no wheel running activity observed within the first two hours of the
novel dark cycle post treatment (Figures 3.2.30 and 3.2.31). The lack of activity
within the first two hours of the novel light/dark cycle was observed whether activity
was assessed using all bursts of activity (independent of amplitude; Figures 3.2.30a
and 3.2.31a), or just the activity bursts which were of a similar amplitude to the
average dark cycle activity (per hour) from the 5 cycles prior to treatment (Figures
3.2.30b and 3.2.31b). By the second dark cycle in the novel lighting regime, the
majority of the mice from each group showed some activity within the first hour of
the onset of darkness, however this was generally of lower amplitude than the pre-
treatment dark cycle activity (Figures 3.2.30 and 3.2.31). One mouse (from the
saline treated group) failed to re-entrain within the 9 days post-surgery and was not
included in the calculation of re-entrainment time. In summary, the administration of
PG99-465 did not accelerate the time to phase advance as had been originally
hypothesised.
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Figure 3.2.14 Intensity of mouse running wheel activity over the 12 h light/dark
cycle. The mouse was exposed to a 12 h light/dark cycle as indicated
by the bar at the top of each figure (the light phase is shaded in white,
darkness shaded in grey). The intensity of running wheel activity
(measured in 15 min time bins) is shown for an individual mouse over
a 24 h period (a). The mean profile of activity (± SEM; in 15 min
bins) for the same mouse is shown over a 7 day period prior to
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Figure 3.2.15 Intensity of mouse running wheel activity over the 12 h light/dark
cycle. The mean intensity of running wheel activity over a 7 day
period (measured in 15 min time bins) is shown for all 16 mice used
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Figure 3.2.16
Time (h)
Activity profiles of mice in the moved, surgery and not moved
groups. Representative figures are shown for the individual mice in
the moved (a), surgery (b) and not moved (c) groups. The data
shows the activity profiles of the mice over a 13 day period (12 h
light/dark cycle indicated by the grey box), with the treatment day
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Figure 3.2.17 Activity profdes for mice over a four day period. Average
activity profiles for the moved (a), surgery (b) and not moved (c)
groups are shown over a 4 day period, with baseline activity
calculated from the average of 6 days prior to treatment on day 7*.
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Figure 3.2.18 Light and dark cycle running wheel counts following surgery
and movement. The figures show the average total activity (±
SEM) counts for the three groups of mice examined in the study
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Movement of mice caused a significant short term drop in total
activity within the dark cycle. Total activity within the 12 h of the
dark cycle was expressed as a proportion of the average activity (±
SEM) over the first five dark cycles for each treatment group. The
activities of all groups were significantly different on the 1st and 2nd
dark cycles post treatment compared to the rest of the experiment, as
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Figure 3.2.21 Sequential activity profiles following an 8 h phase shift. Wheel
running activity was plotted in 1 h bins, with the baseline calculated
from the mean of 5 days stable entrainment on light/dark cycle 1
(lights on: 0700 - 1900 h). An 8 h advance in the dark cycle (cycle
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Figure 3.2.22
Dark cycle post 8 h phase advance
Timing of activity onset in mice following an 8 h phase advance.
The percentage of mice active within either the first hour (< 1 h), the
second hour (1 h - 2 h) or more than two hours (> 2 h) after the new
onset of the dark cycle was assessed. Data are shown for the first
two cycles after the phase advance, initially with all activity recorded
(a) and latterly, using only activity bursts of comparable amplitude
to the average dark cycle activity (per h) from the 5 cycles prior to





















Figure 3.2.24 Sequential activity profiles following a 6 h phase shift. Wheel
running activity was plotted in 1 h bins, with the baseline calculated
from the mean of 5 days stable entrainment on light/dark cycle 1
(lights on 0700 - 1900). A 6 h advance in the dark cycle (cycle 2)
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Dark cycle post 6 h phase advance
Timing of activity onset in mice following a 6 h phase advance.
Data are shown for the first two cycles following the 6 h phase
advance, initially with all activity recorded (a) and latterly, using
only activity bursts of greater or equal amplitude to the average dark
cycle activity (per h), calculated from the 5 cycles prior to the phase
advance (b). The percentage of mice active within either the first
hour (< 1 h), the second hour (1 h - 2 h) or more than two hours (> 2
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Figure 3.2.26 The potency of PG99-465 is not altered by the removal of BSA.
hVPACiR-expressing cells were seeded overnight in 96-well plates
(100,000 cells/well). After loading with calcium dye for 1 h at 37
°C, cells were incubated with PG99-465 (with or without 0.1 mg/ml
BSA) for 10 min prior to VIP addition. Fluorescence levels (max-
min) were determined using the FlexStation®. IC50 values for
PG99-465 with and without BSA, were 2.8 and 5.5 nM respectively.
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Figure 3.2.27 Confirmation of hVPAC2R antagonism using the in vivo PG99-
465 solution. PG99-465 was prepared in saline (0.1 mM) and then
diluted in assay buffer. Pre-incubation with CHO-hVPAC2R cells
for 10 min resulted in a concentration dependent inhibition of the
VIP stimulated response (IC50 = 6.5 nM).
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Figure 3.2.28 Activity profiles for PG99-465 and saline treated animals.
Representative actograms are shown for the mice treated with either
PG99-465 (a) or saline (b) prior to a 6 h phase advance in the light
dark cycle. The time of surgical intervention is indicated (*), with
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Figure 3.2.29 Activity profiles following drug treatment and a 6 h phase shift.
Wheel running activity was plotted in 1 h bins, with the mean of 5
days stable entrainment on light/dark cycle 1 (lights on 0700 - 1900)
used as a baseline. A 6 h darkness advance (cycle 2) was carried out
and activity measured for the next 7 days. Activity is only shown
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Dark cycle post phase advance
Figure 3.2.30 Timing of activity onset in mice following drug treatment and 6
h phase advance. Data are shown for the first two cycles following
the 6 h phase advance for the PG99-465 treated mice, with the
percentage of mice active within either the first hour (< 1 h), the
second hours (1 h - 2 h) or more than two hours (> 2 h) after the new
onset of the dark cycle shown. The data was initially calculated with
all activity recorded (a) and latterly, using only activity bursts of
comparable amplitude to the average dark cycle activity from the 5
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Figure 3.2.31 Timing of activity onset in mice following drug treatment and 6
h phase advance. Data are shown for the first two cycles following
the 6 h phase advance for the saline treated mice, with the proportion
of mice active within the first hour (< 1 h), the second hour (1 h - 2
h) or more than two hours (> 2 h) after the onset of the novel dark
cycle shown. Data were initially calculated with all activity recorded
(a) and latterly, using only activity bursts of similar amplitude to the
average dark cycle activity from the 5 cycles prior to treatment (b).
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3.3. Discussion
The peptides VIP and PACAP, together with their cognate receptors
(VPACi, VPAC2 and PACi) have been implicated in a plethora of physiological
processes, as discussed in the general introduction. In this chapter, I have explored
the actions of the peptides and receptors and their roles in two distinct central
themes; the first being the modulation of astrocyte function with regard to
VIP/PACAP mediated neuroprotection and the second, the specific role of VPAC2R
in the control of circadian rhythms of activity.
3.3.1. VIP/PACAP modulation of astrocyte function
Since the initial studies by Brenneman and colleagues (1987), it is now clear
that astrocytes play important roles in VIP/PACAP induced neuroprotection. The
protective effects of the peptides have been demonstrated in a wide array of in vitro
and in vivo models, as discussed extensively in the introduction. Such studies have
led to the isolation of highly potent, neuroprotective factors, which have been shown
to be under the control of VIP/PACAP activity (Brenneman et al., 1998; Gozes &
Brenneman, 2000). Indeed, these factors have been shown to provide
neuroprotection at low concentrations and NAP, an ADNP derivative, is currently
progressing through clinical trials as a potential neuroprotective treatment for
Alzheimer's disease (Gozes et al., 2005). Despite these exciting developments, the
underlying mechanism/receptors responsible for astrocyte mediated VIP/PACAP
neuroprotection remain to be fully elucidated, but do currently appear to involve the
secretion of a complex balance of both cytokines and neurotrophic factors (Dejda et
al., 2005). Furthermore the pharmacology of the VPAC/PAC receptors expressed on
astrocytes and their intracellular signalling pathways have been poorly characterised.
To try to address these issues, VPAC/PAC receptor pharmacology in primary
cultures of rat cortical astrocytes was thoroughly characterised using the HT-
amenable [cAMP], and [Ca2+]j assays previously described (methods, B.3.I., p 62).
3.3.1.1. VPAC/PACR pharmacology in rat cortical astrocytes
The current investigation of VPAC/PAC receptor pharmacology in primary
cultures of rat cortical astrocytes provides the most comprehensive characterisation
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of astrocytic VPAC/PAC receptors to date. Although previous reports have
demonstrated VPAC/PACR mediated cAMP elevations, these studies have almost
exclusively involved the evaluation of only a single agonist, usually PACAP-38
(Grimaldi & Cavallaro, 1999; Masmoudi et al., 2003; Li. et al., 2005). The most
extensive study prior to the current investigation was reported by Hashimoto and
colleagues over 10 years ago, in which a concentration dependent increase in cAMP
was demonstrated in RCA following application of VIP, PACAP-27 and PACAP-38.
Furthermore, only a single report to date has fully characterised a VPAC/PACR
mediated calcium response in this cell type, and again this involved the evaluation of
PACAP-38 alone (Masmoudi et al., 2003). This is in contrast to other investigations
of VPAC/PACR mediated calcium signalling in astrocytes, in which no stimulation
of calcium was reported (Grimaldi & Cavallaro, 1999; Hashimoto et al., 2003). In
the current studies, the six VPAC/PACR agonists evaluated in chapter one were
2_j_assessed for their ability to stimulate [cAMPJj and [Ca ]; in RCA, with full
concentration response curves determined for the majority of agonists in both assays.
The agonist ROP was identical between assays for the astrocytes and was also
consistent with the CHO-hPACiR and SHSY-5Y cells characterised in chapter one,
indicating a predominantly PAQR expression. In addition, agonist induced
responses (~ EC50) in both assays were fully inhibited by the PACiR antagonist M65,
which again is suggestive of a primarily PACiR mediated response. Although the
expression of VPACR has been reported in RCA, the majority of studies have
suggested a predominant PACiR expression, which is consistent with the ROP
produced in the current studies (Grimaldi & Cavallaro, 1999; Hashimoto et al., 1993,
2003). The difference in potency detected between the PACAPs and VIP in our
cAMP studies (~ 170 fold) and the corresponding EC50 values (VIP = 179 nM,
PACAP-27 = 0.68 nM, PACAP-38 = 2.2 nM), are very similar to those reported
previously by Hashimoto and colleagues (VIP = ~ 300 nM, PACAP-27 =1.1 nM,
PACAP-38 = 2.4 nM; Hashimoto et al., 1993). In general, the VPAC/PACR
agonists stimulated calcium responses from RCA with approximately 10 fold lower
potency than agonist induced cAMP responses. Although the magnitude of the
potency shift between assays was less pronounced in the astrocyte studies, the
reduction in agonist potency in the calcium assay was consistent with the data
presented in chapter one, both for the CHO-hPACiR and SHSY-5Y cells.
Furthermore a lower potency in stimulating calcium relative to cAMP in RCA was
also found for PACAP-38 in the study by Masmoudi and colleagues (2003), although
again the fold shift (~ 60 fold) was larger than that detected in the current studies.
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3.3.1.2. Maximum agonist induced responses from RCA
In agreement with data generated for the VPAC/PAC receptor expressing
cell lines in chapter one (p 104), maximum agonist induced [cAMPji responses from
RCA were similar within assays. However, the peak responses observed between
assays were considerably more variable, perhaps reflecting the heterogeneous nature
of primary cell cultures. In the calcium assay, a differential profile of peak responses
was observed with the agonists, with concentration curves for the PACAP peptides
being approximately one third larger than the other agonists. This profile is identical
to that determined for the hPACiR expressing SHSY-5Y cell line in chapter one (p
128), in which concentration response curves for the PACAPs were again larger than
the other agonists in the calcium assay, despite no differences in the maximum
cAMP responses from that cell line. In recent studies reported by Dejda and
colleagues (2006), although no EC50 values or concentration response curves were
shown, PACAP-38 and VIP were demonstrated to stimulate IP3 accumulation in
RCA with apparently different maximum responses. It is not clear from the data
presented in that report whether the maximum IP3 responses for each peptide were
achieved, particularly for PACAP-38. However, at micromolar peptide
concentrations VIP responses appeared to be maximal, which would be consistent
with the findings presented from the current studies, and in addition were
approximately 30 % lower than the corresponding PACAP-38 response (at 5 pM).
Akin to the SHSY-5Y cells, RCA have been shown to express multiple PAC|R
splice variants, comprising the null, hopl, hop2 variants, as well as the more recently
identified PACi(3a) variant (Ashur-Fabian et al., 1997; Hashimoto et al., 2003;
Pilzer & Gozes, 2006a). It is possible that the combined presence ofmultiple PAQR
splice variants, in both of these cell types, may contribute to the differential calcium
responses observed. Furthermore, the expression of VPACR in RCA may also
contribute to the observed profile of responses. The expression of VPACiR in RCA
appears to be minimal both from prior studies and the current investigations, in
which the selective VPACjR agonist, [Ala1''22'28]VIP was without effect in the
[cAMP]j and [Ca2,]j assays (Ashur-Fabian et al., 1997). However, as expression of
the VPAC2R in RCA has been reported in several studies, we attempted to evaluate
the contribution of this receptor to agonist induced responses by examining the effect
of PG99-465 (Ashur-Fabian et al., 1997; Grimaldi & Cavallaro, 1999; Moreno et al.,
2000). In preliminary studies, a small inhibition of PACAP-27 induced cAMP
responses was observed at micromolar PG99-465 concentrations, however the degree
of inhibition appeared to be variable. Similarly, in the calcium assay, a small degree
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of inhibition was observed with higher PG99-465 concentrations, however the
independence of this inhibition from a small agonist effect when tested alone, could
not be confirmed in these studies. Due to the limited availability of astrocyte
cultures, it was not possible to extensively investigate these responses, however it
would be of interest to do so in future studies to try and identify the cause of the
intriguing differential responses observed in the calcium assay.
3.2.1.3. RCA agonist responses - [Ca2+]i assay traces
In the characterisation studies of PACiR mediated calcium responses in
chapter one (CHO-hPACiR and SHSY-5Y cells), it was observed that the
fluorescence traces produced by different agonists had distinct shapes with regard to
the duration of the agonist induced response. Similarly, agonist stimulated
fluorescence responses from RCA were also distinct, with PACAP and maxadilan
responses after 90 s being ~ 80 % of the peak signal. This is in contrast to VIP, for
which responses were ~ 50 % of the peak signal at this time-point. This profile was
very similar to that reported for the SHSY-5Y cell line (at 90 s; Figure 1.2.34, p
133). In addition, the difference between the duration of the PACAP and VIP
responses is also consistent with data produced using the CHO-hPACiR cell line (at
200 s; Figure 1.2.21, p 115). Unfortunately the availability of astrocyte cultures was
limited and as a result it was not possible to extend the comparison of agonist
induced calcium responses to 200 s, as was presented for the CHO-hPACiR in
chapter one, however it would be interesting to compare these responses in future
studies. VPAC/PACR stimulated calcium responses have previously been reported
in rat cortical neurons and were shown to consist of two phases, an initial calcium
release from intracellular stores which subsequently triggered a sustained influx of
extracellular calcium across the plasma membrane (Grimaldi & Cavallaro, 1999).
With the demonstration of relatively robust VPAC/PACR mediated calcium
responses from cortical astrocytes in the present studies, future investigations could
determine if such a pattern of calcium release is also observed in these cells.
Furthermore, if a similar pattern was observed, the possibility of differential
modulation of the extracellular influx by the agonists would be interesting to
determine, as described in chapter one for the CHO-PACiR cell line. Clearly RCA
predominantly express PACiR variants and further investigation of the signalling
pathways and pharmacology of the individual PACiR splice variants in these cells, as
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described in this section, may help to delineate the function of VIP/PACAP in these
cells.
3.3.1.4. VPAC/PACR mediated cytokine production from RCA
Given the important contribution of VPAC/PACR activation in astrocyte
mediated neuroprotective effects, the role of the receptors in stimulating cytokine
production from the RCA was explored in preliminary studies. Elevated levels of
both IL-ip (VIP and PACAP-27) and TNF-a (PACAP-27) were secreted from the
astrocytes in response to VPAC/PACR activation, confirming earlier reports by
Brenneman et al. (1995, 2003). In agreement with these previous studies, a peak in
cytokine secretion was detected with nanomolar concentrations of peptide in the
current investigation (Brenneman et al., 2003). Although the pattern of cytokine
release presented by Brenneman and colleagues (2003) appeared to be vaguely
biphasic, the peaks of cytokine release at picomolar peptide concentrations were
considerably more pronounced in the current studies. These differences in cytokine
expression may simply reflect the distinct assay procedures used and the condition of
astrocyte cultures used in both studies. In parallel studies, the modulation of other
cytokines (RANTES, IL-6) was also examined, however no clear responses were
produced in these preliminary assays. As the availability of astrocyte cultures was
limiting, it was not possible to perform more extensive investigations into the
modulation of cytokine release by VPAC/PACR ligands. However in future studies
it would be interesting to examine the pharmacology of the IL-1|3 and TNF-a
responses. Optimising the assay procedure through time-course and cell densities
studies would perhaps produce clearer results and allow for a full characterisation of
the cytokines (and neurotrophic factors) released form RCA upon VPAC/PACR
stimulation. Furthermore it would be pertinent to explore the pharmacology of the
agonist induced cytokine and neurotrophic factor release using receptor selective
ligands such as maxadilan and M65, in an attempt to delineate the contribution of
individual VPAC/PACR subtypes as this has not previously been evaluated. In the
longer term, it would also have been very interesting to further explore the putative
impact of VIP/PACAP and their receptors in TBI, a model in which their
neuroprotective role has not been extensively studied. Only a handful of relatively
recent studies have been described in which VIP/PACAP and/or their cognate
receptors have been studied in models of TBI, as discussed in the introduction (p
210). In addition, some of these studies have produced conflicting data regarding the
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involvement of the peptides and receptors in the aftermath of TBI (Skoglosa et al.,
1999; Jaworski, 2000). However, the use of different injury models may underlie
these conflicting results (stab wound injury versus weight drop technique), especially
when it is considered that the stab wound injury induces a much smaller
inflammatory response than the weight drop injury. Given the finding that
exogenous administration of VIP/PACAP in models of TBI can reduce the extent of
neurodegeneration, it would be valuable to further explore the putative protective
effects conferred by endogenous VIP and PACAP (Delgado & Ganea, 2003; Farkas
et al., 2004). If time had permitted, I had planned to use the lateral fluid percussion
model of TBI in rats, to further investigate the expression and possible
neuroprotective effects of VIP/PACAP and their receptors following brain trauma.
3.3.1.5. Summary
In summary, these studies have clearly characterised VPAC/PACR
pharmacology in rat cortical astrocytes. Robust [cAMPjj and [Ca2+]j responses were
detected with a range of agonists, the ROP of which indicated a predominant
expression of PACiR, although the contribution of VPAC2R mediated responses
could not be excluded. The considerable production of intracellular calcium with a
range of ligands has not been previously reported in RCA and should be further
investigated for its functional significance and possible contribution to VPAC/PACR
mediated neuroprotection. The link between second messenger production, the
increase in IL-1 (3, TNF-a and other cytokines, and their roles in neuroprotection
remains to be evaluated in future studies.
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3.3.2. Pharmacological modulation of VPAC2R in vivo
The mammalian circadian clock is located in the suprachiasmatic nucleus
and is essential for the normal expression of circadian rhythms (Weaver, 1998;
Hastings et a!., 2003). The peptides VIP and PACAP, together with the VPAC2 and
PACi receptors have been shown to have important modulatory roles in the normal
function of the SCN. The PAC)R has been shown to be important in mediating
phase shifts in response to light stimulation during the dark cycle and is suggested to
control the sensitivity of the SCN to light (Hannibal et al., 2001). Importantly, the
expression of the VPAC2R in the SCN has been shown to be critical in the normal
expression of circadian activity rhythms and in the re-entrainment of the SCN to
novel light/dark cycles. Studies delineating the role of VPAC2R in circadian rhythm
generation have focussed on the characterisation of circadian activity rhythms of
transgenic mice and on the in vitro electrophysiological properties of SCN cells in
brain slices (from wild-type and transgenic mice) treated with VPAC/PACR ligands
(Shen et al., 2000; Harmar et al., 2002; Cutler et al., 2003). More recently, real-time
imaging of clock gene expression {Per) in SCN cells from the VPAC2R null mice
has further elucidated the precise role of this receptor in the circadian cycle
(Maywood et al., 2006). However, the in vivo pharmacological modulation of the
VPAC2R and corresponding effects on circadian activity patterns has not been
reported. With the potential benefits VPAC2R modulation could have as a
therapeutic route with which to treat circadian rhythm disorders, the evaluation of
receptor modulating drugs is extremely pertinent. In the studies of VPAC2R null
mice, the activity cycles of the mice were demonstrated to be almost exclusively
governed by the timing of the light/dark cycle, with these mice displaying only
weakly rhythmic intrinsic circadian cycles (Harmar et al., 2002). The
pharmacological blockade of VPAC2R function in vivo, through the use of receptor
selective antagonists would be expected to mimic such behaviours. Therefore, we
hypothesised that administration of PG99-465, the only reportedly selective VPAC2R
antagonist described to date, may induce a more rapid entrainment to phase advances
in the light/dark cycle.
3.3.2.1. Evaluation of PG99-465 administration on re-entrainment
As PG99-465 has not previously been evaluated in vivo, the selected route
of drug administration was through i.c.v. injection, in order to avoid the potentially
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problematic transport of the peptide across the blood-brain-barrier. As the process
of injection into the SCN has been shown previously to cause small phase shifts
(Piggins et al., 1995), the impact of i.e.v. surgery on activity levels was assessed
prior to the drug study. Following the stable entrainment of the mice to a 12 hour
light/dark cycle, the effects on activity of simply moving the mice, as well as
anaesthesia and i.e.v. surgery were assessed. In the first two dark cycles post
treatment, both the 'surgery' group and the 'moved' group displayed considerable
reductions in dark cycle activity, indicating that the movement of the mice was as
disruptive to their activity patterns as undergoing anaesthesia and surgery. Previous
studies have shown that manual drug/vehicle administration can have considerable
phase effects on activity and with the combined effects of anaesthesia, a drop in
activity following surgery was not unexpected (Hastings et al., 1992). However the
impact on activity of moving the mice was surprising, considering the mice were
only handled very briefly during the transfer to and from an incubator. The effects of
such brief episodes of handling have not previously been reported to disrupt activity
cycles. However, similar protocols (10 s period of handling) have been show to
produce significantly elevated serum levels of various factors (IL-ip, ACTH, P-
endorphin) which may be involved in stress responses (Ottaviani & Franceschi,
1996; Hale et al., 2003). Previous behavioural studies of VPAC2R transgenic mice,
in addition to other circadian cycle studies, have utilised phase shifts of 8 h to
evaluate and compare re-entrainment times (Shen et al., 2000; Harmar et al., 2002;
Satoh et al., 2006). To facilitate the planned surgical procedures a 6 h phase advance
was more desirable, thus the ability of mice to adapt to this magnitude of shift was
compared to that of an 8 h shift. The mice stably entrained to the shorter phase shift
as readily as the standard 8 h protocol, with the re-entrainment time in both cases
being ~ 6 days. The time to re-entrain was consistent with those of the previous
VPAC2R transgenic studies, in which groups of wild-type mice were shown to re-
entrain to an 8 h phase advance in ~ 6 days (Shen et al., 2000; Harmar et al., 2002).
Although 6 h phase shifts have not been routinely used in circadian biology studies
of VPAC2R transgenic mice, several reports have described the use of this shorter
phase advance in the examination of other mouse lines and in drug studies (Moriya et
al., 2000; Sollars et al., 2002; Horikawa & Shibata, 2004). In these studies, re-
entrainment of C57BL/6J mice appeared to take slightly longer than that observed
with the 8 h advance, with average re-entrainment times reported to be ~ 8 days.
However differences in experimental protocols and testing methods could account
for the small difference between this and our 6 day re-entrainment period.
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Subsequent to the demonstration of successful re-entrainment to a 6 h phase
advance, the mice were entrained to a 12 h light/dark cycle in preparation for the
PG99-465 study. During the light cycle, PG99-465 (1 pM) or vehicle was injected
into the lateral ventricles and following a full hour of recovery, the mice were
subjected to a 6 h advance in the dark cycle and their activity monitored
continuously. In previous studies, VPAC2R null mice were exposed to unexpected
and brief (2 h) periods of darkness during the light cycle (Harmar et al., 2002).
During these periods the transgenic mice showed strong bursts of activity in response
to these unexpected dark periods, whereas wild-type mice showed minimal
responsiveness to the lighting change. As it was hypothesised that PG99-465
antagonism of the VPAC2 receptor in vivo might produce a similar effect, the activity
of the PG99-465 and vehicle groups in the initial 2 h period of darkness following
the phase shift was assessed. The disruptive effect of surgery reported earlier was
not expected to interfere with the identification of potential PG99-465 effects as only
the amplitude and not the onset of activity was affected following surgery. Indeed,
following drug treatment there was a small reduction in total dark cycle activity,
however the onset of activity was not altered. These effects were independent of
treatment group and were completely consistent with the previously determined
effect of surgery upon activity levels. Administration of PG99-465 did not increase
responsiveness to the novel light/dark cycle in this study, with no alterations in
response time to the phase advance detected when compared to vehicle.
3.3.2.2. Stability of PG99-465 in vivo
PG99-465 is an analogue of VIP, in which a fatty acid (myristoyl group)
was attached to the amino terminal of the peptide (Moreno et al., 2000). Although
fatty acid modification of peptides has been suggested to improve the stability of
peptides in vivo, including VIP derivates, no data regarding the stability of PG99-465
has been reported (Gozes et al., 1996; Dasgupta et al., 1999). Therefore it is
uncertain whether this compound remains active once delivered into the brain. In
vitro, brief administration (10 min) of PG99-465 alone to SCN slice preparations did
not affect overall firing rhythms, however it did attenuate responses induced from
exogenous VIP application, in both mouse and rat tissues (Reed et al., 2002; Cutler
et al., 2003). Interestingly, Cutler and colleagues (2003) reported that chronic
application (7 h) of PG99-465 prevented normal electrical firing rhythms in mouse
SCN slices during the light cycle. Furthermore, studies have shown that a single i.v.
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bolus injection of PACAP-38 had no protective effects following a forebrain
ischemic episode, in contrast to i.c.v. infusion of the peptide (over a period of 7 days)
which produced a significant increase in the number of viable hippocampal cells
(Somogyvari-Vigh et al., 1998). These studies may imply that prolonged application
of PG99-465 may be necessary to observe inhibition of endogenous VIP induced
responses through the VPAC2R. In addition, the complex pharmacology of PG99-
465 presented in chapter one may also have contributed to the lack of effect seen on
re-entrainment rates. VPACi receptors are unlikely to be involved in SCN responses
to PG99-465, as the expression of these receptors in the SCN is negligible
(Shinohara et al., 1999). However, given the expression of PACiR in the SCN and
the agonist effects reported in chapter one for PG99-465 at this receptor, an
interaction with these receptors is plausible (Cagampang et al., 1998a). Although the
use of lower peptide concentrations may have reduced potential interactions with
PACiR, this may also have precluded the detection of VPAC2R antagonist effects in
vivo.
3.3.2.2. Future studies using PG99-465 in vivo
In future studies the putative effects of PG99-465 on re-entrainment times in
response to phase advances could be studied with the use of mini-pumps, allowing a
longer term infusion of the peptide. Ideally, such in vivo evaluation of receptor
function would be performed using non-peptide antagonists, with a greater selectivity
for the VPAC2R than PG99-465. However, given the paucity of such compounds for
the VPAC2R (and VPACiR and PAQR), the use of PG99-465 is the only
pharmacological means to currently inhibit VPAC2R function.
3.3.3. SCN astrocyte function and circadian rhythms
Although the two areas explored in this final chapter appear quite distinct,
there are some intriguing links between VPAC/PACR activity in astrocytes and
circadian rhythms. To begin with, the SCN as well as containing neurons also
contains a high density of astrocytes, with the astrocyte/neuron ratio estimated to be
1:3 (Morin et al., 1971; Guldner, 1983). The density of astrocytes in the SCN has
been suggested to be temporally regulated, however there are some conflicting data
regarding this diurnal expression (Gerhold & Wise, 2006; Leone et al., 2006). It has
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recently been shown that cortical astrocytes in culture express clock genes, such as
perl and per2, in a rhythmic manner (for up to 7 days) with peak expression around
midday (Prolo et al., 2005). In addition, these studies also demonstrated that the
expression of Per genes in these cells could be phase shifted in response to light
cues. These authors suggest a possible role for glia as modulators of neuronal
rhythms. Further support for an astroglial role in SCN clock function has been
provided from studies in which gap junction blockers have been shown to disrupt
SCN function. More specifically, these studies suggested that the application of gap
junction blockers to SCN slices may desynchronise the phase relationship between
VIP and AVP expression (Shinohara et al., 1995, 2000). Furthermore, it was
recently proposed that SCN astrocytes may be involved in the modulation of SCN
activity through possible inflammatory/immune based mechanisms involving
cytokines such as IL-lp, TNF-a and NF-kB (Leone et al., 2006). These authors also
suggested that light mediated glutamate release might activate the transcription factor
NF-kB in astrocytes. Further support for the role of cytokines in the SCN comes
from studies demonstrating IL-1J3 and TNF-a involvement in the regulation of sleep
cycles (Cearley et al., 2003; Opp, 2006). Although VPAC/PACR expression in
cortical astrocytes has been previously investigated, the specific expression of these
receptors in astrocytes of the SCN has not been reported to date. Given the
VPAC/PACR modulation of cytokines in cortical astrocytes that has been discussed
in this chapter and the suggested link between cytokines and SCN function, it may be
interesting in future studies to explore the potential links between VPAC/PAC





In the past 20 - 30 years, since the isolation of the endogenous peptides
VIP, PACAP-27 and PACAP-38, a wealth of knowledge has been generated with
respect to the distribution of these peptides in the body, the receptors which they
activate and the plethora of physiological functions that they are involved in
regulating. Both the peptides and their established cognate receptors (VPACi,
VPAC2 and PACi) have been shown to be widely distributed throughout the body,
with specific localisations reported in a multitude of cell types, tissues and organs.
This widespread distribution correlates with the many functional roles that have been
reported for these peptides and receptors. In recent years, much of the research effort
in this field has focused on roles for these peptides and receptors in the modulation of
circadian cycles, neuroprotection, glucose homeostasis and immunomodulation.
Many of the physiological effects of VIP and PACAP are known to be
mediated through cAMP, produced via coupling of the VPAC/PAC receptors to Gas.
In addition, several reports have also documented the modulation of intracellular
calcium levels upon receptor activation as well as the stimulation of PLD activity.
However, the link between each receptor and the different pathways appears to
depend on the cell/tissue being studied, with the receptor expression level, G-protein
complement and species of receptor potentially contributing to the differences
reported. In order to attempt to clearly delineate the physiological functions
mediated by individual VPAC/PAC receptors, it is crucial to understand their
pharmacology and the intracellular signalling cascades which they activate.
However, for the VPAC/PAC receptor family although the general characteristics are
established, it is sometimes difficult to gain a clear and consistent description of their
pharmacology/signalling characteristics from reports in the literature, perhaps as a
consequence of the inevitable variation which exists in the assay platforms and
expression systems utilised between different research groups. The relatively small
size of the VPAC/PACR family, makes the full characterisation and comparison of
the receptors in functional assays a manageable task, even more so considering the
relatively small pool of peptide ligands with which they are normally evaluated.
However, reports of systematic comparisons between multiple signalling pathways
for VPAC/PAC receptors are limited, often examining only a very small number of
ligands which reduces the pharmacological value of some of these studies.
Therefore, in this thesis, I performed a thorough and systematic pharmacological
characterisation of all three human VPAC/PAC receptor subtypes using two
standardised, whole-cell based, HT-amenable, non-radioactive functional assays to
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measure intracellular cAMP and calcium. To provide a full pharmacological
evaluation of human VPAC/PACR pharmacology, a number of peptide ligands were
utilised in addition to VIP and PACAP. From the limited number of putatively
receptor selective ligands reported in the literature, an agonist and antagonist for each
receptor were examined (VPACi: [Ala11'22'28]VIP (Nicole et al., 2000), PG97-269
(Gourlet et al., 1997a); VPAC2: R3P65 (Yung et al., 2003), PG99-465 (Moreno et
al., 2000); PACi: maxadilan (Lerner et al., 1991), M65 (Uchida et al., 1998)). Using
receptor expressing stable cell lines, the agonist ROP was demonstrated to be
consistent between assays, although an approximately 100 fold reduction in agonist
potency was observed in the calcium assay. This shift to lower agonist potency in
stimulating calcium was confirmed using the SHSY-5Y cell line which
endogenously expresses PACi, and is also in agreement with a range ofmore limited
studies (Pisegna & Wank, 1993; Delporte et al., 1995; McCulloch et al., 2000;
Langer et al., 2001). Such consistent observations between all three human receptor
subtypes with an extensive range of ligands have not previously been described in a
single study. Furthermore, a number of new findings arose from these studies,
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including the observation of full agonism for [Ala ' ' ]VIP at the PACiR and the
lack of selectivity of R3P65 for the VPAC2R. In addition, the reportedly selective
VPAC2R antagonist PG99-465 was demonstrated to have a complicated
pharmacological profile, with agonist effects at all three VPAC/PACR when tested
alone in the [cAMPJj assay. Being the only VPAC2R antagonist described to date,
PG99-465 has been used in several in vitro investigations of VPAC2R function,
however the findings presented here suggest that the results from such studies could
potentially be complicated by cross receptor activity. Further examination of
VPAC/PACR pharmacology in SHSY-5Y cells and rat cortical astrocytes revealed
differential peak calcium responses for the agonists tested, with the identification of a
PACAP response that was sensitive to M65 (a PACiR antagonist), but insensitive to
maxadilan (a PACiR agonist). This is the first report of such a response and its
occurrence was hypothesised to result from the presence of multiple PAQR splice
variants. Further examination of the receptors mediating these responses could
potentially help to identify the functional properties of PACiR splice variants. A
large proportion of the findings from the current studies have been recently published
in two peer reviewed manuscripts and it is hoped that this will prove useful for other
researchers in the field and facilitate further investigation into VPAC/PACR
pharmacology and function (Dickson et al., 2006a; Dickson et al., 2006b). In
addition these studies also highlight the lack of selective ligands, particularly non-
peptides which are currently available for this receptor family and emphasize that the
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opportunity still exists to identify and develop novel, non-peptide ligands. These
studies also re-iterate the importance of evaluating novel VPAC/PACR ligands in
multiple functional assays in order to fully understand their downstream signalling
characteristics.
In an attempt to identify novel, non-peptide ligands for VPAC/PACR, an
HT-screening study of part of the Astellas Pharma Inc. (formerly the Fujisawa
Pharmaceutical Company) compound library was performed. The screening studies
were designed to identify potential non-peptide VPAC2R antagonists, as it was
hypothesised that such compounds may be of therapeutic value in treating circadian
rhythm disorders, based on studies using transgenic mouse lines (Shen et al., 2000;
Harmar et al., 2002). Following the establishment and optimisation of the calcium
assay for HT-screening, a total of 100,000 compounds were examined for VPAC2R
antagonist activity. A number of potential VPAC2R ligands were identified from
these studies and were fully examined in further potency and selectivity studies. The
compounds identified, although non-peptides, were less potent and selective than the
only currently available peptide antagonist, PG99-465 (Moreno et al., 2000). Due to
a lack of success in hit compound identification/development, the group B GPCR
family, which includes the VPAC/PAC receptors, has been deemed to be a difficult
target in the drug discovery process (Hoare, 2005). As further knowledge is
published examining ligand-receptor interactions for the VPAC/PACR family, it may
help identify the molecular characteristics that non-peptide antagonists are likely to
harbour and so facilitating the optimisation of future screening studies and the
selection of compounds to be screened. Indeed, the possibility that screening studies
to date have simply not tested the most appropriate type of chemical structures
remains a possibility (Macarron, 2006). Astellas Pharma Inc. maintain a general
interest in the VPAC/PAC receptor family, in addition to other neuropeptide
receptors and with the recent formation of the company following a merger, the
expanded compound libraries may provide future opportunities to identify novel
ligands for the individual receptor subtypes.
As discussed throughout this thesis, VPAC/PAC receptors are associated
with numerous interesting physiological roles and in the final section of the current
studies, I have explored two of the aspects that the receptors are involved with in the
CNS. The two areas investigated were VPAC/PACR induced astrocyte-mediated
neuroprotection and VPAC/PACR control of circadian rhythm expression. Both
areas have been the focus of a considerable amount of research in recent years,
perhaps underlying the requirement for developing novel therapeutics in associated
disease states. VIP and PACAP have been known for some time to stimulate the
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release of a number of cytokines and neurotrophic factors from cortical astrocytes,
with the secretion of such molecules shown to confer a degree of neuroprotection to
compromised neurons in a variety of experimental models (Brenneman & Eiden,
1986; Brenneman et al., 1998; Dejda et al., 2005). However, the individual
VPAC/PACR subtypes responsible for mediating the release of these factors remain
to be fully clarified. In addition, the signalling pathways downstream of
VPAC/PACR activation which contribute to such neuroprotective responses have not
been well described. As a consequence, I initially characterised the pharmacology of
VPAC/PACR in primary cultures of rat cortical astrocytes, using the cAMP and
calcium assays described previously. The agonist ROPs obtained for the astrocytes
were consistent between assays and had a predominantly PAQR mediated profile,
which is in agreement with limited published studies (Hashimoto et al., 1993; Ashur-
Fabian et al., 1997). The full characterisation of VPAC/PACR stimulated calcium
responses in rat cortical astrocytes has not been previously described and the robust
coupling of the receptors to this pathway highlights the potential contribution
calcium signalling could make in the secretion of neuroprotective factors. To try to
correlate the stimulation of the cAMP and calcium pathways with cytokine secretion,
the VPAC/PACR mediated secretion of several cytokines from rat cortical astrocytes
was examined. Biphasic secretion of IL-ip and TNF-a was observed upon VIP and
PACAP simulation, with peak responses detected using picomolar and nanomolar
peptide concentrations. Future studies further examining the pharmacology of
cytokine secretion with receptor selective ligands would be useful in order to
delineate the precise receptor subtypes and transduction pathways involved in
VPAC/PACR induced neuroprotection through astrocytes.
The important role of VPAC2R in the control and maintenance of circadian
activity cycles was also explored. Recent studies from Harmar and colleagues using
receptor transgenic mice have highlighted crucial roles for the VPAC2R in the
expression of circadian cycles (Shen et al., 2000; Harmar et al., 2002). These studies
suggested that the modulation of this receptor with pharmacological agents may be a
novel way to therapeutically treat circadian rhythm disorders. Therefore, the
VPAC2R antagonist PG99-465 was evaluated in vivo and its effects on the timing of
activity cycles determined. Following the establishment of a new system of cages
and running wheels, mice were stably entrained to a light/dark cycle and the effects
of movement and surgery on activity levels were determined, prior to drug
administration studies. Interestingly, it was found that simply moving the animals
from their home cages to an incubator was as disruptive to their activity cycles as
exposure to anaesthesia and surgery. This finding has implications for all studies of
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this nature and emphasises that the degree of disruption from surgical procedures
should be fully evaluated prior to any drug treatments. Following i.e.v. injection of
PG99-465 and a 6 h phase advance in the light/dark cycle, no alteration in re-
entrainment rates were observed when compared to the saline treated group. PG99-
465 may have been ineffective in this study for a number of reasons. To my
knowledge, this was the first report of the use of PG99-465 in vivo, and unfortunately
no information is available regarding the in vivo stability or duration of action of this
peptide. Therefore breakdown of the peptide or an inability of the compound to
reach the target area (the SCN) may have also contributed to the ineffectiveness
observed in these studies. Furthermore, the complex pharmacology of this peptide
highlighted in this thesis may have compromised the detection of a VPAC2R
antagonist effect. Future studies examining the chronic administration of this peptide
may prove beneficial in further validating the role of VPAC2R in the control of
circadian rhythms.
Although in some respects, the field of VIP/PACAP and VPAC/PAC
receptor biology is relatively small, the research which has been undertaken to date
and the impact of the published results are considerable and widespread, having
relevance to many physiological functions. As research continues in this area, the
actions of these peptides and their cognate receptors will become clearer and provide
insights into the significance of VIP/PACAP action in normal physiology and the
potential roles for VPAC/PACR in the treatment or prevention of disease. Finally,
clear opportunities still exist to develop non-peptide selective ligands, whose
identification will be pivotal to understanding the roles that these peptides and





5.1. Appendix I: This appendix contains actograms from section 3.2.2.2 in
chapter three (p 242), showing the activity profiles of the 16 mice used in the study,
with the timing of the imposed 12 h dark cycle (1900 to 0700 h) represented by the
grey box. In these and all other actograms presented, each horizontal line represents
a 24 h period with subsequent days continuing directly underneath. Treatments were
administered on 'day 7' of the figures shown. Actogram sets A, B and C correspond
to the mice from the 'moved' (A1 - A6), 'surgery' (B1 - B6) and 'not moved' (CI -
C4) groups respectively.
5.2. Appendix II: Actograms in this appendix are from 16 mice (D1 - D16),
whose activity patterns were monitored in response to an 8 h phase advance in the
light/dark cycle (section 3.2.2.3., chapter three; p 244). Following a period of
entrainment (lights off: 1900 - 0700 h) the mice were subjected to the phase advance
(lights off: 1100 - 2300 h), indicated by the changing position of the grey box (lights
off period) on 'day 6' of the actograms.
5.3. Appendix III: In this appendix, the actograms presented are from 16 mice
(El - 16) that were exposed to a 6 h phase advance in the light/dark cycle (section
3.2.2.3., chapter three; p 244). Initially the mice were entrained to a 12 h light/dark
cycle (lights off: 1900 to 0700 h). On 'day 9' of the actograms the 12 h lights off
period was advanced, beginning at 1300 h, as shown by the position of the grey box.
5.4. Appendix IV: Actograms from the PG99-465 (F1 - F8) and saline (G1 -
G8) treated mice are shown, with dark cycles represented by the grey box. Mice
were entrained to a light/dark cycle (lights off: 2000 to 0800 h), followed by surgery
and drug administration on either 'day 6' or 'day 8' of the actograms. The mice were
treated in two separate groups due to time restraints of the surgical procedures.
Surgery was performed during the light cycle, in the few hours prior to the onset of a
novel dark phase resulting from a 6 h phase advance (lights off: 1300 - 0100 h).
5.5. Appendix V: List of abbreviations.
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5.1. Appendix I
Actograms from section 3.2.2.2. for the 'moved' group (A1 - A6).
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5.2. Appendix II
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Actograms from section 3.2.2.3. for the 6 h phase advance (E9 - El6).
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ADNF activity dependent neurotrophic factor
ADNP activity dependent neurotrophic protein
ADP adenosine diphosphate
ARF ADP-ribosylation factor
AUC area under the curve
BSA bovine serum albumin
Ca2+ calcium
cAMP cyclic adenosine monophosphate
cGMP cyclic guanosine monophosphate
CGRP calcitonin gene related peptide
CHO Chinese hamster ovary
CNS central nervous system
CRE cAMP response element
CSF cerebrospinal fluid
CT circadian time





EGF epidermal growth factor
ELISA enzyme-linked immunoabsorbent assay
FAC final assay concentration
FBS fetal bovine serum
FLIPR fluorometric imaging plate reader
HBSS Hanks' balanced salt solution
G-CSF granulocyte-colony-stimulating factor
GDP guanine diphosphate
GFAP glial fibrillary acidic protein
GHRH growth hormone-releasing hormone
GHT geniculo-hypothalamic tract
GPCR G-protein coupled receptor
GTP guanine triphosphate
h human
HEK human embryonic kidney
HIV human immunodeficiency virus
HT high throughput





ISB inorganic salts buffer
IUPHAR International Union of Pharmacology
i.v. intravenous
KO knock-out
KRBG Krebs-Ringer bicarbonate buffer with glucose
LB Luria Bertani
LPS lipopolysaccharide
LTP long term potentiation
MAPK mitogen activated protein kinase
M-CSF macrophage-colony-stimulating factor
MD Molecular Devices
MEM minimal essential medium
MIP macrophage inflammatory protein
NCE new chemical entity
NMR nuclear magnetic resonance
OE over-expressing
OD optical density
ORF open reading frame
PACAP pituitary adenylate cyclase activating polypeptide
PBS phosphate buffered saline








pMCAO permanent middle cerebral artery occlusion
PNS peripheral nervous system
PRP PACAP-related peptide
r rat
RAMP receptor activity-modifying protein
RANTES regulated upon activation, normal T-cell expressed and secreted factor
RBL rat basophilic leukaemia
RCA rat cortical astrocytes
RGC retinal ganglion cells
RHT retino-hypothalamic tract
RME Basal medium Eagle
ROP rank order of potency
RT room temperature
SCG superior cervical ganglion
SCN suprachiasmatic nucleus
SDS sodium dodecyl sulfate
TAE Tris-acetate-EDTA buffer
TBI traumatic brain injury
TM transmembrane
TNF tumour necrosis factor
Tris-HCl Tris hydrochloride
TTX tetrodotoxin
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